

# Central Lancashire Online Knowledge (CLoK)

Title	Interventions for maintenance of surgically-induced remission in Crohn's					
	disease: a network meta-analysis					
Туре	Article					
URL	https://clok.uclan.ac.uk/id/eprint/25440/					
DOI	https://doi.org/10.1002/14651858.cd013210					
Date	2019					
Citation	Iheozor-Ejiofor, Zipporah, Gordon, Morris, Clegg, Andrew, Freeman, Suzanne C., Gjuladin-Hellon, Teuta, MacDonald, John and Akobeng, Anthony (2019) Interventions for maintenance of surgically-induced remission in Crohn's disease: a network meta-analysis. Cochrane Database of Systematic Reviews, 2018 (11). CD013210.					
Creators	Iheozor-Ejiofor, Zipporah, Gordon, Morris, Clegg, Andrew, Freeman, Suzanne C., Gjuladin-Hellon, Teuta, MacDonald, John and Akobeng, Anthony					

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1002/14651858.cd013210

For information about Research at UCLan please go to <a href="http://www.uclan.ac.uk/research/">http://www.uclan.ac.uk/research/</a>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>



# Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review)

Iheozor-Ejiofor Z, Gordon M, Clegg A, Freeman SC, Gjuladin-Hellon T, MacDonald JK, Akobeng AK

Iheozor-Ejiofor Z, Gordon M, Clegg A, Freeman SC, Gjuladin-Hellon T, MacDonald JK, Akobeng AK. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. *Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD013210. DOI: 10.1002/14651858.CD013210.pub2.

www.cochranelibrary.com

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

# TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	6
OBJECTIVES	7
METHODS	7
RESULTS	12
Figure 1	13
Figure 2	17
Figure 3	18
Figure 4	21
Figure 5	22
Figure 6	23
Figure 7	24
Figure 8	25
Figure 9	26
Figure 10	27
Figure 11	28
Figure 12	29
Figure 13.	30
Figure 14.	31
Figure 15.	32
Figure 16	34
Figure 17.	35
Figure 18	36
ADDITIONAL SUMMARY OF FINDINGS	37
DISCUSSION	44
AUTHORS' CONCLUSIONS	47
ACKNOWLEDGEMENTS	47
REFERENCES	48
CHARACTERISTICS OF STUDIES	56
DATA AND ANALYSES	142
Analysis 1.1 Comparison 1 Direct evidence: 5-ASA versus placebo. Outcome 1 Clinical relapse	147
Analysis 1.2. Comparison 1 Direct evidence: 5-ASA versus placebo, Outcome 2 Adverse events	148
Analysis 1.2. Comparison 1 Direct evidence: 5-ASA versus placebo, Outcome 3 Serious adverse events	149
Analysis 1.9. Comparison 1 Direct evidence: 5-ASA versus placebo, Outcome 4 Withdrawal due to adverse events	149
Analysis 1.5. Comparison 1 Direct evidence: 5-ASA versus placebo, Outcome 5 Endoscopic relapse	150
Analysis 2.1 Comparison 2 Direct evidence: 5-ASA versus adalimumah Outcome 1 Clinical relanse	151
Analysis 2.1. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 2 Adverse events	151
Analysis 2.2. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 3 Endoscopic relanse	152
Analysis 2.9. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 4 Withdrawal due to adverse events	152
Analysis 2.1. Comparison 2 Direct evidence: 5-ASA versus nurine analogues. Outcome 1 Clinical relanse	153
Analysis 3.2. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 2 Adverse events	154
Analysis 3.2. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 3 Serious adverse events	155
Analysis 3.4. Comparison 3 Direct evidence: 5 ASA versus purine analogues, Outcome 4 Withdrawal due to adverse	1))
events	156
Analysis 3.5 Comparison 3 Direct avidence: 5 ASA versus purine analogues Outcome 5 Endosconic release	157
Analysis 3.7. Comparison 5 Direct evidence: antibiotics versus planete analogues, Outcome 1 Clinical release	157
Analysis 4.2. Comparison 4 Direct evidence: antibiotics versus placebo. Outcome 2 Adverse events	150
Analysis 4.2. Comparison 4 Direct evidence, antibiotics versus placebo, Outcome 2 With drawel due to a diverse antibiotics versus placebo.	150
marysis 4.9. Comparison 4 Direct evidence, antibiotics versus placebo, Outcome 5 withdrawal due to adverse events.	1.70

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

i

<ul> <li>Analysis 51. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 1 Clinical relapse.</li> <li>Analysis 52. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 3 Withdrawal due to adverse events.</li> <li>Analysis 54. Comparison 5 Direct evidence: inflixinab versus adalimumab, Outcome 1 Clinical relapse.</li> <li>Analysis 61. Comparison 6 Direct evidence: inflixinab versus adalimumab, Outcome 2 Adverse events.</li> <li>Analysis 61. Comparison 6 Direct evidence: inflixinab versus adalimumab, Outcome 2 Holvescopic relapse.</li> <li>Analysis 63. Comparison 6 Direct evidence: inflixinab versus adulimumab, Outcome 3 Endoscopic relapse.</li> <li>Analysis 64. Comparison 7 Direct evidence: inflixinab versus purine analogues, Outcome 4 Histologic relapse.</li> <li>Analysis 74. Comparison 7 Direct evidence: inflixinab versus purine analogues, Outcome 4 Histologic relapse.</li> <li>Analysis 74. Comparison 7 Direct evidence: inflixinab versus purine analogues, Outcome 4 Histologic relapse.</li> <li>Analysis 74. Comparison 7 Direct evidence: inflixinab versus purine analogues, Outcome 4 Histologic relapse.</li> <li>Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.</li> <li>Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.</li> <li>Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.</li> <li>Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Staiosas deverse events.</li> <li>Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Staiosas deverse events.</li> <li>Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Staiosas deverse events.</li> <li>Analysis 9.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Vithdrawal due to adverse events.</li> <li>Analysis 10.3. Comparison 10 Direct evidence: purine analogues ve</li></ul>	Analysis 4.4. Comparison 4 Direct evidence: antibiotics versus placebo, Outcome 4 Endoscopic relapse	159
Analysis 5.2. Comparison 5 Direct evidence: budsonide versus placebo, Outcome 2 Adverse events.       160         Analysis 5.3. Comparison 5 Direct evidence: inflixinab versus alalimumab, Outcome 1 Clinical relapse.       161         Analysis 6.3. Comparison 6 Direct evidence: inflixinab versus alalimumab, Outcome 2 Adverse events.       162         Analysis 6.3. Comparison 6 Direct evidence: inflixinab versus alalimumab, Outcome 2 Histologic relapse.       163         Analysis 6.3. Comparison 6 Direct evidence: inflixinab versus alalimumab, Outcome 4 Histologic relapse.       164         Analysis 6.4. Comparison 7 Direct evidence: inflixinab versus purine analogues, Outcome 1 Clinical relapse.       164         Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       166         Analysis 7.3. Comparison 7 Direct evidence: prohisina versus purine analogues, Outcome 4 Histologic relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: prohisina versus placebo, Outcome 2 Holvence events.       166         Analysis 8.2. Comparison 9 Direct evidence: prohisinic versus placebo, Outcome 2 Adverse events.       166         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Histologic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168 <td>Analysis 5.1. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 1 Clinical relapse.</td> <td>159</td>	Analysis 5.1. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 1 Clinical relapse.	159
Analysis 5.3. Comparison 5 Direct evidence: budesonide versus placebo, Ourcome 1 Windrawal due to adverse events.       161         Analysis 6.1. Comparison 6 Direct evidence: inflixinab versus adalimumab, Ourcome 1 Clinical relapse.       162         Analysis 6.1. Comparison 6 Direct evidence: inflixinab versus adalimumab, Ourcome 1 Edinocopic relapse.       163         Analysis 6.2. Comparison 6 Direct evidence: inflixinab versus adalimumab, Ourcome 4 Histologic relapse.       163         Analysis 6.3. Comparison 7 Direct evidence: inflixinab versus purine analogues, Ourcome 4 Histologic relapse.       164         Analysis 7.2. Comparison 7 Direct evidence: inflixinab versus purine analogues, Ourcome 1 Edinical relapse.       164         Analysis 7.3. Comparison 7 Direct evidence: inflixinab versus purine analogues, Ourcome 4 Histologic relapse.       165         Analysis 7.4. Comparison 7 Direct evidence: prohiorics versus placebo, Ourcome 1 Edinical relapse.       166         Analysis 8.2. Comparison 8 Direct evidence: prohiorics versus placebo, Ourcome 2 Adverse events.       166         Analysis 8.2. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 1 Edinical relapse.       167         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 1 Edinical relapse.       169         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 2 Adverse events.       169         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 2 Edinoscopic relapse.	Analysis 5.2. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 2 Adverse events.	160
Analysis 5.4. Comparison 5 Direct evidence: infliximab versus adalimumab, Ourcome 1 Clinical relapse.       161         Analysis 6.2. Comparison 6 Direct evidence: infliximab versus adalimumab, Ourcome 3 Endoscopic relapse.       162         Analysis 6.3. Comparison 6 Direct evidence: infliximab versus adalimumab, Ourcome 4 Histologic relapse.       163         Analysis 6.4. Comparison 6 Direct evidence: infliximab versus adalimumab, Ourcome 4 Histologic relapse.       164         Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Ourcome 1 Histologic relapse.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Ourcome 3 Endoscopic relapse.       165         Analysis 7.3. Comparison 7 Direct evidence: probiotics versus placebo, Ourcome 1 Endoscopic relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Ourcome 1 Endoscopic relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Ourcome 1 Stadoscopic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: probiotics versus placebo, Ourcome 1 Stadoscopic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: probiotics versus placebo, Ourcome 2 Adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 2 Adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Ourcome 2 Adverse events.       169	Analysis 5.3. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 3 Withdrawal due to adverse events.	160
Analysis 6.1. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 1 Clinical relapse.       162         Analysis 6.3. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 3 Endoscopic relapse.       163         Analysis 6.3. Comparison 7 Direct evidence: infliximab versus adalimumab, Outcome 4 Histologic relapse.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 2 Withdrawal due to adverse events.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.3. Comparison 10 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Adverse events.       170         Analysis 9.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 A	Analysis 5.4. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 4 Histologic relapse.	161
Analysis 6.2. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 3 Endoscopic relapse.       163         Analysis 6.3. Comparison 7 Direct evidence: infliximab versus adalimumab, Outcome 4 Endoscopic relapse.       163         Analysis 7.1. Comparison 7 Direct evidence: infliximab versus gurine analogues, Outcome 1 Clinical relapse.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Endoscopic relapse.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.       165         Analysis 7.3. Comparison 8 Direct evidence: infliximab versus purine analogues, Outcome 1 Elinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiorics versus placebo, Outcome 2 Adverse events.       166         Analysis 8.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       166         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       167         Analysis 9.1. Comparison 10 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.1. Comparison 10 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       171         Analysis 9.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.	Analysis 6.1. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 1 Clinical relapse.	162
Analysis 6.3. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 3 Endoscopic relapse.       163         Analysis 6.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 1 Clinical relapse.       164         Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 2 Withdrawal due to adverse events.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 7.4. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       167         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.1. Comparison 10 Direct evidence: purine analogues versus alalimumab, Outcome 4 Edinoscopic relapse.       171         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus alalimumab, Outcome 4 Edinoscopic relapse.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus alalimumab, Outcome 4 Edinoscopi	Analysis 6.2. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 2 Adverse events.	162
Analysis 6.4. Comparison 6 Direct evidence: infliximab versus purine analogues, Outcome 1 Clinical relapse.       163         Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 2 Withdrawal due to adverse events.       163         Analysis 7.2. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 1 Histologic relapse.       165         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.       166         Analysis 8.2. Comparison 8 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       166         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical	Analysis 6.3. Comparison 6 Direct evidence: infliximab versus adalimumab. Outcome 3 Endoscopic relapse.	163
Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 1 Clinical relapse.       164         Analysis 7.2. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.       165         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       167         Analysis 8.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus alalimumab, Outcome 4 Mithdrawal due to adverse events.       170         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Adverse events.       172         Analysis 10.4. Comparison 11 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endo	Analysis 6.4. Comparison 6 Direct evidence: infliximab versus adalimumab. Outcome 4 Histologic relapse.	163
Analysis 7.2. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 2 Withdrawal due to adverse events.       164         Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.       165         Analysis 7.4. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.       166         Analysis 8.3. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.       166         Analysis 8.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Endoscopic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Endoscopic relapse.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       170         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus alalimumab, Outcome 2 Mithdrawal due to adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus alalimumab, Outcome 2 Mithdrawal due to adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfa	Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues. Outcome 1 Clinical relapse.	164
cvents.       164         Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 7.4. Comparison 7 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 3 Endoscopic relapse.       166         Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 3 Endoscopic relapse.       167         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Serious adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus alalimumab, Outcome 1 Clinical relapse.       170         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus alalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 11.1. Comparison 10 Direct evidence: sulfasalazine versus placebo, Outcome 2 Micharese (Linical relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.2. Comparison 12 Direct evidence: sulfa	Analysis 7.2 Comparison 7 Direct evidence: infliximab versus purine analogues. Outcome 2 Withdrawal due to adverse	101
Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.       165         Analysis 7.4. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       167         Analysis 8.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 10.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       170         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       169         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 10.4. Comparison 10 Direct evidence: gurine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 11.4. Comparison 10 Direct evidence: gurine analogues versus adalimumab, Outcome 4 Endoscopic r	events	164
Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.       165         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.3. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 3 Endoscopic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Endoscopic relapse.       167         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Endoscopic relapse.       168         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: sulfasalazine versus adalimumab, Outcome 2 Adverse events.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d       174         Analysis 11.2. Comparison 13 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d       174         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0	Analysis 7.3 Comparison 7 Direct evidence: infliximaly versus purine analogues. Outcome 3 Endoscopic relapse	165
Analysis 3: A. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.       166         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       167         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       168         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       169         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.5. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 13.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Adverse events.	Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.	165
Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.       166         Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.       167         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.       169         Analysis 9.4. Comparison 10 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       170         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Adverse events.       172         Analysis 11.1. Comparison 10 Direct evidence: sulfiasalazine versus adalimumab, Outcome 1 Adverse events.       172         Analysis 11.2. Comparison 11 Direct evidence: sulfiasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfiasalazine versus adalimumab, Outcome 1 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfiasalazine versus placebo, Outcome 1 Clinical relapse.       175         Analysis 11.3. Comparison 11 Direct evidence: sulfiasalazine versus adalimumab, Outcome 1 Adverse events.       174 <td>Analysis 7.4. Comparison 7 Direct evidence: minimize versus placeba Outcome 1 Clinical relapse.</td> <td>166</td>	Analysis 7.4. Comparison 7 Direct evidence: minimize versus placeba Outcome 1 Clinical relapse.	166
<ul> <li>Analysis 8.2. Comparison 6 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events</li></ul>	Analysis 8.1. Comparison 8 Direct evidence, problem suspinatedo, Outcome 1 Chinical tetapse.	100
Analysis 8.2. Comparison 8 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       167         Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Mitchawal due to adverse events.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Witchdrawal due to adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 5 Endoscopic relapse.       170         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus adalimumab, Outcome 1 Clinical relapse.       173         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 12.1. Comparison 13 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 Adverse events.       174         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Adverse events.       176         Analysis 13.3. Comparison 13 Direct evidence not in ne	Analysis 8.2. Comparison 8 Direct evidence: problotics versus placebo, Outcome 2 Adverse events.	166
Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       168         Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Serious adverse events.       169         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 5 Endoscopic relapse.       170         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 13.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse.       174         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse.       176         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse.       177         Analysis 13	Analysis 8.3. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 3 Endoscopic relapse.	16/
Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Serious adverse events.       168         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.       170         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.       172         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 12.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.1. Comparison 13 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       176         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 1.40 g/d versus 2.4 g/d       176         Analysis 13.5. Comparison 13 Direc	Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 1 Clinical relapse.	167
Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.       169         Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 5 Endoscopic relapse.       170         Analysis 9.5. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.4. Comparison 11 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence n	Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.	168
Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse       169         Analysis 9.5. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 5 Endoscopic relapse.       171         Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Chinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Chinical relapse.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Chinical relapse.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       175         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.5. Comparison	Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Serious adverse events.	169
events.       169         Analysis 9.5. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.       171         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Miverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 10.4. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 11.3. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Endoscopic versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       17	Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse	
Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus adalimumab, Outcome 5 Endoscopic relapse.       170         Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 12.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 12.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 Clinical relapse.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       175         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiorios versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 S-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Dire	events	169
Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Ourcome 1 Clinical relapse.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Ourcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Ourcome 2 Adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Ourcome 4 Endoscopic relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 13.1. Comparison 13 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 -ASA versus purine analogues.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 -ASA versus purine analogues.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 -ASA versus purine analogues.       178         <	Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 5 Endoscopic relapse.	170
Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.       171         Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       173         Analysis 10.4. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 12.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 13.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       175         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibines versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 Aversus placebo.       177         Analysis 14.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibines versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 Aversus placebo.       177         Analysis 14.1. Compariso	Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.	171
Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to       172         Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       173         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       175         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: adverse events, Outcome 2 Adverse versus placebo.       177         Analysis 13.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 5-ASA versus purine       178         Analysis 14.2. Comparison 14 Direct evidence not in netwo	Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.	171
adverse events.       172         Analysis 10.4. Comparison 11 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       173         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 13.1. Comparison 13 Direct evidence: sulfasalazine versus placebo, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse event	Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to	
Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.       172         Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 14.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 14.1. Comparison 13 Direct evidence not in network: adverse events, Outcome 4 Antibiotics versus placebo.       177         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 Antibiotics versus placebo.       178         Analysis 14.2. Comparison 14 Direct	adverse events. $\ldots$	172
Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.       173         Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       174         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179 <t< td=""><td>Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.</td><td>172</td></t<>	Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.	172
Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.       174         Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       175         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Fusitimab versus placebo.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 S-ASA versus purine analogues.       180 <td>Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.</td> <td>173</td>	Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.	173
Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       175         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       179	Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.	174
events.       174         Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       175         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Infliximab versus placebo       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5	Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse	
Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.       175         Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 5-ASA versus purine       180 <td>events.</td> <td>174</td>	events.	174
Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 16.1. Comparison 15 Direct evidence not in network: adverse events, Outcome 1 5-ASA versus purine analogues.       181 <td>Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.</td> <td>175</td>	Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome 1 Clinical relapse.	175
mesalazine.       175         Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 S-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 16.1. Comparison 15 Direct evidence not in network: adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdra	Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d	
Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 16.1. Comparison 16 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d m	mesalazine.	175
Initialized and the placebolic comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       176         Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 15.1. Compa	Analysis 13.2 Comparison 13 Direct evidence not in network: clinical relapse. Outcome 2 Purine analogues versus	-12
Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 5-ASA versus purine       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus       181         Analysis 16.1. Comparison	nlacebo	176
Analysis 15.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.       177         Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 15.1. Comparison 14 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus       181         Yentions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review)       181	Analysis 13.3 Comparison 13 Direct evidence not in network: clinical relance Outcome 3 Infliximal versus placebo	177
Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antholotics versus placebo.       177         Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d ve	Analysis 13.4. Comparison 13 Direct evidence not in network, clinical relapse, Outcome 4 Antibiotics versus placebo	177
Analysis 15.7. Comparison 15 Direct evidence not in network: chincal relapse, Outcome 5 9-ASA versus purifies       178         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	Analysis 13.4. Comparison 13 Direct evidence not in network, clinical relapse, Outcome 4 Antibiotics versus placedo.	1//
analogues.       1/8         Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181         Yentions for maintenance of surgically induced remission in Crophy's disease: a network meta-analysis (Review)       181	Analysis 15.5. Comparison 15 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine	170
Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d       178         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d versus 2.4 g/d mesalazine.       181		1/8
mesalazine.       1/8         Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d	
Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.       179         Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	mesalazine.	1/8
Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.       179         Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus       181         Yventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review)       181	Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.	179
Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.	179
analogues.       180         Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       180         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine	
Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	analogues	180
placebo.       180         Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus	
Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.       181	placebo	180
analogues.       181         Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus       181         2.4 g/d mesalazine.       181         rventions for maintenance of surgically induced remission in Crophy's disease: a network meta-analysis (Review)       #	Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine	
Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine	analogues	181
2.4 g/d mesalazine	Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 1 4.0 g/d versus	
rventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review)	2.4 g/d mesalazine	181
	rventions for maintenance of surgically induced remission in Crohn's disease a network meta-analysis (Review)	

Analysis 16.2. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 2 Synbiotic	
versus placebo	182
Analysis 16.3. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 3 Probiotics	
versus placebo	182
Analysis 16.4. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 4 Infliximab	
versus placebo	183
Analysis 16.5. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 5 5-ASA versus	
purine analogues	183
Analysis 16.6. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 6 Purine	
analogues versus placebo	184
Analysis 17.1. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 1 4.0 g/d versus 2.4 g/d	
mesalazine.	185
Analysis 17.2. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 2 Probiotics versus placebo.	185
Analysis 17.3. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 3 Infliximab versus	
	186
Analysis 17.4. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 4 5-ASA versus purine	
	186
Analysis 1/.5. Comparison 1/ Direct evidence not in network: endoscopic relapse, Outcome 5 Purine analogues versus	107
	18/
ADDITIONAL TABLES	18/
	210
	241
	241
DIFFERENCES DE I WEEN FROTOCOL AND REVIEW	242

[Intervention Review]

# Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Zipporah Iheozor-Ejiofor<sup>1</sup>, Morris Gordon<sup>1</sup>, Andrew Clegg<sup>2</sup>, Suzanne C Freeman<sup>3</sup>, Teuta Gjuladin-Hellon<sup>1</sup>, John K MacDonald<sup>4</sup>, Anthony K Akobeng<sup>5</sup>

<sup>1</sup>School of Medicine, University of Central Lancashire, Preston, UK. <sup>2</sup>Faculty of Health and Wellbeing, University of Central Lancashire, Preston, UK. <sup>3</sup>Department of Health Sciences, University of Leicester, Leicester, UK. <sup>4</sup>Department of Medicine, University of Western Ontario, London, Canada. <sup>5</sup>Sidra Medicine, Doha, Qatar

Contact address: Anthony K Akobeng, Sidra Medicine, PO Box 26999, Doha, Qatar. aakobeng@sidra.org, akobeng@aol.com.

Editorial group: Cochrane IBD Group. Publication status and date: New, published in Issue 9, 2019.

**Citation:** Iheozor-Ejiofor Z, Gordon M, Clegg A, Freeman SC, Gjuladin-Hellon T, MacDonald JK, Akobeng AK. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. *Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD013210. DOI: 10.1002/14651858.CD013210.pub2.

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# ABSTRACT

#### Background

Crohn's disease (CD) is a chronic disease of the gut. About 75% of people with CD undergo surgery at least once in their lifetime to induce remission. However, as there is no known cure for the disease, patients usually experience a recurrence even after surgery. Different interventions are routinely used in maintaining postsurgical remission. There is currently no consensus on which treatment is the most effective.

## Objectives

To assess the effects and harms of interventions for the maintenance of surgically induced remission in Crohn's disease and rank the treatments in order of effectiveness.

#### Search methods

We searched the Cochrane IBD Group Specialized Register, CENTRAL, MEDLINE, and Embase from inception to 15 January 2019. We also searched reference lists of relevant articles, abstracts from major gastroenterology meetings, ClinicalTrials.gov, and the WHO ICTRP. There was no restriction on language, date, or publication status.

#### Selection criteria

We considered for inclusion randomised controlled trials (RCTs) that compared different interventions used for maintaining surgically induced remission in people with CD who were in postsurgical remission. Participants had to have received maintenance treatment for at least three months. We excluded studies assessing enteral diet, diet manipulation, herbal medicine, and nutritional supplementation.

#### Data collection and analysis

Two review authors independently selected relevant studies, extracted data, and assessed the risk of bias. Any disagreements were resolved by discussion or by arbitration of a third review author when necessary. We conducted a network meta-analysis (NMA) using a Bayesian approach through Markov Chain Monte Carlo (MCMC) simulation. For the pairwise comparisons carried out in Review Manager 5, we calculated risk ratios (RR) with their corresponding 95% confidence intervals (95% CI). For the NMA, we presented hazard ratios (HR) with corresponding 95% credible intervals (95% CrI) and reported ranking probabilities for each intervention. For the NMA, we focused on three main outcomes: clinical relapse, endoscopic relapse, and withdrawals due to adverse events. Data were insufficient to assess time to relapse and histologic relapse. Adverse events and serious adverse events were not sufficiently or objectively reported to permit an NMA. We used CINEMA (Confidence in Network Meta-Analysis) methods to evaluate our confidence in the findings within networks, and GRADE for entire networks.

#### Main results

We included 35 RCTs (3249 participants) in the review. The average age of study participants ranged between 33.6 and 38.8 years. Risk of bias was high in 18 studies, low in four studies, and unclear in 13 studies. Of the 35 included RCTs, 26 studies (2581 participants; 9 interventions) were considered eligible for inclusion in the NMA. The interventions studied included 5-aminosalicylic acid (5-ASA), adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine, and a combination of sulfasalazine and prednisolone. This resulted in 30 direct contrasts, which informed 102 mixed-treatment contrasts.

The evidence for the clinical relapse network (21 studies; 2245 participants) and endoscopic relapse (12 studies; 1128 participants) were of low certainty while the evidence for withdrawal due to adverse events (15 studies; 1498 participants) was of very low certainty. This assessment was due to high risk of bias in most of the studies, inconsistency, and imprecision across networks. We mainly judged individual contrasts as of low or very low certainty, except 5-ASA versus placebo, the evidence for which was judged as of moderate certainty.

We ranked the treatments based on effectiveness and the certainty of the evidence. For clinical relapse, the five most highly ranked treatments were adalimumab, infliximab, budesonide, 5-ASA, and purine analogues. We found some evidence that adalimumab (HR 0.11, 95% Crl 0.02 to 0.33; low-certainty evidence) and 5-ASA may reduce the probability of clinical relapse compared to placebo (HR 0.69, 95% Crl 0.53 to 0.87; moderate-certainty evidence). However, budesonide may not be effective in preventing clinical relapse (HR 0.66, 95% Crl 0.27 to 1.34; low-certainty evidence). We are less confident about the effectiveness of infliximab (HR 0.36, 95% Crl 0.02 to 1.74; very low-certainty evidence) and purine analogues (HR 0.75, 95% Crl 0.55 to 1.00; low-certainty evidence). It was unclear whether the other interventions reduced the probability of a clinical relapse, as the certainty of the evidence was very low.

Due to high risk of bias and limited data across the network, we are uncertain about the effectiveness of interventions for preventing endoscopic relapse. Whilst there might be some evidence of prevention of endoscopic relapse with adalimumab (HR 0.10, 95% CrI 0.01 to 0.32; low-certainty evidence), no other intervention studied appeared to be effective.

Due to high risk of bias and limited data across the network, we are uncertain about the effectiveness of interventions for preventing withdrawal due to adverse events. Withdrawal due to adverse events appeared to be least likely with sulfasalazine (HR 1.96, 95% Crl 0.00 to 8.90; very low-certainty evidence) and most likely with antibiotics (HR 53.92, 95% Crl 0.43 to 259.80; very low-certainty evidence). When considering the network as a whole, two adverse events leading to study withdrawal (i.e. pancreatitis and leukopenia) occurred in more than 1% of participants treated with an intervention. Pancreatitis occurred in 2.8% (11/399) of purine analogue participants compared to 0.17% (2/1210) of all other groups studied. Leukopenia occurred in 2.5% (10/399) of purine analogue participants compared to 0.08% (1/1210) of all other groups studied.

#### Authors' conclusions

Due to low-certainty evidence in the networks, we are unable to draw conclusions on which treatment is most effective for preventing clinical relapse and endoscopic relapse. Evidence on the safety of the interventions was inconclusive, however cases of pancreatitis and leukopenia from purine analogues were evident in the studies. Larger trials are needed to further understand the effect of the interventions on endoscopic relapse.

## PLAIN LANGUAGE SUMMARY

#### Interventions for maintaining surgically included remission in Crohn's disease

#### What is the aim of this review?

The aim of this Cochrane Review was to find out which drugs are most effective for maintaining remission in people with Crohn's disease who have undergone surgery to achieve remission. We collected and analysed all relevant studies to answer this question. We examined these studies using a method known as network meta-analysis (NMA) in order to compare and rank all the treatments in terms of clinical relapse, endoscopic relapse and safety.

#### What was studied in the review?

Crohn's disease is a chronic disease of the gut. It is known to change from periods when people experience a flare-up of the disease (relapse) to periods of good health (remission). Symptoms include abdominal pain, diarrhoea and weight loss. People with Crohn's disease may undergo surgery to remove diseased parts of their gut and achieve remission. However, their symptoms return after a while. Different drugs can be given to ensure that people with Crohn's disease remain in remission for as long as possible. These drugs include mesalazine, antibiotics, corticosteroids, and adalimumab, amongst others. Whilst these drugs have been known to reduce inflammation (pain and swelling) in the gut, side effects can occur with their use. We attempted to find out which treatments are the safest and most effective for maintaining remission in people with Crohn's disease after surgery.

#### How up-to-date is the review?

We searched for studies published up to 15 January 2019.

#### What are the main results of the review?

We included 35 relevant trials, which were published between 1976 and 2018. The studies included a total of 3249 participants who were mostly adults. Our NMA included 26 studies (2581 participants) and compared nine groups of treatments such as 5-aminosalicylic acid, adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine, and a combination of sulfasalazine and prednisolone, which are used in preventing relapse after surgery in people with Crohn's disease. Adalimumab may reduce the chance of clinical relapse compared with placebo (dummy treatment). 5-aminosalicylic acid probably reduces the chance of clinical relapse compared with placebo. Budesonide may not be effective in preventing clinical relapse. The entire network evidence is of low certainty due to the small number of participants included in the studies and high risk of bias. This means that are confidence in these results is limited. Research to understand the effect of the treatments on endoscopic relapse and safety was limited, however cases of pancreatitis and leukopenia were reported in participants who received purine analogues.

#### Key messages

We uncertain about which treatments are most effective in preventing postoperative relapse in Crohn's disease. Alhough there is limited research on the harms (side effects) of these treatments, there were reported instances of pancreatitis and leukopenia in participants who received purine analogues.

# SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

# Estimates of effects, credible intervals, and certainty of the evidence for maintenance of surgically induced remission in Crohn's disease

Patient or population: surgically induced remission in Crohn's disease

Settings: hospital, home, or combination, range of follow-up between 3 and 36 months

Intervention: 5-ASA, adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine, sulfasalazine + prednisolone Comparison: placebo

Outcomes Effects and confidence in the estimate of effects*						of	evi-	Interpretation
Adalimumab	Infliximab	Budesonide	5-ASA	Purine analogues				
onths								
HR 0.11 (0.02 to 0. 33) Network estimate	HR 0.36 (0.02 to 1. 74) Network estimate	HR 0.66 (0.27 to 1. 34) Network estimate	HR 0.69 (0.53 to 0. 87) Network estimate	HR 0.75 (0.55 to 1. 00) Network estimate	⊕⊕⊖⊖ low <sup>1,2</sup> Certainty o	of	evi-	Effect estimates of the best 5 interven- tions have been pre- sented
Rank** 1 (1 to 2)	Rank 2 (1 to 10)	Rank 3 (2 to 10)	Rank 4 (2 to 7)	Rank 5 (3 to 8)	dence of work	the	net-	
onths								
HR 0.10 (0.01 to 0. 32) Network estimate	HR 0.24 (0.01 to 1. 20) Network estimate	Not estimated	HR 1.22 (0.61 to 2. 18) Network estimate	HR 0.85 (0.33 to 1. 61) Network estimate	$\oplus \oplus \bigcirc \bigcirc$ low <sup>1,2</sup> Certainty	of	evi-	Interven- tions reported here were chosen based on the intervention reported for clinical relapse
Rank 1 (1 to 2)	Rank 2 (1 to 6)	Not estimated	Rank 6 (3 to 7)	Rank 4 (4 to 7)	dence of work	the	net-	
	Effects and confiden Adalimumab onths HR 0.11 (0.02 to 0. 33) Network estimate Rank** 1 (1 to 2) Network estimate HR 0.10 (0.01 to 0. 32) Network estimate Rank 1 (1 to 2)	Effects and confidence in the estimate ofAdalimumabInfliximabAdalimumabInfliximabonthsInfliximabHR 0.11 (0.02 to 0. 33)HR 0.36 (0.02 to 1. 74)Network estimateNetwork estimateRank** 1 (1 to 2)Rank 2 (1 to 10)onthsInfliximateHR 0.10 (0.01 to 0. 32)HR 0.24 (0.01 to 1. 20)Network estimateNetwork estimateRank 1 (1 to 2)Rank 2 (1 to 6)	Effects and confidence in the estimate of effects*AdalimumabInfliximabBudesonideanthsSudesonideSudesonideHR 0.11 (0.02 to 0. 33) Network estimateHR 0.36 (0.02 to 1. 74) Network estimateHR 0.66 (0.27 to 1. 34) Network estimateRank** 1 (1 to 2)Rank 2 (1 to 10)Rank 3 (2 to 10)HR 0.10 (0.01 to 0. 32) Network estimateHR 0.24 (0.01 to 1. 20) Network estimateNot estimatedRank 1 (1 to 2)Rank 2 (1 to 6)Not estimated	Effects and confidence in the estimate of effects*AdalimumabInfliximabBudesonide5-ASAAdalimumabInfliximabBudesonide5-ASAonths	Effects and confidence in the estimate of effects*AdalimumabInfliximabBudesonide5-ASAPurine analoguesonths	Effects and confiderer in the estimate of effects*       Certainty dence of genee         Adalimumab       Infliximab       Budesonide       5-ASA       Purine analogues         onths       onths       Network estimate       Network es	Effects and confide-results in the estimate of effects*       Certainty of dence       Certainty of dence       of dence         Adalimumab       Infliximab       Budesonide       5-ASA       Purine analogues       V       V         Anths       HR 0.11 (0.02 to 0. HR 0.36 (0.02 to 1. 34)       HR 0.66 (0.27 to 1. HR 0.69 (0.53 to 0. HR 0.75 (0.55 to 1. 34)       \$\Phi \Phi \Phi \Phi \Phi \Phi \Phi \Phi	Effects and confidence in the estimate of effects*       Certainty of evidence         Adalimumab       Infliximab       Budesonide       5-ASA       Purine analogues         Anths       HR 0.11 (0.02 to 0. HR 0.36 (0.02 to 1. 34)       HR 0.66 (0.27 to 1. 44)       HR 0.69 (0.53 to 0. 410, 55 (0.55 to 1. 00)       Image: Certainty of evidence         Network estimate       Network estimate       Network estimate       Network estimate       Network estimate       Network estimate         Rank**       Rank       Rank       Rank       Rank       Rank       Rank       Rank         32)       20       Network estimate       Not estimated       HR 1.22 (0.61 to 2. 180, 0.33 to 1. 180, 0.33 to 1. 180, 0.33 to 1. 180, 0.33 to 1. 180, 0.31 to 1. 180, 0.41 to 1.

Follow-up: 3 to 36 months

Placebo Co tor	compara-	HR 11.74 (0.12 to 55.06)	HR6.37 (9.14E-04 to 21.74) Network estimate	HR 1.64 (0.17 to 6. 19) Network estimate	HR 1.19 (0.39 to 3. 14) Network estimate	HR 2.51 (0.79 to 7. 35) Network estimate	⊕⊖⊖⊖ very low <sup>2,3</sup> Certainty of e	Interventions were chosen based on the ri- interventions con-
Rank 4 (2 to 7)		7 (1 to 9)	Rank 2 (1 to 9)	Rank 4 (1 to 9)	Rank 4 (2 to 7)	Rank 7 (4 to 9)	dence of the ne work	t- sidered beneficial in terms of clinical re- lapse

\* Estimates are reported as hazard ratio (HR), credible interval. Results are expressed in credible intervals as opposed to confidence intervals as a Bayesian analysis has been conducted

\*\* Median rank and credible intervals for efficacy outcome are presented. Rank statistics are defined as the probabilities that a treatment out of n treatments in a network meta-analysis is the best, the second, the third, and so on, effective treatment

5-ASA: 5-aminosalicylic acid

# GRADE Working Group grades of evidence

High certainty: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low certainty: We are very uncertain about the estimate.

<sup>1</sup>Downgraded two levels: once for high risk of bias and once for imprecision.

<sup>2</sup>There was no significant intransitivity, with comparable distribution of plausible effect modifiers across trials of different

interventions for maintenance of remission.

<sup>3</sup>Downgraded three levels: once for high risk of bias and twice for imprecision.

ы

# BACKGROUND

#### **Description of the condition**

Crohn's disease is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. There is no cure for the disease, so management strategies are instead focused on induction and maintenance of remission, as well as supporting the many other symptoms that impact those affected by the condition. Approximately 75% of people with Crohn's disease will eventually undergo surgical resection (Bernell 2000), with recent studies suggesting a rate of 3.8 operations per 100 person-years (Ma 2017), and this can induce remission. However, endoscopic recurrence of disease has been reported to be as high as 61% six months postsurgery (Orlando 2014), and clinical relapse rates have been reported to range from 20% to 86% at five years postsurgery (Gklavas 2017; Rutgeerts 2002).

Given these high relapse rates, many studies have attempted to identify potential methods of prolonging postoperative remission, but there is no standard therapy for the prevention of postoperative recurrence in Crohn's disease (Hanauer 2001; NICE 2012). A number of agents have been studied, but considerable uncertainty remains as to the efficacy of such treatments.

#### **Description of the intervention**

Corticosteroids, the mainstay of treatment of acute exacerbations, are not effective for maintenance of remission in Crohn's disease (Steinhart 2003), and chronic use is limited by numerous adverse events.

Probiotics and budesonide do not appear to provide any benefit for maintenance of surgically induced remission (Doherty 2009). Nitroimidazole antibiotics may reduce relapse after surgery, although this benefit did not remain significant on sensitivity analysis, and the antibiotics were not well tolerated and were associated with a higher risk of serious adverse events (Doherty 2009).

5-aminosalicylates are a group of compounds that have long been used in inflammatory bowel disease (IBD). The first 5-aminosalicylate agent used in clinical practice was sulfasalazine, which is composed of sulfapyridine linked by an azo bond to 5-aminosalicylic acid (5-ASA). Sulfasalazine was first used in the 1940s as a treatment for arthritis (Svartz 1942). Improvement in gastrointestinal symptoms was noted in patients who had concurrent ulcerative colitis, leading to further use of this agent in IBD. 5aminosalicylic acid has been shown to be safe and may be effective for maintenance of postsurgical remission when compared with placebo (Gjuladin-Hellon 2019a).

Purine analogues, such as azathioprine (AZA) and 6-mercaptopurine (6-MP), have also been shown to be effective when compared with placebo (Gjuladin-Hellon 2019b). However, on review the majority of studies compared these agents with 5-ASA and failed to demonstrate superiority, with more issues leading to withdrawal of therapy noted (Gjuladin-Hellon 2019b). These reviews led the National Institute for Health and Care Excellence (NICE) in the UK to change their guidance for maintenance of postsurgical remission in Crohn's disease to include the option of 5-ASA agents (NICE 2012). Tumour necrosis factor-alpha (TNF- $\alpha$ ) antagonists may provide a benefit in postoperative Crohn's disease (Doherty 2009; Gjuladin-Hellon 2019a), but issues of cost and safety exist (Di Sario 2016).

#### How the intervention might work

Corticosteroids, budesonide, and 5-ASA agents all act as anti-inflammatory agents. Azathioprine is a prodrug that is non-enzymatically degraded to 6-MP, which in turn is metabolised to the active component 6-thioguanine nucleotide (6-TGN). 6-thioguanine nucleotide is thought to work by inhibiting the proliferation of T and B lymphocytes and reducing the numbers of cytotoxic T cells and plasma cells. Some trial data suggest that neutrophil count is a predictor of induction and maintenance of remission in Crohn's disease (Colonna 1994), which may suggest the mechanism of action, although this is not well understood. The major limiting factor for the long-term use of AZA has been the occurrence of adverse events leading to withdrawal of therapy in approximately 10% of patients (Hafraoui 2002), with dose-dependent and idiosyncratic adverse events occurring. Tumour necrosis factor-alpha antagonists are monoclonal antibodies directed towards TNF- $\alpha$ . Although TNF- $\alpha$  antagonists have been the benchmark biologic therapies for more than a decade, the exact mechanism of action is still incompletely understood (Levin 2016). The mechanism by which probiotics and antibiotics may act is poorly understood. Due to the role that dysbiosis plays in IBD, it has been hypothesised that there is benefit in trying to restore the indigenous flora. Several observations, both in humans and animal models, emphasised the importance of bacterial flora in IBD pathogenesis, justifying the current interest in antibiotic and probiotic therapies aimed at the manipulation of enteric flora (Cui 2004).

#### Why it is important to do this review

Given the impact of surgical resection on Crohn's disease patients, clear evidence regarding management strategies to maintain a disease-free state postsurgically is vital for both patients and clinicians. Many researchers have argued that the state of the gut postsurgery is massively different from a histological and clinical standpoint (Gordon 2017), and previous reviews have found that some standard treatments work in this setting and some do not (Gjuladin-Hellon 2019a; Gjuladin-Hellon 2019b). With a wide range of strategies available and no clear hierarchy regarding the efficacy of these treatments, evidence-based decision making is currently not possible. Additionally, given the variability in ad-

verse event profiles and tolerability of the agents being considered, clarification of these issues was needed.

Comparative efficacy and safety data are best achieved by headto-head trials. However, multiple trials of this sort will be needed, and attracting funding to complete these trials may be difficult and take significant time, if these trials are conducted at all. Thus far, there are limited active head-to-head trials comparing treatments for maintaining postsurgical remission in Crohn's disease. An alternative strategy for obtaining comparative data is to conduct a network meta-analysis (NMA) in which multiple treatments are compared using both direct comparisons of interventions within randomised controlled trials (RCTs) and indirect comparisons across trials based on a common comparator (i.e. placebo). In other words, if compound A is compared with compound B in one trial, and the same compound B is compared with compound C in another trial, indirect information can be obtained for the comparison of compound A to compound C using this technique. After publication of the protocol for this review (Clegg 2018), NICE in the UK convened a similar scoped update in this area which has now been published (NICE 2019). However, the NICE guideline is limited to studies that maintained remission for 12 months, unlike the portfolio of IBD maintenance Cochrane Reviews. The NICE guidelines also include studies that do not meet the transitivity assumptions of this Cochrane Review. These factors are bound to result in differences in conclusions. It is also key to recognise that the NICE guideline also includes cost as a key determinate of its recommendations. This will also lead to differences in conclusions between their findings and this review. It was therefore key to complete a Cochrane NMA in this area.

# OBJECTIVES

To assess the effects and harms of interventions for the maintenance of surgically induced remission in Crohn's disease and rank the treatments in order of effectiveness.

# METHODS

#### Criteria for considering studies for this review

#### **Types of studies**

We included RCTs irrespective of language or year of publication. We excluded studies that used quasi-random methods of allocation (e.g. date of birth).

#### **Types of participants**

We considered for inclusion trials enrolling participants of any age with Crohn's disease as defined by conventional clinical, radiological, or endoscopic criteria.

Participants had to be in remission as defined by a recognised Crohn's disease activity index or endoscopy following surgery on recruitment, or to have undergone a surgical resection (as defined by the authors of the primary studies) no more than six months prior to starting maintenance treatment. Studies that recruited participants in any sort of relapse (clinical, endoscopic, or histologic, etc.) were excluded (with the exception of Reinisch 2010, which included some participants with endoscopic recurrence). We only included studies with a mixed population (both medically and surgically induced remission) provided outcome data for participants with surgically induced remission were reported separately.

#### **Types of interventions**

We considered for inclusion trials comparing oral or topical corticosteroids, 5-ASA agents, purine analogues, TNF- $\alpha$  antagonists, other classes of biologic agents, probiotics, antibiotics, or any other pharmaceutical intervention with no treatment, placebo, or another active treatment. For studies to be included, participants had to have received therapy for a minimum period of three months. We included studies where participants received concomitant treatments that are not routinely administered for the purpose of maintaining remission (such as antidiarrhoeal medication, antibiotics, or tapered steroids). We did not include dose optimisation studies. Given the scope of overlapping and ongoing reviews, we did not consider trials assessing enteral diet, diet manipulation, herbal medicine, or nutritional supplementation. We used the term 'comparison' to mean two interventions compared in a single study, and the term 'contrast' to mean two interventions compared across all studies with that comparison. 'Combination treatments' involved two or more active treatments that are used in inducing or maintaining remission in people with Crohn's disease.

#### Types of outcome measures

#### **Primary outcomes**

The primary outcome was clinical relapse. We regarded the following as providing the most relevant measures of outcome for the analyses.

1) The proportion of participants who failed to maintain clinical remission, as defined by the original studies.

2) The time to relapse (survival data: study-level data reported as a hazard ratio (HR) with standard error (SE)).

We accepted the authors' definitions of what constitutes a clinical relapse.

#### Secondary outcomes

1) Endoscopic relapse, as defined by the original studies.

2) Histologic relapse, as defined by the original studies.

3) Adverse events (as defined by FDA 2018. We also noted where studies failed to provide sufficient information and simply reported outcome as 'adverse event').

4) Serious adverse events (as defined by FDA 2018. We also noted where studies failed to provide sufficient information and simply reported outcome as 'serious adverse event').

5) Withdrawal due to adverse events.

We reported outcome measures at the last time point available (assumed to be at the end of follow-up if not specified) and the time point specified in the methods as being of primary interest (if this differed from the last time point available). However, we also indicated when studies reported outcomes at other time points.

#### Search methods for identification of studies

#### **Electronic searching**

We searched the following electronic databases from inception to January 2019 for relevant studies:

1. Cochrane IBD Group Specialized Register (to 31 January 2019)

- 2. CENTRAL (the Cochrane Library 2018, Issue 1);
- 3. MEDLINE (1946 to 31 January 2019);
- 4. Embase (1980 to 31 January 2019);

5. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov/); and

6. World Health Organization International Clinical Trials Registry Platform ( apps.who.int/trialsearch/).

The search strategy was not limited by language (see Appendix 1).

#### Reference searching

We inspected the references of all identified studies and relevant systematic reviews for additional trials.

#### Abstracts of major gastroenterology meetings

We performed a manual search of abstracts submitted to major gastroenterology meetings (2015 to 2018) for the following journals in order to identify trials that may have not been published in full at the time of the review:

1. Gastroenterology (American Gastroenterological

Association);

2. Gut (British Society of Gastroenterology);

3. *American Journal of Gastroenterology* (American College of Gastroenterology);

4. *Canadian Journal of Gastroenterology* (Canadian Association of Gastroenterology);

5. Journal of Pediatric Gastroenterology and Nutrition (European Society for Paediatric Gastroenterology, Hepatology and Nutrition); and

6. *Journal of Pediatric Gastroenterology and Nutrition* (North American Society of Pediatric Gastroenterology, Hepatology and Nutrition).

#### Personal contacts

We contacted leaders in the field (Hans Herfarth) in an attempt to identify additional studies, but received no reply.

#### Drug companies

We contacted Danone for additional data.

#### Data collection and analysis

We carried out data collection and analysis according to methods stated in the published protocol (Clegg 2018), which were based on the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

#### Selection of studies

Two review authors independently screened the titles and abstracts of studies located by the search and identified potentially relevant papers, which were retrieved in full text. The review authors independently assessed the eligibility of the full texts using the abovementioned inclusion criteria. Any disagreements were resolved by discussion and consensus or by consulting a third review author if necessary. We contacted study authors for clarification regarding study eligibility where required. Studies with multiple publications were included only once, however we extracted relevant data from all the reports.

#### Data extraction and management

We developed a data extraction form that we used to extract information on relevant features and results of included studies. Two review authors independently extracted and recorded data on the predefined checklist. We extracted data on the following items:

• characteristics of participants: age, sex, disease distribution, disease duration, disease activity index;

• total number of participants originally assigned to each treatment group;

- intervention: type and dose of agent;
- control: placebo, other drugs;
- concurrent medications; and
- outcomes: time of assessment, length of follow-up, type of Crohn's disease activity index (CDAI) used, definitions of remission and relapse, site of surgery, relapse rates, adverse events.

#### Assessment of risk of bias in included studies

Two review authors independently assessed bias using the Cochrane 'Risk of bias' tool (Higgins 2011). We assessed the following study features:

- random sequence generation;
- allocation concealment;
- blinding of participants and personnel;
- blinding of outcome assessment;
- completeness of outcome data;
- selective reporting; and
- other sources of bias.

We rated each of these factors as low, high, or unclear risk of bias. After carrying out 'Risk of bias' assessment at study level, we then used the CINeMA (Confidence in Network Meta-Analysis) web tool to calculate the percentage contribution of each direct contrast to each network estimate (CINeMA 2017). We also calculated the overall risk of bias for in the entire network. In addition, we produced an all-domain risk of bias for each study as shown in Norman 2018 by assigning four ratings: low, unclear, high and very high. The four ratings were defined as:

• 'very high' - two or more key domains with a high risk of bias or a single domain with very high levels of uncertainty

- 'high' high risk of bias for any one domain;
- 'low' low risk of bias for each of the key domains;
- 'unclear' low risk of bias in all but one domain with insufficient information.

We included it in the risk of bias table for each study.

#### Measures of treatment effect

We calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI) for dichotomous outcomes using a random-effects model. We intended to calculate the mean difference (MD) and corresponding 95% CI for continuous outcomes measured using the same units, and standardised mean differences (SMD) with corresponding 95% CI for continuous outcomes where different scales were used to evaluate the same outcome. We interpreted SMDs according to Cohen 1988: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. The treatment effects of pairwise comparisons were summarised using RR estimates and associated two-sided 95% CIs. Hazard ratios (HRs) and 95% credible intervals (95% CrIs) were calculated for the NMA. Effect estimates and credible intervals with a high number of zeros were reported as exponents. For example 0.0000345 = 3.45E-05; 345000 = 3.45E+05.

#### Unit of analysis issues

Given the nature of the interventions, we assumed that only simple parallel-group design trials would be available, with no cluster-randomised trials. If cluster-randomised trials are identified in future updates, these will be included and, if unit of analysis issues are identified (e.g. randomisation and analysis at different units), the sample sizes or standard errors will be adjusted appropriately (Higgins 2011). Where cross-over trials become available in future, these will be included, and the effect estimates from the first period prior to cross-over included in the meta-analysis. Where outcomes were reported at several time points, analyses were undertaken at the single time point that was consistently reported by the trials and at the longest point of follow-up. For our NMA, we ensured that the effects of correlated effect estimates were accounted for using appropriate methods (see Data synthesis).

#### Dealing with missing data

Where dichotomous outcome data were missing, we used the intention-to-treat principle (ITT) on the assumption that all participants lost to follow-up were treatment failures. We considered this approach appropriate for the clinical and endoscopic relapse outcomes.

#### Assessment of heterogeneity

We assessed heterogeneity and inconsistency to ensure the validity of the analysis. We initially assessed heterogeneity through visual inspection of forest plots and the calculation of the Chi<sup>2</sup> and I<sup>2</sup> statistics (Borenstein 2009). For the NMA, we intended to use the between-study standard deviation to assess heterogeneity, with a threshold of 0.5 indicating heterogeneity (Higgins 2011). We assessed consistency within the analysis through comparison of the estimates of treatment effect for each comparison from the direct and indirect pairwise meta-analyses for the closed loops within the NMA, using a node-splitting approach (Cooper 2009; Dias 2010). It is important that the direct and indirect evidence for the same comparisons agree, as joint analysis on an inconsistent network can be misleading. Possible explanations for heterogeneity were to be examined where sufficient data were available, including factors such as participant characteristics (e.g. age, sex), condition severity, treatment type and dose, healthcare system, and country. Where appropriate, these factors would have been investigated further through subgroup analyses and meta-regression (Borenstein 2009). We explored possible causes of methodological heterogeneity through sensitivity analyses where sufficient data were available (Sutton 2000). This included assessing the effects of studies that may be affected by such factors as risk of bias associated with allocation concealment, high loss to follow-up, or lack of blinding in assessment of outcomes.

#### Assessment of reporting biases

We investigated potential publication bias using funnel plots (trial effects versus trial size). We also scrutinised studies to assess the impact of funding bias and small-study effect.

#### Data synthesis

We synthesised the studies through a narrative review with tabulation of results of included studies. Where possible, we further synthesised treatment effects for all comparisons and outcomes through meta-analyses, with the approach taken dependent on the outcome assessed and the data available (Borenstein 2009). Where the outcomes represented time-to-event data (e.g. time to relapse), the (log) HR with 95% CI or 95% CrI was used as the summary measure, adopting the approaches suggested by Sutton and colleagues given the available data (Egger 2001; Parmar 1998; Sutton 2000).

Different approaches were taken for the meta-analysis. Firstly, direct comparisons of treatment effects were conducted through pairwise meta-analyses. Secondly, the opportunity for estimating an NMA was assessed to compare different interventions through both direct and indirect evidence within connected networks of trials (Spiegelhalter 2004; Welton 2012). Only studies that met the transitivity assumption were included in the NMA. Transitivity is an assumption that an intervention effect for a direct comparison will be equivalent to the same intervention effect for an indirect comparison. Trials that offered participants non-randomised active treatments did not meet the transitivity assumption and were not included in the NMA. The use of direct and indirect evidence can strengthen inferences about the relative efficacy of the interventions being compared, whether due to a lack of, or sparse, evidence comparing the different interventions. Importantly, NMAs allow for the comparison of multiple interventions simultaneously and for an estimation of the rank order based on efficacy (Welton 2012). The network for the models was presented graphically through network diagrams, allowing assessment of both the structure and extent of the evidence available for the different comparisons. Where heterogeneity was identified, its possible causes were to be investigated through the inclusion of participant and study level characteristics as covariate within meta-regression analyses. The meta-regression included factors such as baseline risk (surrogate measure of participant characteristics) and length of followup (Gjuladin-Hellon 2019a; Gjuladin-Hellon 2019b), adopting the approach outlined by Achana and colleagues (Achana 2013). Where multiple active treatment arms of the same class of drug or different doses of the same drug are included, comparisons may be correlated, influencing the outcome measure. Such correlations were accounted for by assuming that the treatment effects from multi-arm studies were from a multivariate normal distribution, decomposing it into a series of conditional univariate distributions (Warren 2014). Some interventions were considered sufficiently similar to have a 'class effect', with meta-analyses 'lumping' these interventions together. Aminosalicylates were split into two separate interventions: sulfasalazine and 5-ASA (e.g. mesalazine, etc.), whilst azathioprine and 6-MP were lumped together. As pooling treatments that may be heterogeneous does not meet the consistency assumption, with the potential to cause conflict between the direct and indirect evidence, NMAs for the individual and

classes of interventions were estimated where evidence allowed, and the estimates compared (Welton 2012). Where interventions routinely used for maintaining remission are administered as concomitant treatments, such studies were excluded from the network.

All NMAs took a Bayesian approach through Markov Chain Monte Carlo (MCMC) simulation. The parameters considered in the models were the treatment effect of an intervention compared with other interventions, with the likelihood function dependent on the outcome used. As the primary outcome (i.e. clinical relapse) represents the number of events that occur within a patient population allocated to a particular treatment, a binomial distribution was assumed for the likelihood and a clog-log link was used for the linear predictor to take time into account. Trial specific log-HRs were assumed to be from the normal distribution. Different prior distributions were to be used for the scale parameters (e.g. a uniform distribution for the base case and halfnormal and inverse gamma distributions for sensitivity analyses). Vague priors were used for the treatment effects in the different models. All models were estimated using two chains starting with different initial values. Convergence was assessed through visual inspection of the Brooks-Gelman-Rubin diagnostic, with convergence assumed to have occurred when the ratio of between- and within-chain variability was stable around one. Varying iterations and burn-in periods were used to ensure convergence, with burnin periods discarded from the analysis. Autocorrelation plots were examined, with different rates of thinning applied to eliminate or reduce its effects where present. We ran all the models based on 100,000 iterations for 2 independent chains after a burn-in of 100,000.

Adequacy of the fit of the models was assessed through a comparison of the residual deviance for the models with the number of unconstrained data points available, with an adequate fit when both closely matched. Model selection and overall goodness of fit were assessed through deviance information criteria (DIC), with a threshold of a difference of three to five points considered significant (lowest DIC most appropriate fit) (Spiegelhalter 2002; Welton 2012). The adequacy of the approach used for the NMA was meant to be assessed using a standard critical appraisal tool (Jansen 2014). Where the threshold of difference was not met, we used the random-effects model to obtain a more conservative interpretation.

We conducted pairwise meta-analyses of direct comparisons using RevMan 5 Version 5.3. (Review Manager 2014) and Stata 2017 software (Stata 2017; Egger 2001; Higgins 2011), whilst NMAs were estimated using the WinBUGS software (version 1.4.3) (MRC Biostatistics Unit, Cambridge, UK) (Lunn 2000).

#### Subgroup analysis and investigation of heterogeneity

As previously noted, where heterogeneity was identified its possible causes were to be investigated through the inclusion of participant and study level characteristics as covariates within a meta-regres-

sion analysis. The meta-regression was to include factors such as baseline risk (surrogate measure of participant characteristics) and length of follow-up (Gjuladin-Hellon 2019a; Gjuladin-Hellon 2019b), adopting the approach outlined by Achana 2013. We did not perform meta-regression due to the small number of trials informing the direct comparisons within the network.

#### Assessment of statistical heterogeneity

We used the I<sup>2</sup> statistic to carry out a statistical assessment of the disagreement between estimates within each pairwise comparison (Higgins 2011). We also visually assessed the overlap of the confidence intervals and the variability in the point estimates. We interpreted I<sup>2</sup> thresholds as follows.

- < 50%: low
- 50 to 75%: moderate
- > 75%: large

#### Assessment of statistical inconsistency

We also assessed whether there were any disagreements between direct and indirect estimates or between indirect estimates through different intermediate treatments in the network. This was done for single loops of evidence within the network and for the network as a whole (Dias 2010; Salanti 2014).

#### Local approaches to evaluating inconsistency

The first stage involved separately synthesising the evidence for each pairwise contrast. This method tested the consistency assumption for each closed loop of the network separately, then the magnitude of the inconsistency factors and their confidence intervals were used to make inferences about the presence of inconsistency in each loop. This was followed by the node-splitting approach to compare direct and indirect relative treatment effects. For instance, a direct estimate of C versus B is compared with the indirect estimate from AB versus AC (Dias 2010). A test of the null hypothesis that there is no inconsistency is obtained using a Z-test. One test was carried out for each treatment comparison. The ratio of odds ratios with confidence interval was calculated each time. A confidence interval excluding 1 indicated statistically significant inconsistency. These were automated in the CINeMA web tool.

#### Global approaches to evaluating inconsistency

Using the CINeMA web tool, we also conducted a global assessment of inconsistency in the network using a Chi<sup>2</sup> test. This was useful in assessing whether the assumption of consistency holds for the entire network. Treatment comparisons that take  $\geq$  90% of the information from direct evidence are unlikely to be of concern for inconsistency. For comparisons with at least 10% of information derived from indirect evidence, a P value < 0.01, 0.01 to < 0.1, and > 0.1 was interpreted as major, some, and no concerns,

respectively. Given that the CINeMA web tool had not been fully adapted for the Bayesian framework at the time of preparing this review, we made adjustments to some interpretations that were not consistent with the results obtained from WinBUGS.

#### Investigation of heterogeneity and inconsistency

If sufficient data become available in future updates of this review, we will perform subgroup analyses assessing the effect of time since surgery ( $\leq$  30 days versus > 30 days) and type of remission (clinical versus endoscopic at the point of recruitment) on the outcomes. We also planned a subgroup analysis on duration of follow-up, however this was no longer deemed necessary as the clog-log link in the simulation models was designed to take time into consideration (Data synthesis).

#### Sensitivity analysis

We examined methodological heterogeneity through sensitivity analysis, including such components of risk of bias as allocation concealment, loss to follow-up, or blinding of outcome assessment. We also excluded studies that were outliers in terms of dose of intervention, definition of outcome, direction or size of treatment effect, or those identified as inconsistent by inconsistency testing.

# Quality assessment of evidence generated from the network meta-analysis

We assessed the certainty of the evidence using GRADE ( Schünemann 2011a; Schünemann 2011b). We applied this methodology to the NMA by focusing on the approach of Salanti 2014. This was carried out using GRADEpro GDT (GRADEpro 2015) and the CINeMA web tool where possible (CINeMA 2017). The CINeMA web tool assesses NMA evidence based on the five GRADE domains listed below, and downgrades pairwise, mixed, and indirect evidence depending on whether there are major, some, or no concerns. We assessed the quality of the evidence in two main ways: firstly, for each contrast, and secondly, for the network as a whole, in order to assess the quality of the ranking order. We assessed individual GRADE factors as follows.

• Risk of bias: we assessed overall risk of bias for each contrast and also for the entire network.

• Indirectness: this relates to whether the population, intervention, and outcome in the studies differ from those we have proposed (see Criteria for considering studies for this review) as well as intransitivity.

• Inconsistency: at the level of the contrast, we considered both heterogeneity in the direct evidence for that comparison and inconsistency related to different routes of analysis for the comparison (e.g. direct versus indirect evidence and two-arm versus three-arm trials). The latter was conducted using a nodesplitting approach (Dias 2010). As well as assessing the metaanalyses of the direct evidence for inconsistency, we considered

the NMA predictive intervals for that comparison in relation to GRADE 'default' minimum important differences (0.75 and 1.25) (Guyatt 2011), using CINeMA. We note that inconsistency can only be assessed where there is both direct and indirect evidence. We assessed GRADE inconsistency as serious limitations if there was heterogeneity in the direct estimate or inconsistency in the network with respect to that comparison. We assessed the comparison as having very serious limitations if there was severe heterogeneity or severe inconsistency or limitations with both heterogeneity and inconsistency. The review authors arrived at judgements on the magnitude of limitations through discussion. Rationales were described transparently in the review report. At the level of the network, we relied on the DIC estimate of the inconsistency model. Additionally, if several contrasts showed direct and indirect results that would have led to different clinical decisions, we considered inconsistency to be present.

• Imprecision: at the level of the contrast, we assessed imprecision for each pairwise comparison using the GRADE default minimally important difference values of 1.25 and 0.75 for the OR. We also took into account the sample size for the direct evidence informing this contrast, and considered it in relation to the optimal information size.

• Publication bias: was also assessed for each pairwise comparison using standard GRADE; we used the contributions matrix to translate these judgements to the network as a whole.

#### 'Summary of findings' table

We presented the main results on clinical relapse, endoscopic relapse, and withdrawal due to adverse events in 'Summary of findings' tables, reporting the results for a representative set of contrasts, with one row for each intervention versus the reference comparator. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data (Schünemann 2011a). 'Summary of findings' tables also include an overall grading of the evidence using the GRADE approach. We adopted a modified version of the new 'Summary of findings' tables format for NMAs (Yepes-Nuñez 2019).

# RESULTS

## **Description of studies**

#### **Results of the search**

The literature search identified a total of 1678 records through database searching. A total of three additional records were identified from other sources. After removal of duplicates 1161 unique records remained. Examination of the titles and abstracts found 110 records for full-text screening. After assessing the full texts of 110 records, we identified 52 reports of 35 studies, 7 ongoing studies, and 2 studies awaiting classification that met the inclusion criteria and were included in the review. We excluded 49 records for various reasons. The results of the search are presented in the PRISMA flow diagram (Figure 1). Detailed information about these studies is presented in the Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies tables, and summarised below.



Figure I. Study flow diagram.

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## **Included studies**

#### Study design and setting

The included studies were RCTs published between 1976 and 2018. The single-centre RCTs were conducted in Italy (Ardizzone 2004; Armuzzi 2013; Prantera 2002; Savarino 2013; Tursi 2014), the USA (Regueiro 2009, Israel (Scapa 2015), and Japan (Yoshida 2012). The multicentre studies were conducted in different locations in the following countries: Germany (Ewe 1989; Ewe 1999), Belgium (D'Haens 2008; Gossum 2007; Rutgeerts 2005), Canada (Fedorak 2015; McLeod 1995), Spain (Lopez Sanroman 2017; Mañosa 2013), the UK (Mowat 2016), Italy (Brignola 1995; Caprilli 1994; Caprilli 2003), Israel (Chermesh 2007), the USA (Herfarth 2013), and Japan (Fukushima 2018); or as a multinational collaboration of several countries across Europe (Fedorak 2015; Hellers 1999; Lochs 2000; Marteau 2006; Reinisch 2010), Europe and the USA (Hanauer 2004), or Europe, Canada, Australia, and the USA (Regueiro 2016). The trials were conducted in gastroenterology hospitals and medical clinics or centres, Chermesh 2007; Ewe 1989; Ewe 1999; Florent 1996; Lochs 2000; Lopez Sanroman 2017; Marteau 2006; Reinisch 2010; Sutherland 1997; Wenckert 1978, or through a collaboration between university clinics and hospitals or medical centres, Ardizzone 2004; Bergman 1976; Brignola 1995; Caprilli 1994; Caprilli 2003; D'Haens 2008; Fedorak 2015; Fukushima 2018; Gossum 2007; Hanauer 2004; Hellers 1999; Herfarth 2013; Lochs 2000; Mañosa 2013; McLeod 1995; Regueiro 2009; Regueiro 2016; Rutgeerts 2005; Savarino 2013; Tursi 2014; Yoshida 2012, and secondary and tertiary hospitals (Mowat 2016). In four studies the care setting was unclear (Armuzzi 2013; Herfarth 2006; Prantera 2002; Scapa 2015).

#### Participants

The 35 included studies involved a total of 3249 participants, with sample sizes ranging between 20, in Tursi 2014, and 324, in Lochs 2000. The majority of the studies recruited participants within three months of surgery or before hospital discharge, except in Reinisch 2010, where participants were enrolled between 6 and 24 months' postsurgery. The time since operation was not reported in two studies (Mañosa 2013; Sutherland 1997). Investigations were carried out before disease activity was established through generally accepted endoscopic, histological, and/or radiological criteria. However, it is important to note that Reinisch 2010 included participants in subsequent postoperative clinical remission (CDAI < 200), but with signs of moderate to severe endoscopic recurrence. The average age of study participants was between 33.6 years, in Lochs 2000, and 38.8 years, in D'Haens 2008. In 11 stud-

ies participant age was reported as a median (Armuzzi 2013; Bergman 1976; Ewe 1989; Herfarth 2013; Lopez Sanroman 2017; Marteau 2006; Regueiro 2009; Rutgeerts 2005; Savarino 2013; Scapa 2015; Wenckert 1978). All studies were conducted in male and female adults except for three studies (Fedorak 2015; Hellers 1999; Mowat 2016), which based on inclusion criteria appear to have included people who were 16 years and older. None of the studies were conducted on paediatric participants alone.

The use of concomitant treatments was reported in 22 studies. Twenty studies prohibited the use of any Crohn's disease therapy other than the study intervention. Seven of these studies used corticosteroids (Armuzzi 2013; Ewe 1999; Hanauer 2004; Hellers 1999; Lochs 2000; Mañosa 2013; Rutgeerts 2005), which had to be gradually tapered within two to six weeks after surgery. In two studies metronidazole was administered to both intervention arms for the first three months (D'Haens 2008; Lopez Sanroman 2017). Mesalazine as concomitant treatment was administered to both intervention arms for the whole duration of the trial in Yoshida 2012. Two studies permitted the use of concomitant immunomodulators and mesalazine amongst participants who had had these drugs prescribed before surgery as long as the medication dose had been stable 12 weeks before surgery and remained so for the duration of the study (Regueiro 2009; Regueiro 2016). In Tursi 2014 both intervention arms received oral mesalazine for two weeks after surgery. The use of antidiarrhoeal drugs was reported in five studies (Ardizzone 2004; Caprilli 2003; Fedorak 2015; Hellers 1999; Lochs 2000). D'Haens 2008 permitted the use of topical therapy for perianal disease and colestyramine for the treatment of bileacid diarrhoea. Continous use of non-steroidal anti-inflammatory drugs was prohibited, and only occasional use of paracetamol and tramadol was allowed in Savarino 2013. In Mowat 2016 any concomitant medications used were documented, and there was no reported use of an active concomitant treatment. In the rest of the studies concomitant treatments were not discussed (Bergman 1976; Brignola 1995; Caprilli 1994; Chermesh 2007; Ewe 1989; Herfarth 2006; Herfarth 2013; McLeod 1995; Prantera 2002; Scapa 2015; Wenckert 1978).

#### Interventions

All included studies were two-arm RCTs except for Hanauer 2004 and Savarino 2013, both of which had three intervention arms. Comparisons were made between oral or topical corticosteroids, immunosuppressants, aminosalicylates, TNF- $\alpha$  antagonists, probiotics, synbiotics and antibiotics or a combination of these treatments, with no treatment, placebo or another active treatment. Information on interventions and concomitant treatments was tabulated (Table 1) and is detailed below.

#### Active intervention versus no treatment

- 5-ASA versus no treatment (Caprilli 1994)
- TNF- $\alpha$  antagonists versus no treatment (Fukushima 2018)

• Prednisolone and sulfasalazine combined versus no treatment (Bergman 1976)

#### Active interventions versus placebo

• 5-ASA versus placebo (Brignola 1995; Ewe 1989; Florent 1996; Hanauer 2004; Lochs 2000; McLeod 1995; Sutherland 1997; Wenckert 1978)

• Immunusuppressants versus placebo (D'Haens 2008; Hanauer 2004; Mowat 2016)

• Budesonide versus placebo (Ewe 1999; Hellers 1999)

• Antibiotics versus placebo (Herfarth 2013; Mañosa 2013; Rutgeerts 2005)

• TNF- $\alpha$  antagonists + immunosuppressants + 5-ASA versus placebo + immunosuppressants + 5-ASA (Regueiro 2009; Regueiro 2016)

• Functional foods (probiotics/synbiotics) versus placebo (Chermesh 2007; Fedorak 2015; Gossum 2007; Marteau 2006; Prantera 2002)

#### Active treatment versus active treatment

• 5-ASA versus immunosuppressants (Ardizzone 2004; Hanauer 2004; Herfarth 2006; Reinisch 2010; Savarino 2013)

- 5-ASAs versus anti-TNF (Savarino 2013)
- High-dose 5-ASA versus low-dose 5-ASA (Caprilli 2003)

• TNF-α antagonists versus immunosuppressants (Armuzzi

2013; Lopez Sanroman 2017; Savarino 2013; Scapa 2015)

- TNF-α antagonists versus TNF-α antagonists (Tursi 2014)
- TNF- $\alpha$  antagonists + 5-ASA versus 5-ASA (Yoshida 2012)

#### Outcomes

Participants were followed up for a duration of three, Fedorak 2015; Florent 1996; Gossum 2007, to 72 months, McLeod 1995, or until relapse. During the study period, outcomes were collected and reported at multiple time points in 14 studies (Bergman 1976; D'Haens 2008; Ewe 1989; Ewe 1999; Florent 1996; Fukushima 2018; Lochs 2000; Mañosa 2013; McLeod 1995; Mowat 2016; Regueiro 2016; Rutgeerts 2005; Wenckert 1978; Yoshida 2012), and at a single time point in the remaining the studies. We disregarded any follow-up data collected after the studies were completed (i.e. post-therapy). Information on outcomes reported and definitions of key outcomes are summarised in Table 2 and also listed below.

Outcomes of interest reported in each included study are as follows.

• Total number of relapsed (a combination of different types of relapse) participants was reported in five studies (Bergman

1976; Caprilli 1994; Ewe 1989; Fukushima 2018; McLeod 1995).

• Clinical relapse was reported in 27 studies (Ardizzone 2004; Armuzzi 2013; Brignola 1995; Caprilli 2003; Chermesh 2007; D'Haens 2008; Ewe 1999; Fukushima 2018; Gossum 2007; Hanauer 2004; Herfarth 2006; Herfarth 2013; Lochs 2000; Lopez Sanroman 2017; Mañosa 2013; Marteau 2006; Mowat 2016; Prantera 2002; Regueiro 2009; Regueiro 2016; Reinisch 2010; Rutgeerts 2005; Savarino 2013; Sutherland 1997; Tursi 2014; Wenckert 1978; Yoshida 2012).

• Endoscopic relapse was reported in 27 studies (Armuzzi 2013; Brignola 1995; Caprilli 2003; Chermesh 2007; D'Haens 2008; Ewe 1999; Fedorak 2015; Florent 1996; Fukushima 2018; Gossum 2007; Hanauer 2004; Herfarth 2013; Lochs 2000; Lopez Sanroman 2017; Mañosa 2013; Marteau 2006; McLeod 1995; Mowat 2016; Prantera 2002; Regueiro 2009; Regueiro 2016; Reinisch 2010; Rutgeerts 2005; Savarino 2013; Scapa 2015; Tursi 2014; Yoshida 2012).

• Adverse events were reported in 24 studies (Ardizzone 2004; Brignola 1995; Caprilli 1994; Caprilli 2003; D'Haens 2008; Ewe 1999; Fedorak 2015; Florent 1996; Gossum 2007; Hanauer 2004; Hellers 1999; Herfarth 2013; Lochs 2000; Lopez Sanroman 2017; Mañosa 2013; Marteau 2006; McLeod 1995; Prantera 2002; Regueiro 2009; Regueiro 2016; Reinisch 2010; Rutgeerts 2005; Savarino 2013; Sutherland 1997).

• Serious adverse events were reported in 11 studies (Ardizzone 2004; Ewe 1999; Gossum 2007; Hanauer 2004; Hellers 1999; Lochs 2000; Lopez Sanroman 2017; Mañosa 2013; McLeod 1995; Reinisch 2010).

• Withdrawal due to adverse events was reported in 28 studies (Ardizzone 2004; Armuzzi 2013; Brignola 1995; Caprilli 1994; Caprilli 2003; D'Haens 2008; Ewe 1999; Fedorak 2015; Florent 1996; Gossum 2007; Hanauer 2004; Hellers 1999; Herfarth 2006; Herfarth 2013; Lopez Sanroman 2017; Mañosa 2013; Marteau 2006; McLeod 1995; Mowat 2016; Prantera 2002; Regueiro 2009; Regueiro 2016; Reinisch 2010; Rutgeerts 2005; Savarino 2013; Sutherland 1997; Tursi 2014; Wenckert 1978; Yoshida 2012).

#### Funding and declaration of interest

About 40% of the included studies failed to report any information regarding funding source and declarations of interest (Ardizzone 2004; Brignola 1995; D'Haens 2008; Ewe 1989; Ewe 1999; Fedorak 2015; Hellers 1999; Lochs 2000; Mañosa 2013; McLeod 1995; Prantera 2002; Regueiro 2009; Rutgeerts 2005; Scapa 2015; Yoshida 2012). Only nine studies provided information on both (Chermesh 2007; Fukushima 2018; Hanauer 2004; Lopez Sanroman 2017; Marteau 2006; Mowat 2016; Regueiro 2016; Reinisch 2010; Savarino 2013. Two studies declared conflicts of interest alone (Armuzzi 2013; Tursi 2014), whilst seven studies declared funding sources only (Bergman 1976; Caprilli

1994; Caprilli 2003; Florent 1996; Gossum 2007; Herfarth 2006; Herfarth 2013).

Of the studies that reported a declaration of interest, the authors declared there were no conflicts of interest in five studies (Chermesh 2007; Hanauer 2004; Mowat 2016; Savarino 2013; Tursi 2014). In the remaining studies, the authors declared educational or research grants, consultant or lecture fees or speakers honoraria.

Six studies were funded by pharmaceutical companies (Caprilli 1994; Caprilli 2003; Florent 1996; Herfarth 2006; Regueiro 2016; Reinisch 2010); two studies were funded by food companies (Gossum 2007; Marteau 2006); five studies received governmental grants (Bergman 1976; Fukushima 2018; Herfarth 2013; Lopez Sanroman 2017; Mowat 2016); and three studies reported that no grants had been received.

## **Excluded studies**

We excluded 49 records for various reasons. The reasons for exclusion of each study are presented in the Characteristics of excluded studies table and are summarised below.

• Not an RCT (Armuzzi 2013; Angelberger 2013; Balzola 2010; Bodini 2014a; Bodini 2015; Bourreille 2005; Doherty

2009; Dumois 2001; Ewe 1980; Ewe 1981; Ford 2010; Herfarth 2014; Kennedy 2015; Manship 2015; Mardini 2005; McLeod 1997; Papamichael 2012; Regueiro 2013; Regueiro 2014; Reibetanz 2015; Sandborn 2004; Steinhart 1992; Yamamoto 2009; Yamamoto 2013)

• Wrong study design (De Cruz 2012; Kamm 2014a; De Cruz 2013b; De Cruz 2013c; De Cruz 2015a; De Cruz 2015b)

Wrong intervention (Ferrante 2014; Kamm 2014b; Liao 2009; NCT00074542; NCT02247258; NCT02255370; Ren 2013; Tao 2009; Wright 2014; Wright 2015; Zhu 2015)

• Duplicate (De Cruz 2013a; NCT01190839; Vera-Mendoza 2017)

• Terminated (NCT01696942; NCT02247258; NCT02997059)

• Preliminary results of an included study (Ewe 1976; Ewe 1984)

#### **Risk of bias in included studies**

We assessed methodological rigour using the Cochrane 'Risk of bias' tool (Higgins 2011). Details of the 'Risk of bias' assessment for each study are presented in Characteristics of included studies, Figure 2, and Figure 3, and are summarised below.









#### Allocation

#### **Random sequence generation**

The method of participant allocation to study groups was described as 'random' in all of the included studies. Twenty-six studies provided sufficient information on random sequence generation and were judged as being at low risk of bias. We were unable to clarify the method of randomisation in nine studies, leading to a judgement of unclear risk of bias (Armuzzi 2013; Brignola 1995; Caprilli 1994; Florent 1996; Hellers 1999; Regueiro 2016; Rutgeerts 2005; Scapa 2015; Tursi 2014).

#### Allocation concealment

Thirteen studies were found to have adequate allocation concealment and were judged as at low risk of bias (Caprilli 2003; Fukushima 2018; Gossum 2007; Hanauer 2004; Herfarth 2006; Herfarth 2013; Marteau 2006; Mowat 2016; Regueiro 2009; Reinisch 2010; Savarino 2013; Sutherland 1997; Yoshida 2012). Twenty-two studies provided insufficient information to permit a judgement. We contacted the authors of these studies for clarification on allocation concealment, but received only one response. This was from Dr McLeod, who confirmed that McLeod 1995 had adequate allocation concealment, resulting in an assessment of low risk of bias. The rest of the studies were assessed as having inadequate description for allocation concealment and were marked 'unclear' (Ardizzone 2004; Armuzzi 2013; Bergman 1976; Brignola 1995; Caprilli 1994; D'Haens 2008; Ewe 1989; Ewe 1999; Fedorak 2015; Florent 1996; Hellers 1999; Lochs 2000; Lopez Sanroman 2017; Mañosa 2013; Prantera 2002; Regueiro 2016; Rutgeerts 2005; Scapa 2015; Tursi 2014; Wenckert 1978). Upon contact, the authors of Chermesh 2007 indicated that the allocation was performed using a predefined note for each participant. We did not consider this sufficient to prevent bias, therefore we assessed this study as at high risk of bias.

#### Blinding

#### Blinding of participants and personnel

We assessed nine studies as being at high risk of bias (Ardizzone 2004; Armuzzi 2013; Bergman 1976; Caprilli 1994; Fukushima 2018; Lopez Sanroman 2017; Savarino 2013; Tursi 2014; Yoshida 2012). These studies were all open-label trials, except for Bergman 1976, which albeit providing insufficient information, was judged to be at high risk of bias due to review authors' doubts about the feasibility of blinding participants and personnel in a non-placebo

trial (i.e. active treatment versus no treatment control). Approximately 57% of the studies gave an adequate description of the blinding method and were judged as at low risk of performance bias. The method of blinding was not adequately described in six studies (Caprilli 2003; D'Haens 2008; Florent 1996; Hanauer 2004; Scapa 2015; Wenckert 1978), which were assessed as at unclear risk of bias. Two studies failed to describe whether the placebo was sufficiently identical to the intervention to blind study participants (Florent 1996; Hanauer 2004), and three studies provided insufficient information to permit an objective assessment (Caprilli 2003; Scapa 2015; Wenckert 1978). D'Haens 2008 was described as a single-blinded study and involved the use of dummy tablets. No other information was provided.

#### Blinding of outcome assessment

We judged five studies as being at high risk of bias due to nonblinding of outcome assessors (Armuzzi 2013; Bergman 1976; Ewe 1989; Fukushima 2018; Tursi 2014). Fourteen studies that failed to adequately describe blinding were assessed as at unclear risk of detection bias (Ardizzone 2004; Chermesh 2007; Ewe 1999; Fedorak 2015; Florent 1996; Mañosa 2013; Prantera 2002; Regueiro 2016; Reinisch 2010; Savarino 2013; Scapa 2015; Sutherland 1997; Wenckert 1978; Yoshida 2012). We judged the remaining studies as having a low risk of detection bias (Brignola 1995; Caprilli 1994; Caprilli 2003; D'Haens 2008; Gossum 2007; Hanauer 2004; Hellers 1999; Herfarth 2006; Herfarth 2013; Lochs 2000; Lopez Sanroman 2017; Marteau 2006; McLeod 1995; Mowat 2016; Regueiro 2009; Rutgeerts 2005).

#### Incomplete outcome data

We judged 82% of the included studies as at low risk of attrition bias. We judged five studies as at unclear risk of bias for various reasons. Bergman 1976 reported low and balanced attrition rates across groups, however failed to provide the reasons for attrition. In Sutherland 1997 attrition rates were not specifically reported for the subpopulation of interest. Two studies failed to report how attrition rates (20% and 25% respectively) compared with the event risk, and it was unclear whether this was sufficient to cause bias (Ewe 1999; Regueiro 2016). Scapa 2015 failed to report the number of randomised and withdrawn participants and reasons for withdrawal. The authors were contacted for clarification, however no additional information was provided, except that the study is under preparation for publication. Two studies had incomplete outcome data and were assessed as at high risk of attrition bias (Herfarth 2006; Herfarth 2013). Herfarth 2013 reported an overall attrition rate of 30%, which when compared to the event risk of 24% raised concerns about bias. More than half of the randomised participants in Herfarth 2006 withdrew due to treatment failure and the trial was discontinued. The remaining 28 studies reported attrition rates that were low and balanced across groups, and in

one trial (Ewe 1989), although the overall attrition rate was high (37%), when compared to the event risk (60%), it was not sufficient to introduce bias. Hence, these studies were judged as at low risk of bias for this domain.

#### Selective reporting

Trial registration was available for 11 studies (Fedorak 2015; Fukushima 2018; Herfarth 2013; Lopez Sanroman 2017; Mañosa 2013; Mowat 2016; Regueiro 2009; Regueiro 2016; Reinisch 2010; Scapa 2015; Yoshida 2012). Twenty-seven studies reported all outcomes that were prespecified in the methods section of the published manuscript or in the protocol and were judged as at low risk of reporting bias. We assessed six studies as at high risk of bias for selective reporting for the following reasons: failure to report a prespecified outcome (Chermesh 2007; Florent 1996; Lopez Sanroman 2017); non-reporting of outcomes that were prespecified in the trial registration and refusal to provide data upon request (Scapa 2015); inadequate reporting of secondary outcomes (Fedorak 2015); and failure to report on adverse event outcomes (Ewe 1989). We assessed two studies as at unclear risk of bias for this domain: Herfarth 2006 was published as an abstract with no trial registration or sufficient information in the methods section to permit a judgement, whilst Wenckert 1978 failed to sufficiently report the results for adverse events.

#### Other potential sources of bias

We judged three studies to be at high risk of bias due to baseline imbalance across groups, Regueiro 2009; Rutgeerts 2005, or for failing to report on baseline characteristics (Bergman 1976). Three studies provided insufficient baseline characteristics of randomised participants to permit a determination of whether there were baseline imbalances and were judged as at unclear risk of bias (Herfarth 2006; Scapa 2015; Wenckert 1978). We assessed 29 studies as at low risk of bias.

#### All-domain risk of bias

We judged 18 studies at high risk of bias for one or more domains as at 'high' or 'very high' risk of bias (Ardizzone 2004; Armuzzi 2013; Bergman 1976; Caprilli 1994; Chermesh 2007; Ewe 1989; Fedorak 2015; Florent 1996; Fukushima 2018; Herfarth 2006; Herfarth 2013; Lopez Sanroman 2017; Regueiro 2009; Rutgeerts 2005; Savarino 2013; Scapa 2015; Tursi 2014; Yoshida 2012). We assessed risk of bias as low or unclear in 17 studies (Brignola 1995; Caprilli 2003; D'Haens 2008; Ewe 1999; Gossum 2007; Hanauer 2004; Hellers 1999; Lochs 2000; Mañosa 2013; Marteau 2006; McLeod 1995; Mowat 2016; Prantera 2002; Regueiro 2016; Reinisch 2010; Sutherland 1997; Wenckert 1978). We judged four studies as at low risk of bias across all domains (Gossum 2007; Marteau 2006; McLeod 1995; Mowat 2016).

#### **Effects of interventions**

See: Summary of findings for the main comparison Estimates of effects, credible intervals, and certainty of the evidence for maintenance of surgically induced remission in Crohn's disease; Summary of findings 2 Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease: BENEFITS; Summary of findings 3 Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease: BENEFITS; Summary of findings 4 Interventions for the maintenance of surgically induced remission in Crohn's disease: HARMS

We have reported the risk ratio (RR) for pairwise comparisons and the hazard ratio (HR) for the NMA as planned due to the nature of the data. Our first primary outcome was dichotomous, and the second was survival data. The included studies did not report on time to relapse as survival data, but reported this as a dichotomous outcome instead (i.e. number of relapses). The NMA was carried out in a way that takes time into account using the clog-log link. The pairwise comparison, on the other hand, did not take time into account and was analysed using the RR as intended.

#### Interventions and comparisons: pairwise comparisons

We performed pairwise comparisons on all the studies that met our inclusion criteria. We first analysed the data included in the NMA (Analyses 1 to 12). This was followed by pairwise comparisons on studies that were not included in the NMA due to concerns about transitivity (Analyses 13 to 17). There were 12 direct comparisons in total, as follows.

• 5-ASA versus placebo (Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis 1.4; Analysis 1.5)

• 5-ASA versus adalimumab (Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4)

• 5-ASA versus purine analogues (Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4; Analysis 3.5)

• Antibiotics versus placebo (Analysis 4.1; Analysis 4.2; Analysis 4.3; Analysis 4.4)

• Budesonide versus placebo (Analysis 5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4)

• Infliximab versus adalimumab (Analysis 6.1; Analysis 6.2; Analysis 6.3; Analysis 6.4)

• Inflximab versus purine analogues (Analysis 7.1; Analysis 7.2; Analysis 7.3; Analysis 7.4)

• Probiotics versus placebo (Analysis 8.1; Analysis 8.2; Analysis 8.3)

• Purine analogues versus placebo (Analysis 9.1; Analysis 9.2; Analysis 9.3; Analysis 9.4; Analysis 9.5)

• Purine analogues versus adalimumab (Analysis 10.1; Analysis 10.2; Analysis 10.3; Analysis 10.4)

• Sulfasalazine versus placebo (Analysis 11.1; Analysis 11.2; Analysis 11.3)

• Sulfasalazine + prednisolone versus no treatment (Analysis 12.1)

#### Interventions and comparisons: network and sensitivity analyses

For the NMA, we focused on three main outcomes: clinical relapse, endoscopic relapse, and withdrawals due to adverse events. Data were insufficient to assess time to relapse, and other outcomes such as histologic relapse, adverse events, and serious adverse events were not sufficiently or objectively reported to permit an NMA. Of the 35 studies that met the inclusion criteria of our review, 26 reported sufficient data on the three outcomes and were included in the network (Table 3). Eleven active treatments (5-ASA, 6-MP, adalimumab, azathioprine, budesonide, metronidazole, ornidazole, infliximab, probiotics, sulfasalazine, sulfasalazine + prednisolone) were studied in the review. However, when azathioprine and 6-MP were lumped together as purine analogues, and metronidazole and ornidazole were lumped as antibiotics, we ended up with nine 'groups' of active treatments. Two studies were three-arm trials (Hanauer 2004; placebo, 5-ASA, and purine analogue; Savarino 2013: 5-ASA, adalimumab, purine analogue). There were a total of 45 comparisons encompassing 2245 randomised participants who experienced a total of 1037 clinical relapses (Table 4). There were 21 comparisons on 1128 randomised participants who experienced a total of 779 endoscopic relapses (Table 5). There were 36 comparisons based on 1498 participants, of which 189 discontinued treatment due to adverse events (Table 6). The number of active treatments studied varied across the three networks: clinical relapse (9 treatments: 21 trials), endoscopic relapse (6 treatments: 12 trials), and withdrawal due to adverse events (8 treatments: 15 trials).

Firstly, we analysed the data using fixed-effect and random-effects models. To compare both models and assess which model had a good fit, we used the DIC estimates. The DIC generated from the clinical relapse (Table 7) and endoscopic relapse (Table 8) data indicated that the fixed-effect model was satisfactory. However, as the difference in DIC was less than the stipulated threshold of three to five points (see Data synthesis), we decided to use a random-effects model instead to obtain more conservative estimates. For the outcome withdrawal due to adverse events, we found the random-effects model to be a good fit for the data (Table 9). We therefore used the random-effects model for the base-case analysis for all three outcomes. We also compared the fixed-effect and random-effects models in a sensitivity analysis and carried out three additional sensitivity analyses for the primary outcome (clinical relapse) alone. We undertook sensitivity analyses to assess the impact of a failure to conceal allocation, loss to follow-up, and nonblinded outcome assessment by removing studies at high or unclear risk of bias. We also sought to understand the effect of the low-dose 5-ASA assessed in McLeod 1995 and the definitions of clinical relapse in Ewe 1989, Wenckert 1978, and Bergman 1976.

The network plots are presented in Figure 4, Figure 5, and Figure 6. For clinical relapse and withdrawals due to adverse events, around half of the interventions were part of at least one loop and the others were 'hanging'. The endoscopic relapse network was more connected, as most of the interventions were part of at least one loop, and only two were 'hanging' (antibiotics and probiotics).







Figure 5. Network plot - endoscopic relapse.



Figure 6. Network plot - withdrawal due to adverse events.

#### Risk of bias for the base-case network

We assessed risk of bias in three different ways: for the individual studies, where we considered selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias; for each contrast in the network (any pair of interventions in the network) as overall risk of bias by considering the bias for each direct comparison and its percentage contributions to the network estimate; and by calculating the overall risk of bias for the entire network. Of the 26 studies included in base-case networks for clinical relapse, endoscopic relapse, and withdrawals due to adverse events, three studies were at low risk of bias; nine were at unclear risk of bias; and 14 were at high risk of bias (Figure 2; Figure 3). Studies at low and unclear risk were grouped together, and those at high risk of bias were further divided into high or very high. For the direct comparisons, the overall risk of bias is indicated in the networks and colour coded for the three bias judgments: low/unclear (green), high (yellow), very high (red). Most of the evidence for clinical and endoscopic relapse appeared to be at high or very high risk of bias, whilst evidence for withdrawal due to adverse events was high/very high to low/unclear risk of bias. The overall withinstudy bias was based on the mean (average) of the three 'Risk of bias' contributions for each contrast (Figure 7; Figure 8; Figure 9).

# Figure 7. Clinical relapse: risk of bias contributions of each piece of study to the network estimate; 21 studies: 8 low, 9 moderate, 4 high. Key: green = low/unclear; yellow = high; red = very high overall risk of bias for the contrast.





Figure 8. Endoscopic relapse: risk of bias contributions of each piece of study to the network estimate; 12 studies: 4 low, 5 moderate, 3 high. Key: green = low/unclear; yellow = high; red = very high overall risk of bias for the contrast.

Figure 9. Withdrawal due to adverse events: risk of bias contributions of each piece of study to the network estimate; 15 studies: 7 low, 7 moderate, 1 high. Key: green = low/unclear; yellow = high; red = very high overall risk of bias for the contrast.



#### Network meta-analysis results

Network meta-analysis results are presented separately for clinical relapse, endoscopic relapse, and withdrawals due to adverse events. We analysed the results as HRs with 95% credible intervals (CrIs) for each contrast (Table 10; Table 11; Table 12); individual treatments (compared to the placebo) (Table 13); and have also displayed these results in forest plots (Figure 10; Figure 11; Figure 12). We then produced a rank order of the interventions in each network (Table 14; Table 15; Table 16), with the probability that a particular intervention is the best, second best, etc. treatment (Figure 13; Figure 14; Figure 15).

Figure 10. Summary plot of clinical relapse showing network estimates of mean hazard ratios (blue diamonds and squares) and their credible intervals (blue horizontal line). Right-hand side = favours named treatment; left-hand side = favours placebo.





Figure 11. Summary plot of endoscopic relapse showing network estimates of mean hazard ratios (blue diamonds and squares) and their credible intervals (blue horizontal line). Right-hand side = favours named treatment; left-hand side = favours placebo.



Figure 12. Summary plot of withdrawal due to adverse events showing network estimates of mean hazard ratios (blue diamonds and squares) and their credible intervals (blue horizontal line). Right-hand side favours placebo; left-hand side favours named treatment.






Figure 15. Rank - withdrawal due to adverse events.

#### **Clinical relapse**

The analysis generated 45 contrasts, that is all possible pairwise combinations of the interventions. Only 7 out of the 45 contrasts had precise estimates. The rest of the CrIs crossed at least one default minimally important difference, that is the value of 0.75 and 1.25. All 7 contrasts with precise estimates involved adalimumab (versus placebo, 5-ASA, antibiotics, probiotics, purine analogues, sulfasalazine, and sulfasalazine + prednisolone), which was studied in 2 trials with a combined total of 3 events from the 26 participants randomised to receive adalimumab. The results of 85% of the contrasts had imprecision (Table 10; Figure 10).

## Endoscopic relapse

There were 21 pairwise combinations of the interventions. Six of the 21 contrasts had precise estimates, whilst the rest of the results included the minimally important difference. Again, all five contrasts with precise estimates involved adalimumab (compared to placebo, 5-ASA, antibiotics, probiotics, and purine analogues). Adalimumab was studied in 3 trials with a combined total of 4 events in the 37 participants randomised to receive it. Results from 71% of the contrasts were imprecise (Table 11; Figure 11).

#### Withdrawal due to adverse events

For this outcome, the analysis generated 36 contrasts, none of which had precise estimates (Table 12; Figure 12).

## **Ranking of treatments**

We summarised the rank of each intervention as median/range (Table 14; Table 15; Table 16; Table 17) and displayed these in histograms (Figure 13; Figure 14; Figure 15). The closer the mean rank is to 1, the better the efficacy or safety.

Adalimumab was ranked best (mean rank of 1.28) and sulfasalazine + prednisolone worst (mean rank of 8.28) for the outcome clinical relapse (Table 14). The fourth-ranking treatment, 5-ASA, was the only other treatment in the ranking other than adalimumab that was effective. The effect estimates for all comparisons with adalimumab, albeit precise, were based on two small studies. As this ranking does not take into account the certainty of evidence or other outcomes of interest, it should be interpreted with caution (Mbuagbaw 2017). Adalimumab was ranked best (mean rank of 1.4) and 5-ASA worst (mean rank of 5.96) for the outcome endoscopic relapse (Table 15). Sulfasalazine ranked best (mean rank of 2.61) and antibiotics ranked worst (mean rank of 7.82) for the outcome withdrawals due to adverse events (Table 16).

#### Certainty of the evidence across the whole network

The criteria used for the GRADE assessment of the evidence are reported in Appendix 2. For clinical relapse, the risk of bias across the network was high, and the effect estimates for most of the contrasts (38 out of 45 contrasts) were imprecise. Three out of the seven contrasts with precise credible intervals were influenced by two small studies (Appendix 3), with 26 participants randomised to receive adalimumab, and which show a positive effect in favour of adalimumab. Whilst this raises concerns over publication bias, these contrasts were not found to contribute substantially to the network (Appendix 4). There was no indirectness, however there was marginal inconsistency within the contrasts, although it had no observable impact on the overall network (DIC inconsistency > DIC consistency: 246.27 versus 244.26). The evidence was downgraded twice (once for risk of bias and once for imprecision), and the network classed as being of low certainty (Appendix 5).

Most of the studies that reported on endoscopic relapse were at high risk of bias (66.7%), and most of the contrasts (71%) had imprecise results. Precision in the network, which was noted in 5 contrasts, could be attributed to the 3 small studies that reported 4 events in 37 participants who received adalimumab (Appendix 6). The contrasts involving these small studies showed a positive effect in favour of adalimumab, therefore publication bias is suspected. There was no indirectness. However, we found marginal inconsistency within the contrasts, which had no impact on the network (DIC inconsistency > DIC consistency: 135.70 versus 133.43). The evidence was downgraded twice (once for risk of bias and once for imprecision), and the network classed as being of low certainty (Appendix 7; Appendix 8).

Of the 15 trials that reported data on withdrawals due to adverse events, nine (60%) were at high risk of bias. The results of all contrasts included the minimally important difference of 0.75 or 1.25. Between-study heterogeneity was also noted, however the DIC estimate in the inconsistency model was not substantially less than that estimated by the consistency model (149.36 versus 151.73), therefore we decided not to downgrade the network for inconsistency. We downgraded the evidence twice (once for risk of bias and once for imprecision), resulting in low-certainty evidence (Appendix 9; Appendix 10; Appendix 11).

When we investigated the three networks for publication bias, there was no evidence of asymmetry in the funnel plots (Figure 16; Figure 17; Figure 18), therefore we did not downgrade for publication bias.

Figure 16. Funnel plot for the clinical relapse network showing comparison-specific pooled effect sizes; 1 = placebo; 2 = 5-ASA; 3 = adalimumab; 4 = antibiotics; 5 = budesonide; 6 = infliximab; 7 = probiotics; 8 = purine analogues; 9 = sulfasalazine; 10 = sulfasalazine + prednisolone.



Figure 17. Funnel plot for the endoscopic relapse network showing comparison-specific pooled effect sizes; I = placebo; 2 = 5-ASA; 3 = adalimumab; 4 = antibiotics; 5 = infliximab; 6 = probiotics; 7 = purine analogues.



Figure 18. Funnel plot for the withdrawal due to adverse events network showing comparison-specific pooled effect sizes; 1 = placebo; 2 = 5-ASA; 3 = adalimumab; 4 = antibiotics; 5 = budesonide; 6 = infliximab; 7 = probiotics; 8 = purine analogues; 9 = sulfasalazine.



# Results and quality assessment for comparisons between individual treatments and reference

For the primary outcome we presented results of the top five interventions. Then we assessed how well these interventions performed with endoscopic relapse and withdrawal due to adverse events. The plan was to use the top-ranking interventions of the primary outcome as a basis for which treatments to focus on in subsequent outcomes (Summary of findings for the main comparison).

## **Clinical relapse**

We compared individual treatments with placebo to further examine the results of the NMA. Given that there had been no previous decision as to which treatments are further assessed, we considered the top five (50%) interventions studied. These were adalimumab, infliximab, budesonide, 5-ASA, and purine analogues. The results from these comparisons are shown in Summary of findings 2. We

used CINeMA methods for assessing the certainty of evidence (CINeMA 2017). The HRs varied across the treatment comparisons, with certainty of evidence ranging from very low to moderate. There was low-certainty evidence that adalimumab may prevent clinical relapses (HR 0.11, 95% credible interval (CrI) 0.02 to 0.33; downgraded twice for across-study bias and imprecision). The evidence on infliximab was uncertain, as the certainty was rated as very low (HR 0.36, 95% CrI 0.02 to 1.74; downgraded twice for within-study bias and once for imprecision). There was low-certainty evidence that budesonide may lead to no clear difference in clinical relapse (HR 0.66, 95% CrI 0.27 to 1.34; downgraded twice for imprecision). There was moderate-certainty evidence that 5-ASA may prevent clinical relapse compared with placebo (HR 0.69, 95% CrI 0.53 to 0.87; downgraded for some within-study bias and incoherence). The certainty of the evidence for the effect of purine analogues on clinical relapse compared to placebo was low (HR 0.75, 95% CrI 0.55 to 1.00; downgraded for risk of bias and imprecision) (Figure 10; Table 10; Table 13).

## Endoscopic relapse

The certainty of the evidence was either low or very low for this outcome (Summary of findings 3). There was low-certainty evidence that adalimumab may prevent endoscopic relapses (HR 0.10, 95% CrI 0.01 to 0.32; downgraded twice for within-study bias and some incoherence). There was low-certainty evidence that infliximab may lead to no clear difference in endoscopic relapse rates compared to placebo (HR 0.24, 95% CrI 0.01 to 1.20; downgraded twice for within-study bias and imprecision). The evidence for the effect of purine analogues on endoscopic relapse was uncertain because the certainty was rated as very low (HR 0.85, 95% CrI 0.33 to 1.61; downgraded twice for within-study bias and twice for imprecision). The evidence for the effect of 5-ASA on endoscopic relapse was uncertain because the certainty was rated as very low (HR 1.22, 95% CrI 0.61 to 2.18; downgraded twice for within-study bias and twice for imprecision) (Figure 11; Table 11; Table 13).

#### Withdrawal due to adverse events

When we evaluated withdrawal due to adverse events, the treatments were ordered as follows: infliximab, 5-ASA, budesonide, purine analogues, and adalimumab. We excluded treatments that were not ranked among the top-five treatments for clinical relapse from this list (see above). The aim of this was to gain insight into how well the top treatments for clinical relapse perform with other outcomes. The effect of infliximab, 5-ASA, budesonide, purine analogues, and adalimumab on withdrawal due to adverse events was uncertain (Summary of findings 4). The evidence was downgraded twice for within-study bias and imprecision (Figure 12; Table 12; Table 13).

When considering the network as a whole, two adverse events leading to study withdrawal (i.e. pancreatitis and leukopenia) occurred in more than 1% of participants treated with an intervention. Pancreatitis occurred in 2.8% (11/399) of purine analogue participants compared to 0.17% (2/1210) of all other groups studied. Leukopenia occurred in 2.5% (10/399) of purine analogue participants compared to 0.08% (1/1210) of all other groups studied.

## Comparison of results from the network metaanalysis with the direct evidence

Of the four contrasts with more than one study reporting on clinical relapse, three contrasts had an I<sup>2</sup> of 0%, and one contrast (probiotics versus placebo) had an I<sup>2</sup> of 49% (Analysis 8.1). However, the evidence was not downgraded as the I<sup>2</sup> was considered to be low. For endoscopic relapse, two (5/12 studies: 5-ASA versus placebo and probiotics versus placebo) out of five contrasts had an I<sup>2</sup> of 53% and were downgraded once for moderate inconsistency (Analysis 1.5; Analysis 8.3). One of the three contrasts with multiple studies (2/14 studies: purine analogues versus placebo) that reported on withdrawal due to adverse events had an I<sup>2</sup> of 51% and was downgraded for moderate inconsistency (Analysis 9.4). The inconsistency model fitted for clinical and endoscopic relapse networks did not show any incoherence between the direct and indirect evidence (Table 18; Table 19). When we assessed the safety data for inconsistency, we noted lower DIC estimates for the inconsistency model (140.01) compared to the consistency model (142.41) (Table 20). The difference (i.e. < 3) between these models was considered insufficient to warrant downgrading of the evidence. For the contrasts, we noted and downgraded the evidence for the following contrasts:

 clinical relapse: adalimumab versus purine analogues; purine analogues versus placebo;

• endoscopic relapse: 5-ASA versus adalimumab;

adalimumab versus purine analogues; and

• withdrawal due to adverse event: 5-ASA versus purine analogues contrast in the network.

## Sensitivity analysis

We carried out sensitivity analyses to assess the impact of our choice of model, bias, variation in dose of 5-ASA, direction of treatment effect, and definition of clinical relapse on the primary outcome (Table 21). We excluded two studies assessing antibiotics and probiotics that were not consistent with the other trials. This resulted in similar results to the main analysis, except for antibiotics and probiotics, which showed a slightly increased effect size. Due to high risk of bias in the studies, we only had a limited amount of data to assess for the sensitivity analyses, therefore not all interventions were analysed. The results of the sensitivity analyses remained consistent with the main analyses for all the interventions studied except purine analogues. Compared to the main analysis (random-effects model: HR 0.75, 95% CrI 0.55 to 1.00), purine analogues appeared to be slightly beneficial in preventing clinical relapse with the fixed-effect model (HR 0.75, 95% CrI 0.58 to 0.94). This was also observed when we analysed studies at low risk of selection bias due to allocation concealment (random-effects: HR 0.68, 95% CrI 0.43 to 0.98). When we removed studies at high risk of detection bias, the results were similar to those obtained from the main analysis for all interventions assessed . Given the limited amount of data and inconsistency, these results should be interpreted with caution.

# ADDITIONAL SUMMARY OF FINDINGS [Explanation]

# BENEFITS

# Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease

Patient or population: surgically induced remission in Crohn's disease

Settings: hospital, home, or combination

Intervention: 5-ASA, adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine, sulfasalazine + prednisolone

Comparator (reference): placebo

Outcome: clinical relapse; range of follow-up between 3 and 36 months

Total studies: 20 RCTs Total participants: 2149	Relative effect (95% Crl)*	Certainty of the evidence (GRADE)	Ranking (95% CrI)**
Adalimumab (2 RCTs; 26 participants)	HR 0.11 (0.02 to 0.33) Network estimate	$\oplus \oplus \bigcirc \bigcirc$ low <sup>1,2</sup>	1 (1 to 2)
Infliximab	HR 0.36 (0.02 to 1.74)	⊕⊖⊖⊖	2 (1 to 10)
(2 RCTs; 21 participants)	Network estimate	very low <sup>2,3</sup>	
Budesonide	HR 0.66 (0.27 to 1.34)	⊕⊕⊖⊖	3 (2 to 10)
(1 RCT; 43 participants)	Network estimate	low <sup>2,4</sup>	
5-ASA	HR 0.69 (0.53 to 0.87)	⊕⊕⊕⊖	4 (2 to 7)
(9 RCTs; 542 participants)	Network estimate	moderate <sup>2,5</sup>	
Purine analogues	<b>HR</b> 0.75 (0.55 to 1.00)	⊕⊕⊖⊖	5 (3 to 8)
(6 RCTs; 316 participants)	Network estimate	low <sup>2,6</sup>	
Sulfasalazine	HR 0.89 (0.55 to 1.30)	⊕⊖⊖⊖	6 (3 to 10)
(2 RCTs; 143 participants)	Network estimate	very low <sup>2,3</sup>	
Antibiotics (2 RCTs; 57 participants)	HR 0.98 (0.50 to 1.71) Network estimate	$\oplus$ $\bigcirc$ $\bigcirc$ very low <sup>2,3</sup>	7 (3 to 10)

Probiotics	<b>HR</b> 1.11 (0.62 to 1.88)	⊕⊖⊖⊖	8 (3 to 10)
(2 RCTs; 105 participants)	Network estimate	very low <sup>2,3</sup>	
Sulfasalazine + prednisolone	<b>HR</b> 1.37 (0.50 to 3.07)	⊕⊖⊖⊖	9 (3 to 10)
(1 RCT; 57 participants)	Network estimate	very low <sup>2,3</sup>	
Placebo (16 RCTs; 935 participants)	Reference comparator	Not estimable	8 (6 to 10)

\* Estimates are reported as hazard ratio (HR), credible interval (Crl). Results are expressed in credible intervals as opposed to confidence intervals as a Bayesian analysis has been conducted

\*\*Median rank and credible intervals for efficacy outcome are presented. Rank statistics are defined as the probabilities that a treatment out of n treatments in a network meta-analysis is the best, the second, the third, and so on, effective treatment

5-ASA: 5-aminosalicylic acid; RCT: randomised controlled trial

## **GRADE Working Group grades of evidence**

High certainty: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low certainty: We are very uncertain about the estimate.

<sup>1</sup>Downgraded two levels: once due to high risk of bias and once for imprecision.

<sup>2</sup>There was no significant intransitivity, with comparable distribution of plausible effect modifiers across trials of different

interventions for maintenance of remission.

<sup>3</sup>Downgraded three levels: once due to high risk of bias and twice for imprecision.

<sup>4</sup>Downgraded two levels for imprecision.

<sup>5</sup>Downgraded one level for high risk of bias.

<sup>6</sup>Downgraded two levels: once for risk of bias and once for inconsistency in the evidence.

## BENEFITS

# Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease

Patient or population: surgically induced remission in Crohn's disease

Settings: hospital, home, or combination

Intervention: 5-ASA, adalimumab, antibiotics, infliximab, probiotics, purine analogues

Comparator (reference): placebo

Outcome: endoscopic relapse; range of follow-up between 3 and 36 months

Total studies: 12 RCTs Total participants: 1128	Relative effect (95% Crl)*	Certainty of the evidence (GRADE)	Ranking (95% Crl)**
Adalimumab	HR 0.10 (0.01 to 0.32)	⊕○○○	1 (1 to 2)
(3 RCTs; 37 participants)	Network estimate	low <sup>1,2</sup>	
Infliximab (2 RCTs; 21 participants)	HR 0.24 (0.01 to 1.20) Network estimate	$\oplus \oplus \bigcirc \bigcirc$ low <sup>1,2</sup>	2 (1 to 6)
Antibiotics	HR 0.80 (0.33 to 1.65)	⊕○○○	3 (2 to 7)
(2 RCTs; 57 participants)	Network estimate	very low <sup>2,3</sup>	
Purine analogues	HR 0.85 (0.33 to 1.61)	⊕⊖⊖⊖	4 (3 to 7)
(4 RCTs; 164 participants)	Network estimate	very low <sup>2,3</sup>	
Probiotics	HR 1.20 (0.62 to 2.19)	⊕○○○	6 (3 to 7)
(3 RCTs; 108 participants)	Network estimate	very low <sup>2,3</sup>	
5-ASA	HR 1.22 (0.61 to 2.18)	⊕⊖⊖⊖	6 (3 to 7)
(3 RCTs; 237 participants)	Network estimate	very low <sup>2,3</sup>	
Placebo (8 RCTs; 507 participants)	Reference comparator	No estimate	5 (3 to 7)

\* Estimates are reported as hazard ratio (HR), credible interval (Crl). Results are expressed in credible intervals as opposed to the confidence intervals as a Bayesian analysis has been conducted

\*\*Median rank and credible intervals for efficacy outcome are presented. Rank statistics are defined as the probabilities that a treatment out of n treatments in a network meta-analysis is the best, the second, the third, and so on, effective treatment

5-ASA: 5-aminosalicylic acid; RCT: randomised controlled trial

# **GRADE** Working Group grades of evidence

High certainty: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low certainty: We are very uncertain about the estimate.

<sup>1</sup>Downgraded two levels: once due to high risk of bias and once for imprecision.

<sup>2</sup>There was no significant intransitivity, with comparable distribution of plausible effect modifiers across trials of different

interventions for maintenance of remission.

<sup>3</sup>Downgraded three levels: once due to high risk of bias and twice for imprecision.

HARMS				
Interventions for the maintenance of surgically induced remission in Crohn's disease				
Patient or population: surgically induced remission in Crohn's disease Settings: hospital, home, or combination Intervention: 5-ASA, adalimumab, antibiotics, budesonide, infliximab, probiotic, purine analogues, sulfasalazine Comparison: placebo Outcome: withdrawal due to adverse events; range of follow-up between 3 and 36 months				
Total studies: 14 RCTs Total participants: 1419	Relative effect (95% Crl)*	Certainty of the evidence (GRADE)	Ranking (95% Crl)**	
Sulfasalazine (1 RCT; 32 participants)	HR 1.96 (3.04E-04 to 8.90)	⊕⊖⊖⊖ very low <sup>1,2</sup>	2 (1 to 9)	
 Infliximab (1 RCT; 11 participants)	HR 6.37 (9.14E-04 to 21.74)	$\bigoplus \bigcirc \bigcirc \bigcirc$ very low <sup>1,2</sup>	2 (1 to 9)	
5-ASA (8 RCTs; 371 participants)	HR 1.19 (0.39 to 3.14)	⊕⊖⊖⊖ very low <sup>1,2</sup>	4 (2 to 7)	
Budesonide (2 RCTs; 106 participants)	HR 1.64 (0.17 to 6.19)	⊕⊖⊖⊖ very low <sup>1,2</sup>	4 (1 to 9)	
Probiotic (1 RCT; 58 participants)	HR 2.44 (0.13 to 9.00)	$\bigoplus \bigcirc \bigcirc \bigcirc$ very low <sup>1,2</sup>	5 (1 to 9)	
Adalimumab (1 RCT; 16 participants)	HR 11.74 (0.12 to 55.06)	$\bigoplus \bigcirc \bigcirc \bigcirc$ very low <sup>1,2</sup>	7 (1 to 9)	
Purine analogues (7 RCTs; 315 participants)	HR 2.51 (0.79 to 7.35)	⊕⊖⊖⊖ very low <sup>1,2</sup>	7 (4 to 9)	
Antibiotics (1 RCT; 16 participants)	HR 53.92 (0.43 to 259.80)	⊕⊖⊖⊖ very low <sup>1,2</sup>	9 (2 to 9)	

42

ntions for	Placebo (10 RCTs; 531 participants)	Reference comparator	No estimate	4 (2 to 7)
maintenan The Coch	*Estimates are reported as hazard ratio (H been conducted	R), credible interval (Crl). Res	sults are expressed in credible interval	s as opposed to confidence intervals as a Bayesian analysis has
nce of surgi	**Median rank and credible intervals for efficacy outcome are presented. Rank statistics are defined as the probabilities that a treatment out of n treatments in a network meta-analysis is the best, the second, the third, and so on, effective treatment 5-ASA: 5-aminosalicylic acid; RCT: randomised controlled trial			
cally	CRADE Working Croup grades of syldenes			

## GRADE Working Group grades of evidence

High certainty: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low certainty: We are very uncertain about the estimate.

<sup>1</sup>Downgraded three levels: once due to high risk of bias and twice for imprecision across the network.

<sup>2</sup>There was no significant intransitivity, with comparable distribution of plausible effect modifiers across trials of different interventions for maintenance of remission.

## DISCUSSION

## Summary of main results

The NMA conducted to determine the effectiveness of interventions for maintaining surgically induced remission in Crohn's disease assessed three main outcomes: clinical relapse, endoscopic relapse, and withdrawal due to adverse events (Summary of findings for the main comparison). The results from the network for prevention of clinical relapse (21 studies) demonstrate just two therapies as effective (Summary of findings 2): adalimumab (ranked first) and 5-ASA (mesalazine, ranked fourth). These results were consistent with the direct evidence (Gjuladin-Hellon 2019a; Gjuladin-Hellon 2019b). Analysis of a study comparing adalimumab, purine analogues, and 5-ASA demonstrated that adalimumab was more effective for preventing clinical relapse, with one study comparing adalimumab with infliximab finding no difference in relapse rates. The direct evidence for 5-ASA also shows effectiveness for preventing clinical relapse when compared to placebo, and no difference in relapse rates when compared to purine analogues (Gjuladin-Hellon 2019a). There was little or no difference in prevention of clinical relapse with budesonide when compared with placebo. Purine analogues were shown to lead to a slight reduction in clinical relapse rates when a fixed-effect model was used, however this effect was not sustained with a randomeffects model (the main analysis). Due to concerns about inconsistency and risk of bias, we downgraded the evidence to low certainty.

The results for prevention of endoscopic relapse (13 studies) demonstrated just one effective therapy, adalimumab (ranked first) (Summary of findings 3). The direct evidence also demonstrated adalimumab as the only effective therapy for preventing endoscopic relapse across all the possible comparisons from the 13 studies reporting on this outcome.

The results for withdrawal of therapy due to adverse events showed no therapy to be at higher risk for withdrawal in the network (Summary of findings 4). Sulfasalazine was demonstrated to be safe in the network and antibiotics unsafe. In the network, sulfasalazine did not appear to be associated with an increased risk of withdrawal due to adverse events, whilst antibiotics appeared to be associated with an increased risk of withdrawal due to adverse events. However, these results needs to be interpreted with caution given the low certainty of the evidence. The direct evidence for all comparisons showed no difference in rates of withdrawal due to adverse events across studies, except for 5-ASA, which was shown to be superior to purine analogues. Despite the limited evidence across the network, the occurrence of two specific adverse events (i.e. pancreatitis and leukopenia) that led to withdrawal in more than 1% of treated participants must be noted. These adverse events occurred in participants who received purine analogues.

A previous review has demonstrated that adalimumab maintains medically induced remission (Behm 2008), which is consistent with the result found in this NMA. This was not the case for 5-ASA preparations, which are ineffective for maintenance of medically induced remission in Crohn's disease (Akobeng 2016). It is not clear why the evidence suggests a difference in efficacy for 5-ASA agents in patients with medically and surgically induced remission. One possibility is that assessments of disease activity used at study entry may not be comparable. The limitations of a CDAI score within clinical trials has been previously noted (Caprilli 1994), and most of the clinical trials performed to evaluate the role of 5-ASA in the maintenance of medically induced remission defined remission using the CDAI score. As most of the trials involved in this review used surgical resection of macroscopically diseased bowel as their inclusion criterion, it follows that many of these patients may actually have less active disease compared to patients in trials of medically induced remission. This may explain the observed difference in efficacy of 5-ASA agents.

It is also possible that the length of time in remission may partly explain this difference in efficacy. Many of the studies in the review of medically induced remission included patients who had been in remission for significant periods of time at study entry (Akobeng 2016). By contrast, most of the studies in this review required entry and initiation of therapy within 12 weeks of surgery. Evidence obtained from studies with a follow-up of greater than 12 months still favoured the use of 5-ASA agents, but as the longest study follow-up was 36 months, it is possible that if a longer follow-up was used this effect would not be sustained.

The situation with purine analogues is also complex. These drugs have been identified as effective for medically induced maintenance of remission in Crohn's disease (Chande 2015). However, when considering the wider evidence from this medical maintenance review (Chande 2015), meta-analysis when compared with 5-ASA agents did not show superiority. This is consistent with the previous postsurgical remission review (Gjuladin-Hellon 2019b), which did show efficacy versus placebo, but again failed to demonstrate superiority versus 5-ASA. In this NMA, as well as in the previous two, the GRADE rankings for such findings were all low, suggesting that more research is likely to change the findings.

# Overall completeness and applicability of evidence

The most important issue to address is the size and breadth of evidence, as this clearly has implications for current practice and future research. The key intervention that has been demonstrated to be effective for preventing both endoscopic and clinical relapse is adalimumab. However, this is based on low-certainty evidence from one study with 26 participants receiving the intervention for prevention of clinical relapse. This clearly limits the applicability of these findings to practice. Indeed, the large HR observed (HR 0.11) is not at a level seen across the field, with just 1 case of clinical relapse seen in adalimumab-treated participants compared with 12 cases in purine analogues and 9 cases in 5-ASA participants. This

raises a real question of imprecision and renders this key result limited in its utility for practice at present.

The evidence for 5-ASA was from a larger evidence base with 9 studies across the network with 542 participants included. This led to a result that was of moderate certainty. Conversely, the evidence for endoscopic relapse was far less complete for 5-ASA, with just three studies (501 participants) reporting on this outcome. Considering the remaining interventions across the network, the evidence is capricious. The evidence for purine analogues was of reasonable size, with 6 studies considering 316 participants who received purine analogues for prevention of clinical relapse. The findings of lack of efficacy across the network for both clinical and endoscopic remission are particularly relevant to practice, as purine analogues are used across the field and feature in a number of international Crohn's disease treatment guidelines (Gionchetti 2017; NICE 2012). For all other agents, the completeness of the evidence (i.e. small number of studies and participants) across the network remains an issue. This imprecision must be considered when interpreting these results for treatments that do not reflect current practice or guidance.

The second major issue that pervaded the network was the heterogeneity of study design, outcome measures employed, and the reporting of these outcomes. Some studies looked at clinical relapse as a key outcome, whilst other studies used endoscopic investigation. The follow-up time varied widely, a key issue that impacts the utility of studies of maintenance of remission. The specific manner in which the two key outcomes were reported varied in minor, but in significant ways that limited the scope for some analyses. In particular, the use of the CDAI involved a number of different thresholds for clinical relapse, and these different thresholds could have had a substantial effect on findings. Similarly, the scoring systems used to report endoscopic relapse were also subject to interstudy variation. A recent process has sought to reach an international consensus on such outcomes and is key for preventing such factors that limit the evidence (Kim 2017).

The assessment of safety was difficult across the studies in this review. Whilst terms such as 'serious adverse event' and 'minor side effects' may seem clear, the reporting of adverse event outcomes was extremely heterogenous across studies. A number of studies only reported occurrence rates or the number of events rather than the actual numbers of participants affected. Similarly, some events were reported as serious adverse events, but were clearly not clinically relevant (e.g. the occurrence of pregnancy). Whilst this may be in line with the individual protocols of the studies, it has made analysis very difficult. This is why we chose to use withdrawal due to adverse events as a key outcome for the NMA, as this outcome is usually reported in a very clear fashion and does have clinical relevance. However, this led to much lower occurrence numbers, and therefore imprecision for this outcome across the network. This limits the completeness of the evidence base for adverse events.

The third issue relates to the use of concomitant therapy. We

were unable to include several studies in the network because of concomitant therapies used during part or all of the maintenance period. As these treatments were not randomised, and some were included as active comparators in other parts of the network (e.g. the use of antibiotics or 5-ASA), this meant that these studies could not be included in the network.

## Quality of the evidence

Key to interpreting the results in such a network analysis is the consideration of the range of tools used to assess certainty, quality, and risk of bias. Adalimumab was included in just two studies in the network, with 26 participants receiving the intervention. The certainty of the evidence was thus low due to very serious imprecision and risk of bias, a key issue that limits the evidence for this intervention. Conversely, the ranking for 5-ASA, as the only other therapy effective for preventing clinical relapse in the network, was based on eight studies (1124 participants), therefore the certainty of the evidence was not affected by imprecision, and was downgraded only once due to high risk of bias.

Only four out of 26 studies included in the three networks were at low risk of bias. This was mostly due to lack of blinding (performance and detection bias). Allocation concealment was unclear for most studies as well. We found that most of the comparisons were made between active interventions and reference comparator, with only five studies comparing active treatments only. This resulted in a poorly connected network. For the number of treatments that were assessed, the number of included studies may have been insufficient and inadequately powered, giving rise to imprecision across all three networks. Some of the contrasts across all three networks had some degree of inconsistency. Incoherence was noted in the endoscopic relapse and withdrawal due to adverse events networks, albeit insufficient to warrant downgrading. We cannot rule out the possibility of publication bias resulting from small-study effects in the three small studies on adalimumab. Given the ranking and apparent efficacy of adalimumab, assessment for publication bias is key. However, given the low number of studies published, an accurate consideration of this is not permitted until further studies are published. We found no evidence of publication bias in any of the networks. By following strict inclusion criteria, we were able to avoid indirectness and did not downgrade the evidence for it.

## Potential biases in the review process

There were a number of studies that reported sufficient data but were excluded from the network. We are aware of the fact that this could amount to reporting bias, and it did reduce the volume of evidence, giving rise to imprecision. However, the exclusion of such studies was based on advice from clinician authors, as participants were given active interventions to which they were not

randomised to receive. Due to clinical differences in interventions between studies in the same contrast, the decision was made to exclude these studies and avoid transitivity. The studies are still included in the review for completeness. In summarising the evidence, we focused on the best five treatments in clinical relapse and performance with other outcomes. The decision to disregard the worst five treatments was based on the fact that whilst these treatments are used capriciously without efficacy, the top five treatments have been studied in separate reviews where they have been shown to be efficacious.

We initially planned to evaluate clinical relapse and withdrawal due to adverse events. However, when the draft NICE guideline was completed (NICE 2019), we decided to include endoscopic relapse in the summary of evidence. This was solely to ensure consistency, given that this review and the NICE guideline are addressing the same question using a similar evidence base and methods.

Decisions on which interventions to include in the base case, lumping and splitting, as well as sensitivity analysis were made independently by two clinician authors who had no access to the data at that point in time.

# Agreements and disagreements with other studies or reviews

Several guidelines on the maintenance of surgically induced remission in Crohn's disease have been published by European Crohn's and Colitis Organisation (ECCO), the American College of Gastroenterology, and the National Institute of Health and Care Excellence (NICE). Only the NICE guideline used an NMA methodology (NICE 2019). As discussed in the Background, there are small but stark differences in inclusion criteria, methodology, and most importantly decision-making processes between this Cochrane Review and the NICE guidance in the UK. The NICE guideline process meant that whilst there was agreement on the best-ranking treatment for both clinical and endoscopic maintenance of remission (adalimumab) between the two reviews, NICE did not recommend the use of adalimumab based on cost-effectiveness. The same conclusion was made in this review, but it was based on low-certainty evidence for the network rather than cost. There were differences in how the certainty of the evidence was judged in the two reviews. This review is aligned with the Cochrane Handbook for Systematic Reviews of Interventions and associated guidance (Higgins 2011), but whilst our review has rated the network as low certainty, the NICE guidance has arrived at a moderate rating (completed as per the NICE methodological guidance).

The NICE guideline recommends azathioprine with or without metronidazole, which is in disagreement with our review. This was due to a key difference between the two systematic reviews. It has been noted that several included studies that exerted influence on the network included participants who received non-randomised active agents, specifically metronidazole. However, metronidazole has been studied as a primary active interventional agent within this context. As such, we did not believe it was appropriate to include these studies in the network because this does not meet the transitivity assumptions for NMA and therefore limits the conclusions that can be made from the NICE meta-analysis.

Our review assessed azathioprine and 6-MP together as purine analogues and did not find clear evidence of effectiveness for either clinical or endoscopic maintenance of remission. Given that it included a number of extra studies that used purine analogues with concomitant metronidazole, the NICE review arrived at a different conclusion, recommending this combination as primary therapy. This was not consistent with the findings of our review. 5-aminosalicylic acid was found to be safe and beneficial for preventing clinical relapse and was recommended in the 2012 NICE guideline. However, this recommendation was removed from the update guideline, stating that 5-ASA had not been shown to be clinically or cost-effective in terms of endoscopic relapse rates (NICE 2019). This was not consistent with the findings of our review. This difference in findings was due to the exclusion of a number of studies, which was the result of the difference in inclusion criteria (Florent 1996; Herfarth 2006; Reinisch 2010; Sutherland 1997). We permitted the inclusion of abstract publications and studies with less than 12 months' follow-up. Interestingly, one of the recommendations for future research within this NICE guideline was for studies assessing 5-ASA compared to no treatment. Based on our findings of moderate-certainty evidence supporting the effectiveness of 5-ASA when compared to placebo, this is another area of disagreement with the NICE guideline, and further research in this area may not be warranted.

The European Crohn's and Colitis Organisation (ECCO) released an update to their international guidance on Crohn's management in 2017, which covered postsurgical treatment to maintain remission (Gionchetti 2017). Their recommendation 8G states: "Prophylactic treatment is recommended after ileocolonic intestinal resection in patients with at least one risk factor for recurrence [EL2]. To prevent post-operative recurrence the drugs of choice are thiopurines [EL2] or anti-TNFs [EL2]. High dose mesalazine is an option for patients with an isolated ileal resection [EL2]. Imidazole antibiotics have been shown to be effective after ileocolic resection but are less well tolerated [EL1]". The findings of our review would not fully support this current advice. The evidence does not support the use of thiopurines and does raise some specific safety issues that are not mentioned in this guidance, namely the occurrence of pancreatitis (leukopenia is mentioned). The evidence does support the use of one specific ant-TNF, but within the limitations noted. There is evidence to support the advice for 5-ASA in all patients. However, we found no evidence to support the use of antibiotics.

The American College of Gastroenterology released updated guidelines in 2018, which also address this issue (Lichtenstein 2018). These are as follows.

Recomendation 55 states: "Mesalamine is of limited benefit in

preventing postoperative Crohn's disease, but in addition to no treatment is an option for patients with an isolated ileal resection and no risk factors for recurrence (moderate level of evidence)". This agrees with the findings of this review.

However, recommendation 56 states: "Imidazole antibiotics (metronidazole and ornidazole) at doses between 1 and 2 g/day can be used after small intestinal resection in Crohn's disease patients to prevent recurrence (conditional recommendation, low level of evidence)". This was not completely supported by our findings, although the conditional nature of the recommendation and its associated GRADE rating was noted.

Similarly, recommendation 57 states: "Thiopurines may be used to prevent clinical and endoscopic recurrence and are more effective than mesalamine or placebo. However, they are not effective at preventing severe endoscopic recurrence (strong recommendation, moderate level of evidence)". Our findings do not support this. This recommendation cites the results of an out-of-date Cochrane Review and does not cite our last review of thiopurines (Gjuladin-Hellon 2019b).

Finally, recommendation 58 states: "In high-risk patients, anti-TNF agents should be started within four weeks of surgery in order to prevent postoperative Crohn's disease recurrence (conditional recommendation, low level of evidence)". This agrees with our findings.

# AUTHORS' CONCLUSIONS

## Implications for practice

We were unable to draw conclusions on which treatment is most effective in preventing clinical relapse and endoscopic relapse because the certainty of the evidence for the networks was either low or very low. Our review found some evidence indicating that adalimumab and 5-aminosalicylic acid (5-ASA) may prevent clinical relapse. Budesonide may not be effective in preventing clinical relapse, thus may not be useful in practice for the purpose of maintaining surgically induced remission. These findings must be considered in the context of the low certainty of the evidence of the network. There is insufficient evidence to determine which treatment is safest or most effective in preventing endoscopic relapse, as the certainty of evidence was very low. Whilst safety advice is well recognised for thiopurines, the finding of a higher number of cases of pancreatitis is worth noting.

## Implications for research

The need for future research must be grounded in the current evidence base synthesised within this network. Given the widespread use of both adalimumab and infliximab in medically induced maintenance therapy and the results within the network, both treatments require further research. Such trials may consider multiple trial arms including both placebo and other 'standard' therapies, such as 5-ASA. Similarly, given the lack of evidence to support the use of thiopurines despite their widespread use and recognition in international guidelines, future research involving these agents is clearly key. Placebo trials are not needed, rather trials comparing with either biologic or 5-ASA therapy may have the most utility. Whilst other agents may need researching, these would not currently be priorities.

The design of such studies is key. We would highly recommend that researcher consider the core set of outcome measures recently proposed (Kim 2017). Additionally, longer follow-up will be of significant benefit for clinicians interpreting results with clearer reporting on withdrawals from study.

The issue of sample size must be highlighted. Many of the studies included in this review were very small. We would strongly advise the use of indicative odds ratios from this review when performing power calculations. Such accurate calculations are vital to halt the large number of low-powered studies and include the precision of findings.

In terms of study design, allocation concealment and blind outcome assessment were major sources of bias in the review, which should be improved on in future trials. There is also a need for better outcome reporting, in particular adverse events, which will provide a much needed understanding of the safety of these interventions.

## ACKNOWLEDGEMENTS

• Funding for the Cochrane IBD Group (1 May 2017 to 30 April 2022) has been provided by Crohn's and Colitis Canada (CCC).

• Funding for Zipporah Iheozor-Ejiofor and Teuta Gjuladin-Hellon and partial funding for Morris Gordon was provided through a larger National Institute for Health Research Cochrane Programme Grant in the UK.

• Andrew Clegg is partially funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC) and through an NIHR Cochrane Programme Grant. The views expressed herein are those of the authors and not necessarily those of the National Health Service (NHS), NIHR, or Department of Health and Social Care.

• Suzanne Freeman is partially funded by the National Institute for Health Research (NIHR) Complex Reviews Support Unit (project number 14/178/29). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS), or the Department of Health.

## REFERENCES

## References to studies included in this review

#### Ardizzone 2004 {published data only}

Ardizzone S, MacOni G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. *Gastroenterology* 2004;**127**(3):730–40.

## Armuzzi 2013 {published data only}

Armuzzi A, Felice C, Marzo M, Pugliese D, Andrisani G, Papa A, et al. Prevention of postoperative recurrence with azathioprine or anti-TNF alpha in patients with Crohn's disease: an open-label pilot study. *Gastroenterology* 2012; **142**(5):S780.

\* Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. *Journal of Crohn's and Colitis* 2013;7(12):623–9.

#### Bergman 1976 {published data only}

Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. *Scandinavian Journal* of Gastroenterology 1976;**11**(7):651–6.

## Brignola 1995 {published data only}

Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. *Gastroenterology* 1995;**108**(2):345–9.

## Caprilli 1994 {published data only}

Caprilli R, Andreoli A, Capurso L, Corrao G, D'Albasio G, Gioieni A. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. *Alimentary Pharmacology & Therapeutics* 1994;**8**(1): 35–43.

#### Caprilli 2003 {published data only}

Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. *Alimentary Pharmacology & Therapeutics* 2003;**17**(4): 517–23.

## Chermesh 2007 {published data only}

Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. *Digestive Diseases and Sciences* 2007;**52**(2):385–9.

## D'Haens 2008 {published data only}

D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's Disease: a controlled randomized trial. *Gastroenterology* 2008;**135**(4):1123–9.

#### Ewe 1989 {published data only}

Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. *Digestion* 1989;**42**(4):224–32.

## Ewe 1999 {published data only}

Ewe K, Böttger T, Buhr HJ, Ecker KW, Otto HF. Lowdose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. *European Journal of Gastroenterology* & *Hepatology* 1999;11(3):277–82.

## Fedorak 2015 {published data only}

Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. *Gastroenterology and Hepatology* 2015;**13**:928–35.

NCT00175292. A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's. clinicaltrials.gov/ct2/show/ NCT00175292 (first received 15 September 2005).

## Florent 1996 {published data only}

Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. *European Journal of Gastroenterology & Hepatology* 1996;**8**(3):229–33.

## Fukushima 2018 {published data only}

\* Fukushima K, Sugita A, Futami K, Takahashi KI, Motoya S, Kimura H, et al. Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan. *Surgery Today* 2018;**48**(6): 584–90.

JPRN-UMIN000002604. Combined therapy of infliximab with surgery in maintenance of remission in Crohn's disease. upload.umin.ac.jp/cgi-open-bin/ctr\_e/ctr\_view.cgi?recptno= R000003157 (first received 1 November 2009).

## Gossum 2007 {published data only}

Gossum A, Dewit O, Louis E, Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. *Inflammatory Bowel Diseases* 2007;**13**(2):135–42.

## Hanauer 2004 {published data only}

Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Can we prevent the inevitable? The use of 6-mercaptopurine or mesalamine to

prevent postoperative recurrence in patients with Crohn disease. *Evidence-Based Gastroenterology* 2005;**6**(1):17–9. \* Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. *Gastroenterology* 2004;**127**(3):723–9.

## Hellers 1999 {published data only}

Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. *Gastroenterology* 1999;**116**(2):294–300.

#### Herfarth 2006 {published data only}

Herfarth H, Obermeier F, Tjaden C, Lukas M, Serclova Z, Dignass AU, et al. Double-blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5-ASA) for prevention of postoperative endoscopic recurrence in Crohn's disease. Gastroenterology 2006; Vol. 130, issue 4 Suppl 2:A480–1.

\* Herfarth H, Tjaden C, Lukas M, Obermeier F, Dilger K, Muller R, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. *Gut* 2006;**55**(10):1525–6. Muller R, Herfarth H. More information on study in 2006 Gut [personal communication]. Email to: M Gordon 2 May 2012.

## Herfarth 2013 {published data only}

Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV Jr, Sands BE, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. *Inflammatory Bowel Diseases* 2013;**19**(5):1073–9. NCT00609973. Ciprofloxacin for the prevention of postoperative endoscopic recurrence in Crohn's disease. clinicaltrials.gov/ct2/show/NCT00609973 (first received 7 February 2008).

#### Lochs 2000 {published data only}

Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. *Gastroenterology* 2000;**118**(2): 264–73.

#### Lopez Sanroman 2017 {published data only}

Lopez-Sanroman A, Vera-Mendoza I, Domenech E, Taxonera C, Vega V, Marin-Jimenez I, et al. APPRECIA: adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A GETECCU multicenter randomized trial. *United European Gastroenterology Journal* 2015;1:A3.

\* Lopez-Sanroman A, Vera-Mendoza I, Domenech E, Taxonera C, Vega V, Marin-Jimenez I, et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial. *Journal of Crohn's and Colitis* 2017;**11**(11):1293–301.

NCT01564823. Adalimumab on preventing post-chirurgic recurrence on Crohn's disease. clinicaltrials.gov/ct2/show/ NCT01564823 (first received 28 March 2012).

Taxonera C, Lopez-Sanroman A, Vera I, Nos P. Healthrelated quality of life improves during one year of postoperative prophylactic drug therapy after ileocecal intestinal resection in Crohn's disease patients: results of the APPRECIA randomized trial. *Gastroenterology* 2016;1: S442–3.

#### Mañosa 2013 {published data only}

Manosa M, Cabre E, Bernal I, Esteve M, Garcia-Planella E, Ricart Gomez E, et al. Azathioprine versus azathioprine plus metronidazole for the prevention of postoperative endoscopic recurrence of Crohn's disease: a randomized, placebo-controlled trial. *Journal of Crohn's and Colitis* 2012; **1**:S93.

\* Mañosa M, Cabré E, Bernal I, Esteve M, Garcia-Planella E, Ricart E, et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Inflammatory Bowel Diseases* 2013;**19**(9):1889–95.

## Marteau 2006 {published data only}

Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. *Gut* 2006;**55**(6):842–7.

## McLeod 1995 {published data only}

McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. *Gastroenterology* 1995;**109**(2):404–13.

#### Mowat 2016 {published data only}

Arnott I, Mowat C, Ennis H, Keerie C, Lewis S, Cahill A, et al. The TOPPIC trial: a randomised, double-blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. *Gut* 2016;**65**:A43–4.

ISRCTN89489788. Randomised controlled trial of 6-Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ ISRCTN89489788 (first received 15 June 2007).

\* Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. *Lancet Gastroenterology and Hepatology* 2016;**1**(4):273–82.

#### Prantera 2002 {published data only}

Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. *Gut* 2002;**51**(3): 405–9.

## Regueiro 2009 {published data only}

NCT00688636. Infliximab for the prevention of recurrent Crohn's disease after surgery. clinicaltrials.gov/ct2/show/ NCT00688636 (first received 3 June 2008).

Regueiro M, El-Hachem S, Kip KE, Schraut W, Baidoo L, Watson A, et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. *Digestive Diseases and Sciences* 2011;**56**(12):3610–5.

\* Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. *Gastroenterology* 2009;**136** (2):441–50.

#### Regueiro 2016 {published data only}

EUCTR2010-018431-18-DE. A multicenter trial comparing REMICADE (infliximab) and placebo in the prevention of recurrence in Crohn's disease patients undergoing surgical resection who are at an increased risk of recurrence. clinicaltrialsregister.eu/ctr-search/trial/2010-018431-18/GB (first received 6 July 2010).

\* Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. *Gastroenterology* 2016;**150**(7):1568–78.

## Reinisch 2010 {published data only}

Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. *Gut* 2010;**59**(6):752–9. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Greinwald R, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence: follow-up data of a randomised, double-blind, double-dums, 1-year, multicentre trial. *Journal of Crohn's and Colitis* 2013;**7**(1): S254.

#### Rutgeerts 2005 {published data only}

Rutgeerts P, Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. *Gastroenterology* 2005;**128**(4):856–61.

#### Savarino 2013 {published data only}

Bodini G, Pellegatta G, Giannini EG, Savarino V, Savarino EV. Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post-hoc analysis of a prospective randomized study. *Gastroenterology* 2017;**152**(5 Suppl 1): S774.

Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. *American Journal of Gastroenterology* 2013;**108**:1731–42.

#### Scapa 2015 {published data only}

Scapa E, Maharshak N, Kariv Y, Ben-Horin S, White ID, Santo E, et al. Early initiation of adalimumab significantly diminishes post-operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. *Gastroenterology* 2015;**148**(4 Suppl 1):S240–1.

#### Sutherland 1997 {published data only}

Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. *Gastroenterology* 1997;**112**(4):1069–77.

#### Tursi 2014 {published data only}

Tursi A, Elisei W, Picchio M, Zampaletta C, Pelecca G, Faggiani R, et al. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. *Techniques in Coloproctology* 2014;**18**(11): 1041–6.

### Wenckert 1978 {published data only}

Wenckert A, Kristensen M, Eklund AE, Barany F, Jarnum S, Worning H, et al. The long-term 20 prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with 21 Crohn's disease. A controlled double-blind trial. *Scandinavian Journal of Gastroenterology* 1978;**13**(2): 161–7.

#### Yoshida 2012 {published data only}

Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. *Inflammatory Bowel Diseases* 2012;**18**(9):1617–23.

#### References to studies excluded from this review

## Angelberger 2013 {published data only}

Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. *Inflammatory Bowel Diseases* 2013;**19**(3):590–8.

## Armuzzi 2015 {published data only}

Armuzzi A, Felice C, Marzo M, Pugliese D, Andrisani G, Papa A, et al. Infliximab is more effective than azathioprine in the long-term prevention of postoperative recurrence of Crohn's disease. *Gastroenterology* 2015;**148**(4):S856.

## Balzola 2010 {published data only}

Balzola F, Bernstein C, Van Assche G. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study: Commentary. *Inflammatory Bowel Disease Monitor* 2010;**10**(3):102–3.

#### Bodini 2014a {published data only}

Bodini G, De Cassan C, Savarino V, Savarino E. Letter: Biological therapies are effective for prevention of

post-operative Crohn's disease recurrence. *Alimentary Pharmacology and Therapeutics* 2014;**40**(3):322.

#### Bodini 2014b {published data only}

Bodini G, Savarino V, Peyrin-Biroulet L, deCassan C, Dulbecco P, Baldissarro I, et al. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. *Digestive and Liver Disease* 2014;**46**(11):1043–6.

## Bodini 2015 {published data only}

Bodini G, Savarino V, Marabotto E, Savarino E. Antitumor necrosis factor antibodies for prevention of Crohn's disease recurrence after surgery: more than a hope. *Clinical Gastroenterology and Hepatology* 2015;**13**(10):1856.

## Bourreille 2005 {published data only}

Bourreille A. Efficacy of azathioprine and its derivative, 6-mercaptopurine in the prevention of post operative recurrent Crohn's disease [Efficacité de l'azathioprine et de son dérivé la 6-mercaptopurine pour la prévention des rechutes post-opératoires de maladie de Crohn]. *Gastroentérologie Clinique et Biologique* 2005;**29**(3):319–21. DOI: http://dx.doi.org/10.1016/S0399-8320(05)80774-2

## De Cruz 2012 {published data only}

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Gorelik A, Liew D, et al. Adalimumab prevents postoperative Crohn's disease recurrence, and is superior to thiopurines: early results from the POCER study. *Journal of Gastroenterology and Hepatology* 2012;4:100.

#### De Cruz 2013a {published data only}

De Cruz P, Kamm M, Hamilton A, Ritchie K, Gearry R (editors). Strategic timing of anti-TNF therapy in postoperative Crohn's disease: comparison of routine use immediately postoperatively with selective use after demonstrated recurrence at 6 month endoscopy. Results from POCER. *Journal of Gastroenterology and Hepatology* 2013;**28**(Suppl 2):92.

#### De Cruz 2013b {published data only}

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Smoking is the key risk factor that doubles the risk of postoperative recurrence of Crohn's disease despite preventive drug treatment. Results from the POCER study. *United European Gastroenterology Journal* 2013;**1**:A95.

## De Cruz 2013c {published data only}

De Cruz P, Kamm M, Hamilton A, Ritchie K, Krejany S, Gorelik A, et al. Strategic timing of anti-TNF therapy in postoperative Crohn's disease: comparison of routine use immediately postoperatively with selective use after demonstrated recurrence at 6 month endoscopy: results from POCER. *United European Gastroenterology Journal* 2013;**1**:A16.

#### De Cruz 2015a {published data only}

De Cruz P, Kamm A, Hamilton KJ, Ritchie EO, Krejany A, Gorelik D, et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. *Alimentary Pharmacology & Therapeutics* 2015;**42**(7):867–79.

#### De Cruz 2015b {published data only}

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. *Lancet* 2015;**385** (9976):1406–17. DOI: 10.1016/S0140-6736(14)61908-5

#### Doherty 2009 {published data only}

Doherty GA, Cheifetz AS. Targeting TNF in postoperative recurrence of Crohn's disease: can we extinguish the fire before it starts?. *Inflammatory Bowel Diseases* 2009;**15**(12): 1925–6.

## Dumois 2001 {published data only}

Dumois RA, Herrera JL. Can postoperative relapse of Crohn's disease be prevented?. *American Journal of Gastroenterology* 2001;**96**(1):249.

## Ewe 1976 {published data only}

Ewe K, Holtermuller KH, Baas U, Eckardt V, Kreig H, Kutzner J, et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double-blind study [Rezidivprophylaxenach darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine doppelblindstudie]. *Verhandlungen der Deutschen Gesellschaft fur Innere Medizin* 1976;**82**(Pt 1):930–2.

#### Ewe 1980 {published data only}

Ewe K, Herfarth C, Malchow H. Surgical and internal medicine therapy study of the postoperative prevention of recurrence in Crohn's disease - completion of a partly randomized study. *Verhandlungen der Deutschen Gesellschaft fur Innere Medizin* 1980;**86**:1327–37.

#### Ewe 1981 {published data only}

Ewe K. Effectiveness of Azulfidine/Salazopyrin in the postoperative prevention of recurrence in Crohn disease [Wirksamkeit von Azulfidine/Salazopyrin zur postoperativen rezidivprophylaxe bei Morbus Crohn]. Zeitschrift fur Gastroenterologie - Verhandlungsband 1981;**19**: 41–4.

## Ewe 1984 {published data only}

Ewe K, Malchow H, Herfarth C. Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study - initial results. *Langenbecks Archiv fur Chirurgie* 1984;**364**:427–30.

#### Ferrante 2014 {published data only}

Ferrante M, Papamichael K, Duricova D, D'Haens GH, Vermeire S, Archavlis EJ, et al. Systematic versus endoscopydriven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence: interim results from a randomized, multicenter trial. *Gastroenterology* 2014;**146**(5 Suppl 1):S–592.

#### Ford 2010 {published data only}

Ford AC. Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. *Gut* 2010;**59**(12):1731–2.

#### Herfarth 2014 {published data only}

Herfarth HH. Anti-tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery. *Clinical Gastroenterology and Hepatology* 2014;**12**(9):1503–6.

## Kamm 2014a {published data only}

Kamm MA, De Cruz PP, Wright EK, Hamilton AL, Ritchie KJ, Krejany EO, et al. Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study. *Gastroenterology* 2014;1:S164.

## Kamm 2014b {published data only}

Kamm MA, De Cruz PP, Wright EK, Hamilton AL, Ritchie KJ, Krejany EO. Optimising post-operative Crohn's disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. *Journal of Crohn's and Colitis* 2014;**8**:S13.

## Kennedy 2015 {published data only}

Kennedy NA, Ennis H, Gaya DR, Mowat C, Arnott IDR. Interobserver agreement in assessment of Rutgeerts' score of endoscopic recurrence of ileal Crohn's disease: a substudy of the TOPPIC trial. *Journal of Crohn's and Colitis* 2015;**9**: S231–2.

## Liao 2009 {published data only}

Liao NS, Ren JA, Fan CG, Wang GF, Zhao YZ, Li JS. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease. *Chinese Journal of Gastrointestinal Surgery* 2009;**12**(2): 167–9.

## Manship 2015 {published data only}

Manship TA, Ford AC. VSL#3 in postoperative Crohn's disease. *Clinical Gastroenterology and Hepatology* 2015;**13** (10):1855.

## Mardini 2005 {published data only}

Mardini HE. Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: is no evidence of effect an evidence of no effect? [3] (multiple letters). *Gastroenterology* 2005;**128**(1):246–9.

## McLeod 1997 {published data only}

McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. *Gastroenterology* 1997;**113**(6):1823–7.

## NCT00074542 {published data only}

NCT00074542. An efficacy and safety study of Omega-3 free fatty acids (Epanova<sup>TM</sup>) for the maintenance of symptomatic remission in subjects with Crohn's disease. clinicaltrials.gov/ct2/show/NCT00074542 (first received 16 December 2003).

## NCT01190839 {published data only}

NCT01190839. A multicenter trial comparing REMICADE (Infliximab) and placebo in the prevention of recurrence in Crohn's disease (CD) patients undergoing surgical resection who are at an increased risk of recurrence. clinicaltrials.gov/ct2/show/NCT01190839 (first received 30 August 2010).

## NCT01696942 {published data only}

NCT01696942. Cimzia versus mesalamine for Crohn's recurrence. clinicaltrials.gov/show/NCT01696942 (first received 2 October 2012).

#### NCT02247258 {published data only}

NCT02247258. Azathioprine in the prevention of ileal Crohn's disease postoperative recurrence. clinicaltrials.gov/ ct2/show/NCT02247258 (first received 23 September 2014).

#### NCT02255370 {published data only}

NCT02255370. Curcumin associated with thiopurin in the prevention of post-op recurrence in Crohn disease. clinicaltrials.gov/ct2/show/NCT02255370 (first received 2 October 2014).

## NCT02997059 {published data only}

NCT02997059. Effect of fluconazole on the levels of ASCA after surgical resection for Crohn's disease. clinicaltrials.gov/ ct2/show/NCT02997059 (first received 19 December 2016).

## Papamichael 2012 {published data only}

Papamichael K, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. *Journal of Crohn's and Colitis* 2012;**6**(9): 924–31.

## Regueiro 2013 {published data only}

Regueiro M, Baidoo L, Kip KE, Swoger JM, Binion DG, Hashash JG, et al. Infliximab maintenance beyond one year prevents postoperative Crohn's disease recurrence: longterm follow-up from the randomized controlled pilot study. *Gastroenterology* 2013;**144**(5 Suppl 1):S173.

#### Regueiro 2014 {published data only}

Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. *Clinical Gastroenterology and Hepatology* 2014;**12**(9):1492–502.e1.

## Reibetanz 2015 {published data only}

Reibetanz J, Germer CT. Optimal management of Crohn's disease after intestinal resection. *Der Chirurg; Zeitschrift fur alle Gebiete der Operativen Medizen* 2015;**86**(11):1070.

## Ren 2013 {published data only}

Ren J, Wu X, Liao N, Wang G, Fan C, Liu S, et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. *Journal of International Medical Research* 2013;**41**(1): 176–87.

## Sandborn 2004 {published data only}

Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. *Gastroenterology* 2004;**127**(3):990–3.

#### Steinhart 1992 {published data only}

Steinhart AH, O'Rourke K, Wolff BG, McLeod RS. Application of a stopping rule based on total treatment failures: the postoperative Crohn's disease trial. *Journal of Clinical Epidemiology* 1992;**45**(5):495–504.

## Tao 2009 {published data only}

Tao QS, Ren JA, Ji ZL, Li JS, Wang XB, Jiang XH. Maintenance effect of polyglycosides of Tripterygium

wilfordii on remission in postoperative Crohn disease. *Chinese Journal of Gastrointestinal Surgery* 2009;**12**(5): 491–3.

#### Vera-Mendoza 2017 {published data only}

Vera-Mendoza I, Domenech E, Taxonera C, Ruiz VV, Marin-Jimenez I, Guardiola J, et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial. *Journal* of Crohn's and Colitis 2017;**11**(11):1293–301.

## Wright 2014 {published data only}

Wright EK, Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany S, et al. Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study. *Gastroenterology* 2014;**156**:S435.

## Wright 2015 {published data only}

Wright EK, Kamm MA, Cruz P, Hamilton AL, Ritchie K, Bell SJ, et al. Structured post-operative treatment and monitoring to prevent Crohn's disease recurrence is cost effective. Results from the POCER study. *Journal of Gastroenterology and Hepatology* 2015;**30**:145.

## Yamamoto 2009 {published data only}

Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. *Inflammatory Bowel Diseases* 2009; **15**(10):1460–6.

#### Yamamoto 2013 {published data only}

Yamamoto T. Adalimumab or infliximab for the prevention or treatment of post-operative recurrence in Crohn's disease. *Journal of Crohn's and Colitis* 2013;7(4):157.

## Zhu 2015 {published data only}

Zhu W, Li Y, Gong J, Zuo L, Zhang W, Cao L, et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. *Digestive and Liver Disease* 2015;47(1):14–9.

#### References to studies awaiting assessment

#### NCT00976690 {published data only}

NCT00976690. Comparison azathioprine to mesalazine for the prevention of postoperative recurrence in the Crohn Disease (IMURELPOST). clinicaltrials.gov/ct2/show/ NCT00976690 (first received 14 September 2009).

#### NCT01698970 {published data only}

NCT01698970. Effect of the consumption of a probiotic strain on the prevention of post-operative recurrence in Crohn's disease. clinicaltrials.gov/ct2/show/NCT01698970 (first received 3 October 2012).

## References to ongoing studies

## EUCTR2015-000555-24-NL {published data only}

EUCTR2015-000555-24-NL. Randomized, placebocontrolled, double-blind, multicenter study to determine the effectiveness and safety of vedolizumab in prevention of recurrence of Crohn's disease of the mucosa in patients with surgical removal of the area between the small and the large bowel. clinicaltrialsregister.eu/ctr-search/trial/2015-000555-24/NL (first received 2 October 2016).

## NCT01015391 {published data only}

NCT01015391. Efficacy study of T2 versus AZA to maintain clinical and endoscopic remission in postoperative Crohn's disease. clinicaltrials.gov/show/NCT01015391 (first received 18 November 2009).

## NCT02834754 {published data only}

NCT02834754. A randomized, double-blind, placebo controlled study of vedolizumab for the prevention of postoperative Crohn's disease recurrence. clinicaltrials.gov/ show/NCT02834754 (first received 15 July 2016).

## NCT03185611 {published data only}

NCT03185611. Effectiveness of rifaximin combined with thiopurine on preventing postoperative recurrence in Crohn's disease. clinicaltrials.gov/show/NCT03185611 (first received 14 June 2017).

## NCT03185624 {published data only}

NCT03185624. Effectiveness of rifaximin on preventing postoperative recurrence in Crohn's disease. clinicaltrials.gov/ct2/show/NCT03185624 (first received 14 June 2017).

## NCT03456752 {published data only}

NCT03456752. Perioperative dexamethasone on postoperative outcome in IBD. clinicaltrials.gov/show/ NCT03456752 (first received 7 March 2018).

## NL6213 (NTR6385) {published data only}

NL6213 (NTR6385). A trial to compare if the diseased area between the colon and the small bowel of patients with Crohn's disease stays free of disease after surgery between a group of patients whom receive no medication versus a group whom receive vedolizumab. https:// www.trialregister.nl/trial/6213 (first received 24 April 2017).

## Additional references

## Achana 2013

Achana FA, Cooper NJ, Dias S, Lu G, Rice SIC, Kendrick D, et al. Extending methods for investigating the relationship between treatment effect and baseline risk for pairwise meta-analysis to network meta-analysis. *Statistics in Medicine* 2013;**32**:752–71.

## Akobeng 2016

Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medicallyinduced remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2016, Issue 9. DOI: 10.1002/ 14651858.CD003715.pub3

## Behm 2008

Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2008, Issue 1. DOI: 10.1002/14651858.CD006893

#### Bernell 2000

Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. *Annals of Surgery* 2000;**231**:38–45.

## Borenstein 2009

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, West Sussex, UK: John Wiley & Sons Ltd, 2009.

#### Chande 2015

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2015, Issue 10. DOI: 10.1002/14651858.CD000067.pub3

#### CINeMA 2017 [Computer program]

Institute of Social and Preventive Medicine, University of Bern. CINeMA: Confidence in Network Meta-Analysis. Bern: University of Bern, accessed 9 February 2019.

#### Cohen 1988

Cohen J. *Statistical Power Analysis in the Behavioral Sciences.* 2nd Edition. Hillsdale (NJ): Lawrence Erlbaum Associates Inc, 1988.

## Colonna 1994

Colonna T, Korelitz BI. The role of leukopenia in the 6mercaptopurine induced remission of refractory Crohn's disease. *American Journal of Gastroenterology* 1994;**89**: 362–6.

## Cooper 2009

Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. *Statistics in Medicine* 2009;**28**:1861–81.

## Cui 2004

Cui HH. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. *World Journal of Gastroenterology* 2004;**15**:1521–5.

## Di Sario 2016

Di Sario A, Bendia E, Schiadà L, Sassaroli P, Benedetti A. Biologic drugs in Crohn's disease and ulcerative colitis: safety profile. *Current Drug Safety* 2016;**11**:55–61.

#### Dias 2010

Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Statistical Methodology* 2010;**29**:932–44.

## Egger 2001

Egger M, Davey-Smith G, Altman D (editors). *Systematic Reviews in Health Care: Meta-Analysis in Context.* 2nd Edition. London: BMJ Publishing Group, 2001.

#### FDA 2018

US Food, Drug Administration. Code of Federal Regulations Title 21.:21CFR312.32. https:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ cfrsearch.cfm?fr=312.32 (accessed 10 January 2018).

#### Gionchetti 2017

Gionchetti P, Dignass A, Danese S, Dias FJM, Rogler G, Lakatos PL. ECCO; 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations. *Journal of Crohn's and Colitis* 2017;**11**:135–49.

## Gjuladin-Hellon 2019a

Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2019, Issue 6. DOI: 10.1002/14651858.CD008414.pub3

## Gjuladin-Hellon 2019b

Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2019, Issue 8. DOI: 10.1002/14651858.CD010233.pub3

#### Gklavas 2017

Gklavas A, Dellaportas D, Papaconstantinou I. Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors. *American Journal of Gastroenterology* 2017;**30**:598–612.

## Gordon 2017

Gordon M. 5-aminosalicylates to maintain remission in Crohn's disease: interpreting conflicting systematic review evidence. *World Journal of Gastrointestinal Pharmacology and Therapeutics* 2017;**8**(8):99–102. DOI: 10.4292/ wjgpt.v8.i2.99

#### GRADEpro 2015 [Computer program]

McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.).

## Guyatt 2011

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6: rating the quality of evidence - imprecision. *Journal of Clinical Epidemiology* 2011;**64**(12):1283–93.

#### Hafraoui 2002

Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, et al. Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate [Le mycophénolate mofétil dans les formes chroniques actives de la maladie de Crohn après échec de lazathioprine ou du méthotrexate]. *Gastroenterologie Clinique et Biologique* 2002;**26**:17–22.

## Hanauer 2001

Hanauer SB, Sandborn W. Management of Crohn's disease in adults. *American Journal of Gastroenterology* 2001;**96**: 635–43.

#### Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

#### Jansen 2014

Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. *Value Health* 2014;**17**:157–73.

## Kim 2017

Kim A, Roberts C, Feagan B, Banerjee R, Bemelman W, Bodger K. Developing a standard set of patient-centred outcomes for inflammatory bowel disease - an international, cross-disciplinary consensus. *Journal of Crohn's and Colitis* 2017;**12**:408–18.

## Levin 2016

Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. *Journal of Crohn's and Colitis* 2016;**10**:989–97.

#### Lichtenstein 2018

Lichtenstein G, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Management of Crohn's disease in adults. *American Journal of Gastroenterology* 2018;**113**:481–517.

## Lunn 2000

Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS a Bayesian modelling framework: concepts, structure, and extensibility. *Statistics and Computing* 2000;**10**:325–37.

## Ma 2017

Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JH, et al. Surgical rates for Crohn's disease are decreasing: a population-based time trend analysis and validation study. *American Journal of Gastroenterology* 2017; **112**:1840–8.

## Mbuagbaw 2017

Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. *Systematic Reviews* 2017;**6**(1):79.

#### NICE 2012

Mayberry JF, Lobo A, Ford AC, Thomas A. NICE clinical guidelines (CG152): the management of Crohn's disease in adults, children and young people. *Alimentary Pharmacology* & *Therapeutics* 2012;**37**(2):195–203. DOI: 10.1111/apt.12102

## **NICE 2019**

National Institute of Health and Care Excellence. Crohn's disease: management [NG129]. www.nice.org.uk/ guidance/ng129/evidence/postsurgical-maintenance-of-remission-pdf-6777581006 (accessed 12 June 2019).

## Norman 2018

Norman G, Westby MJ, Rithalia AD, Stubbs N, Soares MO, Dumville JC. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database of Systematic Reviews* 2018, Issue 6. DOI: 10.1002/14651858.CD012583.pub2

#### Orlando 2014

Orlando A, Mocciaro F, Renna S, Scimeca D, Rispo A, Scribano ML, et al. Early post-operative endoscopic

recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. *Journal of Crohn's and Colitis* 2014;**8**(10):1217–21.

### Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistical Methodology* 1998;17: 2815–34.

#### Review Manager 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

## Rutgeerts 2002

Rutgeerts P. Crohn's disease recurrence can be prevented after ileal resection. *Gut* 2002;**51**:152–3.

#### Salanti 2014

Salanti G, Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network metaanalysis. *PLOS ONE* 2014;**9**:e99682.

## Schünemann 2011a

Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

#### Schünemann 2011b

Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

## Spiegelhalter 2002

Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. *Journal of the Royal Statistical Society: Series B* 2002;**64**:583–639.

## Spiegelhalter 2004

Spiegelhalter DJ, Abrams KR, Myles JP. *Bayesian Approaches to Clinical Trials and Health-Care Evaluation*. Chichester, West Sussex, UK: John Wiley and Sons Ltd, 2004.

#### Stata 2017 [Computer program]

StataCorp LLC. Stata Statistical Software. Version Release 15. College Station, TX: StataCorp LLC, 2017.

## Steinhart 2003

Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2003, Issue 4. DOI: 10.1002/14651858.CD000301

## Sutton 2000

Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. *Methods for meta-analysis in medical research*. Chichester, West Sussex, UK: John Wiley & Sons Ltd, 2000.

## Svartz 1942

Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. *Acta Medica Scandinavica* 1942;**110**:557–90.

## Warren 2014

Warren FC, Abrams KR, Sutton AJ. Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes. *Statistics in Medicine* 2014;**33**:2449–61.

## Welton 2012

Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades

AE. Evidence synthesis in decision making in healthcare. Chichester, West Sussex, UK: John Wiley & Sons Ltd, 2012.

## Yepes-Nuñez 2019

Yepes-Nuñez JJ, Lic S-A, Gordon Guyatt G, Jack SM, Brozek JL, Beyene J, et al. Development of the summary of findings table for network meta-analysis. *Journal of Clinical Epidemiology* 2019;**115**:1–13. DOI: 10.1016/ j.jclinepi.2019.04.018

## References to other published versions of this review

#### Clegg 2018

Clegg A, Iheozor-Ejiofor Z, Gordon M, MacDonald JK, Akobeng AK. Interventions for maintenance of surgicallyinduced remission in Crohn's disease: a network metaanalysis. *Cochrane Database of Systematic Reviews* 2018, Issue 11. DOI: 10.1002/14651858.CD013210

\* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

# Characteristics of included studies [ordered by study ID]

## Ardizzone 2004

Methods	<b>Study design:</b> RCT, single centre <b>Setting:</b> University "L.Sacco" Hospital (Milan, Italy), 1994 to 2001
Participants	<b>Inclusion:</b> Adult (18 to 70 years) participants who underwent surgery for symptomatic intestinal stenosis or occlusion, which is clinically quiescent (CDAI ≤ 150); able to start oral nutrition and oral medication within the first 2 postoperative weeks <b>Exclusion:</b> Contraindications for use of MES or AZA and pre-existing hepatic disease, renal dysfunction, clinically important lung disease, systemic infection, short-bowel syndrome, presence of alcoholic stoma, history of cancer, hypersensitivity to MES or AZA, erythrocyte macrocytosis, use of immunosuppressive drugs in the past 3 months; patients who had received treatment with anti-TNF- <i>α</i> within 6 months before surgery; pregnancy/breastfeeding; patients who had undergone surgical procedures other than conservative surgery or for perianal disease only; history of corticosteroid-dependent disease <b>Age (IG1/IG2) mean:</b> 38.4 years mean overall <b>Sex (M:F):</b> 95:52 overall; (45:26) vs (50:26) <b>Type of surgery:</b> Stricturoplasty 36; minimal bowel resection 70; minimal bowel resection stricturoplasty 36 <b>Previous surgery (IG1 + IG2):</b> 69/142 overall (38/71) vs (31/71) <b>Start of intervention after surgery:</b> < 2 weeks <b>Medication use (IG1 + IG2):</b> MES or sulfasalazine 62; corticosteroids 41; immuno- suppressants 9; none 30 <b>Smoker (IG1/IG2):</b> (28/71) vs (36/71) <b>Number randomised (n = 142):</b> 71 vs 71 <b>Number analysed (n = 138):</b> (69/71) vs (69/71) (ITT); 50/71 vs 61/71 (per protocol) <b>Postrandomisation exclusion (n = 11):</b> (6/71) vs (5/71) (did not start the treatment (3) (2 vs 1); lost to follow-up (8) (4 vs 4))
Interventions	<b>Group 1:</b> AZA administered at a dosage of 2 mg/kg/day <b>Group 2:</b> MES was administered at a dosage of 3 g/day divided into 3 doses <b>All participants:</b> Treatment with aminosalicylates, metronidazole, and any other CD- specific treatment had to be discontinued. Corticosteroids were allowed to be tapered by standardised stepwise dose reductions within 6 weeks after surgery at the latest. Symp- tomatic treatment with antacids, antidiarrhoeal agents, or spasmolytic agents was allowed but had to be scrupulously recorded. Compliance with treatment was evaluated by a simple questionnaire in which adverse events were also recorded. Participants receiving AZA were regularly assessed by total blood cell count and serum transaminase values to monitor any myelotoxicity and hepatotoxicity of the treatment. Participants were seen at baseline and every 6 months
Outcomes	<b>Duration of study:</b> 24 months 1. <b>Clinical relapse</b> defined as the presence of symptoms related to CD, variably associated with radiologic, endoscopic, and laboratory findings, with a CDAI score > 200, which is considered severe enough to warrant treatment with a systemic corticosteroid at a

# Ardizzone 2004 (Continued)

	medium-high dose 2. <b>Surgical relapse</b> defined as the presence of symptoms refractory to medical treatment or complications requiring another surgical procedure (e.g. occlusive disease, intra-ab- dominal abscesses, or high-flow fistulas) 3. <b>Adverse events</b>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Sample size:</b> Based on a maximum relapse rate at 2 years of 45% MES, 62 participants per treatment group was considered sufficient to detect a difference of $\geq 25\%$ for the AZA treatment group (type 1 error of 5%). The number of participants in each group was increased to 68 to compensate for an anticipated dropout rate of 10%

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "After surgery, participants who met the inclusion criteria and who agreed to enter the study were randomised to receive mesalamine or AZA by a computer-gen- erated list" and "Randomization was per- formed in blocks of 10" Comment: computer-generated block ran- domisation
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: the study is open-label and blinding is not performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment, however it is unlikely
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quotes: "In the intention-to-treat analysis, all randomised participants who received at least one dose of the study drug and were subjected to the baseline evaluation were considered for the analysis." and "Outcome measures were analysed in all randomised participants who had taken at least one dose of the study medication (intention-to-treat population)" Comment: withdrawals were low and bal- anced across groups

# Ardizzone 2004 (Continued)

Selective reporting (reporting bias)	Low risk	Trial registration not available, however, all outcomes stated in the method section were assessed and reported
Other bias	Low risk	Quote: "No significant differences were ob- served between the 2 treatment groups re- garding age, sex, duration of disease, lo- cation of disease, fistula and abscess at surgery, surgical procedure, previous oper- ations, and CD therapy during the previ- ous 6 months" Comment: baseline characteristics well bal- anced across groups
All domain risk of bias	Unclear risk	High

## Armuzzi 2013

Methods	<b>Study design:</b> RCT, single centre <b>Setting:</b> Italy, 2007 to 2011
Participants	<b>Inclusion:</b> Consecutive CD participants who underwent curative ileocolonic resection (all macroscopically inflamed tissues were removed and operative margins were disease- free at histopathology examination) and considered at "high risk" of postoperative re- currence were enrolled <b>Exclusion:</b> Active perianal disease, presence of stoma, adverse events during previous therapy with infliximab or azathioprine, age > 70 years, surgical complications, active infectious diseases, history of cancer, renal, cardiac, or hepatic failure, history of acute or chronic pancreatitis, severe leukopenia (WBC < 3000 $\mu$ U/mL, lymphocyte count < 1000 $\mu$ U/mL), and pregnancy <b>Age (IG1/IG2) median (range):</b> 32 (18 to 70) overall <b>Sex (M:F):</b> 15:7 overall; (7:4) vs (8:3) <b>Type of surgery:</b> Not reported <b>Previous surgery (IG1 + IG2):</b> Not reported <b>Start of intervention after surgery:</b> 2 to 4 weeks <b>Medication use (IG1 + IG2):</b> Previous treatment with AZA-5; previous treatment with IFX -10 <b>Smoker (IG1/IG2):</b> Not reported <b>Number randomised (n = 22):</b> 11/11 <b>Number analysed (n = 22):</b> (11/11) vs (11/11) <b>Postrandomisation exclusion (n = 0)</b>
Interventions	<b>Group 1:</b> Infliximab (5 mg/kg) at 0, 2, and 6 weeks and then every 8 weeks for 1 year <b>Group 2:</b> Azathioprine (2.5 mg/kg/day) for 1 year <b>All participants:</b> All participants also received oral metronidazole (500 mg twice daily) for 2 weeks after surgery. No other CD-related drugs were admitted during the study. Participants were evaluated monthly, according to laboratory tests, the Harvey-Bradshaw Index (HBI) calculation, and the adverse event report

# Armuzzi 2013 (Continued)

Outcomes	<ul> <li>Duration of study: 12 months and follow-up at 40 months</li> <li>1.Clinical recurrence defined by a HBI ≥ 8</li> <li>2. Endoscopic recurrence defined by a Rutgeerts' score ≥ i2 at 12 months and 40 months (follow-up)</li> <li>3. Histologic activity score based on a Histology Score System modified from Regueiro and colloacture</li> </ul>
	4. Adverse events
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Authors declare the following conflict of interest: AA received: consultancy from Abbvie, MSD; lecture fees from Abbvie, MSD, Chiesi, Ferring, Ny- comed, Otsuka; educational grants from Abbvie, MSD, Ferring, Nycomed. LG received: educational grants from Abbvie, MSD. CF, AP, MM, DP, GA, FF, IDV, GLR: nothing to declare

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Subjects were randomised with a simple unblinded 1:1 allocation ratio to re- ceive" Comment: simple randomisation per- formed, however insufficient information on the method of randomisation used
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label study
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "One unblinded endoscopist (AP) did all the examinations and calculated scores. Two further unblinded endoscopists (IDV and GA) separately reviewed videos and in case of discordance a consensus agreement was reached among the three op- erators." Comment: blinding of outcome assessors not performed
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "One patient did not tolerate aza- thioprine because of severe nausea with epi- gastric pain and withdrew from the study after 5 weeks of treatment" Comment: only one participant withdrew from the study and reason described

# Armuzzi 2013 (Continued)

Selective reporting (reporting bias)	Low risk	All outcome data stated in the method sec- tion were reported.
Other bias	Low risk	Groups well balanced at baseline and no other apparent sources of bias detected
All domain risk of bias	High risk	Very high
Bergman 1976		
Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Sweden/University Hospital Upsal Falun, 1969 to 1972	a, Country hospitals in Vastergas, Gavle and
Participants	<ul> <li>Inclusion: Participants with a true path-anatomical diagnosis of CD who had undergone macroscopically and microscopically radical resection of the gut in the mentioned hospitals between September 1969 and April 1972</li> <li>Exclusion: Salazopyrin intolerance, patients unable to follow given instructions for the medical therapy</li> <li>Age (IG1/IG2) median: Not reported; 28 years overall</li> <li>Sex (M:F): Not reported (reported for those 84 who completed the study: (20:29) vs (18:17))</li> <li>Type of surgery: Primary radical resection (70)</li> <li>Previous surgery (IG1 + IG2): Not reported</li> <li>Start of intervention after surgery: 7 to 8 days</li> <li>Medication use (IG1 + IG2): Previous treatment with AZA-5; previous treatment with INF -10</li> <li>Smoker (IG1/IG2): Not reported</li> <li>Number randomised (n = 97): 57/40</li> <li>Number analysed (n = 84): (49/57) vs (35/40)</li> <li>Postrandomisation exclusion (n = 13): (8/57) vs (5/40) (reasons not reported)</li> </ul>	
Interventions	<ul> <li>Group 1: Combination of sulfasalazine (Salazopyrin) and corticosteroids for 33 weeks. Salazopyrin tablets were administered in a dose of 3 g daily for 16 weeks, and then 1.5 g daily for 17 weeks. Prednisolone tablets were given 15 mg daily from the 7th to 8th postoperative day for 2 weeks, then 10 mg daily for 14 weeks, and 5 mg daily for the last 17 weeks</li> <li>Group 2: No treatment</li> <li>All participants: During the first postoperative year, all participants were checked up in the outpatient clinics at the time of changing medical treatment. Participants were followed up until 3 years after operation. Participants were seen at least once a year, and at least once a year (and when necessary) an X-ray was performed</li> </ul>	
Outcomes	<b>Duration of study:</b> 33 weeks 1. <b>Recurrence</b> based on typical roentgenolo and $> 2 \le 3$ years)	gic findings for CD (*reported $\leq 1$ , > 1 $\leq 2$ ,

# Bergman 1976 (Continued)

Notes Funding source: Supp Conflict of interest: N Power calculation: No *Data from > $1 \le 2$ ar was 33 weeks	orted by the Swedish Medical Research Council lot reported at reported ad > 2 ≤ 3 years not included in analysis as treatment duration
--	---

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "groups assigned by drawing a lot" Comment: simple randomisation
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Insufficient information provided, but blinding very unlikely
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "All the X-rays were scrutinised by a radiologist at the University Hospital in Upsala. The repeated examinations per- formed during the postoperative observa- tion years made it easier to diagnose a re- currence" Comment: insufficient information pro- vided, however it is unlikely
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition rates were low and balanced across groups, however reasons were not reported
Selective reporting (reporting bias)	Low risk	All outcomes stated in the methods section were reported.
Other bias	High risk	Baseline characteristics not provided. Im- balance in numbers randomised (40 vs 57)
All domain risk of bias	High risk	Very high

# Brignola 1995

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Italy, 8 centres, 1990 to 1992 enrolment
Participants	<b>Inclusion:</b> Patients with so-called curative resection, such as those who have undergone removal of all macroscopic disease in the ileal or ileocaecal region <b>Exclusion:</b> Patients with localisation of CD in another region or having resection of >

# Brignola 1995 (Continued)

	100 cm were excluded
	Age (IG1/IG2) mean (SD): 36.5 ± 14 overall; (39 ± 17) vs (34 ± 10)
	Sex (M:F): 42:45 overall; (22:22) vs (20:23)
	Type of surgery: Not reported
	<b>Previous surgery (IG1 + IG2):</b> 24 overall; (13/44) vs (11/43)
	Start of intervention after surgery: $\leq 1$ month
	Medication use (IG1 + IG2): Not reported
	Smoker (IG1/IG2): 44 overall (22/44) vs (22/43)
	Number randomised (n = $87$ ): $44/43$
	Number analysed (n = 85): $(43/44)$ vs $(42/43)$
	<b>Postrandomisation exclusion (n = 10)</b> : $(6/44)$ vs $(4/43)$ (side effects 8 $(5/3)$ ; lost to follow-up 1 $(1/0)$ ; protocol violation 1 $(0/1)$
Interventions	<b>Group 1:</b> MES tablets 3 g/day for 12 months (2 tablets Pentasa (500 mg) 3 times a day) <b>Group 2:</b> Identical placebo tablets <b>All participants:</b> Laboratory tests performed at baseline after 1 month and then every 3 months for evaluation of haematologic, renal, and hepatic function
Outcomes	<b>Duration of study:</b> 12 months 1. <b>Clinical recurrence</b> defined as worsening of symptoms by at least 100 CDAI points above the level at the previous visit and attainment of a CDAI score of more than 150 2. <b>Endoscopic recurrence</b> based on a standardised form for description of endoscopic lesions by type (aphthous lesion, large ulcer, nodule, or narrowing) and characteristics (number, size, and whether a diffuse or skip lesion) 3. <b>Severe endoscopic recurrences</b> (i score of 3 and 4) 4. <b>Withdrawal due to adverse events</b>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Sample size:</b> The severe endoscopic recurrence (score 3 to 4) rate in the placebo group was estimated to be 50%. The decision was made to enrol 80 participants (40 per group) to detect a significant difference in comparison with the active group (30% recurrence) (1-tailed test; $\alpha$ level, 5%)

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Each center received material for at least 4 cases labelled with a patient code number according to a randomisation made in balanced blocks" Comment: block random sequence gener- ation, but method not described
Allocation concealment (selection bias)	Unclear risk	Quote: "Each center received material for at least 4 cases labelled with a patient code number according to a randomisation made in balanced blocks"

# Brignola 1995 (Continued)

		Comment: unclear whether drug contain- ers were identical. Insufficient information to make judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The treatment blinding code was broken in September 1993 when all the as- sessments were finished; no serious adverse event necessitated breaking of the code be- forehand" Comment: double-blind trial, participants received placebo tablets that were identical to the study intervention
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Endoscopists, unaware of the treatment that the patient had received, recorded on a standardized form a descrip- tion of endoscopic lesions by typeAt the end of the trial, two investigators not pre- viously involved in the patients' follow-up and unaware of which treatment the pa- tients had received and also of the overall assessments provided by each center, inde- pendently evaluated all of the standardized forms with a description of endoscopic and radiological responses; their assessments were then compared with those furnished by the investigators from the original cen- terThe treatment blinding code was bro- ken in September 1993 when all the as- sessments were finished; no serious adverse event necessitated breaking of the code be- forehand" Comment: blinding maintained until after assessments were finished
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates were low and balanced across groups with reasons reported
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "Clinical characteristics that were considered in our trial were well balanced between the mesalamine group and the placebo" Comment: groups well balanced at base- line. No other apparent biases

# Brignola 1995 (Continued)

All domain risk of bias	Low risk	Low/unclear
Caprilli 1994		
Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Italy, 15 collaborating centres, 1990 to 1992 enrolment	
Participants	Inclusion: Age between 18 and 65 years for both sexes, disease limited to the terminal ileum with or without involvement of caecum-ascending colon; resection had to be the first one and judged to be 'radical' (complete removal of the macroscopically involved intestinal segment) by the surgeon during operation; absence of skip lesions; diagnosis of Crohn's disease confirmed macroscopically and microscopically by standard criteria <b>Exclusion:</b> Localisation of the disease to the jejunum, proximal ileum, left colon, or ano-rectum; known side effects from sulfasalazine or salicylates; severe diseases unrelated to Crohn's disease (e.g. renal or liver dysfunction); treatment with drugs that may alter intestinal pH (H,-receptor antagonists, omeprazole); pregnancy; questionable ability to co-operate and give consent Age (IG1/IG2) mean (range): 35.5 (16 to 61) vs 33.7 (16 to 58) Sex (M:F): 55:40 overall; (32:15) vs (23:25) Type of surgery: Elective 71; emergency 24 Previous surgery (IG1 + IG2): Not reported Start of intervention after surgery: $\leq 2$ weeks Medication use (IG1 + IG2): MES 46; corticosteroids 59; metronidazole 25; sulfasalazine 21 Smoker (IG1/IG2): Not reported Number randomised (n = 110): 55/55 Number analysed (n = 95): (47/55) vs (48/55) Postrandomisation exclusion (n = 17): (9/55) vs (8/55) (randomised, no endoscopy at base 15 (8/7): dropout 2 (1/1)	
Interventions	<ul> <li>Group 1: 2.4 g/day of Eudragit-S coated MES</li> <li>Group 2: No treatment</li> <li>All participants: Participants were seen for clinical and laboratory assessment at 2 weeks after surgery, at 3, 6, and 12 months, and annually thereafter. Colon-ileoscopy was performed at 6 and 12 months, and annually thereafter. Clinical, laboratory, and endoscopic examinations were brought forward if symptoms recurred. Participants requiring corticosteroids or surgery were withdrawn from the study. Participants who stopped the treatment for more than 2 weeks or who presented with severe side effects were considered to be dropouts. Adverse events and reported compliance with the drug were recorded at each visit</li> </ul>	
Outcomes	<b>Duration of study:</b> 24 months 1. <b>Recurrence</b> defined as the presence of t the neoterminal ileum or anastomosis, or Rutgeerts and colleagues (judged as no, mil 2. <b>Adverse events</b> (skin rash, epigastric pair 3. <b>Withdrawal due to adverse events</b>	ypical endoscopic Crohn's disease lesions in both according to the criteria proposed by d, or severe) 1, nausea, vomiting)

# Caprilli 1994 (Continued)

Notes	Funding source: Supported in part by Bracco SpA (Milan)
	Conflict of interest: Not reported
	Sample size: The study enrolled 55 consecutive participants in each arm of the trial,
	which was sufficient to demonstrate a fall in the recurrence rate from $90\%$ to $80\%$ with
	a power of 0.90 and a 0.05 one-sided type I error. Only the 95 participants with almost
	6 months of observation were considered in the statistical analysis

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Eligible patients were randomly al- located to receive 2.4 g/day of Eudragit- S coated mesalazine (Asacol, Bracco SPA, Italy) or no treatment at all" Comment: insufficient information on random sequence generation
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "This multicentre study was not blind" Comment: open-label study design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "On the first occasion, the endo- scopist was unaware of the treatment; on the second, the tapes were shown with a different sequence and the endoscopist was informed of treatment The variabil- ity sources of the recurrence classification were evaluated However, the results of the reliability study suggest that lack of blind- ness in the endoscopists collaborating on the trial was no relevant. In fact, we found that the endoscopists were not in disagree- ment in the assessment of recurrence nor was the diagnosis of recurrence affected by endoscopists' awareness of the kind of treat- ment" Comment: there was some form of blind outcome assessment, and the reliability study comparing blind vs unblind assess- ment showed that lack of blinding had no effect on outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The cumulative proportions of symptomatic recurrence and asymptomatic recurrence were estimated by the lifetable

# Caprilli 1994 (Continued)

		method on the intention-to-treat princi- ple" Comment: attrition rate was low and bal- anced across groups
Selective reporting (reporting bias)	Low risk	All outcome data stated in the methods sec- tion were reported
Other bias	Low risk	Quote: "the groups were homogenous for age, duration of the disease, site and extent of the lesions, clinical course perforating or non-perforating), previous treatment, indi- cation and type of surgery, and CDAI score at operation. Males more common in MEZ group" Comment: groups well balanced at base- line. No other apparent sources of bias de- tected
All domain risk of bias	Unclear risk	High

# Caprilli 2003

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Italy, 17 collaborating centres, enrolment 1997 to 2000
Participants	Inclusion: Adults (18 to 65 years) with CD limited to the terminal ileum (lesions not exceeding 1 m), with or without involvement of the caecum/ascending colon, evaluated by colonoscopy and small bowel follow-through within 1 month before surgery; 1st or 2nd resection, and considered by the surgeon during the operation to be 'radical' (complete removal of the macroscopically involved intestinal segment); absence of skip lesions; diagnosis of CD confirmed macroscopically and microscopically by standard criteria Exclusion: Localisation of the disease to the jejunum, proximal ileum, transverse colon, left colon, or ano-rectum; small bowel resection exceeding 1 m; known side effects from sulfasalazine or salicylates; severe diseases unrelated to Crohn's disease (e.g. renal or liver dysfunction); treatment with drugs likely to affect intestinal pH; pregnancy; questionable ability to co-operate; inability to give informed consent Age (IG1/IG2) mean: 33.8 vs 36.4; overall age not reported Sex (M:F): 114:93 overall; (49:52) vs (64/41) Type of surgery: Emergency 45; elective 161 Previous surgery (IG1 + IG2): First 166; second 40 Start of intervention after surgery: $\leq$ 2 weeks Medication use (IG1 + IG2): MES 153; steroids 123; antibiotics 71; immunosuppressants 20 Smoker (IG1/IG2): (21/ 101) vs (27/105) Number randomised (n = 206): 101/105 Number analysed (n = 202): (99/101) vs (103/105)
### Caprilli 2003 (Continued)

	<b>Postrandomisation exclusion (n = 61)</b> : Withdrawals from clinical control (n = 20) (6 vs 14); withdrawals from endoscopy (n = 41) (17 vs 24)
Interventions	<b>Group 1:</b> 4.0 g/day of oral Eudragit-S-coated MES (Asacol). Participants received 5 tablets of MES (800 mg) divided into 3 doses (1 + 2 + 2 tablets) <b>Group 2:</b> 2.4 g/day of oral Eudragit-S-coated MES (Asacol). Participants received 3 tablets of MES (800 mg) divided into 3 doses (1 + 1 + 1 tablets) plus 2 tablets of placebo identical in appearance <b>All participants:</b> No other pharmacological treatment was given, with the exception of antidiarrhoeal drugs on demand. Participants were seen for clinical and laboratory assessment 2 weeks after surgery, and then at 6 and 12 months. Colon ileoscopy was performed at 12 months. Clinical, laboratory, and endoscopic examinations were brought forward if recurrence of symptoms was reported before the scheduled follow-up. Adverse events and reported compliance with the drug were recorded at each visit
Outcomes	<ul> <li>Duration of study: 12 months</li> <li>1. Endoscopic recurrence defined as the presence of typical endoscopic CD lesions in the neoterminal ileum or anastomosis, or both, and was graded according to the criteria of Rutgeerts and colleagues. 3 different degrees of endoscopic recurrence were evaluated: (i) an endoscopic score of &gt; 0; (ii) an endoscopic score of &gt; 1; and (iii) an endoscopic score of &gt; 2 (severe recurrence)</li> <li>2. Clinical recurrence defined as CDAI &gt; 150 points or an increase in CDAI score of &gt; 100 points</li> <li>3.Adverse events</li> <li>4. Withdrawals due to adverse events</li> </ul>
Notes	<b>Funding source:</b> Supported by a grant from Giuliani SpA, Milan, Italy <b>Conflict of interest:</b> Not reported <b>Sample size:</b> Assuming that 2.4 g/day MES would reduce severe endoscopic recurrence from 70% to 55% at 1 year of follow-up, it was hypothesised that 4.0 g/day MES would reduce the rate of severe endoscopic recurrence to 30%. The number of participants needed to ensure a type 1 and type 2 error level of 5% calculated was 85 participants per group plus 25% dropouts (i.e. a further 43 participants). The total number of participants required was therefore 213

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomised in blocks of four according to a computer- generated randomization scheme provided by an independent institution at the begin- ning of the trial and forwarded to the De- partment of Clinical Trials at Giuliani SpA" Comment: computer-generated randomi- sation

### Caprilli 2003 (Continued)

Allocation concealment (selection bias)	Low risk	Quote: "provided by an independent in- stitution at the beginning of the trial and forwarded to the Department of Clinical Trials at Giuliani SpA" Comment: central allocation
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "All patients and investigators were blind with regard to treatment allocation" Comment: double-blinded RCT, but no explanation of how conditions of blind- ing were achieved. Given the variation in doses between study groups (5 vs 3 tablets) , blinding is unlikely
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "The treatment blinding code was broken in June 2000 when all assessments had been completed" Comment: assessors were blinded to treat- ment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Outcome measures were analysed in all randomized patients who had taken at least one dose of the study medication (intention-to-treat population)" Comment: attrition rates were similarly low and balanced across groups, except for the endoscopy outcome where attrition rates were about 20%
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated at the methods section were reported adequately
Other bias	Low risk	Groups well balanced at baseline, compli- ance satisfactory; no other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

#### Chermesh 2007

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> 4 medical centres in Israel, enrolment 1997 to 2000
Participants	<b>Inclusion:</b> CD participants undergoing resection in 1 of the medical centres affiliated with the study and who were eligible to take part according to their physician participated in the study <b>Exclusion:</b> not reported

### Chermesh 2007 (Continued)

	Age (IG1/IG2) mean (SD): 35.7 ± 12.2 overall; 36.1 ± 13.0 vs 34.7 ± 9.9
	Sex (M:F): 23:7 overall; (15:5) vs (8:2)
	Type of surgery: Not reported
	Previous surgery (IG1 + IG2): Not reported
	Start of intervention after surgery: As soon as participants resumed oral intake after
	surgery
	Medication use (IG1 + IG2): 5-ASA 58; immunosuppressants 59; at least 1 course of steroids 60
	Smoker (IG1/IG2): 10/30 overall: (8/20) vs (2/10)
	Number randomised ( $n = 30$ ): 20/10
	Number analysed (n = 30): $(20/20)$ vs $(10/10)$
	Postrandomisation exclusion (IG1/IG2) (n = 10): (6/20) vs (4/10); self-withdrawal 8
	(5/3); pregnancy 2 (1/1)
Interventions	Group 1: 1 daily dose of Synbiotic 2000, which contains a mixture of prebiotics and
	probiotics
	Group 2: Placebo
	All participants: Treatment began as soon as participants resumed oral intake after
	surgery. All participants were treated with at least 1 course of steroids. Follow-up visits
	were scheduled at 0, 1, 2, and 3 months and every 3 months thereafter until 24 months
	postsurgery. Follow-up consisted of endoscopic, clinical, and laboratory parameters
Outcomes	Duration of study: 24 months
	1. Rutgeerts score
	2.CDAI score
Notes	<b>Funding source:</b> No funding: probiotics and placebo provided free of charge (via cor-
	respondence with authors 3 August 2018)
	<b>Conflict of interest:</b> Authors declare no conflict of interest (via correspondence with
	authors 3 August 2018)
	Power calculation: Not stated

#### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomized to active treatment or placebo in a 2:1 ratio" Comment: insufficient information pro- vided, however authors contacted on 3 Au- gust 2018 and indicated that randomisa- tion was done manually at the medical cen- tre
Allocation concealment (selection bias)	High risk	Insufficient information provided, how- ever authors contacted and confirmed that "predefined notes with allocation were pre- pared, and for each patient a note with the treatment group allocation was drawn". We

### Chermesh 2007 (Continued)

		do not consider this sufficient to prevent bias
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The study was placebo-blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The study was referred to as double- blinded, however there is insufficient infor- mation to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Half of the randomised participants dropped out of the trial. This early discon- tinuation of the study was due to an in- terim analysis that found no benefit of the active treatment. We do not consider this a source of bias
Selective reporting (reporting bias)	High risk	Trial registration was not available. CDAI and Rutgeerts mean score were reported for the control group, but not for the active treatment group; instead they merely re- ported as 'NS' (not significant)
Other bias	Low risk	Quote: "No differences were found be- tween the 2 treatment groups regarding gender, age at diagnosis, age at surgery, weight, smoking status, type of disease, length of resected segment, or medical treatment prior to surgery" Comment: groups balanced at baseline. No other apparent sources of bias detected
All domain risk of bias	High risk	Very high

#### D'Haens 2008

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Belgium/University Hospital Leuven and Imelda General Hospital, Bonheiden; 1999 to 2005
Participants	<b>Inclusion:</b> Adult participants (18 to 70 years) who underwent curative ileal or ileocolonic resection with ileocolonic anastomosis for CD with a presence of 1 risk factor for the development of early/severe postoperative recurrence of their CD. Participants had to understand and sign a written informed consent form. Women of childbearing age needed to have a negative pregnancy test and had to use adequate birth control measures during the whole study <b>Exclusion:</b> Presence of macroscopic evidence for CD proximally or distally to the site of resection or the presence of frank pancolitis or an ileorectal anastomosis (ileosigmoidal

### D'Haens 2008 (Continued)

	anastomosis was allowed); patients with a stoma; operation for fibrostenosis only, without evidence of inflammatory activity on histology; former intolerance to metronidazole or AZA or both; who wished to become pregnant; low white blood cell count at inclusion (4000); alcohol or drug abuse; use of AZA in the 2 months before surgery; patients with malignancies and/or ongoing infectious disease (hepatitis, tuberculosis, AIDS) with the exception of herpes simplex infection. Former use of biologicals was not permitted <b>Age (IG1/IG2) mean:</b> 38.8 (22 to 67) vs 40.0 (21 to 69); overall age not reported <b>Sex (M:F):</b> 44:37 overall; (24:16) vs (20:21) <b>Type of surgery:</b> Not reported <b>Previous surgery (IG1 + IG2):</b> 2nd surgery 20 (12/8); 3rd surgery 3 (2/1) <b>Start of intervention after surgery:</b> $\leq$ 2 weeks <b>Medication use (IG1 + IG2):</b> AZA past use: 5 (3/2); steroid use at surgery: 21 (12/9) <b>Smoker (IG1/IG2):</b> (13/40) vs (17/41) <b>Number randomised (n = 81):</b> 40/41 <b>Number analysed (n = 81):</b> (40/40) vs (2/141) <b>Postrandomisation exclusion (n = 5):</b> (3/40) vs (2/41) (withdrawal of consent 5 (3/2))
Interventions	<b>Group 1:</b> 3 months of metronidazole therapy at a dose of 250 mg 3 times per day plus AZA depending on body weight. AZA only for the rest of the study. Participants whose body weight was under 60 kg received 2 tablets of AZA (100 mg), whereas participants weighing over 60 kg received 3 tablets or 150 mg AZA <b>Group 2:</b> 3 months of metronidazole therapy at a dose of 250 mg 3 times per day plus placebo. Placebo only for the rest of the study <b>All participants:</b> Participants intolerant to metronidazole were switched to ornidazole 500 mg twice per day orally. All concomitant anti-inflammatory medications were discontinued, except for glucocorticosteroids, which were gradually tapered over 6 weeks after surgery. Antibiotics were allowed during the study for concurrent infections, but not for CD. Topical therapy for perianal CD could be continued if necessary. Colestyramine was allowed for the treatment of bile acid diarrhoea. Participants underwent clinical evaluation with physical examination and biochemical analysis at baseline and weeks 2, 6, 12, 20, 28, 36, 44, and 52 after randomisation. Participants underwent an ileocolonoscopy at week 12 and 52. Adverse events and concomitant medication were recorded at every scheduled or unscheduled visit
Outcomes	Duration of study: 12 months <ol> <li>Endoscopic recurrence in the neoterminal ileum defined as an endoscopic index ≥ 2 according to Rutgeerts' endoscopic score</li> <li>Clinical recurrence defined as CDAI &gt; 250</li> <li>Adverse events</li> <li>Withdrawal due to adverse events</li> </ol>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation:</b> It was estimated on the basis of prior recurrence-prevention stud- ies, that 50% to 55% of participants in the placebo group would have an endoscopic recurrence at 1 year. Assuming an efficacy of 65% of AZA, it was calculated that 80 participants would need to be enrolled in the trial to detect differences in significant endoscopic recurrence amongst the groups

### D'Haens 2008 (Continued)

#### Risk of bias

Alsk of Duis			
Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Low risk	Quote: "The random allocation sequence was delivered by a randomization program written in Visual Basic version 6" Comment: computer-generated randomi- sation	
Allocation concealment (selection bias)	Unclear risk	Quote: "Randomization took place in the pharmacy of the Leuven University Hospi- tals within 2 weeks after surgery" Comment: insufficient information to make judgement	
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Dummy tablets used, study was single- blinded. It is unclear whether personnel were blinded or not	
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "At week 12 and 52, an ileo- colonoscopy was performed with determi- nation of Rutgeerts' score for ileal recur- rence of CD by an endoscopist who was unaware of treatment assignment" Comment: probably done	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Both intention-to treat and per- protocol analyses were performed" Comment: ITT analysis applied, and attri- tion rates were similarly low across groups	
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were adequately reported	
Other bias	Low risk	Quote: "The characteristics of the study populations in the AZA and placebo group were comparable'" Comment: groups well balanced at base- line, no other apparent sources of bias de- tected	
All domain risk of bias	Low risk	Low/unclear	

Ewe 1989

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Germany/16 surgical and medical centres; study period not reported	
Participants	Inclusion: Adult participants resected for CD by 1 of the medical centres; resection had to be curative with no macroscopically inflamed intestine left; diagnosis of CD had to be confirmed macro- and microscopically Exclusion: Patients not resected according to the standard policy of the individual (radical or non-radical) operating centre; inability/refusal to give written consent; questionable ability to co-operate; age less than 18 years Age (IG1/IG2) median (range): 31 (15 to 66) overall; 32 (16 to 66) vs 30 (15 to 62) Sex (M:F): 113:119 overall; (48:63) vs (65:56) Type of surgery: Not reported Previous surgery (IG1 + IG2): 94 (48/46) Start of intervention after surgery: Immediately postoperatively Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 232): 111/121 Number analysed (n = 206): (101/101) vs (105/105) Postrandomisation exclusion (n = 88): (47/111) vs (41/121) (non-co-operative 57 (31/26); technical 18 (8/10); medical 13 (8/5))	
Interventions	<ul> <li>Group 1: Sulfasalazine 3 g daily for 3 years</li> <li>Group 2: Similar placebo (size, colour, form)</li> <li>All participants: Medication initiated whilst in hospital. Control visits at 3 months and every 6 months thereafter. Colonoscopy not obligatory, although encouraged</li> </ul>	
Outcomes	<b>Duration of study:</b> 3 years 1. <b>Recurrence of CD</b> proven by radiology, endoscopy, or operation (> 3 months, > 1 year, > 2 years, 3 years)	
Notes	<b>Funding source:</b> Supported by Deutsche Forschungsgemeinschaft grant Ew 4/12,14, 16/1-3 <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Not reported	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Yes, we carried out random allo- cation. We got the key from our statistical department" Comment: whilst the medical treatment part of the study is reported as randomised and double-blind, there was no further in- formation on this in the trial. However, based on correspondence on 11 October 2018 with the lead author (Professor Ewe) , we conclude that random allocation was

#### **Ewe 1989** (Continued)

		probably done
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Medical treatment part of the study is re- ported as randomised and double-blind. Dummy tablet similar to sulfasalazine was used
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote "Yes, the people who assessed the outcomes were aware of the intervention patients were allocated to" Comment: confirmed via correspondence on 11 October 2018 with the lead author (Professor Ewe)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Overall attrition rate was around 37%, however compared to the event risk (60%) , it was not sufficient to introduce bias
Selective reporting (reporting bias)	High risk	Trial registration not available and adverse events outcome not reported
Other bias	Low risk	Baseline characteristics appear to be bal- anced across groups
All domain risk of bias	High risk	Very high

### Ewe 1999

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Germany/university hospitals in Heidelberg, Homburg, and Mainz; 1992 to 1994
Participants	Inclusion: Patients who have undergone curative resection for ileal, ileo-colonic, or colonic CD (i.e. without grossly visible disease at the resection margins) and had an anastomosis that was accessible to colonoscopy Exclusion: Not reported Age (IG1/IG2) mean (SD): $34 \pm 10$ overall; $35 \pm 12$ vs $33 \pm 9$ Sex (M:F): $37:46$ overall; $(21:22)$ vs $(16:24)$ Type of surgery: Ileal resection or stricturoplasty 15 (8/7); ileo-caecal resection (right hemicolectomy) 49 (26/23); segmental colonic resection 11 (5/6); colectomy 4 (1/3) Previous surgery (IG1 + IG2): $52 (25/27)$ Start of intervention after surgery: $\leq 2$ weeks Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 83): $40/43$ Number analysed (n = 83): $(43/43)$ vs $(40/40)$

### **Ewe 1999** (Continued)

	Postrandomisation exclusion (n = 20): (1	1/43) vs (9/40) (non-compliance 20 (11/9))
Interventions	Group 1: 1 budesonide gelatine capsule 3 budesonide in approximately 400 microgr modified release with Eudragit L, which di Group 2: 1 placebo capsule indistinguish before meals All participants: No other drugs used in t other glucocorticoids, or immunosuppressi stopped and in case of glucocorticoids was were scheduled for the first visit 6 weeks af 3, 6, 9, and 12 months postoperatively. At obtained and symptoms and signs suggesti of CD were recorded	times daily before meals containing 1 mg of anules 1 mm in diameter and coated for pH ssolves at pH > 6.4 able from budesonide capsules 3 times daily he treatment of CD such as aminosalicylates, ves were allowed. Preoperative treatment was tapered to zero within 4 weeks. Participants ter operation. Further visits were arranged at e each visit the clinical and blood status were ve of budesonide side effects or of recurrence
Outcomes	of CD were recorded <b>Duration of study:</b> 12 months 1. <b>Endoscopic recurrence</b> graded according to a slightly modified scoring system ba on Rutgeerts and colleagues (0, normal mucosa; 1, reddening and/or oedema with circumscribed lesions; 2, five aphthoid lesions within normal mucosa; 3, six aphth lesions within normal mucosa or isolated areas with greater ulcers; 4, diffusely inflar mucosa containing aphthoid lesions or small ulcers; 5, diffuse inflammation with lau ulcers, pseudopolyps, and/or stenosis; an endoscopy score of 2 was defined as recurre and treatment failure) 2. <b>Clinical recurrence</b> defined as rise in CDAI from 60 up to 200 from the first foll- up or a CDAI > 200. Symptoms and signs characteristic of CD were taken as recurre in cases where colonoscopy was refused. (ITT derived from number of clinical relap plus number with no available data.) 3. <b>Histologic recurrence</b> graded as follows: 0 = normal mucosa; 1 = scanty infiltrat with Iymphocytes and solitary neutrophils and eosinophils but more histiocytic infil tion of the lamina propria; crypt distortion; 2 = disturbed villous and crypt architect densely packed inflammatory cells; ulceration of surface epithelium; 3 = diffuse infla- mation with inflammatory polyps; crypt distortion, crypt abscesses; lymphoid folli in lamina propria 4. <b>Health-related quality of life</b> based on participants' global judgement (good; medit bad) 5. <b>Adverse events</b> 6. <b>Severe adverse events</b> 7. <b>Withdrawal due to adverse event</b>	
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : A minimum sample siz was calculated by taking the following consi 1 year under placebo 70% and under bude overall sample size of 80 participants was a	e of 60 participants (30 per treatment group) derations into account: recurrence rate within sonide 35%. To compensate for dropouts, an greed upon
Risk of bias		
Bias	Authors' judgement	Support for judgement

### **Ewe 1999** (Continued)

Random sequence generation (selection bias)	Low risk	Quote: "83 patients were randomized ac- cording to a computer-generated list" Comment: computer random number generator
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "This study is a double-blind placebo-controlled clinical trial involving three university-based medical centres [] Placebo medication was indistinguishable from budesonide" Comment: placebo-controlled
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "All biopsies were evaluated inde- pendently by the pathologists at the three study centres and uncertain diagnoses were discussed at a joint meeting" Comment: the study was reportedly dou- ble-blinded, however there is insufficient information to determine whether the pathologists were aware of the interven- tions to which participants were allocated
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "Calculations were performed based on all patients with Crohn's disease who had been operated on as outlined above and had taken the study medication for at least 1 day (intention-to-treat)" Comment: ITT was performed. However, over 20% of participants were withdrawn from the study, and there is insufficient in- formation to determine how this compares with the event risk
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "Both groups were comparable with regard to their demographic and dis- ease characteristics" Comment: both groups well balanced at baseline
All domain risk of bias	Low risk	Low/unclear

Fedorak 2015

Methods	<b>Study design:</b> RCT (phase 1), multicentre <b>Setting:</b> Canada/17 tertiary inflammatory bowel disease university-associated centres; 2003 to 2007
Participants	Inclusion: 16 years of age or older with a radiologic, endoscopic, or surgical diagnosis of Crohn's disease of at least 3 months duration. Patients who underwent resection of ileocolonic Crohn's disease at the physician's discretion, with margins macroscopically free of disease, and small bowel-to-colon anastomosis no more than 30 days before randomisation Exclusion: Patients with residual luminal disease; receiving a TNF antagonist within 8 weeks of resection Age (IG1/IG2) mean (SD): $36.7 \pm 12.1$ overall; $37.6 \pm 12.4$ vs $35.91 \pm 1.8$ Sex (M:F): $62:58$ overall; $(30:28)$ vs $(32:30)$ Type of surgery: Not reported Previous surgery (IG1 + IG2): 1st 35 (20/15); 2nd 8 (4/4) Start of intervention after surgery: $\leq 2$ weeks Medication use (IG1 + IG2): Prior MES use $96 (47/49)$ ; prior corticosteroid use 101 ( $50/51$ ); prior immune modifier agents $64 (29/35)$ ; prior infliximab use $16 (7/9)$ Smoker (IG1/IG2): $32 \text{ total}$ ; $(13/58) \text{ vs} (19/62)$ Number randomised (n = 120): $58/62$ Number randomised (n = 120): $(58/58) \text{ vs} (62/62)$ Postrandomisation exclusion (n = 15): ( $10/58$ ) vs ( $5/62$ ) (withdrew consent 8; lost to follow-up 3; non-compliance 3; other 1)
Interventions	<ul> <li>Group 1: 1 sachet of VSL#3 (a mixture of 8 different bacteria, 900 billion/sachet) twice daily for 3 months</li> <li>Group 2: Placebo identical sachets containing 3 g cornstarch for 3 months</li> <li>All participants: After resection, treatment of Crohn's disease was not permitted. Codeine, loperamide, diphenoxylate, and colestyramine were allowed for diarrhoea. Participants were reviewed at days 30 and 90. Telephone contacts occurred on days 14 and 60. At each visit a physical exam and medication adherence check were performed, and CDAI and IBDQ were calculated. At day 90, participants underwent a colonoscopy to evaluate endoscopic recurrence according to the Rutgeerts score</li> </ul>
Outcomes	Duration of study: 3 months 1. Endoscopic recurrence defined as Rutgeerts score ≥ 1 2.Severe endoscopic relapse defined as Rutgeerts score ≥ 3 3.Adverse events 4.Serious adverse events 5. Withdrawal due to adverse events
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Under the assumption that the rate of severe endoscopic recurrence in placebo-treated participants would be 45%, 52 evaluable participants per group were required to detect an absolute difference of 25% (i.e. 20% rate of severe endoscopic recurrence in participants treated with VSL#3) at the .05 level of significance with 80% power. Consequently, a total of 120 participants were enrolled, allowing for a non- evaluable rate of up to 13%

### Fedorak 2015 (Continued)

Risk	of bias

Ask of ous		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Eligible subjects were assigned to 1 of 2 treatment groups in a 1:1 ratio by random allocation that was based on a computer-generated randomization sched- ule prepared before the study by Robarts Inc" Comment: computer-generated randomi- sation
Allocation concealment (selection bias)	Unclear risk	Quote: "The site investigator, study coordi- nator, and patient were blinded to the treat- ment allocation during double-blind treat- ment days 1-90" Comment: insufficient information to make judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Investigators and patients were un- aware of the treatment assignment." And "The study drug and the placebo were iden- tical in taste, smell, colour, texture, and consistency" Comment: double-blind study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "Investigators and patients were un- aware of the treatment assignment" Comment: study was also referred to as "double-blinded". Probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The primary efficacy analyses were performed according to the intent-to-treat principle" Comment: proportion and reasons for at- trition were balanced across groups
Selective reporting (reporting bias)	High risk	Quote: "The CDAI and IBDQ scores were similar in the 2 treatment groups (data not shown)" Comment: trial registration available (NCT00175292), however results of pro- posed secondary outcomes of quality of life and disease activity were only reported as being similar between groups. No further information provided for this outcome

### Fedorak 2015 (Continued)

Other bias	Low risk	Quote: "The baseline characteristics were similar in the 2 treatment groups. No important differences were observed in age, gender, duration or characteristics of Crohn's disease, medication use immedi- ately before surgery, number of previous surgical resections, CDAI, or IBDQ scores" Comment: groups well balanced at base- line. Study funded by VSL Pharmaceuticals Inc. Authors indicate that representatives from VSL Pharmaceuticals Inc had the op- portunity to review and comment on the study design and on the manuscript, how- ever the principal investigators made the final decisions regarding the design of the trial, and all of the authors had access to the study data and reviewed and approved the content of the manuscript. No other apparent sources of bias detected
All domain risk of bias	Unclear risk	High
Florent 1996		
Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> France and Belgium; 12 medical c	entres; 1989 to 1991
Participants	Inclusion: All patients treated by "curative" resection for CD and whose anastomosis was within the reach of colonoscopy were eligible for the study. Crohn's disease diagnosis was established by the convergence of clinical, radiological, endoscopic, and histological data Exclusion: Pregnant or breastfeeding women; women of childbearing potential not receiving effective contraception; having a permanent stoma; having undergone a small intestinal resection of more than 100 cm prior to the pretrial operation; and a history of peptic ulcer, a known hypersensitivity to salicylates, or a significant renal, hepatic, or haematological disorder Age (IG1/IG2) mean (SD): 33.5 ± 12 overall; 35 ± 13 vs 32 ± 11; overall age not reported Sex (M:F): 56:70 overall; (23:42) vs (33:28) Type of surgery: Emergency 45; elective 161 Previous surgery (IG1 + IG2): 1st 166; 2nd 40 Start of intervention after surgery: $\leq$ 15 days Medication use (IG1 + IG2): MES 153; steroids 123; antibiotics 71; immunosuppres- sants 20 Smoker (IG1/IG2): (17/65) vs (22/61) Number randomised (n = 126): 65/61 Number analysed (n = 106): (55/65) vs (51/61) Postrandomisation exclusion (n = 14): (8/65) vs (6/61) (lost to follow-up 5 (5/0)):	

### Florent 1996 (Continued)

	intercurrent pathology 2 (1/1); protocol violation 3 (2/1); error of inclusion 1 (0/1); colonoscopy failure/refusal 3 (0/3))
Interventions	Group 1: MES (Claversal), two 500 mg tablets 3 times daily Group 2: Placebo, two 500 mg tablets 3 times daily All participants: Metronidazole and antibiotics were allowed within the perioperative period. Sulfasalazine, corticosteroids (except for substitutive doses of hydrocortisone in participants with poststeroid adrenal insufficiency), and immunosuppressive agents were not allowed during the trial
Outcomes	<b>Duration of study:</b> 12 weeks 1. <b>Endoscopic recurrence</b> defined as the presence of ulcerative lesions at the anastomotic level (aphthous, superficial or deep) owing to its poor reproducibility, classified according to Rutgeerts and colleagues ( $i \ge 1$ ) 2. <b>CDAI score</b>
Notes	<b>Funding source:</b> Supported by a grant from SmithKline Beecham Laboratories <b>Conflict of interest:</b> Not reported <b>Power calculation:</b> An assumption was made that 80% of participants on placebo would have an endoscopic relapse. A reduction of 30% in the relapse rate in the Claversal group was considered as the minimal clinical significant decrease. The number of participants required was 50 per arm. Estimating that 20% of patients would prove to be not evaluable, a total of 126 participants were randomised

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Randomization was carried out us- ing a permutation table within each centre" Comment: participants were classified into 3 categories, and it seems stratified ran- domisation using permuted blocks was used. However, no further details provided
Allocation concealment (selection bias)	Unclear risk	Quote: "The treatment was started as soon as feeding was resumed, and no later than the 15th postoperative day, and was admin- istered blindly over 12 weeks" Comment: insufficient information to make judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "The treatment was started as soon as feeding was resumed, and no later than the 15th postoperative day, and was admin- istered blindly over 12 weeks" Comment: study is placebo controlled, but no information is provided regarding the placebo tablet or whether interventions

### Florent 1996 (Continued)

		were sufficiently identical to ensure blind- ing of personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Rates and reasons for attrition were bal- anced across groups.
Selective reporting (reporting bias)	High risk	Data on CDAI reported as means $\pm$ SD. Clinical relapse CDAI $\geq$ 200 as one of reasons for withdrawal not reported, although it should have been as CDAI was assessed at 12 weeks
Other bias	Low risk	Groups balanced at baseline, except for ESR, which was significantly higher in the MES group. We did not consider this suffi- cient to introduce bias. No other apparent sources of bias detected
All domain risk of bias	Unclear risk	High

### Fukushima 2018

Methods	Study design: RCT, multicentre Setting: Japan/13 centres
Participants	Inclusion: Patients who underwent intestinal or colonic resection, or both, with anastomosis between normal ileum and colon (ileo-colonic anastomosis) or colon and colon (colo-colonic anastomosis), with no macroscopic lesions left in the remnant intestine Exclusion: A history of more than 3 intestinal resections; infectious diseases, including sepsis, tuberculosis, viral hepatitis, opportunistic infections, and other chronic infections; demyelinating disease; congestive heart failure; lymph proliferative disorder; malignant tumour; and the presence of a stoma Age (IG1/IG2) mean (range): $36.6 (19 \text{ to } 55) \text{ vs } 37.6 (23 \text{ to } 74)$ ; overall age not reported Sex (M:F): $30:13$ overall; $(17:4) \text{ vs } (13:9)$ Type of surgery: lleum only 1 (0/1); ileo-caecum 24 (11/13); ileo-caecum and colon 3 (2/1); colon only 10 (6/4) Previous surgery (IG1 + IG2): 2nd 5 (2/3); 3rd 1 (0/1) Start of intervention after surgery: $\leq 4$ weeks Medication use (IG1 + IG2): Prior infliximab (4/2) Smoker (IG1/IG2): $(5/21) \text{ vs } (2/22)$ Number randomised (n = 43): $21/22$ Number randomised (n = 43): $(21/21) \text{ vs } (6/22)$ (not meeting criteria 4 (2/2); dropout 5 (2/3); declined participation 1 (0/1))

### Fukushima 2018 (Continued)

Interventions	Group 1: IFX at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years Group 2: No treatment All participants: Participants who had been receiving IFX within 8 weeks before surgery continued to receive IFX with intervals of 8 weeks. The concomitant use of immune modulators (e.g. azathioprine and 6-MP) and immune-suppressants (e.g. cyclosporine and tacrolimus) was not allowed in either group
Outcomes	<ul> <li>Duration of study: 24 months</li> <li>1. Endoscopic and/or clinical recurrence at 2 years: endoscopic recurrence defined by a score of i3 or i4 and/or clinical relapse defined as &gt; 150</li> <li>2. Endoscopic recurrence only defined as score of i3 or i4</li> <li>3. Clinical relapse only defined as CDAI &gt; 150</li> <li>4. Adverse events</li> <li>5.Withdrawal due to adverse events</li> </ul>
Notes	<b>Funding source:</b> Grant from the Intractable Diseases, Health and Labor and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan <b>Conflict of interest:</b> 2 authors serve as consultants for Tanabe Mitsubishi Pharma Co., Ltd; 10 authors received lecture fees from Tanabe Mitsubishi Pharma Co., Ltd <b>Power calculation:</b> Not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Eligible and consenting patients were assigned randomly to be treated with or without infliximab (IFX) by Keio Uni- versity Hospital, Clinical and Translational Research Center, within 4 weeks of resec- tion" Comment: insufficient information to make judgement. However, authors con- tacted, response as follows (quote): "In practice, when patients agreed with the study, we sent a fax to the Keio Univer- sity Hospital, Clinical and Translational Research Center, where randomization was carried out using random number. Then Keio University Hospital, Clinical and Translational Research Center sent back the decision (Infliximab or without in- fliximab). Random number generated by computer". Comment: computer-gener- ated random sequence
Allocation concealment (selection bias)	Low risk	Appears to have been centrally allocated based on the information above

### Fukushima 2018 (Continued)

High risk	Open-label pilot study
High risk	Highly unlikely, open-label pilot study
Low risk	Quote: "Patients who dropped out of fol- low-up, did not undergo endoscopy at 24 months, or had adverse effects leading to withdrawal from the study were treated as recurrent cases" Comment: ITT analysis applied, however there was about 25% attrition rate which was considered insufficient to introduce bias
Low risk	Trial registration available (UMIN000002604), and all proposed outcomes were reported
Low risk	Quote: "There were no statistical differ- ences between the two groups in history of IFX therapy, smoking behavior, surgical in- dication, site of disease, or type of anasto- mosis" Comment: groups balanced at baseline. No other apparent sources of bias detected
High risk	Very high
Study design: RCT, multicentre Setting: Belgium, 9 university/teaching hospitals; 2001 to 2004	
<ul> <li>Inclusion: Patients undergoing a first or subsequent ileocolic resection with a primary anastomosis for disease confined to the ileum and adjacent colon were eligible for enrolment. Patients with minimal evidence of Crohn's disease at other sites (aphthoid erosions or microscopic inflammatory changes)</li> <li>Exclusion: Evidence of gross Crohn's disease at the operative margins or in proximal or distal segments of intestine (excluding perianal disease) at the time of surgery or at pathologic examination</li> <li>Age (IG1/IG2) mean (SD): 37 ± 13 overall; 38.7 ± 14.5 vs 35 ± 11.7</li> <li>Sex (M:F): 37:33 overall; (19:15) vs (18:18)</li> <li>Type of surgery: Not reported</li> <li>Previous surgery (IG1 + IG2): 18 (7/11)</li> </ul>	
	High risk         High risk         Low risk         Low risk         Low risk         Low risk         Isk         High risk         Study design: RCT, multicentre         Setting: Belgium, 9 university/teaching hor         Inclusion: Patients undergoing a first or su anastomosis for disease confined to the ileuu ment. Patients with minimal evidence of Cr or microscopic inflammatory changes)         Exclusion: Evidence of gross Crohn's dise: or distal segments of intestine (excluding pathologic rxamination)         Age (IG1/IG2) maa (SD): 37 ± 13 overa         Sex (M: F): 37:33 overall; (19:15) vs (18:18)         Type of surgery: Not reported         Previous surgery (IG1 + IG2): 18 (7/11)

### Gossum 2007 (Continued)

	Start of intervention after surgery: $\leq 1$ week Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): (13/34) vs (12/36) Number randomised (n = 70): 34/36 Number analysed (n = 70): (34/70) vs (36/70) Postrandomisation exclusion (n = 21): (7/34) vs (14/36) (protocol violation 7 (4/3); dropouts 14 (3/11))
Interventions	<ul> <li>Group 1: Probiotic Lactobacillus johnsonii (LA1, Nestec) in freeze-dried form and blended with maltodextrin at 1010 CFU/day. The LA1 powder was supplied in foil sachets (weight 2 g) containing 1010 CFU of probiotics</li> <li>Group 2: The placebo was maltodextrin only as a powder of the same appearance and weight, also in individual foil packets</li> <li>All participants: Both probiotics and placebo were administered in combination with an enteral formula at 120 mL/day (ACD004, Nunspeet, Netherlands; Konolfingen, Switzerland). No other medication (including antidiarrhoeal agents) was allowed during the study period. No other fermented products or yoghurts were allowed during the 12 weeks of treatment. Participants were enrolled prior to elective ileo-caecal resection. All participants enrolled in the study received 3 days of antibiotics (amoxicillin/clavulanic acid 500 mg orally 3 times a day) prior to surgery (intestinal decontamination)</li> </ul>
Outcomes	<ul> <li>Duration of study: 12 weeks</li> <li>1. Endoscopic recurrence defined as i ≥ 1 according to the Rutgeerts scoring system: i1 to i2 mild to moderate; i3 to i4 severe. Relapse defined as i ≥ 1</li> <li>2. Clinical recurrence defined as CDAI &gt; 150 points or an increase in CDAI score of &gt; 70 points or higher from baseline</li> <li>3.Histological score assessed by the Geboes scoring system</li> <li>4.Adverse events</li> <li>5.Severe adverse events</li> <li>6. Withdrawal due to adverse events</li> </ul>
Notes	<b>Funding source:</b> Study was supported by a research grant from Nestlé Research Center, Vers-chez-les-blanc, Lausanne, Switzerland <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Detection of a difference of 1 endoscopic score (5 scores: i0 to i4) between the 2 groups at 0.05 and 80% requires a sample size of 31 participants per group (Pass 6.0 program). To compensate for potential missing data, 20% additional participants were recruited (37 participants per group)

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization between the two groups was centralized and performed on current smoking status at the time of surgery as balancing the factor using the Nestle Trial Balance program" Comment: centralised random sequence

### Gossum 2007 (Continued)

		generation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The identity of the treatment sa- chet was blind to patients, support staff, and investigators (numerical codes). Treat- ment codes were broken only by the statis- tician after completion of the trial" Comment: double-blinded, placebo-con- trolled trial
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Biopsy samples of the neoterminal ileum were taken and assessed blindly by two pathologists" Comment: outcome assessors blinded to intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "All data were analysed according to both an intention to treat (ITT) and a per-protocol (PP) approach" Comment: ITT analysis applied; all partic- ipants accounted for
Selective reporting (reporting bias)	Low risk	Protocol not available. All outcomes stated in the methods section including adverse events were reported
Other bias	Low risk	Groups well balanced at baseline. No other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

#### Hanauer 2004

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> USA and Belgium/5 centres; 1992 to 1996
Participants	<ul> <li>Inclusion: Between 18 and 65 years of age, with diagnosis of CD for at least 6 months and scheduled for curative ileo-caecal resection; ability to start oral nutrition within 7 days of operation, need for curative ileo-caecal resection, and resection margins free of inflammation</li> <li>Exclusion: Active perianal disease or any active disease in other segments of the intestine, anti-TNF and/or investigational treatment within 4 months prior to surgery; current treatment with 5-ASA, azathioprine/6-MP, or methotrexate; bowel surgery performed less than 3 months previously; history of colostomy or ileostomy; infections, neoplasia, or uncontrolled diseases; or anticipation of non-compliance with protocols. Patients who were receiving steroids preoperatively were tapered and weaned according to a strict schedule</li> </ul>

### Hanauer 2004 (Continued)

	Age (IG1/IG2) mean (SD): $34.4 \pm 11.0$ overall; $34.9 \pm 11.5$ vs $34.1 \pm 10.9$ vs $34.2 \pm 10.9$ Sex (M:F): 60:71 overall; (23:24) vs (19:25) vs (18:22) Type of surgery: Not reported Previous surgery (IG1 + IG2): 18 (7/11) Start of intervention after surgery: Therapy initiated before postoperative hospital discharge Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 131): 47/44/40 Number analysed (n = 131): (47/131) vs (44/131) vs (40/131) Postrandomisation exclusion (n = 27): (12/47) vs (7/44) vs (8/40) (withdrew consent 5 (1/2/2); surgical complication 3 (2/0/1); non-compliance 9 (2/4/3); lost to follow-up 10 (4/2/4))
Interventions	<ul> <li>Group 1: 50 mg of 6-MP (Purinethol) once daily</li> <li>Group 2: 3 g of MES (Pentasa); 4 capsules of 250 mg, 3 times daily</li> <li>Group 3: Identical matching placebo</li> <li>All participants: Presurgical therapy, including aminosalicylates, antibiotics, or immunomodulators, was discontinued before surgical resection and was not allowed during the postoperative trial. Preoperative treatment with corticosteroids was completely tapered by 3 months after hospital discharge at a rate determined by the treating physician. No concurrent treatment for Crohn's disease, aside from topical therapy for perianal disease, was allowed during the duration of the trial. Continuous use of non-steroidal anti-inflammatory drugs was not allowed during the study. If the WBC and platelet counts fell below 4500/L or 150,000/L, respectively, the dosage of 6-MP was reduced by one-half</li> </ul>
Outcomes	<b>Duration of study:</b> 24 months 1. <b>Endoscopic recurrence</b> defined as $i \ge 1$ according to the Rutgeerts scoring system: i1 to i2 mild to moderate; i3 to i4 severe. Relapse defined as $i \ge 1$ 2. <b>Clinical recurrence</b> defined as CDAI > 150 points or an increase in CDAI score of > 70 points or higher from baseline. (ITT data derived from number randomised minus number in clinical remission at the end of the study.) 3. <b>Histological score</b> assessed by the Geboes scoring system 4. <b>Adverse events</b> 5. <b>Serious adverse events</b> 6. <b>Withdrawal due to adverse events</b>
Notes	<ul> <li>Funding source: Not reported, however email received from authors on 2 August 2018 stated that study was funded by Crohn's and Colitis Foundation</li> <li>Conflict of interest: Not reported, however email received from authors on 2 August 2018 declared none</li> <li>Power calculation: Sample size calculations were performed for the endoscopic criteria, using 2-sided of 0.05 and 80% power, based on a predicted endoscopic recurrence of 75% at 1 year in the placebo group. A sample size of 50 in each group allows sufficient power to detect a 40% reduction in mild Crohn's disease lesions and a 75% reduction in more severe lesions at 1 year</li> </ul>

### Hanauer 2004 (Continued)

D'1	C1 · .
KISR	ot plas

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quotes: "Patients were randomized by a central computer by permuted blocks of 6 (unknown to investigators) per center to receive mesalamine (Pentasa; Marion Merrill Dow, Kansas City, MO) 3 g daily, 6-MP (Purinethol; Burroughs Wellcome, Research Triangle Park, NC) 50 mg daily, or placebo" Comment: computer-generated random sequence
Allocation concealment (selection bias)	Low risk	Quotes: "Medications were prepared and dispensed by an assigned pharmacist at each site's investigational pharmacy who was not directly involved in the care of the patients" Comment: treatment controlled by phar- macies at each centre
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quotes: "Medications were prepared and dispensed by an assigned pharmacist at each site's investigational pharmacy who was not directly involved in the care of the patients" and "An evaluating (treating) physician fol- lowed up each patient and was blinded as to the study drug and laboratory results" Comment: placebo-controlled, double- blind RCT. However, it is unclear whether both study drugs were sufficiently identical to the placebo to blind study participants
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quotes: "Patient evaluation consisted of as- sessments of clinical, endoscopic, and ra- diographic disease activity at each study site by the blinded physician" and "Colono- scopic examinations with endoscopic de- scriptions and photography of the anas- tomosis and preanastomotic ileum were performed by the blinded investigators (all gastroenterologists) at months 6, 12, and 24" and "Radiographic interpretations were performed by the blinded inflamma- tory bowel disease radiologist at each insti- tution" Comment: assessors blinded to treatment

### Hanauer 2004 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Quotes: "The clinical recurrence rates were determined using ITT" Comment: ITT analysis applied, attrition was similar, low, and balanced across groups
Selective reporting (reporting bias)	Low risk	Comment: all outcomes stated in the meth- ods section were reported
Other bias	Low risk	Quote: "There were no statistical differ- ences in patient age, sex, disease duration, indications for surgical resection, or preop- erative disease activity among the 3 groups" Comment: groups well balanced at base- line. No other apparent sources of bias de- tected
All domain risk of bias	Low risk	Low/unclear
Hollow 1000		
Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Belgium, Denmark, France, Gerr Sweden/13 centres; 1992 to 1993	many, Italy, the Netherlands, the UK, and
Participants	Inclusion: Patients who were scheduled for resectional surgery for ileocolonic CD who had given their informed consent at the screening visit were eligible for the study Exclusion: Patients who had a septic complication, such as abscess or fistula, or who had previously had more than 100 cm of the terminal ileum resected were excluded Age (IG1/IG2) mean (range): overall not reported; 34 (20 to 76) vs 36 (17 to 81) Sex (M:F): 62:67 overall; (35:28) vs (27:39) Type of surgery: Not reported Previous surgery (IG1 + IG2): 36 (19/17) Start of intervention after surgery: < 2 weeks Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 131): 63/67 Number analysed (n = 129): (63/63) vs (66/67) Postrandomisation exclusion (n = 8): (4/63) vs (4/67) (lost to follow-up 1 (1/0); other reasons 6 (3/3); did not start treatment 1 (0/1))	
Interventions	Group 1: 6 mg/day budesonide as single daily morning doses for 52 weeks Group 2: Placebo as single daily morning doses for 52 weeks All participants: Follow-up visits were carried out after 4 weeks (63 days) and after 13, 26, 39, and 52 weeks of treatment (61 weeks). Use of systemic glucocorticoids had to be discontinued within 30 days of surgery. No other concurrent medication for the treatment of CD, such as sulfasalazine, olsalazine, MES, 4-aminosalicylic acid, metron- idazole, immunosuppressive agents, or tuberculostatic agents, was permitted during the	

### Hellers 1999 (Continued)

	study. Antibiotics were allowed in the immediate postoperative period but had to be discontinued before the study treatment was started. Antidiarrhoeals such as loperamide and other opiates were allowed
Outcomes	Duration of study: 52 weeks <ol> <li>Endoscopic recurrence defined as i ≥ 2 according to the Rutgeerts scoring system:</li> <li>to i2 mild to moderate; i3 to i4 severe. Relapse defined as i ≥ 1</li> <li>Clinical recurrence defined as CDAI &gt; 200</li> <li>Adverse events</li> <li>Serious adverse events</li> <li>Withdrawal due to adverse events</li> </ol>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : With 50 participants per group, there was an 80% probability of a significant difference in endoscopic recurrence rate if the budesonide recurrence rate was 40%

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were then randomized to treatment with either budesonide CIR, 6 mg/day[] The randomization code was not broken until each patient's file was com- plete and approved for statistical analysis and adverse event evaluation" Comment: it is unclear how the randomi- sation codes were generated
Allocation concealment (selection bias)	Unclear risk	Insufficient data to make judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The randomization code was not broken until each patient's file was com- plete and approved for statistical analysis and adverse event evaluation" Comment: study is placebo controlled, and blinding appeared to have remained unbro- ken until all outcomes were collected
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "The randomization code was not broken until each patient's file was com- plete and approved for statistical analysis and adverse event evaluation" Comment: not explicitly stated, however blinding appeared to have remained unbro- ken until all outcomes were collected

### Hellers 1999 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates and reasons were similar and balanced across groups
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "The two groups were similar in terms of characteristics and disease history" Comment: baseline characteristics were balanced across groups, and there were no other apparent biases
All domain risk of bias	Low risk	Low/unclear

# Herfarth 2006

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Not stated (multicentre RCT)
Participants	Inclusion: People with Crohn's who had undergone resective surgery Exclusion: Homozygous thiopurine methyltransferase ( <i>TPMT</i> ) Age: Not reported Sex: Not reported Type of surgery: Not reported Previous surgery: Not reported Start of intervention after surgery: within 2 weeks postoperative Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 79): 42/37 Number analysed (n = 37): 18/19 Postrandomisation exclusion (n = 42)
Interventions	Group 1: 2.0 to 2.5 mg/g body weight/day azathioprine Group 2: 4 g 5-ASA/day All participants: Not stated
Outcomes	<ul> <li>Duration of study: 1 year (study was discontinued after 1 year)</li> <li>1. Treatment failure (due to severe endoscopic recurrence, lack of efficacy, and adverse events related to study drug)</li> <li>2. Clinical or severe endoscopic relapse</li> <li>3. Severe endoscopic relapse</li> <li>4. Clinical relapse (review author calculation: clinical or severe endoscopic relapse minus severe endoscopic relapse)</li> <li>5. Adverse events</li> <li>6. Withdrawal due to adverse events</li> </ul>

### Herfarth 2006 (Continued)

Funding source: Dr. Falk Pharma GmbH, Freiburg, Germany
Conflict of interest: Not reported
Power calculation: Not reported

## Risk of bias

Notes

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients in the present study were assigned to one of the two treatment groups (5-ASA or azathioprine) at random For creation of the randomisation list the programme 'Rancode +' (version 3.6) of IDV, Gauting (Germany) was used. The randomisation into two treatment groups was performed in blocks of four. After voluntary written informed consent was obtained and basic selection criteria were checked, the investigator requested the al- location of a unique patient code number (randomisation number, consecutively al- located to each patient), and received med- ication packs with the randomisation num- ber for the patient" Comment: confirmed by correspondence from Muller R (2 May 2012)
Allocation concealment (selection bias)	Low risk	"The randomization code was prepared and stored by a statistician from a CRO, who was not involved in the conduct nor in the analysis of the study. The Qualified Per- son of the Sponsor and the contract manu- facturer responsible for the preparation of the double-dummy patients sets received a copy of the randomization list, which was safely stored at both sites, without allowing access by other people. Neither the investi- gator nor the study team from the clinical operation from the sponsor nor the CRO had access to the random list" Comment: confirmed by correspondence from Muller R (2 May 2012)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"This was a double-blind, double-dummy study. Patients randomized to administer 5-ASA had to take 5-ASA VERUM tablets AND azathioprine PLACEBO tablets. Pa- tients randomized to receive azathioprine

### Herfarth 2006 (Continued)

		had to administer azathioprine VERUM tablets AND 5-ASA PLACEBO tablets Therefore, neither the investigator, nor the patients, nor the sponsor were ware of the TX a patient received until the database was clean, closed, and the code was broken" Comment: confirmed by correspondence from Muller R (2 May 2012)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"This was a double-blind, double-dummy study. Patients randomized to administer 5-ASA had to take 5-ASA VERUM tablets AND azathioprine PLACEBO tablets. Pa- tients randomized to receive azathioprine had to administer azathioprine VERUM tablets AND 5-ASA PLACEBO tablets Therefore, neither the investigator, nor the patients, nor the sponsor were ware of the TX a patient received until the database was clean, closed, and the code was broken" Comment: confirmed by correspondence from Muller R (2 May 2012)
Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: "The study was stopped prema- turely after an interim-analysis due to a high therapy failure rate. 38 patients (AZA 18 pat.; 5-ASA 20 pat.) completed the study and could be evaluated regarding the primary endpoint therapy failure. The other pat. terminated the trial prematurely due to the study stop, but were also eval- uated for adverse events (AE) and adverse drug reactions (ADR)" Comment: 51% of randomised partici- pants discontinued. High risk for primary outcome and low risk for adverse events and withdrawal due to adverse events
Selective reporting (reporting bias)	Unclear risk	Insufficient information as trial registration was not available and study was published as abstract
Other bias	Unclear risk	Insufficient information as study was pub- lished as abstract
All domain risk of bias	Low risk	Low/unclear

Herfarth 2013

Methods	Study design: RCT, multicentre Setting: USA, 6 centres; 2008 to 2011	
Participants	Inclusion: Patients who had undergone ileal or ileocolonic resection with ileocolonic anastomosis for CD within the previous 2 weeks Exclusion: Gross evidence of CD at the operative margins or in the proximal or distal segments of the intestine. Other exclusion criteria were the presence of a stoma, serum creatinine concentration > 1.5 mg/dL, the desire to become pregnant during the study, known malignancies, intolerance to quinolones, or previous long-term therapy with ciprofloxacin of > 4 weeks prior to surgery Age (IG1/IG2) median (range): overall not reported; 33 (19 to 70) vs 27 (18 to 61) Sex (M:F): 18:15 overall; (10:7) vs (8:8) Type of surgery: Not reported Previous surgery (IG1 + IG2): 18 (7/11) Start of intervention after surgery: $\leq$ 2 weeks Medication use (IG1 + IG2): MES 9 (4/5); immunosuppression 8 (3/5); steroids 11 (7/4) Smoker (IG1/IG2): (4/17) vs (0/16) Number randomised (n = 33): 17/16 Number analysed (n = 33): (17/17) vs (16/16) Postrandomisation exclusion (n = 11): (6/17) vs (5/16) (need for prohibited medica- tion 2 (1/1); non-compliance 5 (3/2); lost to follow-up 3 (2/1); consent withdrawals 1 (0/1))	
Interventions	<b>Group 1:</b> Oral treatment with ciprofloxacin 500 mg twice daily for 6 months <b>Group 2:</b> Oral treatment with identical-appearing placebo twice daily for 6 months <b>All participants:</b> No other treatments for CD or therapies involving more than 10 days of broad-spectrum antibiotics were permitted. Examinations were performed at weeks 4, 12, and 24 after the start of medication and additionally by phone at weeks 8, 18, and 28	
Outcomes	<ul> <li>Duration of study: 6 months</li> <li>1. Endoscopic recurrence defined as i ≥ 2 according to the Rutgeerts score or a Marteau score ≥ c2</li> <li>2. Clinical recurrence (Harvey Bradshaw index ≥ 5)</li> <li>2. Adverse events</li> <li>3. Withdrawal due to adverse events</li> </ul>	
Notes	<b>Funding source:</b> Senior Research Award of the Crohn's and Colitis Foundation of Amer- ica and the National Institute of Diabetes and Digestive and Kidney Diseases <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Not reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomized in a 1: 1 ratio to oral treatment with ciprofloxa-

### Herfarth 2013 (Continued)

		cin 500 mg or identical appearing placebo twice daily for 6 months. Randomization took place at the trial central pharmacy at the University of North Carolina. Ran- domization was performed by permuted block randomization with a block size of 4 per site" Comment: block random sequence gener- ation
Allocation concealment (selection bias)	Low risk	Centralised allocation by the pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo- controlled, double-blind trial, however no information regarding the blinding of per- sonnel provided
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Also photo-documentation of the anastomosis and neoterminal ileum of each patient was reviewed in a blinded fashion by two of the investigators (H.H., K.I.). All scores of this second evaluation were in agreement with the initial evaluation" Comment: outcome assessors blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: "For the ITT analysis patients with- out ileocolonoscopy and clinical evaluation at the 6-months visit were considered to have endoscopic and clinical recurrence of CD" Comment: ITT analysis applied; however, overall attrition rate of over 30% when compared to event risk of 24% raises con- cerns about bias
Selective reporting (reporting bias)	Low risk	Trial registration is available (NCT00609973). All proposed outcomes were reported
Other bias	Low risk	Baseline characteristics balanced. No other apparent sources of bias detected
All domain risk of bias	Unclear risk	High risk

Lochs 2000

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Austria, Denmark, Germany, Norway, Sweden, and Switzerland; 29 university/ teaching hospitals; 1992 to 1996
Participants	Inclusion: Adults (18 to 70 years) who underwent a resective surgical procedure (radical or non-radical) for a CD-specific lesion at 1 of the participating centres; diagnosis of CD established by generally accepted endoscopic, histological, and/or radiological criteria at least 6 months before surgery; evaluation of disease location by a complete investigation of the gastrointestinal tract (gastroscopy, colonoscopy, and small bowel radiography) within a maximum of 1 year before the index surgery; and ability to start oral nutrition (and thus oral medication) within the first 10 postoperative days <b>Exclusion</b> : Exclusion criteria included contraindications for use of MES; pregnancy or intention of pregnancy within the next 18 months; nursing; short bowel syndrome; clinically significant lactase deficiency; any severe additional disease; diagnosis of primary sclerosing cholangitis; presence of an ileocolonic stoma; more than 3 surgeries preceding the index surgery; and failure to obtain informed consent <b>Age (IG1/IG2) mean (SD)</b> : 33.6 ± 10.1 overall; 33.5 ± 10.0 vs 33.8 ± 10.2 <b>Sex (M:F)</b> : 156:162 overall; (71:81) vs (85:81) <b>Type of surgery</b> : radical 244 (121/123); non-radical 75 (35/40) <b>Previous surgery (IG1 + IG2)</b> : 18 (7/11) <b>Start of intervention after surgery</b> : $\leq 10$ days <b>Medication use (IG1 + IG2)</b> : sulfasalazine 190 (96/94); metronidazole 32 (10/22); immunosuppressants 18 (8/10); corticosteroids 187 (86/101); TPN 35 (16/19) <b>Smoker (IG1/IG2)</b> : not reported <b>Number randomised (n = 324)</b> : 154/170 <b>Number randomised (n = 318)</b> : (152/154) vs (166/170) <b>Postrandomisation exclusion (n = 20)</b> : (7/34) vs (13/36) (lost to follow-up 14 (5/9); did not start treatment 6 (2/4))
Interventions	<ul> <li>Group 1: 4 g MES (Pentasa) per day divided into 3 doses (1.5, 1, and 1.5 g). 1 tablet of Pentasa contains 500 mg encapsulated in ethylcellulose microgranules and pressed to form a tablet with microcrystalline cellulose</li> <li>Group 2: Placebo tablets of identical appearance and consistency containing additional microcrystalline cellulose to compensate for the MES microgranules</li> <li>All participants: Corticosteroids were permitted to be tapered by standardised stepwise dose reductions within 6 weeks. Concomitant medication such as glucocorticoids with the exception of initial tapering, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, metronidazole, methotrexate, sulfasalazine, and other 5-aminosalicylates were not allowed. Symptomatic treatment with antidiarrhoeal, antacid, or spasmolytic medication was allowed but had to be thoroughly documented for calculation of the CDAI. Similarly, participants were requested to report precisely any other concomitant medication in their diary. Participants were supplied with study medication for the subsequent 3 months at each follow-up visit. Any tablets not used had to be returned. MES and acetylmesalazine were determined in blood samples drawn at each visit. Participants were considered non-compliant if medication was interrupted for a total of &gt; 10% of their individual trial course. Endoscopic evaluation of the colon and, if possible, of the anastomosis was recommended at 6 weeks and 18 months after surgery or at the time of clinical relapse</li> </ul>

### Lochs 2000 (Continued)

Outcomes	<b>Duration of study:</b> 18 months <b>1. Endoscopic recurrence</b> defined as $i \ge 1$ according to Rutgeerts and colleagues <b>2. Clinical recurrence</b> defined by 1 of the following: increase in CDAI above 250; increase in CDAI above 200 but by a minimum of 60 points over the lowest postoperative value for 2 consecutive weeks, indication for surgery; development of a new fistula; and occurrence of a septic complication. (ITT data estimated as: number randomised – number in remission at 18 months.) <b>3. Adverse events</b> <b>4. Withdrawal due to adverse events</b>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Based on a maximum relapse rate with placebo of 50% and an absolute effect size of 15% with the active drug, a sample size of 150 participants per treatment group was calculated

#### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A computer-generated random- ization scheme was provided by the Insti- tut für Medizinische Dokumentation und Statistik at the University of Köln at the beginning of the trial and forwarded to the Department of Galenics at Ferring A/S, Denmark. Randomization was performed in blocks of 10 for each of the participating centers" Comment: computer-generated random sequence
Allocation concealment (selection bias)	Unclear risk	Quote: "In addition, each center retained sealed opaque envelopes containing patient numbers and treatment allocations, which were only allowed to be opened in case of a serious adverse event that necessitated dis- closure of the type of treatment" Comment: unclear whether envelops were sequentially numbered
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Placebo tablets of identical ap- pearance and consistency contained addi- tional microcrystalline cellulose to com- pensate for the mesalamine microgranules . All patients and investigators were blinded regarding treatment allocation" Comment: placebo blinded

### Lochs 2000 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Randomization was performed in blocks of 10 for each of the participating centers. This information was kept confi- dential at the Department of Quality As- sessment at Ferring and the statistical cen- ter in Cologne and was only available to the Department of Galenics [] An Endpoint Committee consisting of 2 physicians and 1 surgeon, not participating in the trial, made a final decision about questionable cases of protocol violations and relapses" Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quotes: "Outcome measures were analysed in all randomized patients who had taken at least 1 dose of study medication (intention- to-treat population)" Comment: attrition rates and reasons were balanced across groups
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "No significant differences were de- tected between the 2 treatment groups for any of the parameters investigated" Comment: groups well balanced at base- line. No additional sources of bias detected
All domain risk of bias	Low risk	Low/unclear
Lopez Sanroman 2017		
Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Spain, 22 centres; 2012 to 2015	
Participants	<b>Inclusion:</b> Adults (18 to 70 years) who underwent a resective surgical procedure (radical or non-radical) for a CD-specific lesion at 1 of the participating centres; diagnosis of CD established by generally accepted endoscopic, histological, and/or radiological criteria at least 6 months before surgery; evaluation of disease location by a complete investigation of the gastrointestinal tract (gastroscopy, colonoscopy, and small bowel radiography) within a maximum of 1 year before the index surgery; and ability to start oral nutrition (and thus oral medication) within the first 10 postoperative days	

**Exclusion:** Contraindications for use of MES; pregnancy or intention of pregnancy within the next 18 months; nursing; short bowel syndrome; clinically significant lactase deficiency; any severe additional disease; diagnosis of primary sclerosing cholangitis; presence of an ileocolonic stoma; more than 3 surgeries preceding the index surgery; and

### Lopez Sanroman 2017 (Continued)

	failure to obtain informed consent Age (IG1/IG2) median (interquartile range): overall age not reported; 37.00 (31.00 to 47.00) vs 35.00 (30.0 to 40.0) Sex (M:F): 42:42 overall; (23:16) vs (19:26) Type of surgery: Not reported Previous surgery (IG1 + IG2): 6 (3/3) Start of intervention after surgery: After surgery (consent obtained before surgery) Medication use (IG1 + IG2): Glucocorticoids 80 (38/42); immunosuppressants (thiop- urines or methotrexate) 63 (28/35); anti-TNF $\alpha$ 49 (21/28) Smoker (IG1/IG2): 20 (9/11) Number randomised (n = 85): 40/45 Number analysed (n = 84): (39/40) vs (40/40) Postrandomisation exclusion (n = 3): (1/40) vs (2/45) (consent withdrawal before treatment 1 (0/1); loss to follow-up 2 (1/1))
Interventions	<ul> <li>Group 1: AZA 2.5 mg/kg/day for 1 year. Metronidazole 250 mg 3 times a day by mouth was added for the first 3 months</li> <li>Group 2: ADA 160 mg subcutaneously, then 80 mg at Week 2, or 40 mg at Week 4 and every 2 weeks thereafter for 1 year. Metronidazole 250 mg 3 times a day by mouth was added for the first 3 months</li> <li>All participants: Adherence to therapy was assessed by direct questioning and by counting of returned medication</li> </ul>
Outcomes	<ul> <li>Duration of study: 52 weeks</li> <li>1. Endoscopic recurrence defined as i ≥ 2b, 3 and 4 based on Rutgeerts score (24 and 52 weeks)</li> <li>2. Clinical recurrence defined by 1 of the following: increase in CDAI above 200 (24 and 52 weeks) (CDAI ≥ 200: ITT data derived from number randomised – remissions)</li> <li>3. Radiologic recurrence rate</li> <li>4. Health-related quality of life</li> <li>5. Adverse events</li> <li>6. Serious adverse events</li> <li>7. Withdrawal due to adverse events</li> </ul>
Notes	<ul> <li>Funding source: Unrestricted grant from AbbVie (Spanish Working Group on Crohn's Disease and Ulcerative Colitis). The funders had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decisions concerning publication. The authors had unrestricted access to the data; the decision to submit the paper for publication was solely and entirely to theirs</li> <li>Conflict of interest: All authors have declared conflict of interest (mainly grants, personal fees, collaboration with AbbVie outside the submitted work, research funding from AbbVie, etc.)</li> <li>Sample size: The difference in the proportion of endoscopic recurrence between treatment groups was estimated at 35% (10% for ADA + metronidazole and 45% for AZA + metronidazole), considering a type I error of 5%, a 2-tailed contrast with Yates' continuity correction, 90% power (1-type II error), and an allocation ratio of 1:1.38 participants per treatment group would therefore be needed. Withdrawals were estimated at 10%. The minimal sample was estimated at 84 evaluable participants</li> </ul>

### Lopez Sanroman 2017 (Continued)

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Central randomisation was based on a pregenerated block randomisation list stratified by centre." and "Patients were as- signed [1:1] to" Comment: central randomisation
Allocation concealment (selection bias)	Unclear risk	Quote: "Allocation was concealed by means of a computer-generated randomisation schedule without stratification or block al- location" Comment: insufficient description
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Neither patients nor investigators were blinded to the administered treat- ment" Comment: no blinding of personnel and participants performed
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "A video recording of the last 15 cm of the neo-terminal ileum was evaluated by an endoscopist blinded to treatment alloca- tion and experienced in application of the Rutgeerts score [VP]" and "MRE, which was evaluated centrally by an experienced blinded reader [JR]" Comment: outcome assessors were blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "We defined the following popula- tions: 1] the intention-to-treat [ITT] pop- ulation, which included all consenting pa- tients who were randomised and received at least one dose of the study medications" Comment: ITT analysis applied, reasons for withdrawal reported, and attrition rates were balanced across groups
Selective reporting (reporting bias)	High risk	Trial registration was avail- able (NCT01564823), and all prespecified outcomes were reported in the study except for health-related quality of life, which was only reported as a P value in an abstract

#### Lopez Sanroman 2017 (Continued)

Other bias	Low risk	Quote: "The groups were similar regarding baseline characteristics, including smok- ing status, previous resections, CD pheno- type, previous perianal disease, and previ- ous drug exposure" Comment: groups well balanced at base- line. No other apparent sources of bias de- tected
All domain risk of bias	High risk	Very high
Marteau 2006		
Methods	<b>Study design:</b> RCT, multicentre (The GETAID study) <b>Setting:</b> France, Belgium, Switzerland, and the Netherlands; 2002 to 2004	
Participants	<b>Inclusion:</b> Male and female patients at least 18 years of age were eligible to participate if they had: (a) undergone recent surgical resection for ileal, ileocolonic, or colonic CD, removing all macroscopic lesions, with an anastomosis that could be reached by	

CD, removing all macroscopic lesions, with an anastomosis that could be reached by ileocolonoscopy; (b) cumulative small bowel resection(s) of less than 1 m; and (c) no other intestinal resection during the previous 5 years **Exclusion:** Patients receiving antibiotics for more than 2 weeks and those treated with aminosalicylates or immunosuppressants for more than 3 weeks after surgery were not clicible patients are other discase on an disign that michae are other with

eligible, neither were those with any other disease or condition that might interfere with the study assessments (as judged by the investigator). Patients who had participated in another clinical study in the previous 30 days; women of childbearing potential who were not using effective contraception; pregnant or lactating women; and patients who had undergone total or subtotal colectomy, intestinal bypass or stricturoplasty, stomy, carcinoma resection, or abscess drainage were also ineligible

Age (IG1/IG2) median (interquartile range): Not stated overall; 32 (27 to 42) vs 29 (27 to 34) Sex (M:F): 55:43 overall; (26:22) vs (29:21)

Type of surgery: Ileal 7 (6/1); ileocolonic 89 (40/49); colonic (segmental) 2 (2/0) Previous surgery (IG1 + IG2): 16 (7/9) Start of intervention after surgery:  $\leq 21$  days Medication use (IG1 + IG2): Steroid treatment 61 (19/42) Smoker (IG1/IG2): Not reported

Number analysed (n = 98): (48/48) vs (50/50)Postrandomisation exclusion (n = 8): (5/48) vs (3/50) (lost to follow-up 6 (4/2); not evaluated 2 (1/1))

Interventions

**Group 1:** 2 packets per day of lyophilised LA1 (26109 CFU per packet) for 6 months **Group 2:** 2 packets per day of placebo (maltodextrin) for 6 months **All participants:** The packets had to be dissolved in half a glass of water just before con-

sumption. Corticosteroids were allowed if used before surgery but had to be withdrawn gradually within 6 weeks after surgery. Concomitant medication with the following drugs was not allowed: antibiotics for more than 15 days; aminosalicylates; glucocorticoids

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Number randomised (n = 98): 48/50

### Marteau 2006 (Continued)

	(after gradual withdrawal); non-steroidal anti-inflammatory drugs; immunosuppressive drugs; anti-TNF agents; thalidomide; and other probiotics. Loperamide and colestyra- mine were allowed. Study visits were planned at inclusion and 3 and 6 months after surgery, and if clinical signs of recurrence occurred. Ileocolonoscopy was performed at 6 months and in case of clinical recurrence
Outcomes	<ul> <li>Duration of study: 6 months</li> <li>1. Endoscopic recurrence defined grade &gt;1 macroscopic lesions in the ileum or colon, using Rutgeerts' classification for ileal lesions</li> <li>2. Clinical recurrence defined as CDAI of 200 or more</li> <li>3. Severe endoscopic recurrence defined as endoscopic score (maximum of the ileum and colon grades) of &gt;2</li> <li>3. Adverse events</li> </ul>
Notes	<ul> <li>Funding source: Funded by grant support from the Nestlé Research Center, Vevey, Switzerland. Study products were provided by Nestlé. All data analysis and manuscript writing was performed independently by the GETAID Study Group, with no involvement of Nestlé representatives</li> <li>Conflict of interest: All authors declared conflict of interest (supplementary material online)</li> <li>Power calculation: The hypothesis for the sample size calculation was an endoscopic recurrence rate of 50% at 6 months in the placebo group. In order to detect a 30% reduction in the endoscopic recurrence rate in the LA1 treatment arm, it was calculated that 48 participants per group had to be enrolled to guarantee a power of 80% in a 2-sided test with a type I error of 5%</li> </ul>

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: " randomisation was performed by this centre within each stratum per cen- tre, using permutation tables of size 2 or 4, according to expected enrolment within each centre, each centre being blinded to the size of its blocks" Comment: block randomisation
Allocation concealment (selection bias)	Low risk	Quote: "Treatment number was the first free number with the corresponding treat- ment in a randomised list with treatment numbers and their corresponding treat- ment prepared by the biostatistics centre before trial initiation" and "The same infor- mation and allocated treatment were sent to the service in charge of drug delivery, al- lowing the service to check that treatment was in agreement with the predefined list. Treatment was sent by this service to the

### Marteau 2006 (Continued)

		pharmacy of the centre with protocol iden- tification and the patient's dentification" Comment: central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo-blinded study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The study was double-blinded and "un- blinding, if necessary, was made by a re- quest to the biostatistics centre with a spe- cific form" Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The primary efficacy analysis was based on the ITT population, which in- cluded all patients in whom the primary endpoint was assessable" Comment: attrition rates and reasons were balanced across groups
Selective reporting (reporting bias)	Low risk	All outcomes stated in the methods section were reported.
Other bias	Low risk	Quote: "The two treatment groups were well matched, except for a higher propor- tion of patients who underwent ileal and colonic resection in the placebo group, and a higher median CRP level in the LA1 group" Comment: groups well balanced at base- line; no other apparent sources of bias
All domain risk of bias	Low risk	Low/unclear

#### Mañosa 2013

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Spain; 2004 to 2010
Participants	<b>Inclusion:</b> All consecutive adult patients with CD undergoing ileal or ileocolic resection with ileocolic or ileorectal anastomosis between January 2004 and January 2010 were invited to participate in the trial <b>Exclusion:</b> Exclusion criteria included the following: intolerance or known allergy to the study drugs; erythrocyte thiopurine methyltransferase activity < 5 U/mL red blood cells; previous treatment with thiopurines for the same indication (prevention of postoperative recurrence); antecedents of malignancy; ongoing infectious disease; pregnancy or a desire to become pregnant; intolerance to oral intake; and use of any investigational drug in the preceding 6 months
### Mañosa 2013 (Continued)

	Age (IG1/IG2) mean (SD): 35.36 ± 10.13 overall; 36.2 ± 12 vs 34.52 ± 8 Sex (M:F): 27:23 overall; (12:13) vs (15:10) Type of surgery: radical 244 (121/123); non-radical 75 (35/40) Previous surgery (IG1 + IG2): 18 (7/11) Start of intervention after surgery: Not reported Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): 23 (10/13) Number randomised (n = 50): 25/25 Number analysed (n = 50): (25/25) vs (25/25) Postrandomisation exclusion (n = 0)
Interventions	<ul> <li>Group 1: Oral metronidazole 3 times a day for a total dose of 15 to 20 mg/kg per day for the first 3 months after the surgical procedure (AZA + MDZ)</li> <li>Group 2: The same number of placebo pills during the first 3 months after the surgical procedure. (Placebo was prepared and packaged in the Pharmacy Department of the Hospital Universitari Germans Trias i Pujol) (AZA + PLAC)</li> <li>All participants: After signing the informed consent document, all participants were treated with azathioprine (2 to 2.5 mg/kg per day) until the end of the study. Any concomitant treatment for CD (methotrexate, aminosalicylates, corticosteroids, budesonide, metronidazole (except for the first 3 months in participants randomised to metronidazole), ciprofloxacin, or anti-TNF agents) was not allowed during the study</li> </ul>
Outcomes	<b>Duration of study:</b> 12 months 1. <b>Clinical recurrence</b> defined as a Harvey-Bradshaw index of > 7 points, together with morphological disease recurrence as documented by the endoscopic or radiological findings 2. <b>Severe endoscopic relapse</b> defined as a Rutgeerts endoscopic score of $i \ge 3$ 3. <b>Adverse events</b> 4. <b>Withdrawal due to adverse events</b>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : It was not possible to perform a reliable estimation of the sample size. As a consequence the trial was conceived as a pilot study with 25 participants per therapeutic arm Note: The intervention of interest was given only for the first 3 months, and outcome results were not presented for that time point. Azathioprine was given to all participants until month 12, and outcome data were reported at that time point, albeit not useful for the analysis

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was performed on a 1:1 basis, using a computer-generated random allocation sequence of permuted blocks of 4 patients each. The randomiza- tion process was centralized but stratified

### Mañosa 2013 (Continued)

		per participating center" Comment: stratified block randomisation
Allocation concealment (selection bias)	Unclear risk	Quote: "Azathioprine was ordinarily pre- scribed, whereas the study medication (metronidazole or placebo) was dispensed by the pharmacy of each participating hos- pital" Comment: the randomisation process was centralised, and the pharmacy of each par- ticipating hospital dispensed the study in- tervention. Details of central allocation were not clear
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study was placebo-controlled.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Trial was reportedly double blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	There were no withdrawals for reasons other than adverse events
Selective reporting (reporting bias)	Low risk	The authors indicate that the trial was reg- istered (Eudr CT 2004-001795-39). How- ever, we were unable to locate the trial reg- istration. All outcomes stated in the meth- ods section were reported
Other bias	Low risk	Groups well balanced at baseline in all pa- rameters assessed, except for the previous use of thioprines, which was more frequent in the metronidazole group. The review au- thor team did not consider this to be a source of bias
All domain risk of bias	Low risk	Low/unclear

#### McLeod 1995

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Canada; 1986 to 1993
Participants	<b>Inclusion:</b> All patients who had undergone a surgical resection for Crohn's disease at 1 of the participating hospitals and who had no gross residual disease were eligible for entry provided they were randomised within 8 weeks of the date of surgery <b>Exclusion:</b> Patients with residual Crohn's disease (including gastroduodenal Crohn's

### McLeod 1995 (Continued)

Interventions       Group 1: 3 g/day of MES taken as six 250 mg tablets twice daily         Group 2: 6 identical-looking placebo tablets twice daily       All participants: Study medication was mailed to the participant every 3 months. At 3-month intervals, all participants were interviewed by telephone by a research nurse to determine their clinical status; ensure they were not taking any other prescribed medications; and assess their compliance. At yearly intervals, all participants were assessed by an investigator and appropriate radiological or endoscopic investigations performed. If endoscopy could not be performed, then an air contrast barium enema or ileostomy injection was performed. Once participants were judged to have symptoms caused by Crohn's disease that required treatment and there was radiographic or endoscopic confirmation of disease, they were considered a failure. Further treatment was at the discretion of their attending physician or surgeon. Compliance was determined by questioning the participants and by pill counts of all medication returned at the annual visit         Outcomes       Duration of study: Follow-up period 72 months maximum         1. Symptomatic recurrence defined as symptoms compatible with Crohn's disease that were severe enough to warrant treatment in the opinion of the investigator plus radiological or endoscopic covidence of disease using the outlined criteria (at least 1 of the following features had to be present to make the diagnosis of recurrent disease; aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nadularity of the bowel; stricture of the bowel associated with oedema, ulceration, or erythema of the mucosa; pseudopolyps; or mucosal bridging)         0. Endoscopic and radiologic relapse rate defined as the presence of endoscopic or radiological evidence of disease; aphthous ulcers; l		disease) with the exception of asymptomatic anal skin tags or anal stenosis; abnormal renal function with a serum creatinine level > 130 µmol/dL or 1.5 mg/dL; if they were taking prednisone, sulfasalazine, metronidazole, or azathioprine (Imuran) and these drugs could not be discontinued <b>Age (IG1/IG2) mean (SD):</b> 38.0 ± 13.1 overall; 38.9 ± 13.1 vs 38.9 ± 13.2 <b>Sex (M:F):</b> 98:65 overall; (49:38) vs (49:27) <b>Type of surgery:</b> Small bowel resection 15 (8/7); terminal ileal/ileocolic resection 109 (59/50); segmental colon resection 7 (7/0); total abdominal colectomy 3 (1/2); procto- colectomy 25 (13/12); proctectomy 10 (3/7) <b>Previous surgery (IG1 + IG2):</b> 179 surgical resections performed in the 163 participants <b>Start of intervention after surgery:</b> ≤ 8 weeks <b>Medication use (IG1 + IG2):</b> Not reported <b>Smoker (IG1/IG2):</b> Not reported <b>Number randomised (n = 169):</b> 88/81 <b>Number randomised (n = 163):</b> (87/88) vs (76/81) <b>Postrandomisation exclusion (n = 21):</b> (8/88 ) vs (13/81) (randomised but did not give consent 6 (1/5); refused follow-up because of personal reason 11; death due to multiple myeloma 1; moved to Europe 1; bowel resection (suspected Crohn's disease, but resected specimen was pathologically normal) 2 (reasons not reported separately))
<ul> <li>Outcomes</li> <li>Duration of study: Follow-up period 72 months maximum         <ol> <li>Symptomatic recurrence defined as symptoms compatible with Crohn's disease that were severe enough to warrant treatment in the opinion of the investigator plus radiological or endoscopic evidence of disease using the outlined criteria (at least 1 of the following features had to be present to make the diagnosis of recurrent disease: aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nodularity of the bowel; stricture of the bowel associated with oedema, ulceration, or erythema of the mucosa; pseudopolyps; or mucosal bridging)</li> <li>Endoscopic and radiologic relapse rate defined as the presence of endoscopic or radiological evidence of disease and included both asymptomatic and symptomatic participants. At least 1 of the following features had to be present to make the diagnosis of recurrent disease: aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nodularity of the bowel; stricture of the bowel; stricture of the bowel associated with oedema, ulceration, or erythema of the mucosa; pseudopolyps; or mucosal bridging)</li> </ol></li></ul>	Interventions	<b>Group 1:</b> 3 g/day of MES taken as six 250 mg tablets twice daily <b>Group 2:</b> 6 identical-looking placebo tablets twice daily <b>All participants:</b> Study medication was mailed to the participant every 3 months. At 3- month intervals, all participants were interviewed by telephone by a research nurse to determine their clinical status; ensure they were not taking any other prescribed med- ications; and assess their compliance. At yearly intervals, all participants were assessed by an investigator and appropriate radiological or endoscopic investigations performed. If endoscopy could not be performed, then an air contrast barium enema or ileostomy injection was performed. Once participants were judged to have symptoms caused by Crohn's disease that required treatment and there was radiographic or endoscopic confir- mation of disease, they were considered a failure. Further treatment was at the discretion of their attending physician or surgeon. Compliance was determined by questioning the participants and by pill counts of all medication returned at the annual visit
	Outcomes	<ul> <li>Duration of study: Follow-up period 72 months maximum</li> <li>1. Symptomatic recurrence defined as symptoms compatible with Crohn's disease that were severe enough to warrant treatment in the opinion of the investigator plus radiological or endoscopic evidence of disease using the outlined criteria (at least 1 of the following features had to be present to make the diagnosis of recurrent disease: aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nodularity of the bowel; stricture of the bowel associated with oedema, ulceration, or erythema of the mucosa; pseudopolyps; or mucosal bridging)</li> <li>2. Endoscopic and radiologic relapse rate defined as the presence of endoscopic or radiological evidence of disease and included both asymptomatic and symptomatic participants. At least 1 of the following features had to be present to make the diagnosis of recurrent disease: aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nodularity of the bowel; stricture of the bowel; stricture of the bowel; stricture of the mucosa; participants. At least 1 of the following features had to be present to make the diagnosis of recurrent disease: aphthous ulcers; longitudinal or punched-out ulcers; cobblestoning or nodularity of the bowel; stricture of the bowel associated with oedema, ulceration, or erythema of the mucosa; pseudopolyps; or mucosal bridging</li> <li>3. Adverse events</li> </ul>

## McLeod 1995 (Continued)

	4. Withdrawal due to adverse events
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : Based on a review of retrospective studies in the literature, it was estimated that the symptomatic recurrence rate in the control group would be 12.5% per year. Using a sample size calculation based on survival analysis for 2 independent groups with censoring, it was estimated that 178 participants would have to be accrued during a period of 3 years and followed up for a maximum of 6 years to detect a 50% decrease in recurrence (6.25% per year) in the treatment group with a one-tail $\alpha$ of 0. 05 and power of 0.80

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The randomization scheme was computer generated by the Clinical Research Support Unit, University of Toronto, and maintained by the pharma- cies at the Toronto Hospital, General Divi- sion, and St. Mary's Hospital, Rochester" Comment: computer-generated random sequence
Allocation concealment (selection bias)	Low risk	Quote: "All investigators and patients were blinded with respect to treatment alloca- tion" Comment: no further details provided, however the authors confirmed on 27 November 2009 that a central allocation was done by pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Subjects in the control group took six identical-looking placebo tablets twice daily" Comment: participants and investigators were blinded to treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "All patient records were reviewed by an adjudication committee of five inves- tigators (R.S.M., B.G.W., A.H.S., P.W.C., and K.O.) blinded to patient treatment al- location." And "The charts of patients who were noncompliant were reviewed by two blinded gastroenterologists (A.H.S. and P. W.C.), who determined whether noncom- pliance was secondary to adverse effects po- tentially related to the medication"

#### McLeod 1995 (Continued)

		Comment: blinding of assessors performed
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates were low, and reasons for withdrawal were balanced across groups
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in methods section were reported
Other bias	Low risk	Quote: "The characteristics of the two groups, which are listed in Table 1, were similar" Comment: groups balanced at baseline. No other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

#### Mowat 2016

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> UK; 29 secondary and tertiary hospitals; 2008 to 2012	
Participants	Inclusion: Patients aged at least 16 years (Scotland) or 18 years (England and Wales) with a diagnosis of Crohn's disease and an ileocolic or small bowel resection within the preceding 3 months were eligible for inclusion. Patients successfully treated for a malignancy and in remission for at least 5 years were also eligible Exclusion: Residual active Crohn's disease present after surgery, known intolerance or hypersensitivity to thiopurines, known need for further surgery, strictureplasty alone, formation of a stoma, active or untreated malignancy, absent thiopurine methyltransferase activity, substantial abnormalities of liver function tests or full blood count, and pregnancy. Patients receiving treatment for active Crohn's disease at random allocation Age (IG1/IG2) mean (SD): $38.76 \pm 13.1$ overall; $39.2 \pm 12.08$ vs $38.21 \pm 13.4$ Sex (M:F): $94:146$ overall; $(49:79)$ vs $(45:67)$ Type of surgery: Not reported Previous surgery (IG1 + IG2): Not reported Start of intervention after surgery: $\leq 3$ months Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomised (n = 240): $128/112$ Number randomised (n = 240): $(128/128)$ vs $(112/112)$ Postrandomisation exclusion (n = 56): abnormal blood test results 18 $(12/6)$ ; early withdrawal 21 $(8/13)$ ; loss to follow-up 16 $(8/7)$ ; death 1 $(0/1)$	
Interventions	<b>Group 1:</b> Once-daily oral mercaptopurine, at a dose of 1 mg/kg body weight rounded to the nearest 25 mg. Participants with low thiopurine methyltransferase activity were prescribed half the normal dose for 3 years <b>Group 2:</b> Identical matched placebo for 3 years <b>All participants:</b> Blood monitoring was done weekly for the first 6 weeks and thereafter	

## Mowat 2016 (Continued)

	at 6-weekly intervals. Participants with abnormal results had a dose reduction, temporary cessation, or cessation as per a study algorithm. At each study visit, the following data were collected: CDAI, physical examination, concomitant medications, and patient-reported outcomes, including the IBDQ
Outcomes	<ul> <li>Duration of study: 3 years</li> <li>1. Clinical recurrence defined as CDAI score of over 150 and a 100-point increase from baseline AND the need for anti-inflammatory rescue treatment or primary surgical intervention (ITT calculated as: number that discontinued trial)</li> <li>2. Secondary endpoint of clinical recurrence defined as reaching either of the individual components of the primary outcome (i.e. either a CDAI score of &gt; 150 and a 100-point increase from baseline OR the need for anti-inflammatory rescue treatment or primary surgical intervention)</li> <li>3. Endoscopic relapse defined as a Rutgeerts score of ≥ i2</li> <li>4. Crohn's Disease Endoscopic Index of Severity</li> <li>5. Health-related quality of life</li> <li>6. Adverse events</li> <li>8.Withdrawal due to adverse events</li> </ul>
Notes	<ul> <li>Funding source: Funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. They had no role in the study design, data collection, data analysis, data interpretation, or writing of the report</li> <li>Conflict of interest: Authors declare no conflicting interests.</li> <li>Power calculation: A sample size of 234 participants was needed to give 80% power to detect a reduction in the frequency of recurrence from 50% in the placebo group to 30% in the treatment group by 3 years at the 5% level of significance</li> </ul>

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomly assigned (1:1) to mercaptopurine or identical matched placebo using a computer-gen- erated web-based randomisation system managed by the Edinburgh Clinical Trials Unit (University of Edinburgh, Edinburgh, UK)" Comment: computer-generated web-based random sequence
Allocation concealment (selection bias)	Low risk	Quote: "Patients' details were entered into the randomisation system before random allocation and were concealed at randomi- sation" Comment: web-based central allocation

## Mowat 2016 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Patients and their carers and physi- cians were masked to the treatment alloca- tion" Comment: the study is placebo-controlled
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Blood monitoring results were re- viewed by an independent central clini- cian masked to treatment allocation and to mean corpuscular volume results. To pro- tect masking, investigators were informed that sham dose reductions were planned for patients on placebo. However, on the advice of the data monitoring committee, sham dose reductions did not occur; the in- vestigators were not informed of this" Comment: outcome assessors were blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Analyses were by intention to treat" Comment: attrition rate of 23% when compared with the event risk (30%) was not considered sufficient to lead to bias
Selective reporting (reporting bias)	Low risk	Trial registration available (ISRCTN89489788) , and all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "Baseline characteristics were simi- lar between study groups" Comment: groups well balanced at base- line. No other apparent sources of bias de- tected
All domain risk of bias	Low risk	Low/unclear

#### Prantera 2002

Methods	<b>Study design:</b> RCT, single-centre <b>Setting:</b> Italy; 1998 to 2000
Participants	<b>Inclusion:</b> Eligible patients were aged at least 18 years and were scheduled for curative resection for Crohn's disease. Inclusion criteria were: a diagnosis of Crohn's disease, defined by the criteria adopted by Lennard-Jones and confirmed by surgical specimens; complete resection of all diseased intestine, as shown by inspection at surgery; ability to start oral nutrition and therefore the trial itself within 10 days of operation; and informed written consent

### Prantera 2002 (Continued)

Interventions       Group 1: LGG (Dicoflor 60; Dicofarm, Rome, Italy) consisted of 2.46-gram bags ead containing LGG 6 billion CFU and was administered at a dose of 6 billion CFU twi daily. LGG belongs to Lactobacillus casei subspecies rhamnosus, isolated by Goldin ar Gorbach.         Group 2: Placebo consisted of bags of identical appearance to the probiotic. Each be contained maltodextrines 2.060 mg, sorbitol 400 mg, and silicon dioxide 5 mg. TI taste and smell of the active substance and placebo were the same         All participants: The study drugs were administered orally, 1 bag twice daily, mornir and afternoon, dissolved in half a glass of water, for 52 weeks. Treatment was started soon as participants could take solid food by mouth after operation but not later tha 10 days after surgery. Follow-up visits were carried out after 13, 26, 39, and 52 weeks. treatment. Compliance with the study drugs was checked by the investigator by countir the number of bags returned at each visit. Treatment failure during the study period was defined as the appearance of Crohn's disease symptoms and/or signs that need additional medical treatment or operation         Outcomes       Duration of study: 52 weeks         1. Clinical recurrence defined as increase in CDAI to more than 150 points, confirme by endoscopic relapse defined as a Rutgeerts score of ≥ i2         3. Adverse events       4. Serious adverse events         4. Serious adverse events       5. Serious adverse events		<b>Exclusion:</b> Exclusion criteria were: pregnancy and lactation; postoperative septic complications; presence of other concomitant important disease; active perianal disease; presence of Crohn's disease in other intestinal tracts; need for antibiotics for more than 10 days after surgery; intake of steroids for more than 30 days after operation; total parenteral nutrition or elemental diet; and use of other drugs possibly active in Crohn's disease. Antidiarrhoeals such as loperamide or other opiates and colestyramine were allowed provided their use had been calculated in the CDAI <b>Age (IG1/IG2) mean (range):</b> Not reported, overall > 18; 37.3 (22 to 71) vs 36.2 (22 to 64) <b>Sex (M:F):</b> 29:16 overall; (14:9) vs (15:7) <b>Type of surgery:</b> not reported <b>Previous surgery (IG1 + IG2):</b> 11 (5/6) <b>Start of intervention after surgery:</b> $\leq 10$ days <b>Medication use (IG1 + IG2):</b> Not reported <b>Smoker (IG1/IG2):</b> 16 (10/6) <b>Number randomised (n = 45):</b> (23/23) vs (22/22) <b>Postrandomisation exclusion (n = 8):</b> (5/23 ) vs (3/22) (protocol violation 5 (3/2); dropout 3 (2/1))
Outcomes       Duration of study: 52 weeks         1. Clinical recurrence defined as increase in CDAI to more than 150 points, confirmed by endoscopic signs of inflammation         2. Endoscopic relapse defined as a Rutgeerts score of ≥ i2         3. Adverse events         4. Serious adverse events         Notes       Funding source: Not reported         Conflict of interest: Not reported         Power calculation: Not reported	Interventions	<ul> <li>Group 1: LGG (Dicoflor 60; Dicofarm, Rome, Italy) consisted of 2.46-gram bags each containing LGG 6 billion CFU and was administered at a dose of 6 billion CFU twice daily. LGG belongs to <i>Lactobacillus casei</i> subspecies <i>rhamnosus</i>, isolated by Goldin and Gorbach.</li> <li>Group 2: Placebo consisted of bags of identical appearance to the probiotic. Each bag contained maltodextrines 2.060 mg, sorbitol 400 mg, and silicon dioxide 5 mg. The taste and smell of the active substance and placebo were the same</li> <li>All participants: The study drugs were administered orally, 1 bag twice daily, morning and afternoon, dissolved in half a glass of water, for 52 weeks. Treatment was started as soon as participants could take solid food by mouth after operation but not later than 10 days after surgery. Follow-up visits were carried out after 13, 26, 39, and 52 weeks of treatment. Compliance with the study drugs was checked by the investigator by counting the number of bags returned at each visit. Treatment failure during the study period was defined as the appearance of Crohn's disease symptoms and/or signs that needed additional medical treatment or operation</li> </ul>
Funding source:       Not reported         Conflict of interest:       Not reported         Power calculation:       Not reported	Outcomes	<ul> <li>Duration of study: 52 weeks</li> <li>1. Clinical recurrence defined as increase in CDAI to more than 150 points, confirmed by endoscopic signs of inflammation</li> <li>2. Endoscopic relapse defined as a Rutgeerts score of ≥ i2</li> <li>3. Adverse events</li> <li>4. Serious adverse events</li> </ul>
	Notes	Funding source: Not reported Conflict of interest: Not reported Power calculation: Not reported

# Risk of bias

### Prantera 2002 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Using computerised randomisa- tion in blocks of two, patients were allo- cated to receive bags of either Dicoflor 60 or placebo" Comment: probably done
Allocation concealment (selection bias)	Unclear risk	Insufficient information provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The placebo consisted of bags of identical appearance to the probiotic [] The taste and smell of the active substance and placebo were the same" Comment: trial was reportedly double- blinded and placebo controlled; probably done
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition balanced, all participants ac- counted for, withdrawals and reasons re- ported
Selective reporting (reporting bias)	Low risk	All outcomes stated in the methods section were reported.
Other bias	Low risk	Quote: "Demographic and disease charac- teristics did not differ significantly between the two groups but a higher percentage of patients treated with LGG were smokers" Comment: groups balanced at baseline, ex- cept for 1 characteristic. No other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

### Regueiro 2009

Methods	<b>Study design:</b> RCT, single-centre <b>Setting:</b> USA, University of Pittsburgh Medical Center; 2005 to 2007
Participants	<b>Inclusion:</b> Participants underwent ileocolonic resection with primary anastomosis <b>Exclusion:</b> Exclusion criteria included the following: more than 10 years of Crohn's disease requiring first resective surgery for short (10 cm) fibrostenotic stricture; macroscopically active disease not resected at the time of surgery; presence of a stoma; and

### Regueiro 2009 (Continued)

	prior severe reactions to infliximab Age (IG1/IG2) median: Overall not repor Sex (M:F): 16:8 overall; (6:5) vs (10:3) Type of surgery: Not reported Previous surgery (IG1 + IG2): One 16 (7 Start of intervention after surgery: $\leq 4$ w Medication use (IG1 + IG2): Immunomo Smoker (IG1/IG2): 6 (5/1) Number randomised (n = 24): 11/13 Number analysed (n = 24): (11/11) vs (13 Postrandomisation exclusion (n = 3): (2/ nificant infusion reaction 1 (1/0); Crohn's of	ted; 43 vs 32 /9); two 6 (3/3); three 2 (1/1) eeks dulator 11 (4/7); MES 5 (1/4) //13) 11) vs (1/13) (abdominal pain 1 (1/0); sig- lisease exacerbation 1 (0/1))
Interventions	<b>Group 1:</b> Infliximab - first infusion admit time of surgical resection and then 2, 6, immunomodulators and 5-ASA as concom <b>Group 2:</b> Placebo - first infusion administer surgical resection and then 2, 6, and every 8 ulators and 5-ASA as concomitant treatment <b>All participants:</b> No participants received ticipants on corticosteroids at the time of su postoperatively. Participants were assessed 22, 30, 38, 46, and 54), at colonoscopy (9 and at the final study visit at week 66. The In addition, adverse events were ascertaine evaluations at each visit. Participants were temporally recorded as "in the immediate within 8 weeks of surgery, and those "outsi defined as any event that occurred more that	inistered between 2 and 4 weeks from the and every 8 weeks thereafter for 1 year + itant treatments red between 2 and 4 weeks from the time of 8 weeks thereafter for 1 year + immunomod- nts antibiotics in the postoperative setting. Par- rgery were weaned off completely by 2 weeks at each study infusion (weeks 0, 2, 6, 14, weeks 56 to 60 or withdrawal from study), e CDAI was determined at each study visit. d and samples were collected for laboratory prospectively monitored for adverse events, postoperative period," defined as any event de of the immediate postoperative period," an 8 weeks from surgery
Outcomes	Duration of study: 12 months 1. Clinical recurrence defined as increase in 2. Endoscopic relapse defined as a Rutgeer 3. Histologic recurrence based on a histol trophils. The histology scoring system was a maximum score in the grading scheme was 4. Adverse events in the immediate and on	n CDAI to more than 200 points ets score of $\geq$ i2 ogic activity score and the presence of neu- nodified from D'Haens and colleagues. The 14 per biopsy site <b>ttside the immediate postoperative period</b>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation:</b> Specifically, with anticipated 1:1 randomisation of 24 participants, and an endoscopic recurrence of 80% in the placebo group, the study provided 80% power (2-sided type I error rate of 0.05) to detect an absolute difference of 59% associated with infliximab therapy (i.e. 80.0% recurrence in the placebo group, 20.7% recurrence in the infliximab group)	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Regueiro	2009	(Continued)
----------	------	-------------

Random sequence generation (selection bias)	Low risk	Quote: "All 24 patients underwent ileo- colonic resection with primary anastomo- sis and were then randomized to placebo or infliximab" Comment: insufficient information to make judgement. However, email received from authors on 2 August 2018 stating: "The allocation was done by the central (university) pharmacy. The randozimation was blocked" Comment: block randomisation per- formed by a pharmacy
Allocation concealment (selection bias)	Low risk	Quote: "The allocation was done by the central (university) pharmacy. The randoz- imation was blocked" Comment: central allocation. Email re- ceived from authors on 2 August 2018 indicated that "Pharmacy maintained the blind"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Insufficient information to make judge- ment. However email received from au- thors on 2 August 2018 stating: "The study drug (infliximab or placebo) was delivered from the pharmacist to the research nurse and was blinded. The only unblinded per- son was the central pharmacist who did the block allocation for randomization. The study drug was unidentified and all study personnel were not aware of the treatment allocation" Comment: participants and personnel blinded to treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "A blinded investigator (L.B.) re- viewed each patient's video recorded pro- cedure and provided a separate endoscopic score. The colonoscopic video recordings were placed on compact discs that were de- void of patient identifiers (i.e., blinded). At the conclusion of the study, the principal investigator (M.R.) rescored each patient by re-reviewing the video recordings in a random and blinded fashion." And "By us- ing standard biopsy forceps, 6 - 8 biopsy specimens were taken from the neotermi- nal ileum and assessed blindly by a gastroin- testinal pathologist (A.R.S.)"

### Regueiro 2009 (Continued)

		Comment: all outcome assessors blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: low attrition rates, which were balanced across groups (2/11 vs 1/13)
Selective reporting (reporting bias)	Low risk	Trial registration was available (NCT00688636) , and all proposed outcomes were reported
Other bias	High risk	Quote: "In the infliximab group, there were significantly more active smokers (45.5% vs 7.7%; P .06), and a trend for less con- comitant immunomodulators use (36.4 vs 53.8%; P .44) or mesalamine use (9.1% vs 30.8%; P .33). In addition, the median baseline ESR was significantly higher in the infliximab group (40 vs 11; P .004), as was the median CRP concentrations (0.5 vs 0. 1; P .05)" Comment: several significant differences between groups at baseline. There are indi- cations that allocation may not have been truly random
All domain risk of bias	Unclear risk	High

# Regueiro 2016

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Australia, Austria, Belgium, Canada, the Czech Republic, France, Germany, the Netherlands, Hungary, Italy, Poland, the UK, the USA; 104 centres; 2010 to 2012
Participants	<b>Inclusion:</b> Patients (> 18 years) with a confirmed diagnosis of CD who had undergone ileocolonic resection with ileocolonic anastomosis. An end or loop ileostomy within 1 year was permitted if stoma closure and ileocolonic anastomosis occurred within 45 days of randomisation. Patients with no evidence of macroscopic CD, no known active CD elsewhere in the gastrointestinal tract, with a baseline CDAI score < 200 and with at least 1 of the following risk factors for disease recurrence: qualifying surgery that was their 2nd intra-abdominal resection within 10 years; 3rd or more intra-abdominal resection; resection for a penetrating CD complication (e.g. abscess or fistula); a history of perianal visualising CD, provided the event had not occurred within 3 months; or smoking 10 or more cigarettes per day for the past year were eligible for randomisations within 45 days of resection <b>Exclusion:</b> Qualifying surgery more than 10 years after CD diagnosis and surgery performed for stricturing disease involving < 10 cm of bowel <b>Age (IG1/IG2) mean (SD):</b> 36.3 ± 12.96 overall; 37.11 ± 3.49 vs 35.4 ± 12.41 <b>Sex (M:F):</b> 158:139 overall; (77:70) vs (81:69)

### **Regueiro 2016** (Continued)

	Type of surgery: Not reported Previous surgery (IG1 + IG2): 1 or 2 surgeries 114 (63/51); > 2 surgeries 12 (4/8) Start of intervention after surgery: $\leq 45$ days Medication use (IG1 + IG2): Any CD medication 280 (136/144); anti-TNF 67 (37/ 30); adalimumab 38 (21/17); infliximab 33 (18/15); certolizumab 3 (3/0) Smoker (IG1/IG2): Not reported Number randomised (n = 297): 147/150 Number analysed (n = 296): (146/147) vs (150/150) Postrandomisation exclusion (n = 77): (45/147) vs (32/150) (lost to follow-up 12 (3/ 9); withdrew consent 41 (26/15); death 1 (0/1); other 23 (16/7))
Interventions	<ul> <li>Group 1: Infliximab (Remicade; Janssen Biotech Inc, Horsham Township, PA, USA) 5 mg/kg every 8 weeks + continued stable doses of 5-ASA and immunosuppressives postsurgery</li> <li>Group 2: Placebo every 8 weeks + continued stable doses of 5-ASA and immunosuppressives postsurgery</li> <li>All participants: Participants receiving oral MES or immunosuppressives (AZA, 6-MP, or methotrexate) pre-surgery could continue treatment with maintenance of stable doses after resection. Participants not receiving these agents pre-surgery could not receive them postsurgery. Rectal MES was discontinued at least 2 weeks before randomisation. Initiation of corticosteroids or antibiotics for CD treatment was prohibited</li> </ul>
Outcomes	<ul> <li>Duration of study: 104 weeks</li> <li>1. Endoscopic relapse by ileocolonoscopy defined by a Rutgeerts score ≥ i2 or presence of an abscess, fistula recurrence or development, or treatment failure</li> <li>2. Endoscopic recurrence before or at week 76 defined by endoscopic Rutgeerts score ≥ i2 only</li> <li>4. Adverse events</li> </ul>
Notes	<b>Funding source:</b> Funded by Jensen Research & Development <b>Conflict of interest:</b> Declared for each author; mainly consulting fees, advisory board member fees, speakers, small research grants, etc <b>Power calculation</b> : In a study conducted with a patient population similar to that pro- posed for this study, approximately 40% of participants in the placebo group experienced clinical recurrence by week 52. For calculation of sample size, 50% and 30% of placebo- and infliximab-treated participants, respectively, were expected to develop clinical recur- rence by week 76. A sample size of 290 participants, 145 per treatment, provided 93% power to detect a 20% between-group difference in clinical recurrence before or at week 76

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were randomized equally to receive infliximab (Remicade; Janssen Biotech, Inc., Horsham Township, PA) 5 mg/kg or placebo every 8 weeks. Random- ization was stratified by the number of risk

### Regueiro 2016 (Continued)

		factors for recurrence (1 or >1) and current use of an immunosuppressive (yes/no)" Comment: stratified randomisation
Allocation concealment (selection bias)	Unclear risk	Insufficient information on allocation con- cealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Placebo and infliximab infusions were administered in a blinded manner" Comment: double-blind, placebo-con- trolled study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment on blinding of personnel
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "All randomized patients were in- cluded in efficacy analyses according to as- signed treatment, regardless of actual treat- ment received" Comment: however, over 25% of ran- domised participants withdrew for reasons other than relapse or adverse event. Given that the event risk is 21%, there is lack of clarity as to whether this is sufficient to cause bias
Selective reporting (reporting bias)	Low risk	Trial registration was available (NCT01190839) , and all proposed outcomes were reported
Other bias	Low risk	Quote: "Demographics, qualifying char- acteristics, and risk factors of the 297 randomized patients were similar between treatment groups" Comment: groups were reportedly well balanced at baseline. No other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

#### Reinisch 2010

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Austria, the Czech Republic, Germany, and Israel; 21 centres; 2002 to 2007
Participants	<b>Inclusion:</b> Male or female patients aged 18 to 70 years with a diagnosis of CD confirmed by endoscopy and histology were eligible for screening if they had (1) undergone resection of the terminal ileum and partial colectomy with ileocolonic resection for complications

### Reinisch 2010 (Continued)

	of ileal CD with construction of an ileocolonic anastomosis in the preceding 6 to 24 months; (2) not experienced clinical recurrence due to CD since resection; and (3) a CDAI score < 200 in the preceding 1 to 2 weeks. Patients with moderate endoscopic recurrence (Rutgeerts grade i2a: > 5 aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions) or severe endoscopic recurrence (i3 to i4: diffuse aphthous ileitis with diffusely inflamed mucosa, or diffuse inflammation with larger ulcers, nodules and/or narrowing) were recruited into the study <b>Exclusion</b> : Patients with a short bowel syndrome, an ileocolonic stoma, a thiopurine methyltransferase genotype; patients who had received treatment with immunosuppressant agents (methotrexate, ciclosporin, 6-MP, azathioprine, or 6-thioguanine (6-TG) or anti-TNFa) since resection, corticosteroids or oral antibiotics (e.g. metronidazole or ciprofloxacin) for > 4 weeks since resection, NSAIDs within the preceding 2 weeks (other than paracetamol or low-dose acetylsalicylic acid); patients who currently had stricture-plasty (unless the present strictureplasty macroscopically showed no inflammation at the time of the index operation) or had serum creatinine > 130 $\mu$ mol/L. Patients were excluded if endoscopy revealed no lesions (grade i0), < 5 aphthous lesions (grade i1), and/or if lesions were confined to the ileocolonic anastomosis (i.e. < 1 cm long) (grade i2b). Patients in the last category (grade i2b) were excluded since this presentation is associated with a lower risk of clinical recurrence <b>Age (IG1/IG2) mean</b> : 35.8 ± 12.08 overall; 35.5 ± 13.6 vs 36.0 ± 10.7 <b>Sex (M:F)</b> : 44:34 overall; (24:17) vs (20:17) <b>Type of surgery</b> ; Not reported <b>Previous surgery (IG1 + IG2)</b> : MES 54 (28/26); sulfasalazine 5 (4/1); budesonide 22 (9/13); corticosteroids 39 (23/16); AZA 14 (6/8); infliximab 3 (2/1); other 12 (6/6) <b>Smoker (IG1/IG2)</b> : 37 (17/20) <b>Number randomised (n = 78)</b> : (4/14) vs (5/37) (lack of co-operation 7 (4/3); lock of co-operation 7 (4/3)
Interventions	Group 1: AZA 2.0 to 2.5 mg/kg/day (Azafalk 50 mg tablets) + placebo MES tablets Group 2: MES 4 g/day (Eudragit L-coated 500 mg tablets (Salofalk)) + placebo AZA tablets All participants: Medications prohibited during the study: immunosuppressants other than study drug, allopurinol, oxipurinol, or thiopurinol, AZA-containing or MES-con- taining drugs other than study drug, anti-TNFa therapy, oral antibiotics for > 4 weeks or more than 3 cycles of 2 weeks, NSAIDs for > 2 weeks, corticosteroids, and cimetidine
Outcomes	<b>Duration of study:</b> 52 weeks 1. <b>Therapeutic failure (clinical relapse)</b> defined as CDAI score $\geq$ 200 and an increase of $\geq$ 60 points from baseline or study drug discontinuation due to lack of efficacy or an intolerable adverse drug reaction (*at 54 weeks, 2 and 3 years) (ITT data were calculated using per-protocol results plus missing data (missing data = randomised minus per protocol)) 2. <b>Endoscopic recurrence</b> defined by endoscopic Rutgeerts score $\geq$ i2 only 3. <b>Health-related quality of life</b> based on IBDQ score at 12 months 4. <b>Adverse events</b>

### Reinisch 2010 (Continued)

	<b>5. Clinical recurrence follow-up</b> defined as a Rutgeerts score between i2 and i4 within 24 months after the 1-year treatment
Notes	<b>Funding source:</b> Dr. Falk Pharma GmbH, Freiburg, Germany <b>Conflict of interest:</b> WR has received an unrestricted grant from Dr. Falk Pharma. EFS and KRH have received speaker's honoraria. KD, RG, and RM are employees of Dr. Falk Pharma. SA, WP, OS, ML, SB-M, AT, ES, and MS have no conflicts of interest to declare. AT, ES, and MS are supported in part by the Robert Bosch Foundation, Stuttgart, Germany <b>Power calculation:</b> The sample size calculation for the primary endpoint estimated that 62 evaluable participants (31 per treatment arm) were needed to have 80% power to detect a difference of 35% in favour of AZA versus MES for the reduction in the 1-year therapeutic failure rate (1-sided $\alpha = 0.025$ ). To allow for non-evaluable participants, a population size of 76 participants (38 per treatment arm) was planned *Data from 2 and 3 years were not included in the analysis as treatment lasted for 54 weeks

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "a central randomisation was per- formed via five computer-generated ran- domisation lists (using the program 'Ran- code +' (version 3.6) of IDV, Gauting, Ger- many), which were generated for the five body weight classes (40-50 kg, 51-60 kg, 61-75 kg, 76-100 kg and 101-128 kg), each in blocks of four, with medication dis- tributed to each centre according to this list" Comment: centralised randomisation in blocks of 4
Allocation concealment (selection bias)	Low risk	Central randomisation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "To maintain investigator and pa- tient blinding, patients randomised to azathioprine received verum azathioprine tablets and placebo mesalazine tablets; those randomised to mesalazine received verum mesalazine tablets and placebo aza- thioprine tablets" Comment: a double-blind, double- dummy RCT
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment

### Reinisch 2010 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "The intention-to-treat (ITT) pop- ulation was defined as all randomised pa- tients who received 1 dose of study medi- cation" Comment: the ITT population was de- fined as all randomised participants who had received 1 dose of study medication
Selective reporting (reporting bias)	Low risk	Trial regis- tration available (NCT00946946), and all prespecified outcomes were reported
Other bias	Low risk	Quote: "Baseline characteristics were simi- lar between treatment groups apart from a lower mean CDAI value in the azathioprine cohort (70 vs 102 in the mesalazine arm) and a higher proportion of azathioprine pa- tients with a penetrating disease behaviour (66% vs 43%)" Comment: some differences at baseline; study supported by Falk Pharma but con- flict of interest declared. No other apparent sources of bias detected
All domain risk of bias	Low risk	Low/unclear

#### **Rutgeerts 2005**

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Belgium; 2 centres; time period not reported	
Participants	Inclusion: Only patients with ileal involvement with or without right colonic disease within 1 week of resection of all macroscopically involved bowel with anastomosis of non-involved ileum to normal colon (ileocolonic anastomosis) were included in the study Exclusion: Pure fibrostenotic disease without biologic inflammation, strictureplasties, 2-step resections with temporary ileostoma, or allergy to nitroimidazole antibiotics Age (IG1/IG2) median (range): 18 to 70 overall; 35 (26 to 44) vs 30.5 (24 to 41.25) Sex (M:F): 36:42 overall; (16:22) vs (20:20) Type of surgery: Not reported Previous surgery (IG1 + IG2): 21 (12/9) Start of intervention after surgery: < 2 weeks Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): 36 (17/19) Number randomised (n = 80): 40/40 Number analysed (n = 78): (38/40) vs (40/40) Postrandomisation exclusion (n = 5): (4/40) vs (1/40) (withdrew consent 2 (2/0); compliance 2 (2/0); pregnancy 1 (0/1))	

## Rutgeerts 2005 (Continued)

Interventions	<ul> <li>Group 1: Ornidazole (Tiberal; Roche, Basel, Switzerland) 500 mg twice daily</li> <li>Group 2: Placebo 500 mg twice daily</li> <li>All participants: All other Crohn's disease-related drugs were discontinued at the time of surgery except for glucocorticosteroids. Steroids were tapered after inclusion and were stopped within 1 month of inclusion</li> </ul>
Outcomes	<ul> <li>Duration of study: 12 months treatment, 2 and 3 years follow-up*</li> <li>1. Clinical recurrence defined as the occurrence of symptoms including diarrhoea, abdominal pain, and decreased well-being regarded by experienced clinicians as a relapse of Crohn's disease symptoms. The CDAI at that time needed to be &gt; 250. In addition, clinical recurrence was also diagnosed if reoperation or other Crohn's disease-related therapy was necessary. (Derived from number of relapses plus number of early withdrawal plus number discontinued due to adverse events)</li> <li>2. Endoscopic recurrence based on a barium meal radiograph follow-through performed 1 year after surgery</li> <li>3. Radiologic recurrence based on IBDQ score at 12 months</li> <li>4. Adverse events</li> </ul>
Notes	Funding source: Not reported Conflict of interest: Not reported Power calculation: We estimated, on the basis of prior recurrence-prevention studies, that 30% of the participants in the placebo group would have clinical recurrence at 1 year. Randomisation of 80 participants would give the study a 1-sided power of 80% to detect an absolute difference of 25% in the primary outcome parameter between study groups *Data from 2 and 3 years follow-up were not included in the analysis as treatment lasted for 54 weeks

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "This randomized double-blind placebo-controlled trial was conducted at the inflammatory bowel disease centers of the University Hospital and 1 large teach- ing hospital" Comment: insufficient information to make judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The patients received either ornidazole (Tiberal; Roche, Basel, Switzer- land) 500 mg twice daily or an identical placebo daily for 54 weeks" Comment: study is a placebo controlled and reported as being double-blind

### Rutgeerts 2005 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Biopsy samples of the neoterminal ileum were taken and assessed blindly by 2 pathologists (G.D.H. and K.G.)" Comment: samples taken and assessed by assessors blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Intention-to-treat analysis was performed that included all patients who started the medication" Comment: low attrition rates, which were balanced across groups
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	High risk	Quote: "There was a significantly longer duration of disease in the ornidazole group than in the placebo group" Comment: 1 observed imbalance at base- line, no other apparent sources of bias de- tected
All domain risk of bias	Unclear risk	High

#### Savarino 2013

Methods	<b>Study design:</b> RCT, single-centre <b>Setting:</b> Italy; University Hospital of Genoa; 2008 to 2010
Participants	<ul> <li>Inclusion: Adult patients with ileal or ileocolonic CD within 4 weeks of resection of macroscopically diseased bowel with anastomosis between normal ileum and colon</li> <li>Exclusion: Patients with more than 10 years of CD requiring first resective surgery for short (10-centimetre) fibrostenotic stricture; macroscopically active disease not resected at the time of surgery; and presence of a stoma</li> <li>Age (IG1/IG2) median (range): Not reported, overall &gt; 18; 45 (22 to 66) vs 46 (25 to 65) vs 49 (24 to 69)</li> <li>Sex (M:F): 25:26 overall; (8:8) vs (9:8) vs (8:10)</li> <li>Type of surgery: Not reported</li> <li>Previous surgery (IG1 + IG2): One 40 (12/15/13); two 9 (3/2/4); three 2 (1/0/1)</li> <li>Start of intervention after surgery: 2 to 4 weeks</li> <li>Medication use (IG1 + IG2): Not reported</li> <li>Smoker (IG1/IG2): 19 (9/4/6)</li> <li>Number randomised (n = 51): 16/17/18</li> <li>Number analysed (n = 51): (16/16) vs (17/17) vs (18/18)</li> <li>Postrandomisation exclusion (n = 5): (1/16 ) vs (2/17) vs (2/18) (unclear)</li> </ul>

Interventions	Group 1: ADA subcutaneous injections 160/80 mg at 0 and 2 weeks, followed by 40		
	Group 2: AZA (Azafor, Sofar S.P.A., Milan	, Italy) at a dose of 2 mg/kg every day for 2	
	years Group 3: MES (Pentasa, Ferring S.P.A., Milan, Italy) at a dose of 3 g/day divided into 3 doses for 2 years All participants: Participants on antibiotics or immunomodulators at entry into the study discontinued these medications 12 weeks before surgery. Continuous use of NSAIDs was not allowed during the study. No other medications were prescribed ex- cept for occasional tablets of paracetamol or tramadol. Participants were subjected to endoscopy at 12 and 24 months; small bowel enteroclysis or magnetic resonance imaging at 12 and 24 months; physical examination with interviews, together with an extensive battery of blood tests weekly for the first 4 weeks and then every 2 months, and com- pleted an IBDQ at 1 month before surgery and at 12 and 24 months after surgery. The CDAI was determined at each study visit. In addition, adverse events were ascertained at each visit		
Outcomes	<b>Duration of study:</b> 2 years 1. <b>Clinical recurrence</b> defined as a score of $\geq 2$ on the clinical recurrence grading scale 1 to 4 proposed by Hanauer and colleagues (derived from author's primary definition of clinical relapse plus number of early withdrawals) 2. <b>Clinical recurrence</b> based on CDAI which was calculated for each participant, and recurrence was set in case of a score > 200, whereas clinical remission was defined as a CDAI score of < 150 2. <b>Endoscopic recurrence</b> defined by a Rutgeerts score of $\geq i2$ 3. <b>Radiologic recurrence</b> defined as a score of $\geq 2$ on the radiographic recurrence grading scale (where 1 indicates normal; 2, mucosal oedema/aphthoid ulcers; 3, linear ulcers/cobblestoning; and 4, strictures/fistulas/inflammatory mass) 4. <b>Health-related quality of life</b> 5. <b>Median Lémann Index</b> 5. <b>Adverse events</b>		
Notes	<ul> <li>Funding source: Supported by research funds of the university</li> <li>Conflict of interest: Authors declare no conflict of interest.</li> <li>Power calculation: We considered it reasonable to hypothesise an endoscopic recurrence rate of ~ 80% and 15% and a clinical recurrence rate of ~ 65% and 5% for the MES and ADA groups, respectively, at 2 years' follow-up. This estimation has been supported by the results shown in previous trials on postoperative CD relapse. Thus, based on these data, 13 participants per treatment group was found to be sufficient to detect a difference of at least 65% for endoscopic recurrence and 60% for clinical recurrence in favour of the ADA group with a power of 80% (global type I error of 5%). The number of participants in each group was increased to 16 to compensate for an anticipated dropout rate of 15%</li> </ul>		
Risk of bias			
Bias	Authors' judgement	Support for judgement	

### Savarino 2013 (Continued)

Random sequence generation (selection bias)	Low risk	Quote: "Eligible and consenting patients were assigned randomly using a computer- generated sequence (www. randomizer.org) to a regimen of" Comment: computer-generated random sequence
Allocation concealment (selection bias)	Low risk	Quote: "Patient allocation was concealed and performed by an independent nurse not involved with the trial" Comment: probably done
Blinding of participants and personnel (performance bias) All outcomes	High risk	Study is open-label design.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "A blinded investigator (P.D.) re- viewed each patient's video-recorded pro- cedure and provided a separate endoscopic score" and "At the conclusion of the study, the principal investigator (E.S.) rescored each patient by re-reviewing the video recordings in a random and blinded man- ner" Comment: assessors were blinded for en- doscopic assessments only. However, no in- formation on clinical assessment of relapse
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Statistical analysis was conducted according to the intention-to-treat princi- ple." Comment: The trial had a low attrition rate. Withdrawals and reasons for with- drawals were balanced across groups (1/16 vs 2/17 vs 2/18)
Selective reporting (reporting bias)	Low risk	Trial registration not available, however all outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "Characteristics were similar for sex, age, smoking, duration of CD, disease behavior, disease location, prior medication exposure, including IFX, and prior surgical resection" Comment: groups well balanced at base- line; no other apparent sources of bias de- tected

## Savarino 2013 (Continued)

All domain risk of bias	Unclear risk	High
Scapa 2015		
Methods	<b>Study design:</b> RCT; abstract <b>Setting:</b> Tel Aviv, Israel; study period not reported	
Participants	Inclusion: All CD patients undergoing a fi cations were prospectively recruited to the P (POPART) Exclusion: Not reported Age (IG1/IG2) median (SD): overall not reported Sex (M:F): Not reported Type of surgery: Not reported Previous surgery (IG1 + IG2): Not report Start of intervention after surgery: < 45 c Medication use (IG1 + IG2): Not reporte Smoker (IG1/IG2): 4 (1/3) Number randomised (n =): ? Number analysed (n = 19): (8/?) vs (11/?) Postrandomisation exclusion (n = ?): Not	rst ileocecectomy for inflammatory compli- lost OPerative Adalimumab Recurrence Trial reported; 30.5 ± 2.3 vs 34.4 ± 2.5 ed lays d
Interventions	Group 1: Thiopurine (6-MP) 1.5 mg/kg/d Group 2: Placebo 500 mg twice daily for 5 All participants: All participants underwe assess for endoscopic recurrence as defined	ay 4 weeks nt ileocolonoscopy at 6 and 12 months to by the Rutgeerts score
Outcomes	<b>Duration of study:</b> 12 months 1. <b>Endoscopic recurrence</b> defined as a Rutg were defined as i2 to i4	eerts score of i0 to i1, whilst advanced lesions
Notes	Funding source: Not reported Conflict of interest: Not reported Power calculation: Not reported	

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to make judge- ment
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to make judge- ment

### Scapa 2015 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "Nineteen patients have reached the 24-week time point" Comment: abstract does not report how many were randomised, the number of withdrawals, and no information is pro- vided regarding any adverse event
Selective reporting (reporting bias)	High risk	Trial registration available (NCT01629628), however clinical relapse not reported in the abstract. Authors in- formed us via correspondence (12 October 2018) that the full trial will be published by the end of 2018. Adverse events were not reported in the abstract
Other bias	Unclear risk	Insufficient information to make judge- ment
All domain risk of bias	Unclear risk	High

Sutherland 1997

Methods	<b>Study design:</b> RCT, multicentre <b>Setting:</b> Canada; 31 hospitals/medical centres; 1990 to 1993
Participants	<ul> <li>Inclusion: Adult patients (18 years and older) with ileal or ileocolonic CD location restrictions not mentioned. CD in remission for 1 month, but at least 2 flare-ups within the last 4 years, 1 within the last 18 months or a recent resection. Remission defined as CDAI &lt; 150 at baseline and no symptoms within last 30 days. No steroid use within a month of study</li> <li>Exclusion: CDAI &gt; 150; previous total proctocolectomy, short bowel syndrome, more than 3 resections within 10 years, chronic perianal disease, ulcer colitis, stool positive for pathogens, parasites, or toxins; drug or alcohol abuse, clinically significant hepatic neurological, endocrine, renal, or other major systemic disease that would make implementation or interpretation of the protocol or results difficult; any history of cancer, allergy to aspirin or MES; patients on immunosuppressant therapy within last 90 days, or corticosteroids within last 30 days or MES/metronidazole within last 7 days before resection</li> <li>Age (IG1/IG2) mean (±SE): 36.5 (0.7) overall; 29.7 (1.1) vs 29.0 (1.0)</li> <li>Sex (M:F): 106:140 overall; (48:70) vs (58:70)</li> <li>Type of surgery: Not reported</li> <li>Previous surgery (IG1 + IG2): Not reported</li> <li>Start of intervention after surgery: 2 to 4 weeks</li> <li>Medication use (IG1 + IG2): Not reported</li> </ul>

#### Sutherland 1997 (Continued)

	<ul> <li>Smoker (IG1/IG2): Not reported</li> <li>Number randomised (n = 66): 31/35 (total number randomised is 293, of which 180 had medically induced remission and 65 surgically induced remission; data presented for the latter only)</li> <li>Number analysed (n = 66): (31/31) vs (35/35)</li> <li>Postrandomisation exclusion (n = ?): Not presented separately for participants with surgical remission</li> </ul>
Interventions	Group 1: 3 capsules of 250 mg MES 4 times a day Group 2: 3 capsules of 250 mg placebo 4 times a day All participants: No steroid, other mesalazine preparations, aspirin or other NSAIDs, immunosuppressives, narcotics except codeine or loperamide, antibiotics for longer than 14 days
Outcomes	<b>Duration of study:</b> 12 months 1. <b>Clinical recurrence</b> defined as 1st occurrence of a CDAI that was > 150 as well as an absolute value of at least 60 points higher than baseline or where physician diagnosed a flare-up of disease but a full diary card was not available for the calculation of the final CDAI
Notes	<b>Funding source:</b> Supported by research funds of the university <b>Conflict of interest:</b> Authors declare no conflict of interest. <b>Power calculation</b> : It was hypothesised that the relapse rate for MES-treated participants would be 25%. Assuming an $\alpha$ of 0.05 and a $\beta$ of 0.20 (power of 0.80), a 2-tailed sample size calculation determined that 150 participants were required for each treatment group

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomisation was performed ac- cording to a computer generated randomi- sation scheme by the study sponsor" Comment: computer-generated randomi- sation scheme
Allocation concealment (selection bias)	Low risk	Quote: "For each patient, the identity of the study medication was concealed in an individual sealed envelope sent with the drug supplies" and "Medication was pack- aged by the sponsor and dispensed to each centre on coded identical-appearing boxes" Comment: sequentially numbered, identi- cally appearing drug packages
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Medication was packaged by the sponsor and dispensed to each centre on coded identical-appearing boxes" Comment: double-blinded, placebo-con-

#### Sutherland 1997 (Continued)

		trolled trial. Probably done
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to make judge- ment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition rates were not reported specifi- cally for the subpopulation of interest in our review (surgical group)
Selective reporting (reporting bias)	Low risk	Although adverse event data were not avail- able for the subpopulation of interest in our review (surgical group), all expected out- comes appear to have been reported for the entire population
Other bias	Low risk	"The demographic characteristics and dis- ease milestones for participants are shown in Table 2. There were no significant dif- ferences between the MES- and placebo- treated groups." Supported by a grant by Marion Merrell Dow. Author contacted and confirmed that company had no part in the design, analy- sis, or write-up of the study
All domain risk of bias	Low risk	Low/unclear

# **Tursi 2014**

Methods	<b>Study design:</b> RCT, single-centre <b>Setting:</b> Italy; 2010 to 2013
Participants	<b>Inclusion:</b> Consecutive CD patients who underwent curative ileocolonic resection and were considered to be at high risk of postoperative recurrence were enrolled <b>Exclusion:</b> Active perianal disease, the presence of stoma, adverse events during previous therapy with IFX or AZA, age over 70 years, surgical complications, active infectious disease, history of cancer, renal, cardiac, or hepatic failure, history of acute or chronic pancreatitis, severe leukopenia (WBC <3000 $\mu$ U/mL, lymphocyte count <1000 $\mu$ U/mL), and pregnancy <b>Age (IG1/IG2) mean (range):</b> 32.5 (20 to 39) overall; 30.5 (20 to 33) vs 34.5 (22 to 39) <b>Sex (M:F):</b> 9:11 overall; (5:5) vs (4:6) <b>Type of surgery:</b> Not reported <b>Previous surgery (IG1 + IG2):</b> 7 (4/3) <b>Start of intervention after surgery:</b> 4 to 6 weeks <b>Medication use (IG1 + IG2):</b> MES 10; previous AZA use 5; previous IFX use 9 <b>Smoker (IG1/IG2):</b> 5 (3/2)

### Tursi 2014 (Continued)

	Number randomised (n = 20): 10/10 Number analysed (n = 20): (10/10) vs (10/10) Postrandomisation exclusion (n = 0)
Interventions	<b>Group 1:</b> Infliximab 5 mg/kg at 0, 2, and 6 weeks and then every 8 weeks for 1 year <b>Group 2:</b> Adalimumab 160 mg subcutaneously, followed by 80 mg 2 weeks later, and then 40 mg every 2 weeks for 1 year <b>All participants:</b> Treatment was started within 4 to 6 weeks after surgery. All participants also received oral metronidazole (500 mg twice daily) for 2 weeks after surgery. No other CD-related drugs were admitted during the study. Participants underwent monthly evaluation by means of laboratory tests, the Harvey-Bradshaw Index, and the adverse event report. Ileocolonoscopy was performed after 6 and 12 months of therapy and video-recorded
Outcomes	<ul> <li>Duration of study: 12 months</li> <li>1. Clinical recurrence defined as a Harvey-Bradshaw Index ≥ 8</li> <li>2. Endoscopic relapse defined as a Rutgeerts score of ≥ i2</li> <li>3. Histologic relapse assessed by the Geboes grading system for CD</li> <li>4. Adverse events</li> </ul>
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Authors declare no conflict of interest. <b>Power calculation</b> : Not reported

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were randomized with a simple unblinded 1:1 allocation ratio…" Comment: insufficient information to make judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to make judge- ment
Blinding of participants and personnel (performance bias) All outcomes	High risk	This is an open-label pilot study, and blind- ing was not performed
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Five unblinded endoscopists (AT, CZ, GP, RF, and GB) did all the examina- tions and calculated scores. Two further un- blinded endoscopists (WE and MP) sepa- rately reviewed videos and in case of discor- dance a consensus agreement was reached among the two operators" Comment: blinding of outcome assessors was not performed

#### Tursi 2014 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data; all participants completed the trial
Selective reporting (reporting bias)	Low risk	All outcomes stated in the methods section were reported.
Other bias	Low risk	Quote: "There were no differences between baseline characteristics of the two groups: age, duration of disease, active smokers, previous surgery, disease behavior and lo- cation, perianal disease at diagnosis, extra intestinal manifestations" Comment: groups well balanced at base- line, and no other apparent sources of bias detected
All domain risk of bias	Unclear risk	High
Wenckert 1978 Methods	<b>Study design:</b> RCT, multicentre	
Participants	Inclusion: No age restrictions mentioned. CD of small or large bowel (or both), 1st resection, and supporting histological evidence of active CD in resected specimens. ESR had to return to normal within 6 weeks of operation, no further remission criteria defined. No steroid use allowed Exclusion: Treatment with a bypass, doubtful diagnosis, allergy to sulfasalazine (Sala- zopyrin) or acetylsalicylic acid, abnormal ESR 6 weeks after operation, lack of co-oper- ation, treatment with corticosteroids or immunosuppressive drugs Age (IG1/IG2) median: 24.5 overall Sex (M:F): 33:33 overall Type of surgery: Not reported Previous surgery (IG1 + IG2): n/a Start of intervention after surgery: 2 to 4 weeks Medication use (IG1 + IG2): Not reported Smoker (IG1/IG2): Not reported Number randomized (n = 60): 32/34	

Interventions

**Group 2:** Placebo 3 g/day for 18 months **All participants:** Other specific treatment was avoided. Relapse-free participants were observed for 24 months

Postrandomisation exclusion (n = 4/66): (2/32) vs (2/36)

Group 1: Sulfasalazine (Salazopyrin) 3 g/day for 18 months

Outcomes 1. **Relapse** was defined clinically, based on the information from special control charts on the presence/absence of fever, diarrhoea, rectal bleeding, abdominal pain, extra-in-

Number analysed (n = 66): (32/32) vs (34/34)

### Wenckert 1978 (Continued)

	testinal manifestations, palpable abdominal masses, fistulae, abscesses, and possible loss of working days. The relapses were not based on index calculation
Notes	Funding source: Not reported Conflict of interest: Not reported Power calculation: Not reported

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The experimental design was dou- ble blind multicentre trial with block-ran- domisation, and no cross-over." Comment: insufficient data to make judge- ment. However, author contacted and con- firmed that block randomisation described was carried out in accordance with estab- lished acceptable randomisation method- ology
Allocation concealment (selection bias)	Unclear risk	Comment: insufficient data to make judge- ment. The author was contacted, but was unable to provide further details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: insufficient data to make judge- ment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: insufficient data to make judge- ment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data reported for those missing; balanced between study groups; reasons for with- drawal unlikely to be related to true out- come
Selective reporting (reporting bias)	Unclear risk	The study includes results for adverse events, but these are not reported clearly enough to permit analysis and a resulting judgement as to risk of bias
Other bias	Unclear risk	Insufficient information to ascertain whether baseline characteristics were balanced
All domain risk of bias	Low risk	Low/unclear

Yoshida 2012

Methods	<b>Study design:</b> RCT, single-centre <b>Setting:</b> Japan; Hyogo College of Medicine; 2007 to 2011
Participants	Inclusion: Patients aged 12 to 65 years, both sexes with illeal or ileocolic CD within 4 weeks after resection Exclusion: Concomitant AZA, or 6-MP that had been started within 8 weeks prior to study; concomitant prednisolone; active infection; macroscopically active disease missed during surgery or the presence of abscess; confirmed tuberculosis; or a history of intol- erance to IFX Age (IG1/IG2) mean (range): 34.8 ± 10.9 overall; 36.9 ± 11.6 vs 32.8 ± 10.2 Sex (M:F): 23:8 overall; (11:4) vs (12:4) Type of surgery: Ileal resection 10 (4/6); ileocaecal resection 21 (11/10) Previous surgery (IG1 + IG2): Not reported Start of intervention after surgery: ± 4 weeks Medication use (IG1 + IG2): MES 31 (15/16); corticosteroids 3 (2/1); immunomod- ulators 5 (3/2); IFX 1 (0/1) Smoker (IG1/IG2): 6 (3/3) Number randomised (n = 31): 15/16 Number analysed (n = 31): (15/15) vs (16/16) Postrandomisation exclusion (n = 0)
Interventions	<ul> <li>Group 1: Infliximab 5 mg/kg intravenously at 8-week intervals (1st infusion 4 weeks after surgery). Also, escalation of the IFX dose above 5 mg/kg/session was avoided + oral MES</li> <li>Group 2: Participants could continue with their ongoing conventional medication (oral MES) which had been started longer than 8 weeks prior to surgery</li> <li>All participants: In both arms an elemental diet less than 1200 kcal/day was permitted during the study. Oral MES (Pentasa; Kyorin Pharma) was given to participants in both arms at the same mean dosage of 2250 mg/day (range 2250 to 3000), and was continued in all participants at 1500 mg/day during the trial. However, if a participant was to receive AZA, 6-MP, or prednisolone, or to increase the dosage of an ongoing medication, withdrawal from the trial was considered. Together with the clinical evaluations, all participants received ileocolonoscopy to assess mucosal disease activity at 12 months</li> </ul>
Outcomes	Duration of study: 36 months 1. Clinical recurrence (CDAI score) considered if a participant required another med- ication or to increase the dosage of an ongoing intervention due to worsening CD based on score CDAI > 150 2. Clinical relapse (IOIBD score) considered if a participant required another medi- cation or to increase the dosage of an ongoing intervention due to worsening CD based on IOIBD ≥ 2 3. Serologic relapse (based on CRP level) defined as failing to maintain CRP level < 0.3 mg/dL 4. Endoscopic relapse defined as an endoscopic score of ≥ i2 5. Adverse events
Notes	<b>Funding source:</b> Not reported <b>Conflict of interest:</b> Not reported <b>Power calculation</b> : A power of 80% and a 2-sided type I error rate of 5% were assumed. The study size was anticipated to be 1:1 randomisation of at least 28 participants (14 in

### Yoshida 2012 (Continued)

Risk	of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomization was done blindly according to a computer-generated scheme with blocks of two (each two pa- tients were randomly assigned to IFX or to control). This was to minimize the risk of unbalanced group size" Comment: computer-generated 1:1 ran- domisation
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was done by a statistician at an independent institute" Comment: probably done
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label pilot study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "Endoscopic evaluations were per- formed using a videoscope (CF260AI; Olympus Optics, Tokyo, Japan) by endo- scopists who were blinded. Video record- ing procedures were independently scored by different endoscopists" Comment: blinding of outcome assessors performed. Insufficient information about clinical assessments
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, only 1 with- drawal during study, which was due to ad- verse events
Selective reporting (reporting bias)	Low risk	Trial registration available (UMIN000004427). All outcomes stated in the methods section were reported
Other bias	Low risk	Quote: "There was no significant difference between the two groups with respect to en- try demography, including smoking behav- ior" Comment: groups well balanced at base- line. No other apparent sources of bias de- tected

#### Yoshida 2012 (Continued)

All domain risk of bias	Unclear risk	High
-------------------------	--------------	------

5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; ADA: adalimumab; AZA: azathioprine; CD: Crohn's disease; CDAI: Crohn's disease; CDAI: Crohn's disease activity index; CFU: colony-forming units; CRP: C-reactive protein; ESR: erythrocyte sediment; IBDQ: inflammatory bowel disease questionnaire; IFX: infliximab; IG; intervention group; IOIBD: International Organization for the Study of Inflammatory Bowel Diseases; ITT: intention-to-treat; kcal: kilocalories; MDZ: metronidazole; MES; mesalazine; n/a: not applicable; NSAID: non-steroidal anti-inflammatory drug; RCT: randomised controlled trial; SD: standard deviation SE: standard error; TNF: tumour necrosis factor; TPN: total parenteral nutrition; WBC: white blood cell count

#### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Angelberger 2013	Not an RCT; a post hoc analysis of a subset of participants of an RCT
Armuzzi 2015	Not an RCT; long-term follow-up observational study
Balzola 2010	Not an RCT; commentary
Bodini 2014a	Not an RCT; commentary on Savarino 2013
Bodini 2014b	Not an RCT; commentary on Savarino 2013
Bodini 2015	Not an RCT; commentary on Savarino 2013
Bourreille 2005	Not an RCT; commentary on Hanauer 2004
De Cruz 2012	Wrong study design; partially randomised
De Cruz 2013a	Duplicate of De Cruz 2013b
De Cruz 2013b	Wrong study design; partially randomised
De Cruz 2013c	Wrong study design; partially randomised
De Cruz 2015a	Wrong study design; partially randomised
De Cruz 2015b	Wrong study design; partially randomised
Doherty 2009	Not an RCT; commentary on Regueiro 2009
Dumois 2001	Not an RCT; commentary on Lochs 2000

#### (Continued)

Ewe 1976	Duplicate containing preliminary results of an included study (Ewe 1989)
Ewe 1980	Not an RCT
Ewe 1981	Not an RCT
Ewe 1984	Duplicate containing preliminary results of an included study (Ewe 1989)
Ferrante 2014	Wrong intervention; AZA vs AZA
Ford 2010	Not an RCT; commentary on Reinisch 2010
Herfarth 2014	Not an RCT; editorial
Kamm 2014a	Wrong study design; partially randomised
Kamm 2014b	Wrong intervention; colonoscopy vs no colonoscopy
Kennedy 2015	Not an RCT;
Liao 2009	Wrong intervention; herb
Manship 2015	Not an RCT; commentary on Hanauer 2004 and Ardizzone 2004
Mardini 2005	Not an RCT; commentaries on Hanauer 2004 and Ardizzone 2004
McLeod 1997	Not an RCT; non-randomised follow-up of McLeod 1995
NCT00074542	Wrong intervention; nutritional supplements
NCT01190839	Duplicate of the trial registration (EUCTR2010-018431-18-DE) of an included study (Regueiro 2016), but was terminated by sponsor
NCT01696942	Terminated trial
NCT02247258	Trial was terminated due to slow recruitment.
NCT02255370	Wrong intervention; nutritional supplements
NCT02997059	Terminated trial
Papamichael 2012	Not an RCT
Regueiro 2013	Not an RCT; follow-up of the control group Regueiro 2009
Regueiro 2014	Not an RCT; follow-up of the control group Regueiro 2009

#### (Continued)

Reibetanz 2015	Not an RCT; commentary on De Cruz 2015a
Ren 2013	Wrong intervention; herb
Sandborn 2004	Not an RCT; editorial
Steinhart 1992	Not an RCT
Tao 2009	Wrong intervention; herb
Vera-Mendoza 2017	Duplicate of Lopez Sanroman 2017
Wright 2014	Wrong intervention; colonoscopy vs no colonoscopy
Wright 2015	Wrong intervention; colonoscopy vs no colonoscopy
Yamamoto 2009	Not an RCT
Yamamoto 2013	Not an RCT; commentary on an excluded study (Papamichael 2012)
Zhu 2015	Wrong intervention; herb

AZA: azathioprine; RCT: randomised controlled trial

## Characteristics of studies awaiting assessment [ordered by study ID]

#### NCT00976690

Methods	RCT
Participants	<ul> <li>83 participants</li> <li>Inclusion criteria: <ul> <li>More than 18 years old</li> <li>Clinical remission at inclusion time (CDAI &lt; 150)</li> <li>Having ileocolonic or colon resection 21 days before inclusion</li> <li>Resection &gt; 50 cm or subtotal colectomy with ileorectal anastomosis</li> </ul> </li> <li>Exclusion criteria: <ul> <li>Intolerance to 1 or both study treatments</li> <li>Liver failure (TP &lt; 60%)</li> <li>Renal failure (creatinine &lt; lab results)</li> </ul> </li> </ul>
Interventions	1. Azathioprine: 2 mg/kg/day 2. Mesalazine: 4 g/day
Outcomes	Clinically and endoscopically recurrence at 12 and 24 months [ Time Frame: 12 and 24 months ]

#### NCT00976690 (Continued)

Notes	Under preparation for publication (as informed by authors' response to email from MG) Contact details: LEMANN.marc@lemann.com
	MG emailed - they are working on the results and preparing publication

#### NCT01698970

Methods	RCT
Participants	<ul> <li>122 participants</li> <li>Inclusion criteria: <ul> <li>Male/female at least 18 years old</li> <li>Diagnosis of Crohn's disease defined by the criteria usually adopted (Gower-Rousseau 1994)</li> <li>Crohn's disease mainly limited to the terminal ileum and/or the ascending and transverse colon</li> <li>Diagnosis of Crohn's disease in agreement with surgical specimen analysis</li> <li>Patient having given written consent to take part in the study</li> <li>Complete resection of all main macroscopic ileo-colonic lesions, as shown by inspection at surgery</li> <li>To have an ileo-colic resection (right, transverse, left) with an anastomosis that can be inspected by endoscopy</li> <li>Ability to start oral nutrition and therefore the consumption of the study product within 21 days of surgery</li> <li>Patient receiving no antibiotics at the beginning of the product consumption</li> </ul> </li> </ul>
Interventions	1. Freeze-dried probiotics provided in capsule (150 mg) containing 1,0 x 10E10 colony forming units per capsule (test)
Outcomes	Recurrent endoscopic ileo-colonic lesions 12 months after surgery
Notes	Danone France (MG contacted Danone UK but they were not able to help)

CDAI: Crohn's disease activity index; RCT: randomised controlled trial; TP: total protein

### Characteristics of ongoing studies [ordered by study ID]

#### EUCTR2015-000555-24-NL

Trial name or title	Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis : REPREVIO (recurrence prevention with Entyvio)
Methods	Randomised, placebo-controlled, double-blind, multicentre study
Participants	Enrolment: 80 participants, 18+ years, both sexes
Interventions	6 months vedolizumab 60 mg vs placebo

### EUCTR2015-000555-24-NL (Continued)

Outcomes	Primary: endoscopic recurrence ( $i \ge 2$ ) Secondary outcomes: 1. The proportion of participants with any endoscopic recurrence of CD (Modified Rutgeerts Grade > i0)
	2. Changes in the CDAI and Harvey-Bradshaw Index between week 0 and 26. This measure will give an indication for clinical recurrence. Although most participants will remain asymptomatic, we will collect global scores as well as individual components
	<ol> <li>Adverse events and serious adverse events</li> <li>Quality of life measure with a disease-specific instrument (IBDQ) and a generic QoL instrument (SF-36)</li> <li>Serum concentrations of vedolizumab and antibodies to vedolizumab before every infusion</li> </ol>
Starting date	October 2016
Contact information	Academic Medical Centre e.clasquin@amc.uva.nl
Notes	

NCT01015391

Trial name or title	Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease (T2)
Methods	Randomised, parallel assignment, open-label
Participants	100 participants, 18+ years, with surgically induced remission for CD
Interventions	1 year azathioprine (2.5 mg/kg/d orally until progression or unacceptable toxicity develops the 1st month; 1. 5 mg/kg orally once a day the 2nd month; 2.0 mg/kg orally once a day since the 3rd month; 2.5 mg/kg orally once a day) vs T2 1.5 mg/kg/day orally 3 times a day until progression or unacceptable toxicity develops
Outcomes	<ul> <li>Primary: <ol> <li>Clinical remission: the proportion of participants with CDAI &lt; 150 at 26 and 52 weeks</li> <li>Endoscopic remission: the proportion of participants with CDEIS &lt; 6 at 26 and 52 weeks</li> </ol> </li> <li>Secondary: <ol> <li>Time until clinical relapse of CD (CDAI &gt; 150 or an increase of more than 70 points)</li> <li>Time until histological recurrence (determined by biopsies and endoscopic findings)</li> <li>Serum C-reactive protein concentration; erythrocyte sedimentation rate [ Time Frame: 52 weeks ]</li> <li>The proportion of participants experiencing adverse events</li> </ol> </li> </ul>
Starting date	April 2009
Contact information	Weiming Zhu, PhD, MD juwiming@yahoo.com.cn
Notes	

#### NCT02834754

Trial name or title	A Randomized, Double-blind, Placebo Controlled Study of Vedolizumab for the Prevention of Post-operative Crohn's Disease Recurrence
Methods	Randomised, parallel assignment, triple-masking (participant, investigator, outcomes assessor)
Participants	24 participants, 18 years and older, with curative resection and ileocolonic anastomosis for CD
Interventions	52 weeks vedolizumab 300 mg intravenously vs placebo
Outcomes	<ul> <li>Primary: endoscopic recurrence (i ≥ 2)</li> <li>Secondary outcome measures:</li> <li>1. Clinical remission (CDAI &lt; 150)</li> <li>2. Histologic remission (Geboes score)</li> </ul>
Starting date	July 2018
Contact information	Marc B Schwartz, MD mbs53@pitt.edu
Notes	

### NCT03185611

Trial name or title	Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
Methods	Parallel randomised trial, single-masking (outcomes assessor)
Participants	80 participants, 18 to 65 years, both sexes; undergoing intestinal resection of all macroscopic diseased bowel, with an endoscopically accessible ileocolic anastomosis with 1 risk factor for developing recurrence in CD
Interventions	6 months after surgery: rifaximin (600 mg, twice daily) + azathioprine (2.0 to 2.5 mg/kg/day) for 3 months after surgery, and then azathioprine monotherapy (2.0 to 2.5 mg/kg/day) for the next 3 months vs azathioprine (2.0 to 2.5 mg/kg/day)
Outcomes	Primary: difference in incidence of endoscopic recurrence (≥ i2) Secondary: adverse events
Starting date	June 2017
Contact information	Xiang Gao, MD, PhD gaoxiangmed@163.com
Notes	
### NCT03185624

Trial name or title	Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease
Methods	Parallel randomised trial, single-masking (outcomes assessor)
Participants	80 participants, 18 to 65 years, both sexes; undergoing intestinal resection of all macroscopic diseased bowel, with an endoscopically accessible ileocolic anastomosis with 1 risk factor for developing recurrence in CD
Interventions	Rifaximin (600 mg, twice daily) for 3 months after surgery vs blank control (no treatment)
Outcomes	Primary: incidence of endoscopic recurrence (≥ i2) Secondary: adverse effect of rifaximin
Starting date	June 2017
Contact information	Xiang Gao, MD, PhD gaoxiangmed@163.com
Notes	

## NCT03456752

Trial name or title	The Impact of Perioperative Dexamethasone on Postoperative Outcome in Inflammatory Bowel Diseases
Methods	Randomised, parallel assignment, triple-masking (participant, investigator, outcomes assessor)
Participants	302 participants; 18 to 75 years; CD
Interventions	1 year dexamethasone 8 mg vs placebo (saline solution)
Outcomes	Primary: prolonged ileus Secondary: postoperative nausea and vomiting, postoperative fatigue score, GI-2 recovery, blood count, CRP, interleukin-6, procalcitonin, body composition, mortality, surgical site infections, cost
Starting date	March 2018
Contact information	Jianfeng Gong, MD gongjianfeng@aliyun.com
Notes	

### NL6213 (NTR6385)

Trial name or title	Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis
Methods	Randomised, parallel, double-blind
Participants	40 participants, age 18+

### NL6213 (NTR6385) (Continued)

Interventions	1 year vedolizumab 300 mg 8 weekly (4 doses) or placebo 8 weekly (4 doses)
Outcomes	<ul> <li>Primary: <ul> <li>Clinically significant endoscopic recurrence (Rutgeerts i2b, i3, or i4) at week 26</li> </ul> </li> <li>Secondary: <ul> <li>Proportion of participants without endoscopic recurrence (i0)</li> <li>Symptomatic recurrence (CDAI increase &gt; 70 points compared to baseline)</li> <li>Proportion of participants with normalised serum CRP at all time points and CRP at all visits</li> <li>Proportion of participants with normal faecal calprotectin (&lt; 50) at all visits</li> <li>Quality of life measured by IBDQ and SF-36</li> <li>Serum concentrations of vedolizumab and antibodies to vedolizumab before every infusion</li> </ul> </li> </ul>
Starting date	April 2017
Contact information	Prof Dr D'Haens Academic Medical Centre Amsterdam
Notes	

CD: Crohn's disease; CDAI: Crohn's disease activity index; IBDQ: inflammatory bowel disease questionnaire; QoL: quality of life; SF-36: short form-36; AZA: azathioprine; CDEIS: Crohn's disease endoscopic index of severity; GI-2: gastrointestinal - 2; CRP: Creactive protein

### DATA AND ANALYSES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	5	671	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.72, 0.98]
2 Adverse events	4	407	Risk Ratio (M-H, Fixed, 95% CI)	1.66 [0.81, 3.43]
3 Serious adverse events	2	408	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.34, 1.87]
4 Withdrawal due to adverse events	3	320	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [0.71, 3.94]
5 Endoscopic relapse	2	450	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.95, 1.15]

### Comparison 1. Direct evidence: 5-ASA versus placebo

### Comparison 2. Direct evidence: 5-ASA versus adalimumab

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	34	Risk Ratio (M-H, Fixed, 95% CI)	8.0 [1.13, 56.41]
2 Adverse events	1	34	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.75, 1.71]
3 Endoscopic relapse	1	34	Risk Ratio (M-H, Fixed, 95% CI)	13.33 [1.98, 89.95]
4 Withdrawal due to adverse	1	34	Risk Ratio (M-H, Fixed, 95% CI)	2.68 [0.12, 61.58]
events				

### Comparison 3. Direct evidence: 5-ASA versus purine analogues

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	4	347	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.81, 1.11]
2 Adverse events	4	347	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.87, 1.36]
3 Serious adverse events	2	233	Risk Ratio (M-H, Fixed, 95% CI)	1.84 [0.83, 4.07]
4 Withdrawal due to adverse events	4	347	Risk Ratio (M-H, Fixed, 95% CI)	0.53 [0.31, 0.92]
5 Endoscopic relapse	1	35	Risk Ratio (M-H, Fixed, 95% CI)	1.29 [0.86, 1.94]

### Comparison 4. Direct evidence: antibiotics versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	2	113	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.65, 1.38]
2 Adverse events	1	33	Risk Ratio (M-H, Fixed, 95% CI)	0.16 [0.02, 1.16]
3 Withdrawal due to adverse events	1	33	Risk Ratio (M-H, Fixed, 95% CI)	0.24 [0.03, 1.89]
4 Endoscopic relapse	2	113	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.68, 1.07]

### Comparison 5. Direct evidence: budesonide versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	83	Risk Ratio (M-H, Fixed, 95% CI)	0.69 [0.40, 1.18]
2 Adverse events	2	213	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.82, 1.27]
3 Withdrawal due to adverse events	2	210	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.35, 3.14]
4 Histologic relapse	1	86	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.80, 1.12]

### Comparison 6. Direct evidence: infliximab versus adalimumab

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	20	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.07, 13.87]
2 Adverse events	1	20	Risk Ratio (M-H, Fixed, 95% CI)	$0.0 \ [0.0, \ 0.0]$
3 Endoscopic relapse	1	20	Risk Ratio (M-H, Fixed, 95% CI)	2.0 [0.21, 18.69]
4 Histologic relapse	1	20	Risk Ratio (M-H, Fixed, 95% CI)	1.5 [0.32, 7.14]

### Comparison 7. Direct evidence: infliximab versus purine analogues

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	22	Risk Ratio (M-H, Fixed, 95% CI)	0.5 [0.05, 4.75]
2 Withdrawal due to adverse events	1	22	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.02, 7.39]
3 Endoscopic relapse	1	22	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.07, 14.05]
4 Histologic relapse	1	22	Risk Ratio (M-H, Fixed, 95% CI)	0.22 [0.06, 0.80]

### Comparison 8. Direct evidence: probiotics versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	2	115	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.54, 1.46]
2 Adverse events	1	45	Risk Ratio (M-H, Fixed, 95% CI)	0.32 [0.07, 1.41]
3 Endoscopic relapse	3	213	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.85, 1.25]

### Comparison 9. Direct evidence: purine analogues versus placebo

Outcome or subgroup title	No. of No. of studies participants		Statistical method	Effect size
1 Clinical relapse	2	327	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.69, 0.96]
2 Adverse events	1	87	Risk Ratio (M-H, Fixed, 95% CI)	1.91 [0.64, 5.75]
3 Serious adverse events	2	327	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.30, 3.94]
4 Withdrawal due to adverse events	2	327	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.66, 1.30]
5 Endoscopic relapse	1	240	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.81, 1.11]

### Comparison 10. Direct evidence: purine analogues versus adalimumab

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	33	Risk Ratio (M-H, Fixed, 95% CI)	11.29 [1.65, 77.22]
2 Adverse events	1	33	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [0.81, 1.78]
3 Withdrawal due to adverse events	1	33	Risk Ratio (M-H, Fixed, 95% CI)	2.83 [0.12, 64.89]
4 Endoscopic relapse	2	52	Risk Ratio (M-H, Fixed, 95% CI)	8.17 [2.01, 33.25]

#### Comparison 11. Direct evidence: sulfasalazine versus placebo

No. of Dutcome or subgroup title studies		No. of participants	Statistical method	Effect size
1 Clinical relapse	1	66	Risk Ratio (M-H, Fixed, 95% CI)	0.58 [0.24, 1.38]
2 Adverse events	1	66	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.01, 8.38]
3 Withdrawal due to adverse events	1	66	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.01, 8.38]

## Comparison 12. Direct evidence: sulfasalazine + prednisolone versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical relapse	1	97	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [0.57, 2.40]

### Comparison 13. Direct evidence not in network: clinical relapse

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 4.0 g/d versus 2.4 g/d mesalazine	1	202	Risk Ratio (M-H, Fixed, 95% CI)	0.63 [0.37, 1.08]
2 Purine analogues versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3 Infliximab versus placebo	2	53	Risk Ratio (M-H, Fixed, 95% CI)	0.46 [0.16, 1.33]
4 Antibiotics versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5 5-ASA versus purine analogues	1	78	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.71, 1.47]

### Comparison 14. Direct evidence not in network: adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 4.0 g/d versus 2.4 g/d mesalazine	1	206	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.15, 7.24]
2 Probiotics versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3 Infliximab versus placebo	3	362	Risk Ratio (M-H, Fixed, 95% CI)	0.49 [0.34, 0.70]
4 5-ASA versus purine analogues	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5 Purine analogues versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

### Comparison 15. Direct evidence not in network: serious adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 5-ASA versus purine analogues	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 4.0 g/d versus 2.4 g/d mesalazine	1	206	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.15, 7.24]
2 Synbiotic versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3 Probiotics versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4 Infliximab versus placebo	4	393	Risk Ratio (M-H, Fixed, 95% CI)	0.47 [0.31, 0.72]
5 5-ASA versus purine analogues	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
6 Purine analogues versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

## Comparison 17. Direct evidence not in network: endoscopic relapse

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 4.0 g/d versus 2.4 g/d mesalazine	1	206	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.60, 1.04]
2 Probiotics versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3 Infliximab versus placebo	4	395	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.51, 0.74]
4 5-ASA versus purine analogues	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5 Purine analogues versus placebo	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

## Analysis I.I. Comparison I Direct evidence: 5-ASA versus placebo, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: I Direct evidence: 5-ASA versus placebo

Outcome: I Clinical relapse

Study or subgroup	5-ASA	placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Brignola 1995	3/44	14/43	-	6.1 %	0.91 [ 0.48, 1.70 ]
Caprilli 1994	20/55	28/55		12.6 %	0.71 [ 0.46, 1.10 ]
Hanauer 2004	33/44	35/40	-	55.7 %	0.86 [ 0.70, 1.05 ]
Lochs 2000	47/154	59/170	-	24.0 %	0.88 [ 0.64, 1.21 ]
Sutherland 1997	3/3	8/35		1.6 %	0.42 [ 0.12, 1.46 ]
Total (95% CI)	328	343	•	100.0 %	0.84 [ 0.72, 0.98 ]
Total events: 116 (5-ASA)	, 144 (placebo)				
Heterogeneity: $Tau^2 = 0.0$	); Chi <sup>2</sup> = 1.95, df = 4	(P = 0.74); I <sup>2</sup> =0.0%			
Test for overall effect: Z =	= 2.26 (P = 0.024)				
Test for subgroup differen	ces: Not applicable				
			0.01 0.1 1 10 100		

Favours 5-ASA Favours placebo

## Analysis I.2. Comparison I Direct evidence: 5-ASA versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: I Direct evidence: 5-ASA versus placebo

Outcome: 2 Adverse events

Study or subgroup	5-ASA	placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
Brignola 1995	5/44	3/43		28.0 %	1.63 [ 0.41, 6.40 ]
Caprilli 1994	2/55	0/55		4.6 %	5.00 [ 0.25, 101.81 ]
Florent 1996	5/65	3/61		28.6 %	1.56 [ 0.39, 6.27 ]
Hanauer 2004	6/44	4/40		38.7 %	1.36 [ 0.41, 4.48 ]
Total (95% CI)	208	199	•	100.0 %	1.66 [ 0.81, 3.43 ]
Total events: 18 (5-ASA),	I0 (placebo)				
Heterogeneity: $Chi^2 = 0.6$	3, df = 3 (P = 0.89);	$ ^2 = 0.0\%$			
Test for overall effect: $Z =$	I.38 (P = 0.17)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100		
			Favours 5-ASA Favours placebo		

### Analysis 1.3. Comparison I Direct evidence: 5-ASA versus placebo, Outcome 3 Serious adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: I Direct evidence: 5-ASA versus placebo

Outcome: 3 Serious adverse events

-

.

Study or subgroup	5-ASA	placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Hanauer 2004	0/44	2/40		23.4 %	0.18 [ 0.01, 3.68 ]
Lochs 2000	8/154	9/170	-	76.6 %	0.98 [ 0.39, 2.48 ]
Total (95% CI)	198	210	•	100.0 %	0.79 [ 0.34, 1.87 ]
Total events: 8 (5-ASA), I	l (placebo)				
Heterogeneity: Chi <sup>2</sup> = 1.1	2, df = 1 (P = 0.29);	$ ^2 =    \%$			
Test for overall effect: $Z =$	0.53 (P = 0.60)				
Test for subgroup difference	ces: Not applicable				
			0.01 0.1 1 10 100		
			Favours 5-ASA Favours placeb	0	

# Analysis I.4. Comparison I Direct evidence: 5-ASA versus placebo, Outcome 4 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: I Direct evidence: 5-ASA versus placebo

Outcome: 4 Withdrawal due to adverse events

Study or subgroup	5-ASA n/N	placebo n/N	Risk Ratio M-H Fixed 95% Cl	Weight	Risk Ratio M-H Fixed 95% CI
Caprilli 1994	2/55	0/55		6.4 %	5.00 [ 0.25, 101.81 ]
Florent 1996	5/65	3/61		39.8 %	1.56 [ 0.39, 6.27 ]
Hanauer 2004	6/44	4/40		53.8 %	1.36 [ 0.41, 4.48 ]
Total (95% CI)	164	156	-	100.0 %	1.68 [ 0.71, 3.94 ]
Total events: 13 (5-ASA), 7	7 (placebo)				
Heterogeneity: $Chi^2 = 0.6$	3, df = 2 (P = 0.73);	l <sup>2</sup> =0.0%			
Test for overall effect: Z =	1.19 (P = 0.24)				
Test for subgroup difference	es: Not applicable				
- ·					
			0.01 0.1 1 10 100		
			Favours 5-ASA Favours placebo		

### Analysis I.5. Comparison I Direct evidence: 5-ASA versus placebo, Outcome 5 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: I Direct evidence: 5-ASA versus placebo

Outcome: 5 Endoscopic relapse

Study or subgroup	5-ASA n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Florent 1996	38/65	40/61	-	24.5 %	0.89 [ 0.68, 1.17 ]
Lochs 2000	133/154	134/170	•	75.5 %	1.10 [ 0.99, 1.21 ]
Total (95% CI)	219	231	•	100.0 %	1.05 [ 0.95, 1.15 ]
Total events: 171 (5-ASA)	), 174 (Placebo)				
Heterogeneity: $Chi^2 = 2$ .	14, df = 1 (P = 0.14); 1	<sup>2</sup> =53%			
Test for overall effect: Z =	= 0.88 (P = 0.38)				
Test for subgroup differen	ices: Not applicable				
			0.01 0.1 1 10 100		
			Favours 5-ASA Favours placebo		

### Analysis 2.1. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 2 Direct evidence: 5-ASA versus adalimumab

Outcome: I Clinical relapse

.

-

Study or subgroup	5-ASA	Adalimumab	R	isk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixe	ed,95% Cl		M-H,Fixed,95% CI
Savarino 2013	9/18	1/16			100.0 %	8.00 [ 1.13, 56.41 ]
Total (95% CI)	18	16		-	100.0 %	8.00 [ 1.13, 56.41 ]
Total events: 9 (5-ASA), I	(Adalimumab)					
Heterogeneity: not applica	able					
Test for overall effect: Z =	2.09 (P = 0.037)					
Test for subgroup differen	ces: Not applicable					
			0.01 0.1 1	10 100		
			Favours 5-ASA	Favours adalimumat	)	

#### Analysis 2.2. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 2 Direct evidence: 5-ASA versus adalimumab

Outcome: 2 Adverse events

Study or subgroup	5-ASA	Adalimumab			Risk Ra	atio		Weight	Risk Ratio
	n/N	n/N		M-H,	Fixed,95	% CI			M-H,Fixed,95% CI
Savarino 2013	4/ 8	11/16			-			100.0 %	1.13 [ 0.75, 1.71 ]
Total (95% CI)	18	16			•			100.0 %	1.13 [ 0.75, 1.71 ]
Total events: 14 (5-ASA),	II (Adalimumab)								
Heterogeneity: not applica	ible								
Test for overall effect: Z =	0.59 (P = 0.56)								
Test for subgroup differen	ces: Not applicable								
							i.		
			0.01	0.1	I	10	100		
			Favour	rs 5-ASA	Fav	vours a	Idalimumab		

### Analysis 2.3. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 3 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 2 Direct evidence: 5-ASA versus adalimumab

Outcome: 3 Endoscopic relapse

Study or subgroup	5-ASA n/N	Adalimumab n/N	M-H,Fi	Risk Ratio xed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Savarino 2013	15/18	1/16			100.0 %	3.33 [  .98, 89.95 ]
Total (95% CI)	18	16			100.0 %	13.33 [ 1.98, 89.95 ]
Total events: 15 (5-ASA),	I (Adalimumab)					
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 2.66 (P = 0.0078)					
Test for subgroup differen	ces: Not applicable					
			0.01 0.1	I IO IOO		
			Favours 5-ASA	Favours adalimu	mab	

# Analysis 2.4. Comparison 2 Direct evidence: 5-ASA versus adalimumab, Outcome 4 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 2 Direct evidence: 5-ASA versus adalimumab

Outcome: 4 Withdrawal due to adverse events

Study or subgroup	5-ASA	Adalimumab			Risk	Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed	,95% CI			M-H,Fixed,95% CI
Savarino 2013	1/18	0/16			-	•	_	100.0 %	2.68 [ 0.12, 61.58 ]
Total (95% CI)	18	16					-	100.0 %	2.68 [ 0.12, 61.58 ]
Total events:   (5-ASA), 0	(Adalimumab)								
Heterogeneity: not applica	able								
Test for overall effect: Z =	0.62 (P = 0.54)								
Test for subgroup differen	ces: Not applicable								
			1			1			
			0.01	0.1	I	10	100		
			Favour	s 5-ASA		Favours a	adalimumab		

## Analysis 3.1. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 3 Direct evidence: 5-ASA versus purine analogues

Outcome: I Clinical relapse

Study or subgroup	5-ASA	purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Ardizzone 2004	32/71	35/71	-	32.1 %	0.91 [ 0.65, 1.30 ]
Hanauer 2004	33/44	32/47	•	28.3 %	1.10 [ 0.85, 1.43 ]
Herfarth 2006	27/37	33/42	-	28.3 %	0.93 [ 0.72, 1.19 ]
Savarino 2013	9/18	2/ 7	-	11.3 %	0.71 [ 0.41, 1.23 ]
Total (95% CI)	170	177	•	100.0 %	0.95 [ 0.81, 1.11 ]
Total events: 101 (5-ASA)	), 112 (purine anal	ogues)			
Heterogeneity: $Chi^2 = 2.4$	41, df = 3 (P = 0.4	19); 1 <sup>2</sup> =0.0%			
Test for overall effect: Z =	= 0.64 (P = 0.52)				
Test for subgroup differer	ices: Not applicabl	e			

0.01 0.1 I 10 100 Favours 5-ASA Favours purine analogues

## Analysis 3.2. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 3 Direct evidence: 5-ASA versus purine analogues

Outcome: 2 Adverse events

Study or subgroup	5-ASA	Purine analogues			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed,95% Cl			M-H,Fixed,95% CI
Ardizzone 2004	27/71	8/7			-		26.4 %	1.50 [ 0.91, 2.47 ]
Hanauer 2004	6/44	9/47		_	•		12.7 %	0.71 [ 0.28, 1.84 ]
Herfarth 2006	26/37	29/42			•		39.8 %	1.02 [ 0.76, 1.36 ]
Savarino 2013	4/ 8	4/ 7			+		21.1 %	0.94 [ 0.68,  .3  ]
Total (95% CI)	170	177			•		100.0 %	1.09 [ 0.87, 1.36 ]
Total events: 73 (5-ASA),	70 (Purine analog	ues)						
Heterogeneity: $Chi^2 = 3.3$	30, df = 3 (P = 0.3	5); I <sup>2</sup> =9%						
Test for overall effect: Z =	= 0.76 (P = 0.45)							
Test for subgroup differen	ices: Not applicabl	e						
			0.01	0.1	I I0	100		

Favours 5-ASA Favours purine analogues

# Analysis 3.3. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 3 Serious adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 3 Direct evidence: 5-ASA versus purine analogues

Outcome: 3 Serious adverse events

Study or subgroup	Azathioprine	Mesalamine			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed,95% Cl			M-H,Fixed,95% Cl
Ardizzone 2004	5/7	6/71					71.3 %	2.50 [ 1.03, 6.07 ]
Hanauer 2004	0/44	2/47		-			28.7 %	0.21 [ 0.01, 4.32 ]
Total (95% CI)	115	118			-		100.0 %	1.84 [ 0.83, 4.07 ]
Total events: 15 (Azathiop	orine), 8 (Mesalamine)							
Heterogeneity: $Chi^2 = 2.4$	43, df = 1 (P = 0.12); $ ^2$ =	59%						
Test for overall effect: Z =	= 1.51 (P = 0.13)							
Test for subgroup differer	ices: Not applicable							
			0.01	0.1	I I0	100		

Favours azathioprine Favours mesalamine

# Analysis 3.4. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 4 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 3 Direct evidence: 5-ASA versus purine analogues

Outcome: 4 Withdrawal due to adverse events

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Ardizzone 2004	6/71	15/71		47.2 %	0.40 [ 0.16, 0.97 ]
Hanauer 2004	6/44	9/47		27.4 %	0.71 [ 0.28, 1.84 ]
Herfarth 2006	4/37	7/42		20.6 %	0.65 [ 0.21, 2.04 ]
Savarino 2013	0/18	1/17		4.8 %	0.32 [ 0.01, 7.26 ]
Total (95% CI)	170	177	•	100.0 %	0.53 [ 0.31, 0.92 ]
Total events: 16 (5-ASA),	32 (Purine analogi	ues)			
Heterogeneity: $Chi^2 = 0.9$	98, df = 3 (P = 0.8	I); I <sup>2</sup> =0.0%			
Test for overall effect: Z =	= 2.24 (P = 0.025)				
Test for subgroup differer	nces: Not applicable	e			
			0.01 0.1 1 10 1	00	

Favours 5-ASA Favours purine analogues

# Analysis 3.5. Comparison 3 Direct evidence: 5-ASA versus purine analogues, Outcome 5 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 3 Direct evidence: 5-ASA versus purine analogues

Outcome: 5 Endoscopic relapse

-

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/IN	n/IN	M-H,Fixed,95% CI		IM-H,Fixed,95% CI
Savarino 2013	15/18	/ 7		100.0 %	1.29 [ 0.86, 1.94 ]
Total (95% CI)	18	17	•	100.0 %	1.29 [ 0.86, 1.94 ]
Total events: 15 (5-ASA),	I (Purine analogi	ues)			
Heterogeneity: not applica	ble				
Test for overall effect: Z =	I.22 (P = 0.22)				
Test for subgroup difference	es: Not applicable	2			
			0.01 0.1 1 10	100	
			Favours 5-ASA Favours	purine analogues	

### Analysis 4.1. Comparison 4 Direct evidence: antibiotics versus placebo, Outcome 1 Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 4 Direct evidence: antibiotics versus placebo

Outcome: I Clinical relapse

Study or subgroup	Antibiotics	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Herfarth 2013	10/17	8/16	-	29.2 %	1.18 [ 0.63, 2.21 ]
Rutgeerts 2005	17/40	20/40	<b>+</b>	70.8 %	0.85 [ 0.53, 1.37 ]
Total (95% CI)	57	56	•	100.0 %	0.95 [ 0.65, 1.38 ]
Total events: 27 (Antibioti	cs), 28 (Placebo)				
Heterogeneity: $Chi^2 = 0.6$	5, df = 1 (P = 0.42); $I^2$	=0.0%			
Test for overall effect: $Z =$	0.29 (P = 0.77)				
Test for subgroup differen	ces: Not applicable				
			0.01 0.1 1 10 100		
			Favours antibiotics Favours placebo		

### Analysis 4.2. Comparison 4 Direct evidence: antibiotics versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 4 Direct evidence: antibiotics versus placebo

Outcome: 2 Adverse events

.

.

Study or subgroup	Antibiotics	Antibiotics Placebo		Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed	,95% CI		M-H,Fixed,95% Cl
Herfarth 2013	1/17	6/16			100.0 %	0.16 [ 0.02, 1.16 ]
Total (95% CI)	17	16			100.0 %	0.16 [ 0.02, 1.16 ]
Total events: I (Antibiotic	s), 6 (Placebo)					
Heterogeneity: not applica	able					
Test for overall effect: Z =	= 1.81 (P = 0.070)					
Test for subgroup differen	ces: Not applicable					
			0.01 0.1 1	10 100		
			Favours antibiotics	Favours placebo		

# Analysis 4.3. Comparison 4 Direct evidence: antibiotics versus placebo, Outcome 3 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 4 Direct evidence: antibiotics versus placebo

Outcome: 3 Withdrawal due to adverse events

Study or subgroup	Antibiotics	Placebo		Risk Ratio		Weight	Risk Ratio			
	n/N	n/N		M-H,Fixed,95% Cl					M-H,Fixed,95% Cl	
Herfarth 2013	1/17	4/16	-	-+				100.0 %	0.24 [ 0.03, 1.89 ]	
Total (95% CI)	17	16		-	-			100.0 %	0.24 [ 0.03, 1.89 ]	
Total events: I (Antibiotics	s), 4 (Placebo)									
Heterogeneity: not applica	ble									
Test for overall effect: Z =	1.36 (P = 0.17)									
Test for subgroup difference	ces: Not applicable									
			0.01	0.1	Ι	10	100			
			Favours ar	ntibiotics		Favours	placebo			

### Analysis 4.4. Comparison 4 Direct evidence: antibiotics versus placebo, Outcome 4 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 4 Direct evidence: antibiotics versus placebo

Outcome: 4 Endoscopic relapse

-

-

Study or subgroup	Antibiotics	Placebo		Risk Ratio				Weight	Risk Ratio
	n/N	n/N		M-H	l,Fixed	,95% CI			M-H,Fixed,95% CI
Herfarth 2013	/ 7	11/16			+			25.6 %	0.94 [ 0.58, 1.52 ]
Rutgeerts 2005	27/40	33/40			-			74.4 %	0.82 [ 0.63, 1.06 ]
Total (95% CI)	57	56			•			100.0 %	0.85 [ 0.68, 1.07 ]
Total events: 38 (Antibioti	cs), 44 (Placebo)								
Heterogeneity: $Chi^2 = 0.2$	6, df = 1 (P = 0.61); $ ^2$	=0.0%							
Test for overall effect: Z =	1.40 (P = 0.16)								
Test for subgroup differen	ces: Not applicable								
			0.01	0.1	I	10	100		
			Favours a	ntibiotics		Favours	placebo		

#### Analysis 5.1. Comparison 5 Direct evidence: budesonide versus placebo, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 5 Direct evidence: budesonide versus placebo

Outcome: I Clinical relapse

Study or subgroup	Corticosteroids	Placebo			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed,95% Cl			M-H,Fixed,95% Cl
Ewe 1999	14/43	19/40		-	-		100.0 %	0.69 [ 0.40, 1.18 ]
Total (95% CI)	43	40		-	•		100.0 %	0.69 [ 0.40, 1.18 ]
Total events: 14 (Cortico:	steroids), 19 (Placebo)							
Heterogeneity: not applic	able							
Test for overall effect: Z =	= 1.37 (P = 0.17)							
Test for subgroup differer	nces: Not applicable							
			0.01	0.1	I I0	100		
		Fave	ours cortice	osteroids	Favours	placebo		

### Analysis 5.2. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 5 Direct evidence: budesonide versus placebo

Outcome: 2 Adverse events

-

.

Study or subgroup	Corticosteroids	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Ewe 1999	13/43	7/40		12.8 %	1.73 [ 0.77, 3.89 ]
Hellers 1999	44/63	51/67	-	87.2 %	0.92 [ 0.74, 1.13 ]
Total (95% CI)	106	107	•	100.0 %	1.02 [ 0.82, 1.27 ]
Total events: 57 (Corticos	steroids), 58 (Placebo)				
Heterogeneity: $Chi^2 = 2.6$	50, df =   (P = 0.11); $ ^2 = 62$	%			
Test for overall effect: Z =	= 0.19 (P = 0.85)				
Test for subgroup differen	ces: Not applicable				
			0.01 0.1 1 10 100		

Favours corticosteroids Favours placebo

## Analysis 5.3. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 3 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 5 Direct evidence: budesonide versus placebo

Outcome: 3 Withdrawal due to adverse events

Study or subgroup	Corticosteroids	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Ewe 1999	1/40	1/40		17.1 %	1.00 [ 0.06, 15.44 ]
Hellers 1999	5/63	5/67		82.9 %	1.06 [ 0.32, 3.50 ]
Total (95% CI)	103	107	•	100.0 %	1.05 [ 0.35, 3.14 ]
Total events: 6 (Corticost	eroids), 6 (Placebo)				
Heterogeneity: $Chi^2 = 0.0$	00, df = 1 (P = 0.97); $l^2 = 0.0$	0%			
Test for overall effect: Z =	= 0.09 (P = 0.93)				
Test for subgroup differer	nces: Not applicable				
			0.01 0.1 1 10	100	
		Favour	rs corticosteroids Favours	placebo	

### Analysis 5.4. Comparison 5 Direct evidence: budesonide versus placebo, Outcome 4 Histologic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 5 Direct evidence: budesonide versus placebo

Outcome: 4 Histologic relapse

Study or subgroup	Corticosteroids	Placebo		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H	Fixed,95% CI		M-H,Fixed,95% CI
Ewe 1999	36/43	38/43		+	100.0 %	0.95 [ 0.80, 1.12 ]
Total (95% CI)	43	43		•	100.0 %	0.95 [ 0.80, 1.12 ]
Total events: 36 (Cortico:	steroids), 38 (Placebo)					
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 0.62 (P = 0.53)					
Test for subgroup differer	ices: Not applicable					
			0.01 0.1	I IO IOO		
		Fav	ours corticosteroids	Favours placebo		

### Analysis 6.1. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 6 Direct evidence: infliximab versus adalimumab

Outcome: I Clinical relapse

.

-

Study or subgroup	Infliximab	Adalimumab		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,F	ixed,95% Cl		M-H,Fixed,95% CI
Tursi 2014	1/10	1/10			100.0 %	1.00 [ 0.07, 13.87 ]
Total (95% CI)	10	10			100.0 %	1.00 [ 0.07, 13.87 ]
Total events: I (Infliximab	), I (Adalimumab)					
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 0.0 (P = 1.0)					
Test for subgroup differen	ices: Not applicable					
			0.01 0.1	I IO IOO		
			Favours infliximab	Favours adalimun	nab	

#### Analysis 6.2. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 6 Direct evidence: infliximab versus adalimumab

Outcome: 2 Adverse events

Study or subgroup	Infliximab	Adalimumab			Ris	k Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed	d,95% CI			M-H,Fixed,95% Cl
Tursi 2014	0/10	0/10							Not estimable
Total (95% CI)	10	10							Not estimable
Total events: 0 (Infliximab)	, 0 (Adalimumab)								
Heterogeneity: not applica	ble								
Test for overall effect: not	applicable								
Test for subgroup difference	ces: Not applicable								
			0.01	0.1	I	10	100		
			Favours ir	nfliximab		Favours	adalimumab		

### Analysis 6.3. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 3 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 6 Direct evidence: infliximab versus adalimumab

Outcome: 3 Endoscopic relapse

Study or subgroup	Infliximab	Adalimumab			Risk Ratio		Weight	Risk Ratio
	n/N	n/N M-H,Fixed,95% C					M-H,Fixed,95% CI	
Tursi 2014	2/10	1/10		_	-		100.0 %	2.00 [ 0.21, 18.69 ]
Total (95% CI)	10	10		-			100.0 %	2.00 [ 0.21, 18.69 ]
Total events: 2 (Infliximab	), I (Adalimumab)							
Heterogeneity: not applic	able							
Test for overall effect: Z =	= 0.61 (P = 0.54)							
Test for subgroup differer	nces: Not applicable							
			0.01	0.1	I I0	100		
			Favours ir	nfliximab	Favours	adalimumab		

#### Analysis 6.4. Comparison 6 Direct evidence: infliximab versus adalimumab, Outcome 4 Histologic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 6 Direct evidence: infliximab versus adalimumab

Outcome: 4 Histologic relapse

Study or subgroup	Infliximab	Adalimumab			Ris	ik Ratio		Weight	Risk Ratio
	n/N	n/N M-H,Fixed,95			ed,95% CI M			M-H,Fixed,95% Cl	
Tursi 2014	3/10	2/10		-	-			100.0 %	1.50 [ 0.32, 7.14 ]
Total (95% CI)	10	10		-				100.0 %	1.50 [ 0.32, 7.14 ]
Total events: 3 (Infliximab	), 2 (Adalimumab)								
Heterogeneity: not applic	able								
Test for overall effect: Z =	0.51 (P = 0.61)								
Test for subgroup differen	ces: Not applicable								
			0.01	0.1	Ι	10	100		
			Favours in	nfliximab		Favours	adalimumab		

### Analysis 7.1. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 7 Direct evidence: infliximab versus purine analogues

Outcome: I Clinical relapse



# Analysis 7.2. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 2 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 7 Direct evidence: infliximab versus purine analogues

Outcome: 2 Withdrawal due to adverse events

Study or subgroup	Infliximab	Purine analogues	R	sk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixe	ed,95% Cl		M-H,Fixed,95% Cl
Armuzzi 2013	0/11	1/11			100.0 %	0.33 [ 0.02, 7.39 ]
Total (95% CI)	11	11			100.0 %	0.33 [ 0.02, 7.39 ]
Total events: 0 (Infliximat	), I (Purine analogue	s)				
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 0.69 (P = 0.49)					
Test for subgroup differer	nces: Not applicable					
					1	
			0.01 0.1 1	10	100	
			Favours infliximab	Favours pur	rine analogues	

# Analysis 7.3. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 3 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 7 Direct evidence: infliximab versus purine analogues

Outcome: 3 Endoscopic relapse

Study or subgroup	Infliximab	Purine analogues		I	Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fi:	xed,95% Cl			M-H,Fixed,95% Cl
Armuzzi 2013	1/11	1/11					100.0 %	1.00 [ 0.07, 14.05 ]
Total (95% CI)	11	11					100.0 %	1.00 [ 0.07, 14.05 ]
Total events: I (Infliximat	o), I (Purine analogue	es)						
Heterogeneity: not applie	able							
Test for overall effect: Z	= 0.0 (P = 1.0)							
Test for subgroup differen	nces: Not applicable							
			0.01	0.1	I I0	100		
			Favours	infliximab	Favours	nurine analog	ues	

# Analysis 7.4. Comparison 7 Direct evidence: infliximab versus purine analogues, Outcome 4 Histologic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 7 Direct evidence: infliximab versus purine analogues

Outcome: 4 Histologic relapse

Study or subgroup	Infliximab	Purine analogues		Risk Ratio		Weight	Risk Ratio		
	n/N	n/N		M-H,F	ixed,	,95% CI			M-H,Fixed,95% Cl
Armuzzi 2013	2/11	9/11			-			100.0 %	0.22 [ 0.06, 0.80 ]
Total (95% CI)	11	11		-	-			100.0 %	0.22 [ 0.06, 0.80 ]
Total events: 2 (Infliximab									
Heterogeneity: not applic	able								
Test for overall effect: Z =	= 2.30 (P = 0.022)								
Test for subgroup differer	nces: Not applicable								
			0.01	0.1	I.	10	100		
			Favours i	nfliximab		Favours	purine a	nalogues	

### Analysis 8.1. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 1 Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 8 Direct evidence: probiotics versus placebo

Outcome: I Clinical relapse

-

Study or subgroup	Probiotics	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Gossum 2007	11/34	17/36	-	76.4 %	0.69 [ 0.38, 1.24 ]
Prantera 2002	8/23	5/22		23.6 %	1.53 [ 0.59, 3.97 ]
Total (95% CI)	57	58	•	100.0 %	0.88 [ 0.54, 1.46 ]
Total events: 19 (Probiotics	s), 22 (Placebo)				
Heterogeneity: $Chi^2 = 1.98$	B, df = $  (P = 0.16);  ^2$	=49%			
Test for overall effect: Z =	0.48 (P = 0.63)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100		

Favours probiotics Favours placebo

#### Analysis 8.2. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn s disease: a network meta-analysis

Comparison: 8 Direct evidence: probiotics versus placebo

Outcome: 2 Adverse events

Study or subgroup	Probiotics	Placebo	Risk Ratio			Weight	Risk Ratio		
	n/N	n/N		M-H,F	ixed,9	5% CI			M-H,Fixed,95% CI
Prantera 2002	2/23	6/22						100.0 %	0.32 [ 0.07, 1.41 ]
Total (95% CI)	23	22		-				100.0 %	0.32 [ 0.07, 1.41 ]
Total events: 2 (Probiotics	), 6 (Placebo)								
Heterogeneity: not applica	ble								
Test for overall effect: Z =	I.50 (P = 0.13)								
Test for subgroup differen	ces: Not applicable								
			0.01	0.1	I	10	100		
			Favours p	probiotics	F	avours	placebo		

### Analysis 8.3. Comparison 8 Direct evidence: probiotics versus placebo, Outcome 3 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 8 Direct evidence: probiotics versus placebo

Outcome: 3 Endoscopic relapse

-

Study or subgroup	Probiotics	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Gossum 2007	28/34	27/36	•	37.6 %	1.10 [ 0.86, 1.40 ]
Marteau 2006	26/48	33/50	-	46.3 %	0.82 [ 0.59, 1.14 ]
Prantera 2002	17/23	11/22	-	16.1 %	1.48 [ 0.91, 2.40 ]
Total (95% CI)	105	108	•	100.0 %	1.03 [ 0.85, 1.25 ]
Total events: 71 (Probiotic	s), 71 (Placebo)				
Heterogeneity: $Chi^2 = 4.2$	5, df = 2 (P = 0.12); $I^2$	=53%			
Test for overall effect: $Z =$	0.31 (P = 0.75)				
Test for subgroup difference	ces: Not applicable				

0.01 0.1 1 10 100 Favours probiotics Favours placebo

### Analysis 9.1. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 9 Direct evidence: purine analogues versus placebo

Outcome: I Clinical relapse

Study or subgroup	Purine analogues	Placebo	Ri	sk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixe	ed,95% Cl		M-H,Fixed,95% Cl
Hanauer 2004	32/47	35/40	-		33.6 %	0.78 [ 0.62, 0.98 ]
Mowat 2016	66/128	70/112	-		66.4 %	0.83 [ 0.66, 1.03 ]
Total (95% CI)	175	152	•		100.0 %	0.81 [ 0.69, 0.96 ]
Total events: 98 (Purine a	inalogues), 105 (Placebo)					
Heterogeneity: $Chi^2 = 0$ .	$ 4, df =   (P = 0.71);  ^2 = 0.06$	%				
Test for overall effect: Z =	= 2.50 (P = 0.012)					
Test for subgroup differer	nces: Not applicable					
			0.01 0.1 1	10 100		
		Favour	rs purine analogues	Favours placebo		

### Analysis 9.2. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 9 Direct evidence: purine analogues versus placebo

Outcome: 2 Adverse events

Study or subgroup	Purine analogues n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Hanauer 2004	9/47	4/40		100.0 %	1.91 [ 0.64, 5.75 ]
Total (95% CI)	47	40		100.0 %	1.91 [ 0.64, 5.75 ]
Total events: 9 (Purine an	alogues), 4 (Placebo)				
Heterogeneity: not applic	able				
Test for overall effect: Z =	= 1.16 (P = 0.25)				
Test for subgroup differer	ices: Not applicable				
			0.01 0.1 1 10 100		
		Favours	purine analogues Favours placebo		

# Analysis 9.3. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 3 Serious adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 9 Direct evidence: purine analogues versus placebo

Outcome: 3 Serious adverse events

-

1-H,Fixed,95% Cl
).85 [ 0.13, 5.77 ]
.3  [ 0.22, 7.7  ]
[ 0.30, 3.94 ]

 0.01
 0.1
 I
 I.0
 I.00

 Favours purine analogues
 Favours placebo

# Analysis 9.4. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 4 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn s disease: a network meta-analysis

Comparison: 9 Direct evidence: purine analogues versus placebo

Outcome: 4 Withdrawal due to adverse events

Study or subgroup	Purine analogues	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Hanauer 2004	9/47	4/40		9.0 %	1.91 [ 0.64, 5.75 ]
Mowat 2016	39/128	41/112	=	91.0 %	0.83 [ 0.58, 1.19 ]
Total (95% CI)	175	152	•	100.0 %	0.93 [ 0.66, 1.30 ]
Total events: 48 (Purine a	nalogues), 45 (Placebo)				
Heterogeneity: $Chi^2 = 2.0$	03, df =   (P = 0.15); l <sup>2</sup> =519	6			
Test for overall effect: Z =	= 0.42 (P = 0.67)				
Test for subgroup differer	nces: Not applicable				
			0.01 0.1 1 10 100		
		Favours	purine analogues Favours placebo		

# Analysis 9.5. Comparison 9 Direct evidence: purine analogues versus placebo, Outcome 5 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 9 Direct evidence: purine analogues versus placebo

Outcome: 5 Endoscopic relapse

Study or subgroup	Purine analogues	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Mowat 2016	90/128	83/112	-	100.0 %	0.95 [ 0.81, 1.11 ]
Total (95% CI)	128	112	•	100.0 %	0.95 [ 0.81, 1.11 ]
Total events: 90 (Purine a	nalogues), 83 (Placebo)				
Heterogeneity: not applic	able				
Test for overall effect: Z =	= 0.66 (P = 0.51)				
Test for subgroup differer	nces: Not applicable				
			0.01 0.1 1 10 100		
		Favours	purine analogues Favours placeb	þ	

# Analysis 10.1. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 1 Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 10 Direct evidence: purine analogues versus adalimumab

Outcome: I Clinical relapse

.

-

.

.

Study or subgroup	Purine analogues n/N	Adalimumab n/N	٢	Ris 1-H,Fixed	k Ratio d,95% Cl		Weight	Risk Ratio M-H,Fixed,95% Cl
Savarino 2013	12/17	1/16			•		100.0 %	.29 [ .65, 77.22]
Total (95% CI)	17	16					100.0 %	11.29 [ 1.65, 77.22 ]
Total events: 12 (Purine a	analogues), I (Adalimumab	)						
Heterogeneity: not appli	cable							
Test for overall effect: Z	= 2.47 (P = 0.013)							
Test for subgroup differe	nces: Not applicable							
			0.01 0.	I I	10	100		
		Favoi	irs purine analog	ues	Favours	adalimumab		

# Analysis 10.2. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn s disease: a network meta-analysis

Comparison: 10 Direct evidence: purine analogues versus adalimumab

Outcome: 2 Adverse events

Study or subgroup	Purine analogues	Adalimumab			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fi	xed,95% Cl			M-H,Fixed,95% CI
Savarino 2013	4/ 7	11/16			+		100.0 %	1.20 [ 0.81, 1.78 ]
Total (95% CI)	17	16			•		100.0 %	1.20 [ 0.81, 1.78 ]
Total events: 14 (Purine a	analogues), II (Adalimumab)							
Heterogeneity: not applie	able							
Test for overall effect: Z =	= 0.89 (P = 0.37)							
Test for subgroup differen	nces: Not applicable							
			0.01	0.1	I I0	100		
		Favou	rs purine ar	nalogues	Favours	adalimumab		

### Analysis 10.3. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 3 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: 10 Direct evidence: purine analogues versus adalimumab

Outcome: 3 Withdrawal due to adverse events

-

Study or subgroup	Purine analogues	Adalimumab		Risk Ratio	Weigh	t Risk Ratio
	n/N	n/N	M-H,I	Fixed,95% Cl		M-H,Fixed,95% Cl
Savarino 2013	1/17	0/16		-	- 100.0 9	6 2.83 [ 0.12, 64.89 ]
Total (95% CI)	17	16			- 100.0 %	<b>2.83</b> [ <b>0.12</b> , <b>64.89</b> ]
Total events: I (Purine ar	nalogues), 0 (Adalimumab)					
Heterogeneity: not applie	able					
Test for overall effect: Z =	= 0.65 (P = 0.51)					
Test for subgroup differen	nces: Not applicable					
			0.01 0.1	I I0	100	

Favours purine analogues Favours adalimumab

### Analysis 10.4. Comparison 10 Direct evidence: purine analogues versus adalimumab, Outcome 4 Endoscopic relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn s disease: a network meta-analysis

Comparison: 10 Direct evidence: purine analogues versus adalimumab

Outcome: 4 Endoscopic relapse

Study or subgroup	Purine analogues	Adalimumab			Risk Rati	0	Weight	Risk Ratio
	n/N	n/N		M-H,F	ixed,95%	Cl		M-H,Fixed,95% CI
Savarino 2013	/ 7	1/16				-	55.0 %	10.35 [ 1.50, 71.32 ]
Scapa 2015	4/8	1/11					45.0 %	5.50 [ 0.75, 40.36 ]
Total (95% CI)	25	27					100.0 %	8.17 [ 2.01, 33.25 ]
Total events: 15 (Purine a	analogues), 2 (Adalimumab)	)						
Heterogeneity: $Chi^2 = 0$	.21, df = 1 (P = 0.65); l <sup>2</sup> =0	).0%						
Test for overall effect: Z	= 2.93 (P = 0.0034)							
Test for subgroup differe	nces: Not applicable							
			i					
			0.01	0.1	1 1	0 100		
		Favo	urs purine an	alogues	Favo	urs adalimum	ab	

### Analysis 11.1. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 1 Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: II Direct evidence: sulfasalazine versus placebo

Outcome: I Clinical relapse

Study or subgroup	Sulfasalazine	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Wenckert 1978	6/32	11/34		100.0 %	0.58 [ 0.24, 1.38 ]
Total (95% CI)	32	34	•	100.0 %	0.58 [ 0.24, 1.38 ]
Total events: 6 (Sulfasalazir	ne), II (Placebo)				
Heterogeneity: not applica	able				
Test for overall effect: Z =	I.23 (P = 0.22)				
Test for subgroup differen	ces: Not applicable				
			0.01 0.1 1 10 100		
		F	Favours sulfasalazine Favours placebo		

### Analysis 11.2. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 2 Adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohm s disease: a network meta-analysis

Comparison: II Direct evidence: sulfasalazine versus placebo

Outcome: 2 Adverse events

\_

Study or subgroup	Sulfasalazine	Placebo	R	isk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixe	ed,95% Cl		M-H,Fixed,95% Cl
Wenckert 1978	0/32	1/34			100.0 %	0.35 [ 0.01, 8.38 ]
Total (95% CI)	32	34			100.0 %	0.35 [ 0.01, 8.38 ]
Total events: 0 (Sulfasalazir	ne), I (Placebo)					
Heterogeneity: not applica	ble					
Test for overall effect: Z =	0.64 (P = 0.52)					
Test for subgroup differen	ces: Not applicable					
					1	
			0.01 0.1 1	10	100	
		Fav	ours sulfasalazine	Favours pla	cebo	

# Analysis 11.3. Comparison 11 Direct evidence: sulfasalazine versus placebo, Outcome 3 Withdrawal due to adverse events.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: II Direct evidence: sulfasalazine versus placebo

Outcome: 3 Withdrawal due to adverse events

Study or subgroup	Sulfasalazine	Placebo		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fi	xed,95% Cl		M-H,Fixed,95% CI
Wenckert 1978	0/32	1/34			100.0 %	0.35 [ 0.01, 8.38 ]
Total (95% CI)	32	34			100.0 %	0.35 [ 0.01, 8.38 ]
Total events: 0 (Sulfasalazir	ne), I (Placebo)					
Heterogeneity: not applica	ble					
Test for overall effect: $Z =$	0.64 (P = 0.52)					
Test for subgroup differen	ces: Not applicable					
			0.01 0.1	1 10 100	)	
		F	avours sulfasalazine	Favours placeb	00	

### Analysis 12.1. Comparison 12 Direct evidence: sulfasalazine + prednisolone versus placebo, Outcome I Clinical relapse.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 12 Direct evidence: sulfasalazine + prednisolone versus placebo

Outcome: I Clinical relapse

Study or subgroup	Sulfasalazine+ c/steroids	Placebo			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fi	ixed,95% Cl			M-H,Fixed,95% CI
Bergman 1976	15/57	9/40			-		100.0 %	1.17 [ 0.57, 2.40 ]
Total (95% CI)	57	40			•		100.0 %	1.17 [ 0.57, 2.40 ]
Total events: 15 (Sulfasalaz	ine+ c/steroids), 9 (Place	bo)						
Heterogeneity: not applica	ble							
Test for overall effect: $Z =$	0.43 (P = 0.67)							
Test for subgroup difference	ces: Not applicable							
			0.01	0.1	I I0	100		

Favours sulfasalazine+c/s Favours placebo

# Analysis 13.1. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 13 Direct evidence not in network: clinical relapse

Outcome: I 4.0 g/d versus 2.4 g/d mesalazine

Study or subgroup	4.0 g/d	2.4 g/d	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Caprilli 2003	17/101	27/101		100.0 %	0.63 [ 0.37, 1.08 ]
Total (95% CI)	101	101	•	100.0 %	0.63 [ 0.37, 1.08 ]
Total events: 17 (4.0 g/d), 2	27 (2.4 g/d)				
Heterogeneity: not applica	ble				
Test for overall effect: Z =	I.68 (P = 0.093)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100		
			Favours 4.0 g/d Favours 2.4 g/d		
# Analysis 13.2. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 2 Purine analogues versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 13 Direct evidence not in network: clinical relapse

Outcome: 2 Purine analogues versus placebo

Study or subgroup	purine analogues n/N	placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
D'Haens 2008	11/40	19/41			0.59 [ 0.33, 1.08 ]
Test for subgroup differe	nces: Not applicable				
		Favo	0.01 0.1 1 10 100 urs purine analogues Favours placebo		

# Analysis 13.3. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 3 Infliximab versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 13 Direct evidence not in network: clinical relapse

Outcome: 3 Infliximab versus placebo

Study or subgroup	Infliximab	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Regueiro 2009	/	5/11		56.4 %	0.20 [ 0.03, 1.45 ]
Yoshida 2012	3/15	4/16		43.6 %	0.80 [ 0.21, 3.00 ]
Total (95% CI)	26	27	-	100.0 %	0.46 [ 0.16, 1.33 ]
Total events: 4 (Infliximab)	, 9 (Placebo)				
Heterogeneity: Chi <sup>2</sup> = 1.3	5, df = 1 (P = 0.24); l <sup>2</sup>	=26%			
Test for overall effect: Z =	I.43 (P = 0.15)				
Test for subgroup difference	ces: Not applicable				
			0.01 0.1 1 10 100		
			Favours infliximab Favours placebo		

Analysis 13.4. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 4 Antibiotics versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 13 Direct evidence not in network: clinical relapse

Outcome: 4 Antibiotics versus placebo

Study or subgroup	Antibiotics n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Ma osa 2013	3/25	6/25			0.50 [ 0.14, 1.78 ]
Test for subgroup differer	nces: Not applicable				
			0.01 0.1 I 10 100 Favours antibiotics Favours placebo		

# Analysis 13.5. Comparison 13 Direct evidence not in network: clinical relapse, Outcome 5 5-ASA versus purine analogues.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 13 Direct evidence not in network: clinical relapse

Outcome: 5 5-ASA versus purine analogues

-

-

Study or subgroup	5-ASA	Purine analogues		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H	,Fixed,95% CI		M-H,Fixed,95% Cl
Reinisch 2010	25/41	22/37			100.0 %	1.03 [ 0.71, 1.47 ]
Total (95% CI)	41	37		•	100.0 %	1.03 [ 0.71, 1.47 ]
Total events: 25 (5-ASA),	22 (Purine analog	ues)				
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 0.14 (P = 0.89)					
Test for subgroup differer	nces: Not applicabl	e				
			. I		i.	
			0.01 0.1	I I0	100	
			Favours 5-ASA	Favours pu	urine analogues	

# Analysis 14.1. Comparison 14 Direct evidence not in network: adverse events, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 14 Direct evidence not in network: adverse events

Outcome: I 4.0 g/d versus 2.4 g/d mesalazine

Study or subgroup	Favours 4.0 g/d	2.4 g/d			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,F	Fixed,95% Cl			M-H,Fixed,95% Cl
Caprilli 2003	2/101	2/105					100.0 %	1.04 [ 0.15, 7.24 ]
Total (95% CI)	101	105					100.0 %	1.04 [ 0.15, 7.24 ]
Total events: 2 (Favours 4	.0 g/d), 2 (2.4 g/d)							
Heterogeneity: not application	able							
Test for overall effect: Z =	= 0.04 (P = 0.97)							
Test for subgroup differen	ices: Not applicable							
			0.01	0.1	I I0	100		
			Favour	rs 4.0 g/d	Favours	2.4 g/d		

## Analysis 14.2. Comparison 14 Direct evidence not in network: adverse events, Outcome 2 Probiotics versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 14 Direct evidence not in network: adverse events

Outcome: 2 Probiotics versus placebo

Study or subgroup	Probiotics	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Fedorak 2015	4/58	5/62			0.86 [ 0.24, 3.03 ]
Test for subgroup differer	nces: Not applicable				
			0.01 0.1 1 10 100 Favours probiotics Favours placebo		

# Analysis 14.3. Comparison 14 Direct evidence not in network: adverse events, Outcome 3 Infliximab versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 14 Direct evidence not in network: adverse events

Outcome: 3 Infliximab versus placebo

Study or subgroup	Infliximab	Placebo	R	isk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fix	ed,95% Cl		M-H,Fixed,95% CI
Fukushima 2018	3/21	0/22			0.8 %	7.32 [ 0.40, 133.66 ]
Regueiro 2009	8/11	9/11		-	14.3 %	0.89 [ 0.56, 1.40 ]
Regueiro 2016	19/147	54/150	=		84.9 %	0.36 [ 0.22, 0.57 ]
Total (95% CI)	179	183	•		100.0 %	0.49 [ 0.34, 0.70 ]
Total events: 30 (Infliximat	o), 63 (Placebo)					
Heterogeneity: $Chi^2 = 11$ .	57, df = 2 (P = 0.003)	; I <sup>2</sup> =83%				
Test for overall effect: Z =	3.85 (P = 0.00012)					
Test for subgroup differen	ces: Not applicable					
				1 I		
			0.01 0.1 1	10 100		
			Favours infliximab	Favours placebo		

### Analysis 14.4. Comparison 14 Direct evidence not in network: adverse events, Outcome 4 5-ASA versus purine analogues.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 14 Direct evidence not in network: adverse events

Outcome: 4 5-ASA versus purine analogues

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Reinisch 2010	34/37	32/41	+		1.18 [ 0.98, 1.42 ]
Test for subgroup differen	nces: Not applicable				
			0.01 0.1 1 10 100		

Favours 5-ASA Favours purine analogues

### Analysis 14.5. Comparison 14 Direct evidence not in network: adverse events, Outcome 5 Purine analogues versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis							
Comparison: 14 Direct	t evidence not in network: ad	verse events					
Outcome: 5 Purine and	alogues versus placebo						
Study or subgroup	purine analogues n/N	placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl		
D'Haens 2008	22/40	32/41	+		0.70 [ 0.51, 0.97 ]		
Test for subgroup differen	nces: Not applicable						
		Favo	0.01 0.1 I 10 100 urs purine analogues Favours placebo				

# Analysis 15.1. Comparison 15 Direct evidence not in network: serious adverse events, Outcome 1 5-ASA versus purine analogues.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 15 Direct evidence not in network: serious adverse events

Outcome: I 5-ASA versus purine analogues

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Reinisch 2010	0/37	10/41	<b>←</b> +		0.05 [ 0.00, 0.87 ]
Test for subgroup differen	nces: Not applicable				
			0.01 0.1 1 10 100		
			Favours 5-ASA Favours purine ana	logues	

# Analysis 16.1. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome I 4.0 g/d versus 2.4 g/d mesalazine.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 16 Direct evidence not in network: withdrawal due to adverse events

Outcome: I 4.0 g/d versus 2.4 g/d mesalazine

Study or subgroup	4.0 g/d	2.4 g/d	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Caprilli 2003	2/101	2/105		100.0 %	1.04 [ 0.15, 7.24 ]
Total (95% CI)	101	105		100.0 %	1.04 [ 0.15, 7.24 ]
Total events: 2 (4.0 g/d), 2	(2.4 g/d)				
Heterogeneity: not applicat	ole				
Test for overall effect: Z =	0.04 (P = 0.97)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100		
			Favours 4.0 g/d Favours 2.4 g/d		

### Analysis 16.2. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 2 Synbiotic versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 16 Direct evidence not in network: withdrawal due to adverse events

Outcome: 2 Synbiotic versus placebo

Study or subgroup	Synbiotic	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Chermesh 2007	7/20	4/10			0.88 [ 0.33, 2.30 ]
Test for subgroup differenc	es: Not applicable				
			0.01 0.1 1 10 100		

### Analysis 16.3. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 3 Probiotics versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis								
Comparison: 16 Direct	evidence not in network	: withdrawal due to	adverse events					
Outcome: 3 Probiotics	versus placebo							
Study or subgroup	Probiotics	Placebo	Risk Ratio	Weight	Risk Ratio			
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl			
Fedorak 2015	5/58	5/62			1.07 [ 0.33, 3.50 ]			
Test for subgroup differer	nces: Not applicable							
			0.01 0.1 1 10 100					
			Favours probiotics Favours placebo					

## Analysis 16.4. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 4 Infliximab versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 16 Direct evidence not in network: withdrawal due to adverse events

Outcome: 4 Infliximab versus placebo

Study or subgroup	Infliximab	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Fukushima 2018	3/21	0/22		0.9 %	7.32 [ 0.40, 133.66 ]
Regueiro 2009	2/11	1/11		1.8 %	2.00 [ 0.21, 18.98 ]
Regueiro 2016	19/147	54/150		96.4 %	0.36 [ 0.22, 0.57 ]
Yoshida 2012	1/15	0/16		0.9 %	3.19 [ 0.14, 72.69 ]
Total (95% CI)	194	199	•	100.0 %	0.47 [ 0.31, 0.72 ]
Total events: 25 (Infliximal	b), 55 (Placebo)				
Heterogeneity: Chi <sup>2</sup> = 7.7	75, df = 3 (P = 0.05); l <sup>2</sup>	=61%			
Test for overall effect: Z =	= 3.46 (P = 0.00054)				
Test for subgroup differen	ces: Not applicable				
			0.01 0.1 1 10 100		
			Favours infliximab Favours placebo		

# Analysis 16.5. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 5 5-ASA versus purine analogues.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 16 Direct evidence not in network: withdrawal due to adverse events

Outcome: 5 5-ASA versus purine analogues

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Reinisch 2010	1/37	0/4			0.11 [ 0.01, 0.82 ]
Test for subgroup differe	nces: Not applicable				
			0.01 0.1 1 10	100	
			Favours 5-ASA Favours pu	irine analogues	

# Analysis 16.6. Comparison 16 Direct evidence not in network: withdrawal due to adverse events, Outcome 6 Purine analogues versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 16 Direct evidence not in network: withdrawal due to adverse events

Outcome: 6 Purine analogues versus placebo

-

Study or subgroup	purine analogues	placebo	Risk	< Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed	I,95% CI		M-H,Fixed,95% Cl
D'Haens 2008	3/40	4/41		_		0.77 [ 0.18, 3.22 ]
Test for subgroup differ	ences: Not applicable					
		Favo	0.01 0.1 I burs purine analogues	10 100 Favours placeb	10	

### Analysis 17.1. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 1 4.0 g/d versus 2.4 g/d mesalazine.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 17 Direct evidence not in network: endoscopic relapse

Outcome: I 4.0 g/d versus 2.4 g/d mesalazine

Study or subgroup	4.0 g/d	2.4 g/d	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Caprilli 2003	45/101	59/105	+	100.0 %	0.79 [ 0.60, 1.04 ]
Total (95% CI)	101	105	•	100.0 %	0.79 [ 0.60, 1.04 ]
Total events: 45 (4.0 g/d), 5	59 (2.4 g/d)				
Heterogeneity: not applical	ble				
Test for overall effect: $Z =$	I.65 (P = 0.099)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100		
			Favours 4.0 g/d Favours 2.4 g/d		

### Analysis 17.2. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 2 Probiotics versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 17 Direct evidence not in network: endoscopic relapse

Outcome: 2 Probiotics versus placebo

Study or subgroup	Probiotics	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Fedorak 2015	47/58	50/62	-		1.00 [ 0.84, 1.20 ]
Test for subgroup differen	ices: Not applicable				
			0.01 0.1 1 10 100		
			Favours probiotics Favours placebo		

# Analysis 17.3. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 3 Infliximab versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 17 Direct evidence not in network: endoscopic relapse

Outcome: 3 Infliximab versus placebo

-

-

Study or subgroup	Infliximab	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Fukushima 2018	12/21	16/22	-	11.3 %	0.79 [ 0.50, 1.23 ]
Regueiro 2009	1/11	11/13		7.3 %	0.  [0.02, 0.7 ]
Regueiro 2016 (1)	67/147	101/150	-	72.3 %	0.68 [ 0.55, 0.83 ]
Yoshida 2012	4/15	13/16		9.1 %	0.33 [ 0.14, 0.78 ]
Total (95% CI)	194	201	•	100.0 %	0.62 [ 0.51, 0.74 ]
Total events: 84 (Infliximab)	), 141 (Placebo)				
Heterogeneity: $Chi^2 = 7.2I$	, df = 3 (P = 0.07); $I^2$	=58%			
Test for overall effect: $Z =$	5.08 (P < 0.00001)				
Test for subgroup difference	es: Not applicable				
			0.01 0.1 1 10 100	)	
			Favours infliximab Favours placeb	00	

(I) Endoscopic score

## Analysis 17.4. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 4 5-ASA versus purine analogues.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 17 Direct evidence not in network: endoscopic relapse

Outcome: 4 5-ASA versus purine analogues

Study or subgroup	5-ASA	Purine analogues	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Reinisch 2010	1/37	0/4			0.11 [ 0.01, 0.82 ]
Test for subgroup differe	nces: Not applicable				
			0.01 0.1 1 10	100	
			Favours 5-ASA Favours pu	irine analogues	

# Analysis 17.5. Comparison 17 Direct evidence not in network: endoscopic relapse, Outcome 5 Purine analogues versus placebo.

Review: Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Comparison: 17 Direct evidence not in network: endoscopic relapse

Outcome: 5 Purine analogues versus placebo

Study or subgroup	purine analogues	placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
D'Haens 2008	17/40	23/41			0.76 [ 0.48, 1.19 ]
Test for subgroup differe	nces: Not applicable				
			0.01 0.1 1 10 10	00	
		Favo	ours purine analogues Favours place	ebo	

### ADDITIONAL TABLES

Table 1. Summary of interventions and outcome data

Study ID	Group 1	Group 2	Group 3	Relapse	Quailty of life	Adverse events/ serious adverse events
Ardizzone 2004	Azathioprine (2 mg/kg/d)	Mesalazine (3 g/day)	n/a	Clinical: 32/71 vs 35/71 Surgical: 26/71 vs 21/71	n/a	<b>AE:</b> 18/71 vs 27/ 71 <b>SAE:</b> 6/71 vs 15/ 71 <b>Withdrawal:</b> 6/ 71 vs 15/71
Armuzzi 2013	Azathioprine (2.5 mg/kg/d)	Infliximab (5 mg/kg/d)	n/a	Clinical: 2/11 vs 1/11 Endoscopic: 5/ 11 vs 1/11 Histologic: 9/11	n/a	<b>Withdrawal:</b> 0/ 11 vs 1/11

				vs 2/11		
Bergman 1976	Sulfasalazine (Salazopyrin) + prednisolone	No treatment	n/a	<b>Relapse:</b> 15/57 vs 9/40	n/a	Not reported for duration of treat- ment
Brignola 1995	Mesalazine (3 g/d)	Placebo	n/a	<b>Clinical:</b> 13/44 vs 14/43	n/a	<b>Withdrawal:</b> 5/ 44 vs 3/43
Caprilli 1994	Mesalazine (2.4 g/d)	No treatment	n/a	<b>Relapse:</b> 20/55 vs 28/55	n/a	<b>AE:</b> 2/55 vs 0/55 (all withdrawn)
Caprilli 2003	Mesalazine (4 g/d)	Mesalazine (2.4 g/day)	n/a	Clinical: 17/101 vs 27/101 Endoscopic > 1: 45/101 vs 59/ 105	n/a	<b>AE:</b> 2/101 vs 2/ 105 (all with- drawn)
Chermesh 2007	Synbiotic 2000	Placebo	n/a	Clinical: n.s. difference in relapse rate Endoscopic: n.s. difference in re- lapse rate	n/a	Withdrawal: 7/ 20 vs 4/10
D'Haens 2008	Metronidazole (750 mg/d) + azathioprine (100 to 150 mg/ d)	Metronidazole (750 mg/d) + placebo	n/a	<b>Clinical:</b> 11/40 vs 19/41 <b>Endoscopic:</b> 22/ 40 vs 32/41	n/a	<b>AE:</b> 3/40 vs 4/41 <b>Withdrawal:</b> 3/ 40 vs 2/41
Ewe 1989	Sulfasalazine (3 g/d)	Placebo	n/a	<b>Relapse:</b> Total 0 to 36 months: 89/111 vs 99/121	n/a	n/a
Ewe 1999	Budesonide (1 mg/d)	Placebo	n/a	<b>Clinical:</b> 14/43 vs 19/40 <b>Histologic:</b> 36/ 43 vs 38/43	<b>QOL:</b> slight pre- ponder- ance of medium and good at the end in Group 1	<b>AE:</b> 13/43 vs 7/ 40 <b>Withdrawal:</b> 1/ 40 vs 1/40
Fedorak 2015	VSL#3 twice daily	Placebo	n/a	Endoscopic: 47/ 58 vs 50/62	IBDQ: similar between groups (data not shown)	<b>AE:</b> 4/58 vs 5/62 <b>Withdrawal:</b> 5/ 58 vs 5/62

Florent 1996	Mesalazine (Claversal) (1000 mg/d)	Placebo (1000 mg/d)	n/a	<b>Endoscopic:</b> 38/ 65 vs 40/61	n/a	<b>AE:</b> 5/65 vs 3/61 (all withdrawn)
Fukushima 2018	Infliximab (5 mg/kg)	No treatment	n/a	Relapse (endo- scopic or clini- cal or both): 0 to 24 months: 12/21 vs 21/22 Clinical: 0 to 24 months: 9/21 vs 21/22 Endoscopic: 0 to 24 months: 12/21 vs 16/22	n/a	<b>AE:</b> 3/21 vs 0/22 <b>Withdrawal:</b> 3/ 21 vs 0/22
Gossum 2007	Probiotic <i>Lacto-</i> bacillus johnsonii	Placebo	n/a	<b>Clinical:</b> 11/34 vs 17/36 <b>Endoscopic:</b> 28/ 34 vs 27/36 <b>Histological</b> <b>score:</b> changes n. s. P = 0.83	n/a	AE: Group 1: 65% at least 1 AE, 2% prob- ably related to treatment SAE: Group 1: 21% at least 1 SAE (0 related to treatment); Group 2: 22% at least 1 SAE Withdrawal: 9 total
Hanauer 2004	6- mercaptopurine (50 mg/d)	Mesalazine (3 g/ d)	Placebo	Clinical: 32/47 vs 33/44 vs 35/ 40	n/a	<b>AE:</b> 9/47 vs 6/44 vs 4/40 <b>SAE:</b> 2/47 vs 0/ 44 vs 2/40 <b>Withdrawal:</b> 9/ 47 vs 6/44 vs 4/ 40
Hellers 1999	Budesonide (6 mg/d)	Placebo	n/a	Reported according to the site of inflamma- tion but not mu- tually exclusive (neoter- minal ileum and anastomosis)	n/a	Adverse: 44/63 vs 51/67 Withdrawal: 5/ 63 vs 5/67
Herfarth 2006	Azathioprine	5-ASA	n/a	<b>Clinical:</b> 23/42 vs 27/37	n/a	<b>Withdrawal :</b> 7/ 42 vs 3/37

Herfarth 2013	Ciprofloxacin (1000 mg/d)	Placebo	n/a	Clinical: 10/17 vs 8/16 Endoscopic: 11/ 17 vs 11/16	n/a	<b>AE:</b> 1/17 vs 6/16 <b>Withdrawal:</b> 1/ 17 vs 4/16
Lochs 2000	Mesalazine (4 g/d)	Placebo	n/a	<b>Clinical:</b> 47/154 vs 59/170 <b>Endoscopic:</b> 133/154 vs 134/ 170	n/a	<b>SAE:</b> 8/154 vs 9/ 170
Lopez Sanroman 2017	Azathioprine (2.5 mg/kg/d) + metronidazole (750 mg/d)	Adalimumab + metronidazole (750 mg/d)	n/a	Clinical: 14/39 vs 7/45 Endoscopic: 23/ 39 vs 19/45 Radiologic: 26/ 39 vs 22/45	n.s. changes be- tween groups	<b>AE:</b> 20/45 vs 18/ 39 <b>SAE:</b> 9/45 vs 4/ 39 <b>Withdrawal:</b> 1/ 39 vs 9/45
Mañosa 2013	Metronidazole (15 to 20 mg/kg/ d)	Placebo	n/a	Clinical: not reported at 3 months Severe en- doscopic ( $i \ge 3$ ) : not reported at 3 months	n/a	<b>AE:</b> 7/25 vs 12/ 25 <b>SAE:</b> 1/25 vs 4/ 25 <b>Withdrawal:</b> 4/ 25 vs 1/25
Marteau 2006	<i>Lactobacillus johnsonii</i> LA1 (2 packs/d)	Placebo	n/a	<b>Clinical:</b> 9/48 vs 6/50 <b>Endoscopic:</b> 26/ 48 vs 33/50	n/a	<b>AE:</b> 9/48 vs 6/50 <b>Withdrawal:</b> 0
McLeod 1995	Mesalazine (3 g/d)	Placebo	n/a	Symp- tomatic relapse: 35/88 vs 44/81 Endoscopic and radiologic rate: significantly de- creased in Group 1	n/a	<b>AE:</b> 7/88 vs 10/ 81 <b>SAE:</b> 1/88 vs 0/ 81
Mowat 2016	Mercaptopurine (1 mg/kg/d)	Placebo	n/a	<b>Clinical:</b> 66/128 vs 70/112 <b>Endoscopic:</b> 90/ 128 vs 83/112	n.s. differences	<b>SAE:</b> 3/128 vs 2/ 112 <b>Withdawal:</b> 39/ 128 vs 41/112
Prantera 2002	LGG probiotic (2.46 g/d)	Placebo	n/a	Clinical: 8/23 vs 5/22 Endoscopic: 17/ 23 vs 11/22	n/a	<b>AE:</b> 2/23 vs 6/22 <b>Withdrawal:</b> 0

Regueiro 2009	Infliximab	Placebo	n/a	Clinical: 1/11 vs 5/11 Endoscopic: 1/ 11 vs 11/13	n/a	<b>AE:</b> 8/11 vs 9/11 <b>Withdrawal:</b> 2/ 11 vs 1/11
Regueiro 2016	Infliximab (5 mg/kg)	Placebo	n/a	Endo- scopic by ileo- colonoscopy: 90/147 vs 130/ 150 Endoscopic by endoscopic score only: 67/ 147 vs 101/150	n/a	<b>AE:</b> 19/147 vs 54/150 <b>With- drawal:</b> 19/147 vs 54/150
Reinisch 2010	Azathioprine (2.0 to 2.5 mg/ kg/d) + placebo mesalazine	Mesalazine (4 g/d) + placebo azathio- prine	n/a	Not included	Mean IBDQ change P = n.s.	<b>AE:</b> 34/37 vs 32/ 41 <b>SAE:</b> 0/37 vs 10/ 41 <b>Withdrawal:</b> 1/ 37 vs 10/41
Rutgeerts 2005	Ornidazole (1000 mg/d)	Placebo	n/a	Clinical: 17/40 vs 20/40 Endoscopic: 27/ 40 vs 33/40 Radiologic: 24/ 40 vs 33/40	n/a	Not reported
Savarino 2013	Adalimumab (160 to 80 mg 0 to 2 weeks and 40 mg there- after)	Azathioprine (2 mg/kg/d)	Mesalazine (3g/ d)	Clinical by Hanauer score: 2/16 vs 12/17 vs 9/18 Clini- cal by CDAI: 1/ 16 vs 12/17 vs 9/ 18 Endoscopic: 1/ 16 vs 11/17 vs 15/18 Radiologic: 1/16 vs 13/17 vs 15/18	HRQOL (IBDQ > 170): 14/16 vs 2/17 vs 3/18	<b>AE:</b> 11/16 vs 14/ 17 vs 14/18 <b>Withdrawal:</b> 0/ 16 vs 1/17 vs 1/ 18
Scapa 2015	6- mercaptopurine (1.5 mg/kg/d)	Adalimumab (160-80-40 mg/ 2-week intervals)	n/a	Endoscopic: 4/8 vs 1/11	n/a	n/a

Sutherland 1997	Mesalazine (3 g/d)	Placebo	n/a	<b>Clinical:</b> 3/31 vs 8/35	<b>IBDQ</b> <b>score:</b> significant decline in both groups	n/a
Tursi 2014	Infliximab (5 mg/kg) at 0, 2, and thereafter 8- week intervals	Adalimumab (160-80-40 mg/ 2-week intervals)	n/a	<b>Clinical:</b> 1/10 vs 1/10 <b>Endoscopic:</b> 2/ 10 vs 1/10 <b>Histologic:</b> 3/10 vs 2/10	n/a	<b>AE:</b> 0/10 vs 0/10
Wenckert 1978	Sulfasalazine (3 g/d)	Placebo	n/a	<b>Clinical:</b> 6/32 vs 11/34	n/a	<b>AE:</b> 0/32 vs 1/34 (withdrawn)
Yoshida 2012	Infliximab (5 mg/kg at 8- week intervals)	Participant's conventional medication started longer than 8 weeks prior to surgery	n/a	Clinical (CDAI): 3/15 vs 4/16 Clinical (IOIBD score): 1/15 vs 7/16 Endoscopic: 4/ 15 vs 13/16 Serologic: 2/15 vs 10/16	n/a	<b>Withdrawal:</b> 1/ 15 vs 0/16

5-ASA: 5-aminosalicylic acid; AE: adverse events; CDAI: Crohn's disease activity index; HRQOL: health-related quality of life; IBDQ: inflammatory bowel disease questionnaire; IOIBD: International Organization for the Study of Inflammatory Bowel Diseases; n/a: not applicable; n.s.:not significant; QOL: quality of life; SAE: serious adverse events

#### Table 2. Summary of key study characteristics and outcome definition

Comparison	Study	Time from surgery until recruitment	Site of surgery % / *exclusions	Clinical relapse definition	Endoscopic/ histological relapse definition/other		
Sulfasalazine vs placebo							
SFZ 3 g/d vs placebo	Ewe 1989	Immediately after surgery	Ileocolon 92; Ileum 2; colon 6 *Non-standard pol- icy resection (radical or non-radical)	Proven by radiology, endoscopy, or oper- ation	n/a		
SFZ 3 g/d vs placebo	Wenckert 1978	2 to 4 weeks	n/a	Special control charts	n/a		

5-ASA vs no treatment/placebo							
MEZ 2.4 g/d (24 months) vs no treat- ment	Caprilli 1994	2 weeks	Not reported *Disease localisa- tion to the jejunum, proximal ileum, left colon, or ano-rec- tum	CDAI > 150	n/a		
MEZ 3 g/ d vs placebo 3 g (12 months)	Brignola 1995	$\leq 1$ months	Ileum 56, ileocaecal 46 *Surgery other than in ileal or ileocaecal region	CDAI > 150	Standardised form for description of endoscopic lesions by type and charac- teristics		
MEZ 1.5 g/d vs placebo (12 weeks)	Florent 1996	2 weeks	Ileal 44; colonic 6; ileo- colonic 48; anoper- ineal lesion 12 *Permanent stoma, small intestinal re- section of more than 100 cm prior to the pretrial operation	n/a	Rutgeerts i ≥ 1		
MEZ 3 g/d vs placebo (24 months)	Hanauer 2004	Before postoperative hospi- tal discharge	Not reported *Active perianal dis- ease or any active disease in other seg- ments of the intes- tine	Clinical recurrence grading > 2	Rutgeerts $i \ge 2$ <b>Radiographic re-</b> <b>lapse:</b> radiographic recurrence grading > 2		
MEZ 4 g/d vs placebo (18 months)	Lochs 2000	< 10 days	IIeal 49; ileocolonic 56; colonic 5 *Short bowel syn- drome, presence of an ileo- colonic stoma, more than 3 surgeries	CDAI > 250 and CDAI > 200 but minimum 60 points increase for 2 weeks	Rutgeerts i ≥ 2		
Ileum 50, MEZ 3 g/ d vs placebo	McLeod 1995	≤ 8 weeks	IIeal 21; ileocolonic 46; colonic 33	Severe symptoms to warrant treat- ment and radiolog- ical or endoscopic evidence of disease	Presence of endoscopic or ra- diological evidence of disease and in- cluded both asymp- tomatic and symp- tomatic patients		

MEZ 3 g/d vs placebo	Sutherland 1997	2 to 4 weeks	Ileal 49, ileocolonic 50, unknown 1	CDAI > 150 as well as the absolute value of at least 60 points higher than baseline	n/a
5-ASA vs purine and	alogues				
MEZ 3 mg/kg vs AZA 2 mg/kg	Ardizzone 2004	Max 2 weeks	Small bowel only 25. 3; colon 5.6; small bowel and colon 9. 8; upper gastroin- testinal tract 16.2 *Surgical pro- cedures other than conservative surgery or for perianal dis- ease only	CDAI > 200	n/a Surgical relapse: need for an- other surgical proce- dure
MEZ 3 g/d vs 6-MP 50 mg/d	Hanauer 2004	Before postoperative hospi- tal discharge	Not reported *Active perianal dis- ease or any active disease in other seg- ments of the intes- tine	Clinical recurrence grading > 2 (Hanauer and col- leagues)	Rutgeerts $i \ge 2$ Radiographic re- lapse: radiographic recurrence grading > 2
AZA 2.0 to 2.5 mg/ kg body weight/day vs 5-ASA 4 g/day	Herfarth 2006	2 weeks	Not reported	Described as treat- ment failure due to adverse events, seri- ous endoscopic re- lapse, and lack of ef- ficacy	
MEZ 4 g/d vs AZA 2 mg/ kg/d (52 weeks)	Reinisch 2010	6 to 24 months	Not reported *Short bowel syndrome, an ileocolonic stoma	CDAI > 200	Rutgeerts i ≥ 2 HRQOL: IBDQ
MEZ 3 g/d vs AZA 2 mg/kg/d	Savarino 2013	2 to 4 weeks	Ileum 49, Ileocolonic 51 *Fibrostenotic stric- ture, macroscop- ically active disease not resected at the time of surgery, and presence of a stoma	<ol> <li>2 clinical recurrence grading scale (Hanauer and colleagues)</li> <li>CDAI &gt; 200</li> </ol>	Rutgeerts $i \ge 2$ Radiologic relapse: $\ge 2$ radiographic recurrence grading scale HRQOL: IBDQ > 170

### 5-ASA vs adalimumab

MEZ 3 g/d vs adali- mumab	Savarino 2013	2 to 4 weeks	Ileum 49, Ileocolonic 51 *Fibrostenotic stric- ture, macroscop- ically active disease not resected at the time of surgery, and presence of a stoma	<ol> <li>2 on the clinical recurrence grading scale by Hanauer</li> <li>CDAI &gt; 200</li> </ol>	Rutgeerts $i \ge 2$ <b>Radiologic relapse:</b> $\ge 2$ radiographic recurrence grading scale <b>HRQOL:</b> IBDQ > 170			
5-ASA vs 5-ASA								
4.0 g/d MEZ vs 2.4 g/d MEZ (12 months)	Caprilli 2003	2 weeks	Ileum 64; Ileum/caecum/ ascending colon 36 *Disease local- isation to jejunum, proximal ileum, transverse colon, left colon or anorectum	CDAI > 150 points or an increase in CDAI score of + 100 points from baseline	Rutgeerts $i \ge 1$			
Purine analogues vs	Purine analogues vs placebo							
AZA 100 to 150 mg/d + metronida- zole 750 mg/d vs placebo + metron- idazole 750 mg/d (12 months)	D'Haens 2008	2 weeks	Perforating disease 48 *Macroscopic evi- dence for CD prox- imally or distally to the site of resection or the presence of frank pancolitis or an ileorectal anasto- mosis, participants with a stoma; oper- ation for fibrosteno- sis only	CDAI > 250	Rutgeerts i ≥ 2			
6-MP 50 mg/d vs placebo	Hanauer 2004	Before postoperative hospi- tal discharge	Not reported *Active perianal dis- ease or any active disease in other seg- ments of the intes- tine	Clinical re- currence grading > 2 (Hanauer)	Rutgeerts $i \ge 2$ Radiographic re- lapse: radiographic recurrence grading > 2			
6-MP 1 mg/kg/d vs placebo	Mowat 2016	$\leq$ 3 months	Ileal 39; colonic 2; ileocolonic 59 *Need for further surgery, stricture- plasty alone, forma- tion of a stoma	CDAI > 150 and a 100-point increase from baseline	Rutgeerts $i \ge 2$ <b>HRQOL:</b> IBDQ scores			

Table 2.	Summar	y of ke	y study	characteristics and	l outcome definition	(Continued)
						· · · · · · · · · · · · · · · · · · ·

Purine analogues vs 5-ASA							
AZA 2 mg/kg vs MEZ 3 mg/kg	Ardizzone 2004	Max 2 weeks	Small bowel only 25. 3; colon 5.6; small bowel and colon 9. 8; upper gastroin- testinal tract 16.2 *Surgical pro- cedures other than conservative surgery or for perianal dis- ease only	CDAI > 200	n/a Surgical relapse: need for an- other surgical proce- dure		
6-MP 50 mg/d vs MEZ 3 g/d	Hanauer 2004	Before postoperative hospi- tal discharge	Not reported *Active perianal dis- ease or any active disease in other seg- ments of the intes- tine	Clinical recurrence grading > 2	Rutgeerts $i \ge 2$ Radiographic re- lapse: radiographic recurrence grading > 2		
AZA 2 mg/kg/d vs MEZ 4 g/d (52 weeks)	Reinisch 2010	6 to 24 months	Not reported *Short bowel syndrome and ileo- colonic stoma	CDAI > 200	Rutgeerts i ≥ 2 HRQOL: IBDQ		
AZA 2 mg/kg/d vs MEZ 3 g/d	Savarino 2013	2 to 4 weeks	Ileum 49, ileocolonic 51 *Fibrostenotic stric- ture, macroscop- ically active disease not resected at the time of surgery, and presence of a stoma	1. ≥ 2 on the clinical recurrence grading scale by Hanauer 2. CDAI > 200	Rutgeerts $i \ge 2$ Radiologic relapse: $\ge 2$ radiographic recurrence grading scale HRQOL: IBDQ > 170		
Purine analogues vs	adalimumab						
AZA 2.5 mg vs INF 5 mg/kg	Armuzzi 2013	2 to 4 weeks	Not reported *Active perianal dis- ease, presence of stoma	HBI ≥ 8	Rutgeerts' score ≥ i2		
AZA 2 mg/kg/d vs adalimumab	Savarino 2013	2 to 4 weeks	Ileum 49, ileocolonic 51 *Fibrostenotic stric- ture, macroscop- ically active disease not resected at the time of surgery, and	1. ≥ 2 on the clinical recurrence grading scale by Hanauer 2. CDAI > 200	Rutgeerts $i \ge 2$ Radiologic relapse: $\ge 2$ radiographic recurrence grading scale HRQOL: IBDQ >		

			presence of a stoma		170
AZA 2.5 mg/kg/d vs adalimumab (12 months)	Lopez Sanroman 2017	2 weeks	Ileal 58, ileocolonic 41 *Postsurgical stoma, resec- tion for short indo- lent stenosis, inac- cessible anastomosis to endoscopy	CDAI > 200	Rutgeerts i ≥ 2
6-MP 1.5 mg/kg/d vs adalimumab (12 months)	Scapa 2015	< 45 days	Not reported *Not reported	n/a	Rutgeerts $i \ge 2$
Functional foods vs	placebo				
Synbiotic 2000 vs placebo (24 months)	Chermesh 2007	As soon as partic- ipants resume oral intake after surgery	Not reported *Not reported	CDAI, definition not stated (presented as mean change)	Rutgeerts score, def- inition not stated (presented as mean change)
VSL#3, 2 sachets/d vs placebo 3 g/d	Fedorak 2015	< 30 days	Not reported *Residual luminal disease; participants receiving anti-TNF	Not reported	Rutgeerts score ≥ 1 HRQOL: IBDQ
Probiotic LA1, 2 g/d vs placebo (3 months)	Gossum 2007	< 7 days	Ileum only 9; colon only 4; ileo-colonic 87 *Active perianal dis- ease or any active disease in other seg- ments of the intes- tine; bowel surgery performed less than 3 months previously; history of colostomy or ileostomy	CDAI > 150, and increase of minimum 70 points from baseline	Rutgeerts score ≥ 1
Probiotic LA1, 2 sa- chets/d vs placebo (6 months)	Marteau 2006	< 21 days	Ileum 55; ileocolon 41; colon 4 *Total or subtotal colectomy, intesti- nal bypass or stric- turoplasty, stomy, carcinoma resection, or abscess	CDAI ≥ 200	Rutgeerts i ≥ 2

			drainage		
Probiotic LGG, 5 g/d vs placebo (12 months)	Prantera 2002	< 10 days	Ileum 78; ileocolon 13; colon 9 *Active perianal dis- ease; presence of CD in other intesti- nal tracts; postoper- ative septic compli- cations	CDAI > 150	Rutgeerts i $\ge 2$
Budesonide vs place	bo				
Budesonide 3 mg/ d vs placebo (12 months)	Ewe 1999	< 2 weeks	Ileum 25, colon 15, ileocolon 60 *Not reported	CDAI > 200, rise for 60 points	Rutgeerts $i \ge 2$
Budesonide 6 mg/ d vs placebo (12 months)	Hellers 1999	< 2 weeks	Not reported *Sep- tic complications, > 100 cm of terminal ileum resected	CDAI score presented is mean change.	Rutgeerts $i \ge 2$
Antibiotics vs placel	00				
Ciprofloxacin 1 g/ d vs placebo (6 months)	Herfarth 2013	< 2 weeks	Non-stricturing, non-penetrating 18; stricturing 55; pen- etrating 27 *Gross evidence of CD at the operative margins or in the proximal or distal segments of the in- testine, presence of a stoma	HBI ≥ 5	Rutgeerts score ≥ i2 or Marteau score ≥ c2
Ornidazole 1 g/d vs placebo (12 months)	Rutgeerts 2005	0 to 1 week	Not reported *Pure fibrostenotic disease without bio- logic inflammation, stricture- plasties, 2-step re- sections with tem- porary ileostoma	CDAI > 250	Rutgeerts score ≥ i2
Metronidazole 20 mg/kg/d + AZA 2 to 2.5 mg/kg/d	Mañosa 2013	As soon as partic- ipants resume oral intake after surgery	IIeal 64, colonic 2, ileocolonic 34	HBI > 7	Rutgeerts score $\geq$ i2

vs placebo + AZA 2 to 2.5 mg/kg/d

#### Infliximab vs inactive treatment IFX 5 mg/kg vs Fukushima 2018 0 to 4 weeks Ileum 26; colon 10; CDAI > 150 Rutgeerts score $\geq$ i3 no treatment (24 ileocolon 54 months) \*More than 3 intestinal resections, presence of a stoma 0 to 4 weeks 21; CDAI > 200 IFX vs placebo (12 Regueiro 2009 Ileum only Rutgeerts score $\geq$ i2 months) ileum and colon 79 \*Not reported Ileum 98; colon 55. CDAI > 200 IFX 5 mg/kg vs Regueiro 2016 $\leq$ 45 days Rutgeerts score $\geq$ i2 placebo (104 weeks) 7; proximal small intestine, stomach, and/ or oesophagus 4.1; perianal 10.1; extraintestinal manifestations 12.2 \*Surgery more than 10 years after CD diagnosis, stricturing disease involving < 10 cm of bowel Infliximab + 5-ASA vs 5-ASA IFX 5 mg/kg + Yoshida 2012 0 to 4 weeks Ileum 26, ileocolon 1. CDAI >150 Rutgeerts score $\geq$ i2 MEZ (36 months) 74 2. IOIBD $\geq 2$ Serologic relapse: vs MEZ (if any) \*Macro-CRP level > 0.3 mg/ started > 8 weeks scopically active disdL prior to surgery ease missed during surgery or the presence of abscess Infliximab vs adalimumab IFX 5 mg/kg vs adal- Tursi 2014 4 to 6 weeks Not reported HBI > 8Rutgeerts score $\geq$ i2 imumab 160 mg \*Active perianal dis-(12 months) ease, the presence of stoma

Prednisolone + sulfasalazine vs no treatment

Sulfasalazine (Sala-	Bergman 1976	Not reported	Not reported	X-ray	n/a
zopyrin) +			*Not reported	Typical roentgeno-	
prednisolone				logical findings for	
vs no treatment (36				CD	
months)					

5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; AZA: azathioprine; CD: Crohn's disease; CDAI: Crohn's disease activity index; CRP: C-reactive protein; HBI: Harvey-Bradshaw Index; HRQOL: health-related quality of life; IBDQ: inflammatory bowel disease questionnaire; IFX: infliximab; IOIBD: International Organization for the Study of Inflammatory Bowel Diseases; MEZ: mesalazine; n/a: not applicable; SFZ: sulfasalazine; TNF: tumour necrosis factor

#### Table 3. Studies included in the network meta-analysis

Included studies	Considered for inclu- sion in network	Studies in network with clini- cal relapse data	Studies in network with endo- scopic relapse data	Studies in network with safety data
Ardizzone 2004	Ardizzone 2004	Ardizzone 2004	Armuzzi 2013	Ardizzone 2004
Armuzzi 2013	Armuzzi 2013	Armuzzi 2013	Florent 1996	Armuzzi 2013
Bergman 1976	Bergman 1976	Bergman 1976	Gossum 2007	Brignola 1995
Brignola 1995	Brignola 1995	Brignola 1995	Hanauer 2004	Caprilli 1994
Caprilli 1994	Caprilli 1994	Caprilli 1994	Hellers 1999	Ewe 1999
Caprilli 2003 <sup>a</sup>	Ewe 1989	Ewe 1989	Herfarth 2013	Fedorak 2015
Chermesh 2007 <sup>b</sup>	Ewe 1999	Ewe 1999	Marteau 2006	Florent 1996
D'Haens 2008 <sup>b</sup>	Fedorak 2015	Gossum 2007	Mowat 2016	Hanauer 2004
Ewe 1989	Florent 1996	Hanauer 2004	Rutgeerts 2005	Hellers 1999
Ewe 1999	Gossum 2007	Herfarth 2006	Savarino 2013	Herfarth 2006
Fedorak 2015	Hanauer 2004	Herfarth 2013	Scapa 2015	Herfarth 2013
Florent 1996	Hellers 1999	Lochs 2000	Tursi 2014	Mowat 2016
Fukushima 2018 <sup>b</sup>	Herfarth 2006	Marteau 2006	Wenckert 1978	Reinisch 2010
Gossum 2007	Herfarth 2013	McLeod 1995		Savarino 2013
Hanauer 2004	Lochs 2000	Mowat 2016		Sutherland 1997

Table 3.	Studies	included	in the	network meta	a-analysis	(Continued)
----------	---------	----------	--------	--------------	------------	-------------

Hellers 1999	Marteau 2006	Prantera 2002	Wenckert 1978
Herfarth 2006	McLeod 1995	Rutgeerts 2005	
Herfarth 2013	Mowat 2016	Savarino 2013	
Lochs 2000	Prantera 2002	Sutherland 1997	
Lopez-Sanroman 2017 <sup>b</sup>	Reinisch 2010 <sup>c</sup>	Tursi 2014	
Marteau 2006	Rutgeerts 2005	Wenckert 1978	
Mañosa 2013 <sup>b</sup>	Savarino 2013		
McLeod 1995	Scapa 2015		
Mowat 2016	Sutherland 1997		
Prantera 2002	Tursi 2014		
Regueiro 2009 <sup>b</sup>	Wenckert 1978		
Regueiro 2016 <sup>b</sup>			
Reinisch 2010			
Rutgeerts 2005			
Savarino 2013			
Scapa 2015			
Sutherland 1997			
Tursi 2014			
Wenckert 1978			
Yoshida 2012 <sup>b</sup>			

<sup>*a*</sup>Randomised participants to receive active treatments that they were receiving prior to randomisation.

<sup>b</sup>Compared two different doses of mesalazine.

<sup>c</sup>Potentially includes people who were not in clinical relapse, therefore only data for withdrawal due to adverse events included, whilst relapse data ignored.

	Study ID	Treat- ment 1	Events	N	Treatment 2	Events	N	Treatment 3	Events	Ν
1	Ardizzone 2004	5-ASA	32	71	Purine ana- logues	35	71	NA	NA	NA
2	Armuzzi 2013	Infliximab	1	11	Purine ana- logues	2	11	NA	NA	NA
3	Bergman 1976	Placebo	9	40	Sul- fasalazine + pred- nisolone	15	57	NA	NA	NA
4	Brignola 1995	Placebo	14	43	5-ASA	13	44	NA	NA	NA
5	Caprilli 1994	Placebo	28	55	5-ASA	20	55	NA	NA	NA
6	Ewe 1989	Placebo	99	121	Sul- fasalazine	89	111	NA	NA	NA
7	Ewe 1999	Placebo	19	40	Budesonide	14	43	NA	NA	NA
8	Gossum 2017	Placebo	17	36	Probiotics	11	34	NA	NA	NA
9	Hanauer 2004	Placebo	35	40	5-ASA	33	44	Purine analogues	32	47
10	Herfarth 2006	5-ASA	27	37	Purine ana- logues	33	42	NA	NA	NA
11	Herfarth 2013	Placebo	8	16	Antibiotics	10	17	NA	NA	NA
12	Lochs 2000	Placebo	59	170	5-ASA	47	154	NA	NA	NA
13	Marteau 2006	Placebo	6	50	Probiotics	10	48	NA	NA	NA
14	McLeod 1995	Placebo	44	81	5-ASA	35	88	NA	NA	NA
15	Mowat 2016	Placebo	70	112	Purine ana- logues	66	128	NA	NA	NA

Table 4. Number of participants who experienced clinical relapse

16	Prantera 2002	Placebo	5	22	Probiotics	8	23	NA	NA	NA
17	Rutgeerts 2005	Placebo	20	40	Antibiotics	17	40	NA	NA	NA
18	Savarino 2013	5-ASA	9	18	Adali- mumab	2	16	Purine analogues	13	17
19	Suther- land 1997	Placebo	8	35	5-ASA	3	31	NA	NA	NA
20	Tursi 2014	Adali- mumab	1	10	Infliximab	1	10	NA	NA	NA
21	Wenckert 1978	Placebo	11	34	Sul- fasalazine	6	32	NA	NA	NA

 Table 4. Number of participants who experienced clinical relapse
 (Continued)

5-ASA: 5-aminosalicylic acid; N: total number of participants; NA: not applicable

	Study ID	Treat- ment 1	Events	N	Treatment 2	Events	Ν	Treatment 3	Events	Ν
1	Armuzzi 2013	Infliximab	1	11	Purine ana- logues	1	11	NA	NA	NA
2	Florent	Placebo	40	61	5-ASA	38	65	NA	NA	NA
3	Gossum 2007	Placebo	27	36	Probiotics	28	34	NA	NA	NA
4	Herfarth 2013	Placebo	11	16	Antibiotics	11	17	NA	NA	NA
5	Lochs	Placebo	134	170	5-ASA	133	154	NA	NA	NA
6	Marteau 2006	Placebo	33	50	Probiotics	26	48	NA	NA	NA
7	Mowat 2016	Placebo	83	112	Purine ana- logues	90	128	NA	NA	NA
8	Prantera	Placebo	11	22	Probiotics	17	23	NA	NA	NA
9	Rutgeerts 2005	Placebo	33	40	Antibiotics	27	40	NA	NA	NA

 Table 5. Number of participants who experienced endoscopic relapse

10	Savarino 2013	5-ASA	15	18	Adali- mumab	1	16	Purine analogues	11	17
11	Scapa 2015	Adali- mumab	1	11	Purine ana- logues	4	8	NA	NA	NA
12	Tursi 2014	Adali- mumab	2	10	Infliximab	1	10	NA	NA	NA

 Table 5. Number of participants who experienced endoscopic relapse
 (Continued)

5-ASA: 5-aminosalicylic acid; N: total number of participants; NA: not applicable

Table 6. Number of withdrawals due to adverse events

	Study ID	Treat- ment 1	Events	N	Treatment 2	Events	N	Treatment 3	Events	Ν
1	Ardizzone 2004	5-ASA	6	71	Purine ana- logues	15	71	NA	NA	NA
2	Armuzzi 2013	Infliximab	0	11	Purine ana- logues	1	11	NA	NA	NA
3	Brignola 1995	Placebo	3	43	5-ASA	5	44	NA	NA	NA
4	Caprilli 1994	Placebo	0	55	5-ASA	2	55	NA	NA	NA
5	Ewe 1999	Placebo	1	40	Budesonide	1	43	NA	NA	NA
6	Fedorak 2015	Placebo	5	62	Probiotics	5	58	NA	NA	NA
7	Florent 1996	Placebo	3	61	5-ASA	5	65	NA	NA	NA
8	Hanauer 2004	Placebo	4	40	5-ASA	6	44	Purine analogues	9	47
9	Heller 1999	Placebo	5	67	Budesonide	5	63	NA	NA	NA
10	Herfarth 2006	5-ASA	3	37	Azathio- prine	7	42	NA	NA	BA
11	Herfarth 2013	Placebo	1	17	Antibiotics	4	16	NA	NA	NA

12	Mowat 2016	Placebo	41	112	Purine ana- logues	39	128	NA	NA	NA
13	Reinisch 2010	5-ASA	1	37	Purine ana- logues	10	41	NA	NA	NA
14	Savarino 2013	5-ASA	0	18	Adali- mumab	1	16	Purine analogues	1	17
15	Wenckert 1978	Placebo	1	34	Sul- fasalazine	0	32	NA	NA	NA

 Table 6. Number of withdrawals due to adverse events
 (Continued)

5-ASA: 5-aminosalicylic acid; N: total number of participants; NA: not applicable

#### Table 7. Clinical relapse: model fit

Treatment	Fixed-effect mod	el		Random-effects model					
	Mean	SD	95% CrI	Mean	SD	95% CrI			
5-ASA	0.7	0.07	[0.57, 0.85]	0.69	0.09	[0.53, 0.87]			
Adalimumab	0.12	0.08	[0.02, 0.32]	0.11	0.08	[0.02, 0.33]			
Antibiotics	0.97	0.27	[0.54, 1.60]	0.98	0.31	[0.50, 1.71]			
Budesonide	0.65	0.24	[0.29, 1.22]	0.66	0.28	[0.27, 1.34]			
Infliximab	0.33	0.52	[0.02, 1.52]	0.36	0.63	[0.02, 1.74]			
Probiotic	1.09	0.30	[0.62, 1.78]	1.11	0.33	[0.62, 1.88]			
Purine analogues	0.75	0.09	[0.58, 0.94]	0.75	0.12	[0.55, 1.00]			
Sulfasalazine	0.91	0.14	[0.66, 1.22]	0.89	0.19	[0.55, 1.30]			
Sulfasalazine + prednisolone	1.35	0.64	[0.53, 2.93]	1.37	0.7	[0.50, 3.07]			
Between-study heterogeneity	-	-	-	0.13	0.11	[0.01, 0.40]			
Total residual de- viance <sup>a</sup>	42.91	7.89	[29.45, 60.17]	42.21	8.223	[27.98, 60.07]			
DIC <sup>b</sup>	242.60			244.26					

#### Table 7. Clinical relapse: model fit (Continued)

pD	29.58	31.95
----	-------	-------

Hazard ratios (mean and SD) with credible intervals (Crl); 5-ASA: 5-aminosalicylic acid; DIC: deviance information criterion; pD: number of parameters; SD: standard deviation

<sup>a</sup>Compared to 45 data points.

<sup>b</sup>Difference in DIC (1.65 points) is not significant.

#### Table 8. Endoscopic relapse: model fit

Treatment	Fixed-effect mod	el		Random-effects model				
	Mean	SD	95% CrI	Mean	SD	95% Crl		
5-ASA	1.18	0.14	[0.94, 1.48]	1.22	0.63	[0.61, 2.18]		
Adalimumab	0.10	0.06	[0.02, 0.26]	0.10	0.25	[0.01, 0.32]		
Antibiotics	0.72	0.18	[0.44, 1.13]	0.80	1.19	[0.33, 1.65]		
Infliximab	0.21	0.37	[0.01, 1.02]	0.24	1.75	[0.01, 1.20]		
Probiotic	1.09	0.20	[0.76, 1.53]	1.20	0.53	[0.62, 2.19]		
Purine analogues	0.87	0.13	[0.64, 1.16]	0.85	0.54	[0.33, 1.61]		
Between-study heterogeneity	-	-	-	0.37	0.43	[0.03, 1.58]		
Total residual de- viance <sup>a</sup>	29.39	6.12	[19.4, 43.22]	26.22	6.77	[14.62, 41.05]		
DIC	133.40			133.43				
pD	17.66			20.86				

Hazard ratios (mean and SD) with credible intervals (Crl); 5-ASA: 5-aminosalicylic acid; DIC: deviance information criterion; pD: number of parameters; SD: standard deviation

<sup>a</sup>Compared to 21 data points.

<sup>b</sup>Difference in DIC is not significant (0.03 points).

Treatment	Fixed-effect mod	el		Random-effects mo	odel		
	Mean	SD	95% Crl	Mean	SD	95% Crl	
5-ASA	0.699	0.1916	[0.40, 1.14]	1.187	1.103	[0.39, 3.14]	
Adalimumab	3.144	10.19	[0.10, 16.04]	11.74	300.8	[0.12, 55.06]	
Antibiotics	38.61	679.1	[0.78, 186.70]	53.92	1058	[0.43, 259.80]	
Budesonide	1.252	0.8457	[0.32, 3.42]	1.636	11.77	[0.17, 6.19]	
Infliximab	1.111	8.673	[3.69E-04, 6.57]	6.374	726.8	[9.14E-04, 21.74]	
Probiotics	1.337	1.029	[0.29, 3.98]	2.436	65.24	[0.13, 9.00]	
Purine analogues	1.169	0.2339	[0.78, 1.69]	2.512	4.357	[0.79, 7.35]	
Sulfasalazine	1.025	7.989	[4.18E-04, 6.052]	1.96	207.6	[3.04E-04, 8.90]	
Between-study heterogeneity <sup>a</sup>	-	-	-	0.74	0.40	[0.14, 1.70]	
Total residual de- viance <sup>b</sup>	39.95	7.192	[27.92, 55.94]	31.95	7.96	[18.28, 49.23]	
DIC <sup>c</sup>	155.346			151.73			
pD	21.733			26.115			

Table 9. Withdrawals due to adverse event: model fit

Hazard ratios (mean and SD) with credible intervals (Crl); 5-ASA: 5-aminosalicylic acid; DIC: deviance information criterion; pD: number of parameters; SD: standard deviation

<sup>a</sup>Compared to 36 data points.

<sup>b</sup>SD exceeds the 0.5 threshold.

<sup>c</sup>DIC is lower with the random-effects model by 3.6, therefore random-effects model will be reported.

#### Table 10. Clinical relapse: relative effectiveness of all pairwise comparisons

	Placebo	5-ASA	Adali- mumab	Antibi- otics	Budes- onide	Inflix- imab	Probiotics	Purine analogues	Sul- fasalazine
5-ASA	0.69 [0.53, 0.87]								
Adali- mumab	0.11 [0.02, 0.33]	0.17 [0.02, 0.47]							

Antibiotics	0.98 [0.50, 1.71]	1.44 [0.71, 2.65]	16.03 [2. 50, 63.86]						
Budes- onide	0.66 [0.27, 1.34]	0.97 [0.38, 2.04]	10.96 [1. 44, 44.37]	0.74 [0.24, 1.74]					
Infliximab	0.36 [0.02, 1.74]	0.52 [0.02, 2.50]	4.40 [0.20, 23.93]	0.40 [0.02, 2.01]	0.65 [0.02, 3.31]				
Probiotic	1.11 [0.62, 1.88]	1.64 [0.86, 2.90]	17.96 [2. 84, 72.01]	1.25 [0.51, 2.59]	2.00 [0.67, 4.84]	13.91 [0. 56, 75.55]			
Purine analogues	0.75 [0.55, 1.00]	1.09 [0.82, 1.45]	11.90 [2. 29, 45.20]	0.84 [0.40, 1.57]	1.35 [0.53, 2.90]	9.15 [0.44, 48.37]	0.73 [0.37, 1.29]		
Sul- fasalazine	0.89 [0.55, 1.30]	1.31 [0.77, 2.04]	14.48 [2. 49, 55.60]	1.00 [0.43, 1.98]	1.60 [0.58, 3.58]	11.15 [0. 48, 60.37]	0.87 [0.39, 1.61]	1.22 [0.68, 1.93]	
Sul- fasalazine + pred- nisolone	1.37 [0.50, 3.07]	2.02 [0.71, 4.63]	21.95 [2. 77, 92.35]	1.55 [0.45, 3.96]	2.46 [0.61, 6.87]	16.76 [0. 61, 91.89]	1.33 [0.40, 3.34]	1.87 [0.64, 4.36]	1.61 [0.52, 3.94]

 Table 10. Clinical relapse: relative effectiveness of all pairwise comparisons (Continued)

Hazard ratios (mean and standard deviation) with credible intervals. 5-ASA: 5-aminosalicylic acid

	Placebo	5-ASA	Adalimumab	Antibiotics	Infliximab	Probiotic
5-ASA	1.22 [0.61, 2.18]					
Adalimumab	0.10 [0.01, 0.32]	0.09 [0.01, 0.27]				
Antibiotics	0.80 [0.33, 1.65]	0.75 [0.23, 1.78]	32.71 [1.86, 64. 26]			
Infliximab	0.24 [0.01, 1.20]	0.30 [0.01, 1.04]	2.81 [0.13, 13. 41]	0.42 [0.01, 1.89]		
Probiotic	1.20 [0.62, 2.19]	1.12 [0.41, 2.46]	26.31 [3.16, 94. 44]	1.88 [0.57, 4.38]	36.15 [0.85, 176.30]	
Purine analogues	0.85 [0.33, 1.61]	0.75 [0.27, 1.47]	14.40 [2.69, 51. 40]	1.37 [0.32, 3.06]	19.64 [0.69, 102.60]	0.80 [0.23, 1.74]

Table 11. Endoscopic relapse: relative effectiveness of all pairwise comparisons

Hazard ratios (mean and standard deviation) with credible intervals. 5-ASA: 5-aminosalicylic acid

	Placebo	5-ASA	Adali- mumab	Antibiotics	Budesonide	Infliximab	Probiotics	Purine ana- logues
5-ASA	1.19 [0.39, 3.14]							
Adali- mumab	11.74 [0.12, 55.06]	8.62 [0.12, 45.32]						
Antibiotics	53.92 [0.43, 259.80]	61.39 [0.32, 283.20]	87.42 [0.04, 299.50]					
Budesonide	1.64 [0.17, 6.19]	1.92 [0.12, 7.39]	3.78 [0.01, 14.02]	1.02 [0.00, 4.16]				
Infliximab	6.37 [0.00, 21.74]	4.21 [0.00, 19.84]	12.53 [0.00, 19.28]	3.11 [0.00, 7.97]	21.68 [0.00, 31.10]			
Probiotic	2.44 [0.13, 9.00]	3.28 [0.09, 10.20]	13.83 [0.01, 16.96]	2.53 [0.00, 5.18]	6.38 [0.06, 16.67]	2997.00 [0.03, 1553. 00]		
Purine ana- logues	2.51 [0.79, 7.35]	2.27 [0.86, 5.35]	3.97 [0.05, 16.47]	1.79 [0.01, 6.71]	4.45 [0.28, 19.17]	1579.00 [0.12, 2047. 00]	8.39 [0.20, 25.04]	
Sul- fasalazine	1.96 [0.00, 8.90]	1.97 [0.00, 9.96]	15.58 [0.00, 10.09]	2.30 [0.00, 3.47]	3.57 [0.00, 13.31]	54220.00 [0.00, 607. 10]	117.10 [0. 00, 14.60]	0.94 [0.00, 5.01]

Table 12. Withdrawals due to adverse events: relative effectiveness of all pairwise comparisons

Hazard ratios (mean and standard deviation) with credible intervals. 5-ASA: 5-aminosalicylic acid

Table 13. Interventions compared to reference treatment

	Clinical relapse		Endoscopic	Endoscopic relapse			Withdrawal due to adverse events			
	Random-effects model		Random-effects model			Random-effects model				
	Mean	SD	95% Crl	Mean	SD	95% CrI	Mean	SD	95% CrI	
5-ASA	0.69	0.09	[0.53, 0. 87]	1.22	0.63	[0.61, 2.18]	1.19	1.10	[0.39, 3.14]	
Adali- mumab	0.11	0.08	[0.02, 0. 33]	0.10	0.25	[0.01, 0.32]	11.74	300.8	[0.12, 55.06]	

Antibiotics	0.98	0.31	[0.50, 1. 71]	0.80	1.19	[0.33, 1.65]	53.92	1058	[0.43, 259.80]
Budes- onide	0.66	0.28	[0.27, 1. 34]	-	-	-	1.64	11.77	[0.17, 6.19]
Infliximab	0.36	0.63	[0.02, 1. 74]	0.24	1.75	[0.01, 1.20]	6.37	726.8	[9.14E-04, 21.74]
Probiotic	1.11	0.33	[0.62, 1. 88]	1.20	0.53	[0.62, 2.19]	2.44	65.24	[0.13, 9.00]
Purine analogues	0.75	0.12	[0.55, 1. 00]	0.85	0.54	[0.33, 1.61]	2.51	4.357	[0.79, 7.35]
Sul- fasalazine	0.89	0.19	[0.55, 1. 30]	-	-	-	1.96	207.6	[3.04E-04, 8.90]
Sul- fasalazine + pred- nisolone	1.37	0.7	[0.50, 3. 07]	-	-	-	-	-	-
Between- study het- erogeneity	0.13	0.11	[0.01, 0. 40]	0.37	0.43	[0.03, 1.58]	0.74	0.40	[0.14, 1.70]
To- tal residual deviance	42.21	8.223	[27.98, 60. 07]	26.22	6.77	[14.62, 41. 05]	31.95	7.96	[18.28, 49.23]
DIC	244.26			133.43			151.73		
pD	31.95			20.86			26.115		

 Table 13. Interventions compared to reference treatment
 (Continued)

Hazard ratios (mean and SD) with credible intervals (Crl); 5-ASA: 5-aminosalicylic acid; DIC: deviance information criterion; pD: number of parameters; SD: standard deviation

Table 14. Clinical	relapse:	ranking	of treatments
--------------------	----------	---------	---------------

Treatment code	Treatment definition	Median rank	Mean rank	Range
3	Adalimumab	1	1.28	(1, 2)
6	Infliximab	2	2.50	(1, 10)
5	Budesonide	3	4.27	(2, 10)

#### Table 14. Clinical relapse: ranking of treatments (Continued)

2	5-ASA	4	4.30	(2, 7)
8	Purine analogues	5	5.06	(3, 8)
9	Sulfasalazine	6	6.51	(3, 10)
4	Antibiotics	7	6.96	(3, 10)
1	Placebo	8	7.88	(6, 10)
7	Probiotics	8	7.90	(3, 10)
10	Sulfasalazine + prednisolone	9	8.28	(3, 10)

### Table 15. Endoscopic relapse: ranking of treatments

Treatment code	Treatment definition	Median rank	Mean rank	Range
3	Adalimumab	1	1.40	(1, 2)
5	Infliximab	2	1.82	(1, 6)
4	Antibiotics	3	3.81	(2, 7)
7	Purine analogues	4	4.09	(3, 7)
1	Placebo	5	5.17	(3, 7)
6	Probiotic	6	5.76	(3, 7)
2	5-ASA	6	5.96	(3, 7)

5-aminosalicylic acid

#### Table 16. Withdrawals due to adverse events: ranking of treatments

Treatment code	Treatment definition	Median rank	Mean rank	Range
9	Sulfasalazine	2	2.61	(1, 9)
6	Infliximab	2	3.40	(1, 9)
2	5-ASA	4	4.31	(2, 7)
1	Placebo	4	4.37	(2, 7)
---	------------------	---	------	--------
5	Budesonide	4	4.67	(1, 9)
7	Probiotic	5	4.80	(1, 9)
3	Adalimumab	7	6.36	(1, 9)
8	Purine analogues	7	6.67	(4, 9)
4	Antibiotics	9	7.82	(2, 9)

 Table 16. Withdrawals due to adverse events: ranking of treatments
 (Continued)

5-aminosalicylic acid

Table 17. Overall rank of treatment and certainty of evidence

Rank	Clinical relapse	Endoscopic relapse	Withdrawal due to adverse events
1	Adalimumab	Adalimumab	Sulfasalazine
2	Infliximab	Infliximab	Infliximab
3	Budesonide	Antibiotics	5-ASA
4	5-ASA	Purine analogues	Placebo
5	Purine analogues	Placebo	Budesonide
6	Sulfasalazine	Probiotics	Probiotic
7	Antibiotics	5-ASA	Adalimumab
8	Placebo		Purine analogues
9	Probiotics		Antibiotics
10	Sulfasalazine + prednisolone		

5-aminosalicylic acid

Treatment	Network meta model)	-analysis	s (consistency	Inconsistency model		
	Mean	SD	95% Crl	Mean	SD	95% Crl
5-ASA vs PLA	0.69	0.09	[0.53, 0.87]	0.72	1.15	[0.55, 0.94]
ANT vs PLA	0.98	0.31	[0.50, 1.71]	0.94	1.35	[0.52, 1.71]
BUD vs PLA	0.66	0.28	[0.27, 1.34]	0.61	1.49	[0.28, 1.32]
INF vs PLA	0.36	0.63	[0.02, 1.74]	1.18	2.97E+43	[9.23E-86, 2.18E+85]
PLA vs PRO	1.11	0.33	[0.62, 1.88]	1.08	1.34	[0.61, 1.92]
PLA vs PUR <sup>a</sup>	0.75	0.12	[0.55, 1.00]	0.66	1.21	[0.45, 0.96]
PLA vs SUL	0.89	0.19	[0.55, 1.30]	0.87	1.24	[0.55, 1.30]
PLA vs S+P	1.37	0.70	[0.50, 3.07]	1.22	1.58	[0.50, 3.07]
5-ASA vs ADA	0.17	0.12	[0.02, 0.47]	0.12	2.35	[0.02, 0.51]
5-ASA vs PUR	1.09	0.16	[0.82, 1.45]	1.28	1.23	[0.86, 1.93]
ADA vs INF	4.40	9.20	[0.20, 23.93]	1.13	6.35	[0.03, 56.77]
ADA vs PUR <sup>a</sup>	11.90	19.08	[2.29, 45.20]	1.39	2.27E+43	[1.68E-85, 2.67E+85]
INF vs PUR	9.15	22.87	[0.44, 48.37]	2.80	4.58	[0.18, 88.15]
Between-study heterogeneity	0.13	0.11	[0.01, 0.40]	0.13	0.11	[3.67E+3, 0.42]
Total residual de- viance <sup>b</sup>	42.21	8.223	[27.98, 60.07]	42.61	8.52	[27.83, 61.09]
DIC	244.26			246.27		
pD	31.95			33.55		

Hazard ratios (mean and SD) with credible intervals (Crl); DIC: deviance information criterion; pD: number of parameters; SD: standard deviation; 5-ASA: 5-aminosalicylic acid; PLA: placebo; ANT: antibiotics; BUD: budesonide; INF: infliximab; PRO: probiotics; PUR: purine analogues; SUL: sulfasalzine; S+P: sulfasalzine+prednisolone; ADA: adalimumab

<sup>a</sup>Difference between consistency and inconsistency model.

<sup>b</sup>Compared to 45 data points.

Treatment	Network meta model)	-analysis	s (consistency	Inconsistency model					
	Mean	SD	95% Crl	Mean	SD	95% Crl			
5-ASA:PLA	1.22	0.63	[0.61, 2.18]	1.29	20.38	[0.42, 2.56]			
ANT:PLA	0.80	1.19	[0.33, 1.65]	0.91	8.22	[0.27, 1.99]			
PLA:PRO	1.20	0.53	[0.62, 2.19]	1.27	1.60	[0.54, 2.61]			
PLA:PUR	0.85	0.54	[0.33, 1.61]	1.88	130.90	[0.25, 3.23]			
5-ASA:ADA <sup>a</sup>	0.09	1.86	[0.01, 0.27]	0.30	94.01	[7.54E-04, 0.22]			
5-ASA:PUR	0.75	0.78	[0.27, 1.47]	1.32	100.20	[0.13, 2.48]			
ADA:INF	2.81	18.95	[0.13, 13.41]	2.42	209.90	[0.01, 7.09]			
ADA:PUR <sup>a</sup>	14.40	19.78	[2.69, 51.40]	192.30	3.07E+04	[0.84, 312.70]			
INF:PUR	19.64	78.72	[0.69, 102.60]	22.73	2231.00	[0.02, 51.02]			
Between-study heterogeneity	0.37	0.43	[0.03, 1.58]	0.47	0.42	[0.02, 1.55]			
Total residual de- viance <sup>b</sup>	26.22	6.77	[14.62, 41.05]	26.19	7.25	[13.89, 42.17]			
DIC	133.43			135.70					
pD	20.86			23.16					

Table 19. Endoscopic relapse: inconsistency model

Hazard ratios (mean and SD) with credible intervals (Crl); DIC: deviance information criterion; pD: number of parameters; SD: standard deviation; 5-ASA: 5-aminosalicylic acid; PLA: placebo; ANT: antibiotics; INF: infliximab; PRO: probiotics; PUR: purine analogues; ADA: adalimumab

<sup>a</sup>Difference between consistency and inconsistency model.

<sup>b</sup>Compared to 21 data points.

#### Table 20. Withdrawal due to adverse events: inconsistency model

	Network meta-ar	nalysis (cons	istency model)	Inconsistency model						
	Mean	SD	95% Crl	Mean	SD	95% Crl				
5-ASA:PLA	1.19	1.10	[0.39, 3.14]	1.55	1.65 [0.63, 4.51]					

ANT:PLA	53.92	1058	[0.43, 259.8]	7.73	4.68	[0.58, 264.54]
BUD:PLA	1.64	11.77	[0.17, 6.19]	1.03	2.16	[0.22, 4.85]
PLA:PRO	2.44	65.24	[0.13, 9.00]	1.07	2.43	[0.18, 6.27]
PLA:PUR	2.51	4.36	[0.79, 7.35]	1.10	1.65	[0.44, 3.30]
PLA:SUL	1.96	207.6	[3.04E-04, 8.90]	0.13	12.60	[0.00, 7.74]
5-ASA:ADA	8.62	95.82	[0.12, 45.32]	3.55	4.41	[0.18, 67.29]
5-ASA:PUR <sup>a</sup>	2.27	1.58	[0.86, 5.35]	3.58	1.64	[1.43, 10.17]
ADA:PUR	3.97	112.5	[0.05, 16.47]	1.23	2.97E+43	[9.23E-86, 2.95E+85]
INF:PUR	1579	5.58E+04	[0.12, 2047]	7.50	12.35	[0.13, 3010.92]
Between-study heterogeneity	0.74	0.40	[0.14, 1.70]	0.47	0.36	[0.02, 1.34]
Total residual de- viance <sup>b</sup>	31.95	7.96	[18.28, 49.23]	30.64	7.65	[17.55, 47.43]
DIC <sup>c</sup>	151.73			149.36		
pD	26.12			26.06		

Table 20. Withdrawal due to adverse events: inconsistency model (Continued)

Hazard ratios (mean and SD) with credible intervals (Crl); DIC: deviance information criterion; pD: number of parameters; SD: standard deviation; 5-ASA: 5-aminosalicylic acid; PLA: placebo; ANT: antibiotics; INF: infliximab; PRO: probiotics; PUR: purine analogues; SUL: sulfasalzine; ADA: adalimumab

<sup>a</sup>Difference between consistency and inconsistency model.

<sup>b</sup>Compared to 36 data points.

<sup>c</sup>DIC inconsistency < DIC consistency indicates some level of inconsistency.

Table 21	Sensitivity	analysis	for clinical	relance
1abic 21.	Sensitivity	anary 515	ior cinnea	relapse

Net- work meta- analysis*	Main analy- sis	Fixed-effect	Allo- cation con- cealment	Blinding	Attrition	Low dose of 5-ASA	Definition of outcome	Effect size	
5-ASA	0.69 [0.53, 0.87]	0.7 [0.57, 0. 85]	0.64 [0.43, 0.90]	0.73 [0.54, 0.95]	0.71 [0.53, 0.92]	0.70 [0.51, 0.92]	0.69 [0.53, 0.88]	0.69 [0.53, 0.87]	
Adali- mumab	0.11 [0.02, 0.33]	0.12 [0.02, 0.32]	-	-	0.12 [0.02, 0.36]	0.12 [0.01, 0.34]	0.12 [0.02, 0.35]	0.12 [0.01, 0.34]	

Antibiotics	0.98 [0.50, 1.71]	0.97 [0.54, 1.60]	1.54 [0.43, 4.02]	0.86 [0.36, 1.72]	0.87 [0.36, 1.74]	0.98 [0.50, 1.76]	0.99 [0.51, 1.73]	0.86 [0.37, 1.70]
Budesonide	0.66 [0.27, 1.34]	0.65 [0.29, 1.22]	-	-	-	0.66 [0.27, 1.35]	0.65 [0.27, 1.32]	0.65 [0.27, 1.35]
Infliximab	0.36 [0.02, 1.74]	0.33 [0.02, 1.52]	-	-	0.34 [0.01, 1.70]	0.37 [0.01, 1.74]	0.33 [0.02, 1.59]	0.35 [0.02, 1.74]
Probiotics	1.11 [0.62, 1.88]	1.09 [0.62, 1.78]	1.02 [0.47, 1.94]	0.99 [0.47, 1.83]	1.12 [0.60, 1.95]	1.12 [0.60, 1.93]	1.13 [0.62, 1.91]	1.00 [0.48, 1.80]
Purine ana- logues	0.75 [0.55, 1.00]	0.75 [0.58, 0.94]	0.68 [0.43, 0.98]	0.71 [0.49, 1.00]	0.75 [0.53, 1.06]	0.76 [0.54, 1.04]	0.75 [0.55, 1.01]	0.75 [0.55, 1.01]
Sul- fasalazine	0.89 [0.55, 1.30]	0.91 [0.66, 1.22]	-	-	0.88 [0.52, 1.33]	0.88 [0.53, 1.32]	-	0.89 [0.55, 1.31]
Sul- fasalazine + pred- nisolone	1.37 [0.50, 3.07]	1.35 [0.53, 2.93]	-	-	-	1.39 [0.49, 3.24]	-	1.39 [0.49, 3.23]

 Table 21. Sensitivity analysis for clinical relapse
 (Continued)

5-ASA: 5-aminosalicylic acid

\*Random-effects model was used for the main analysis and all sensitivity analyses except the fixed-effect model. Results represent hazard ratios with 95% credible intervals.

## APPENDICES

### Appendix I. Search strategies

Embase

- 1. random\$.mp.
- 2. factorial\$.mp.
- 3. (crossover\$ or cross over\$ or cross-over\$).mp.
- 4. placebo\$.mp.
- 5. single blind.mp.
- 6. double blind.mp.
- 7. triple blind.mp.
- 8. (singl\$ adj blind\$).mp.
- 9. (double\$ adj blind\$).mp.
- 10. (tripl\$ adj blind\$).mp.
- 11. assign\$.mp.
- 12. allocat\$.mp.
- 13. crossover procedure/

- 14. double blind procedure/
- 15. single blind procedure/
- 16. triple blind procedure/
- 17. randomized controlled trial/
- 18. or/1-17
- 19. Exp Crohn disease/
- 20. Crohn\*.mp.
- 21. IBD.mp.
- 22. Inflammatory bowel disease\*.mp.
- 23. or/ 19-22
- 24. Exp Surgery/
- 25. Surgical\*.mp.
- 26. Surgical resection.mp.
- 27. Colectomy.mp.
- 28. Resection\*.mp.
- 29. or/24-28
- 30. Exp Post Operation/
- 31. Post-operative.mp.
- 32. Post opera\*.mp.
- 33. Postopera\*.mp.
- 33. or/ 30-33
- 34. Exp Corticosteroids/
- 35. (Corticosteroid\* or Budesonide or Prednisolone or Prednisolone or Hydrocortisone or Methylprednisolone).mp.
- 36. Exp 5-ASA/
- 37. (5- aminosalicylic acid or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine).mp.
- 39. Exp Purine analogues/
- 40. Tumor necrosis factor inhibitor\*.mp.
- 41. TNF-antagonist.mp.
- 41. (Immunomodulator\* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or Natalizumab or Vedolizumab or Ustekinumab).mp.
- 42. Exp Antibiotics/
- 43. (Antibiotic\* or Ciprofloxacin or Metronidazole).mp.
- 44. (Probiotic\* or Prebiotic\* or Supplement\* or Calcium or Acetaminophen or Ibuprofen or Fiber\*).mp.
- 45. or/34-44
- 46. 18 and 23 and 29 and 33 and 45

#### MEDLINE

- 1. random\$.tw.
- 2. factorial\$.tw.
- 3. (crossover\$ or cross over\$ or cross-over\$).tw.
- 4. placebo\$.tw.
- 5. single blind.mp.
- 6. double blind.mp.
- 7. triple blind.mp.
- 8. (singl\$ adj blind\$).tw.
- 9. (double\$ adj blind\$).tw.
- 10. (tripl\$ adj blind\$).tw.
- 11. assign\$.tw.
- 12. allocat\$.tw.
- 13. randomized controlled trial/
- 14. or/1-13
- 15. Exp Crohn disease/
- 16. Crohn\*.mp.
- 17. IBD.mp.

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18. Inflammatory bowel disease\*.mp.

- 19. or/ 15-18
- 20. Exp Surgery/
- 21. Surgical\*.mp.
- 22. Surgical resection.mp.
- 23. Colectomy.mp.
- 24. Resection\*.mp.
- 25. or/20-24
- 26. Post operation.mp.
- 27. Post-operative.mp.
- 28. Post opera\*.mp.
- 29. Postopera\*.mp.
- 30. or/26-29
- 31. Exp Corticosteroids/
- 32. (Corticosteroid\* or Budesonide or Prednisolone or Prednisolone or Hydrocortisone or Methylprednisolone).mp.
- 33. Exp aminosalicylic acid/
- 34. (5- ASA or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine).mp.
- 35. Purine analogues.mp.
- 36. Tumor necrosis factor inhibitor\*.mp.
- 37. TNF-antagonist.mp.
- 38. (Immunomodulator\* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or Natalizumab or Vedolizumab or Ustekinumab).mp.
- 39. Exp Antibiotics/
- 40. (Antibiotic\* or Ciprofloxacin or Metronidazole).mp.
- 41. (Probiotic\* or Prebiotic\* or Supplement\* or Calcium or Acetaminophen or Ibuprofen or Fiber\*).mp.
- 42. or/31-41
- 43. 14 and 19 and 25 and 30 and 42

#### Cochrane CENTRAL

- #1 MeSH: [Inflammatory bowel disease] explode all trees
- #2 Crohn Disease
- #3 Crohn
- #4 IBD
- #5 #1 or #2 or #3 or #4
- #6 MeSH: [Colectomy] explode all trees
- #7 Surgery
- #8 Surgical\*
- #9 Surgical resection
- #10 Resection\*
- #11 #6 or #7 or #8 or #9 or #10
- #12 Post operation
- #13 Post-operative
- #14 Post opera\*
- #15 Postopera\*
- #16 #12 or #13 or #14 or # 15
- #17 Corticosteroid\* or Budesonide or Prednisone or Prednisolone or Hydrocortisone or Methylprednisolone
- #18 5- ASA or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine or Aminosalicylic acid
- #19 Purine Analogues
- #20 Tumor Necrosis Factor-alpha
- #21 Tumor necrosis factor inhibitor\*
- #22 Immunomodulator\* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or Natalizumab or Vedolizumab or Ustekinumab
- #23 MeSH: [Anti-Bacterial Agents] explode all trees
- #24 Antibiotic\* or Ciprofloxacin or Metronidazole

#25 MeSH: [Probiotics] explode all trees
#26 Probiotic\* or Prebiotic\*or Supplement\* or Calcium or Acetaminophen or Ibuprofen or Fiber\*
#27 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
#28 #5 and #11 and #16 and #27

ClinicalTrials.gov/WHO ICTRP

1. Inflammatory bowel disease and surgery

- 2. Crohn's disease and surgery
- 2. Cronn's disease and surgery
- 3. Inflammatory bowel disease and resection
- 4. Crohn's disease and resection

#### Appendix 2. Quality assessment of the evidence

#### GRADE assessment applied network:

Risk of bias: 33% of studies in network at moderate or high risk of bias

Indirectness: 33% of studies with PICO not directly relevant to network meta-analysis question

Imprecision: 33% of the studies in the network contribute to imprecise results in the mixed and indirect evidence (determined from Appendix 6 to Appendix 11)

Heterogeneity: based on the I<sup>2</sup> threshold of 0.5

Consistency: if deviance information criterion (DIC) in inconsistency model < DIC in consistency model

Publication bias: suspected small-study effect in majority of the evidence in the network

## CINeMA quality assessment:

\*Assessment of risk of bias, indirectness, heterogeneity, and publication bias were the same as GRADE.

Imprecision: whether confidence interval or credible interval of individual contrasts include clinically important effects in either or both directions (effect estimates less than 0.75 or greater than 1.25)

Incoherence: based on discordance in direction of effect between individual contrasts in the consistency versus inconsistency model

Ran- dom OR	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Mixe es- ti- mate																					
5- ASA: ADA	7. 29	0. 94	0. 00	1. 10	1. 57	0. 00	0. 00	0. 00	3. 96	2. 96	0. 00	4. 19	0. 00	3. 99	0. 00	3. 15	0. 00	66. 33	0. 45	4. 09	0. 00
5- ASA: PLA	5. 26	0. 09	0. 00	11. 22	15. 94	0. 00	0. 00	0. 00	7. 27	2. 14	0. 00	42. 63	0. 00	9. 26	0. 00	0. 24	0. 00	1. 27	4. 54	0. 15	0. 00

#### Appendix 3. Clinical relapse: per study contribution matrix

5- ASA: PUR	30. 38	0. 29	0. 00	2. 68	3. 80	0. 00	0. 00	0. 00	15. 80	12. 35	0. 00	10. 17	0. 00	16. 18	0. 00	0. 26	0. 00	6. 97	1. 08	0. 03	0. 00
ADA	0.	10.	0.	1.	2.	0.	0.	0.	1.	0.	0.	6.	0.	3.	0.	15.	0.	26.	0.	30.	0.
INF	42	98	00	61	28	00	00	00	26	17	00	11	00	94	00	67	00	72	65	19	00
ADA	7.	2.	0.	0.	0.	0.	0.	0.	4.	3.	0.	2.	0.	6.	0.	2.	0.	63.	0.	5.	0.
PUR	90	32	00	65	92	00	00	00	41	21	00	47	00	52	00	88	00	26	26	20	00
ANT	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	29.	0.	0.	0.	0.	0.	70.	0.	0.	0.	0.
PLA(	00	00	00	00	00	00	00	00	00	00	11	00	00	00	00	00	89	00	00	00	00
BUD	0.	0.	0.	0.	0.	0.	100.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
Pla(	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00
INF:	1.	12.	0.	0.	1.	0.	0.	0.	2.	0.	0.	3.	0.	9.	0.	58.	0.	5.	0.	4.	0.
PLA(	60	01	00	90	27	00	00	00	25	65	00	41	00	39	00	10	00	17	36	90	00
INF:	4.	26.	0.	0.	1.	0.	0.	0.	4.	1.	0.	3.	0.	16.	0.	24.	0.	7.	0.	7.	0.
PUR	70	58	00	96	36	00	00	00	47	91	00	64	00	07	00	92	00	89	39	10	00
PLA(	0.	0.	0.	0.	0.	0.	0.	43.	0.	0.	0.	0.	33.	0.	23.	0.	0.	0.	0.	0.	0.
PRO	00	00	00	00	00	00	00	03	00	00	00	00	50	00	48	00	00	00	00	00	00
PLA(	9.	0.	0.	2.	4.	0.	0.	0.	12.	4.	0.	10.	0.	50.	0.	0.	0.	2.	1.	0.	0.
PUR	93	61	00	89	11	00	00	00	04	04	00	98	00	91	00	73	00	48	17	12	00
PLA(	0.	0.	0.	0.	0.	75.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	24.
SUL	00	00	00	00	00	16	00	00	00	00	00	00	00	00	00	00	00	00	00	00	84
PLAC	0.	0.	100.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
SUL-	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00
In- di- rect es- ti- mates																					

5- ASA: ANT	3. 51	0. 07	0. 00	5. 61	7. 97	0. 00	0. 00	0. 00	4. 21	1. 43	13. 47	21. 31	0. 00	6. 18	0. 00	0. 18	32. 80	0. 89	2. 27	0. 11	0. 00
5- Asa: Bud	3. 51	0. 07	0. 00	5. 61	7. 97	0. 00	46. 27	0. 00	4. 21	1. 43	0. 00	21. 31	0. 00	6. 18	0. 00	0. 18	0. 00	0. 89	2. 27	0. 11	0. 00
5- ASA: INF	7. 58	12. 86	0. 00	4. 12	5. 86	0. 00	0. 00	0. 00	4. 57	3. 08	0. 00	15. 66	0. 00	0. 05	0. 00	28. 66	0. 00	8. 58	1. 67	7. 31	0. 00
5- ASA: PRO	3. 51	0. 07	0. 00	5. 61	7. 97	0. 00	0. 00	19. 91	4. 21	1. 43	0. 00	21. 31	15. 50	6. 18	10. 86	0. 18	0. 00	0. 89	2. 27	0. 11	0. 00
5- ASA: SUL	3. 51	0. 07	0. 00	5. 61	7. 97	34. 77	0. 00	0. 00	4. 21	1. 43	0. 00	21. 31	0. 00	6. 18	0. 00	0. 18	0. 00	0. 89	2. 27	0. 11	11. 49
5- ASA: SUL-	3. 51	0. 07	46. 27	5. 61	7. 97	0. 00	0. 00	0. 00	4. 21	1. 43	0. 00	21. 31	0. 00	6. 18	0. 00	0. 18	0. 00	0. 89	2. 27	0. 11	0. 00
ADA	0.	0.	0.	2.	3.	0.	0.	0.	2.	0.	9.	9.	0.	10.	0.	3.	23.	28.	1.	4.	0.
ANT	93	68	00	47	51	00	00	00	65	38	46	39	00	45	00	41	03	55	00	10	00
ADA	0.	0.	0.	2.	3.	0.	32.	0.	2.	0.	0.	9.	0.	10.	0.	3.	0.	28.	1.	4.	0.
Bud	93	68	00	47	51	00	49	00	65	38	00	39	00	45	00	41	00	55	00	10	00
ADA	1.	0.	0.	3.	5.	0.	0.	0.	3.	0.	0.	13.	0.	15.	0.	5.	0.	42.	1.	5.	0.
Plac	21	85	00	65	19	00	00	00	87	49	00	88	00	67	00	12	00	60	48	97	00
ADA	0.	0.	0.	2.	3.	0.	0.	13.	2.	0.	0.	9.	10.	10.	7.	3.	0.	28.	1.	4.	0.
Pro	93	68	00	47	51	00	00	98	65	38	00	39	88	45	63	41	00	55	00	10	00
ADA	0.	0.	0.	2.	3.	24.	0.	0.	2.	0.	0.	9.	0.	10.	0.	3.	0.	28.	1.	4.	8.
SUL	93	68	00	47	51	42	00	00	65	38	00	39	00	45	00	41	00	55	00	10	07
ADA	0.	0.	32.	2.	3.	0.	0.	0.	2.	0.	0.	9.	0.	10.	0.	3.	0.	28.	1.	4.	0.
SUL-	93	68	49	47	51	00	00	00	65	38	00	39	00	45	00	41	00	55	00	10	00

ANT	0.	0.	0.	0.	0.	0.	50.	0.	0.	0.	14.	0.	0.	0.	0.	0.	35.	0.	0.	0.	0.
BUD	00	00	00	00	00	00	00	00	00	00	55	00	00	00	00	00	45	00	00	00	00
ANT	1.	8.	0.	0.	0.	0.	0.	0.	1.	0.	11.	2.	0.	6.	0.	29.	29.	3.	0.	3.	0.
INF	25	12	00	69	97	00	00	00	60	51	91	60	00	26	00	05	02	97	28	77	00
ANT	0.	0.	0.	0.	0.	0.	0.	21.	0.	0.	14.	0.	16.	0.	11.	0.	35.	0.	0.	0.	0.
PRO	00	00	00	00	00	00	00	51	00	00	55	00	75	00	74	00	45	00	00	00	00
ANT	6.	0.	0.	1.	2.	0.	0.	0.	6.	2.	12.	7.	0.	25.	0.	0.	30.	1.	0.	0.	0.
PUR	62	41	00	93	74	00	00	00	88	69	47	33	00	45	00	50	38	72	78	09	00
ANT	0.	0.	0.	0.	0.	37.	0.	0.	0.	0.	14.	0.	0.	0.	0.	0.	35.	0.	0.	0.	12.
SUL	00	00	00	00	00	58	00	00	00	00	55	00	00	00	00	00	45	00	00	00	42
ANT	0.	0.	50.	0.	0.	0.	0.	0.	0.	0.	14.	0.	0.	0.	0.	0.	35.	0.	0.	0.	0.
SUL-	00	00	00	00	00	00	00	00	00	00	55	00	00	00	00	00	45	00	00	00	00
BUD	1.	8.	0.	0.	0.	0.	40.	0.	1.	0.	0.	2.	0.	6.	0.	29.	0.	3.	0.	3.	0.
INF	25	12	00	69	97	00	93	00	60	51	00	60	00	26	00	05	00	97	28	77	00
BUD	0.	0.	0.	0.	0.	0.	50.	21.	0.	0.	0.	0.	16.	0.	11.	0.	0.	0.	0.	0.	0.
PRO	00	00	00	00	00	00	00	51	00	00	00	00	75	00	74	00	00	00	00	00	00
BUD	6.	0.	0.	1.	2.	0.	42.	0.	6.	2.	0.	7.	0.	25.	0.	0.	0.	1.	0.	0.	0.
PUR	62	41	00	93	74	00	85	00	88	69	00	33	00	45	00	50	00	72	78	09	00
BUD	0.	0.	0.	0.	0.	37.	50.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	12.
SUL	00	00	00	00	00	58	00	00	00	00	00	00	00	00	00	00	00	00	00	00	42
BUD	0.	0.	50.	0.	0.	0.	50.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.
SUL-	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00	00
INF:	1.	8.	0.	0.	0.	0.	0.	17.	1.	0.	0.	2.	13.	6.	9.	29.	0.	3.	0.	3.	0.
PRO	25	12	00	69	97	00	00	61	60	51	00	60	71	26	61	05	00	97	28	77	00

INF:	1.	8.	0.	0.	0.	30.	0.	0.	1.	0.	0.	2.	0.	6.	0.	29.	0.	3.	0.	3.	10.
SUL	25	12	00	69	97	76	00	00	60	51	00	60	00	26	00	05	00	97	28	77	17
INF:	1.	8.	40.	0.	0.	0.	0.	0.	1.	0.	0.	2.	0.	6.	0.	29.	0.	3.	0.	3.	0.
SUL-	25	12	93	69	97	00	00	00	60	51	00	60	00	26	00	05	00	97	28	77	00
PRO	6.	0.	0.	1.	2.	0.	0.	18.	6.	2.	0.	7.	14.	25.	10.	0.	0.	1.	0.	0.	0.
PUR	62	41	00	93	74	00	00	44	88	69	00	33	35	45	06	50	00	72	78	09	00
PRO	0.	0.	0.	0.	0.	37.	0.	21.	0.	0.	0.	0.	16.	0.	11.	0.	0.	0.	0.	0.	12.
SUL	00	00	00	00	00	58	00	51	00	00	00	00	75	00	74	00	00	00	00	00	42
PRO	0.	0.	50.	0.	0.	0.	0.	21.	0.	0.	0.	0.	16.	0.	11.	0.	0.	0.	0.	0.	0.
SUL-	00	00	00	00	00	00	00	51	00	00	00	00	75	00	74	00	00	00	00	00	00
PUR	6.	0.	0.	1.	2.	32.	0.	0.	6.	2.	0.	7.	0.	25.	0.	0.	0.	1.	0.	0.	10.
SUL	62	41	00	93	74	21	00	00	88	69	00	33	00	45	00	50	00	72	78	09	65
PUR	6.	0.	42.	1.	2.	0.	0.	0.	6.	2.	0.	7.	0.	25.	0.	0.	0.	1.	0.	0.	0.
SUL-	62	41	85	93	74	00	00	00	88	69	00	33	00	45	00	50	00	72	78	09	00
SUL:	0	0.	50.	0.	0.	37.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	0.	12.
SUL-		00	00	00	00	58	00	00	00	00	00	00	00	00	00	00	00	00	00	00	42

## Appendix 4. Clinical relapse: per comparison contribution matrix

Ran- dom	5- ASA: ADA	5- ASA: PLAC	5- ASA: PUR	ADA: INF	ADA: PUR	ANT: PLAC	BUD: PLAC	INF: PLAC	INF: PUR	PLAC: PRO	PLAC: PUR	PLAC: SUL	PLAC: SUL+PRE
Mixed e	stimates												
5- ASA: ADA	47	7.6775	14.515	4.0875	18.105	0	0	3.15	0.9375	0	4.5275	0	0
5- ASA: PLAC	0.2708	78.14	10.485	0.15	0.1208	0	0	0.2375	0.0875	0	10. 5183	0	0

5- ASA: PUR	0.9567	18. 6383	60.51	0.0267	0.93	0	0	0.2633	0.29	0	18.375	0	0
ADA: INF	12. 0383	11. 1933	0.845	30.19	14. 6083	0	0	15. 6717	10.975	0	4.4783	0	0
ADA: PUR	20.265	4.52	15.745	5.1983	41.67	0	0	2.8833	2.315	0	7.4033	0	0
ANT: PLAC	0	0	0	0	0	100	0	0	0	0	0	0	0
BUD: PLAC	0	0	0	0	0	0	100	0	0	0	0	0	0
INF: PLAC	3.0467	6.2433	3.1967	4.8967	1.85	0	0	58.1	12. 0067	0	10.66	0	0
INF: PUR	2.6967	6.67	9.3667	7.1017	4.405	0	0	24.92	26.58	0	18.25	0	0
PLAC: PRO	0	0	0	0	0	0	0	0	0	100	0	0	0
PLAC: PUR	0.3467	20. 1217	19.775	0.1233	0.47	0	0	0.7333	0.61	0	57.82	0	0
PLAC: SUL	0	0	0	0	0	0	0	0	0	0	0	100	0
Indirect	estimates												
5- ASA: ANT	0.2055	39.07	6.99	0.1125	0.093	46. 2655	0	0.1805	0.068	0	7.015	0	0
5- Asa: Bud	0.2055	39.07	6.99	0.1125	0.093	0	46. 2655	0.1805	0.068	0	7.015	0	0
5- ASA: INF	5.02	28.715	15. 0883	7.3133	2.2933	0	0	28.655	12.855	0	0.06	0	0
5- ASA: PRO	0.2055	39.07	6.99	0.1125	0.093	0	0	0.1805	0.068	46. 2655	7.015	0	0

5- ASA: SUL	0.2055	39.07	6.99	0.1125	0.093	0	0	0.1805	0.068	0	7.015	46. 2655	0
5- ASA: SUL+PF	0.2055 R	39.07	6.99	0.1125	0.093	0	0	0.1805	0.068	0	7.015	0	46. 2655
ADA: ANT	15. 3667	17. 2112	1.8445	4.0953	13. 0292	32. 4912	0	3.4133	0.682	0	11. 8667	0	0
ADA: BUD	15. 3667	17. 2112	1.8445	4.0953	13. 0292	0	32. 4912	3.4133	0.682	0	11. 8667	0	0
ADA: PLAC	23.05	25. 4525	2.4025	5.9725	19.35	0	0	5.12	0.8525	0	17.8	0	0
ADA: PRO	15. 3667	17. 2112	1.8445	4.0953	13. 0292	0	0	3.4133	0.682	32. 4912	11. 8667	0	0
ADA: SUL	15. 3667	17. 2112	1.8445	4.0953	13. 0292	0	0	3.4133	0.682	0	11. 8667	32. 4912	0
ADA: SUL+PF	15. R 3667	17. 2112	1.8445	4.0953	13. 0292	0	0	3.4133	0.682	0	11. 8667	0	32. 4912
ANT: BUD	0	0	0	0	0	50	50	0	0	0	0	0	0
ANT: INF	2.285	4.775	2.49	3.765	1.48	40. 9317	0	29.05	8.1167	0	7.1067	0	0
ANT: PRO	0	0	0	0	0	50	0	0	0	50	0	0	0
ANT: PUR	0.26	13. 4433	13. 1833	0.0925	0.3525	42. 8525	0	0.4992	0.4067	0	28.91	0	0
ANT: SUL	0	0	0	0	0	50	0	0	0	0	0	50	0
ANT: SUL+PF	0 R	0	0	0	0	50	0	0	0	0	0	0	50
BUD: INF	2.285	4.775	2.49	3.765	1.48	0	40. 9317	29.05	8.1167	0	7.1067	0	0
BUD: PRO	0	0	0	0	0	0	50	0	0	50	0	0	0

BUD: PUR	0.26	13. 4433	13. 1833	0.0925	0.3525	0	42. 8525	0.4992	0.4067	0	28.91	0	0
BUD: SUL	0	0	0	0	0	0	50	0	0	0	0	50	0
BUD: SUL+PI	0 R	0	0	0	0	0	50	0	0	0	0	0	50
INF: PRO	2.285	4.775	2.49	3.765	1.48	0	0	29.05	8.1167	40. 9317	7.1067	0	0
INF: SUL	2.285	4.775	2.49	3.765	1.48	0	0	29.05	8.1167	0	7.1067	40. 9317	0
INF: SUL+PF	2.285 R	4.775	2.49	3.765	1.48	0	0	29.05	8.1167	0	7.1067	0	40. 9317
PRO: PUR	0.26	13. 4433	13. 1833	0.0925	0.3525	0	0	0.4992	0.4067	42. 8525	28.91	0	0
PRO: SUL	0	0	0	0	0	0	0	0	0	50	0	50	0
PRO: SUL+PI	0 R	0	0	0	0	0	0	0	0	50	0	0	50
PUR: SUL	0.26	13. 4433	13. 1833	0.0925	0.3525	0	0	0.4992	0.4067	0	28.91	42. 8525	0
PUR: SUL+PI	0.26	13. 4433	13. 1833	0.0925	0.3525	0	0	0.4992	0.4067	0	28.91	0	42. 8525
SUL: SUL+PI	0	0	0	0	0	0	0	0	0	0	0	50	50

## Appendix 5. Clinical relapse: CINeMA quality assessment report

Compari- son	Number of studies	Within- study bias	Across- studies bias	Indirect- ness	Impreci- sion	Hetero- geneity	Incoher- ence	Confidence rating						
Mixed evidence														
5-ASA:ADA	1	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low						

5-ASA: PLAC	5	No concerns	Undetected	No concerns	Some concerns	No concerns	No concerns	Moderate
5-ASA:PUR	4	Some concerns	Undetected	No concerns	Some concerns	No concerns	No concerns	Low
ADA:INF	1	Some concerns	Suspected	No concerns	Major con- cerns	No concerns	No concerns	Very low
ADA:PUR	1	Some concerns	Suspected	No concerns	No concerns	No concerns	Major con- cerns	Very low
ANT:PLAC	2	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:PLAC	1	No concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Low
INF:PLAC	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:PUR	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PLAC:PRO	3	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PLAC:PUR	2	Some concerns	Undetected	No concerns	Some concerns	No concerns	Some concerns	Low
PLAC:SUL	2	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
PLAC: SUL+PRE	1	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
Indirect evide	nce							
5-ASA: ANT	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA: BUD	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA:PRO	0	No concerns	Undetected	No concerns	Some concerns	No concerns	No concerns	Moderate

5-ASA:SUL	0	Major con- cerns	Undetected	No concerns	Some concerns	No concerns	No concerns	Low
5-ASA: SUL+PRE	0	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
ADA:ANT	0	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low
ADA:BUD	0	No concerns	Suspected	No concerns	Some concerns	No concerns	No concerns	Low
ADA:PLAC	0	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low
ADA:PRO	0	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low
ADA:SUL	0	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low
ADA: SUL+PRE	0	Some concerns	Suspected	No concerns	No concerns	No concerns	No concerns	Low
ANT:BUD	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PUR	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT: SUL+PRE	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:INF	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:PRO	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:PUR	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low

BUD:SUL	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD: SUL+PRE	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Low
INF:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF: SUL+PRE	0	Major con- cerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Very low
PRO:PUR	0	Some concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Very Low
PRO:SUL	0	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
PRO: SUL+PRE	0	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
PUR:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PUR: SUL+PRE	0	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
SUL: SUL+PRE	0	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low

# Appendix 6. Endoscopic relapse: per study contribution matrix

Ran- dom OR	1	2	3	4	5	6	7	8	9	10	11	12
Mixed esti- mates												
5-ASA: ADA	2.505	5.8829	0	0	6.7121	0	12.595	0	0	58. 1433	11. 6467	2.505

5-ASA: PLA	0.165	39. 6412	0	0	45. 2288	0	6.8283	0	0	7.3423	0.6293	0.165
5-ASA: PUR	0.62	13. 3235	0	0	15. 2015	0	28.525	0	0	39. 0295	2.6805	0.62
ADA: INF	17. 1458	0.8746	0	0	0.9979	0	1.8725	0	0	10. 8684	7.6507	60.59
ADA: PUR	5.945	2.6079	0	0	2.9755	0	5.5833	0	0	42. 7354	34. 2079	5.945
ANT: PLA	0	0	0	39.958	0	0	0	0	60.042	0	0	0
INF: PUR	51.3	1.0813	0	0	1.2337	0	2.315	0	0	13. 4301	9.4533	21. 1867
PLA: PRO	0	0	29. 8631	0	0	42. 9191	0	27. 2178	0	0	0	0
PLA: PUR	0.3	5.8634	0	0	6.6899	0	72.18	0	0	13. 4989	1.1577	0.3
Indi- rect es- timates												
5-ASA: ANT	0.132	19. 8206	0	18.822	22. 6144	0	4.6695	0	28. 2825	5.055	0.472	0.132
5-ASA: INF	20. 8567	6.4827	0	0	7.3965	0	13. 8792	0	0	28. 8711	3.3864	19. 1275
5-ASA: PRO	0.132	19. 8206	14. 0668	0	22. 6144	20. 2168	4.6695	12. 8208	0	5.055	0.472	0.132
ADA: ANT	2.136	6.2594	0	12. 7363	7.1416	0	18. 4733	0	19.138	21. 7536	10. 2257	2.136
ADA: PLA	2.67	9.1314	0	0	10. 4186	0	27.71	0	0	32. 0711	15. 3289	2.67
ADA: PRO	2.136	6.2594	9.5187	0	7.1416	13. 6802	18. 4733	8.6755	0	21. 7536	10. 2257	2.136
ANT: INF	16. 6967	3.9735	0	11. 3525	4.5335	0	19. 9042	0	17. 0586	11. 3167	3.4398	11. 7145

ANT: PRO	0	0	14. 9315	19.979	0	21. 4596	0	13. 6089	30.021	0	0	0
ANT: PUR	0.24	4.0095	0	17. 8509	4.5747	0	36.09	0	26. 8233	9.2934	0.8683	0.24
INF: PLA	25.045	5.1795	0	0	5.9096	0	29. 3217	0	0	14. 7215	4.4468	15. 3658
INF: PRO	16. 6967	3.9735	8.4844	0	4.5335	12. 1938	19. 9042	7.7329	0	11. 3167	3.4398	11. 7145
PRO: PUR	0.24	4.0095	13. 3411	0	4.5747	19. 1738	36.09	12. 1593	0	9.2934	0.8683	0.24

## Appendix 7. Endoscopic relapse: per comparison contribution matrix

Random OR	5-ASA: ADA	5-ASA: PLA	5-ASA: PUR	ADA:INF	ADA:PUR	ANT:PLA	INF:PUR	PLA:PRO	PLA:PUR				
Mixed estimates													
5-ASA: ADA	37.56	12.595	11.07	2.505	21.16	0	2.505	0	12.595				
5-ASA: PLA	1.3083	84.87	5.52	0.165	1.1433	0	0.165	0	6.8283				
5-ASA: PUR	5.49	28.525	31.35	0.62	4.87	0	0.62	0	28.525				
ADA:INF	3.2458	1.8725	1.3733	60.59	13.9	0	17.1458	0	1.8725				
ADA:PUR	10.1883	5.5833	4.605	5.945	62.15	0	5.945	0	5.5833				
ANT:PLA	0	0	0	0	0	100	0	0	0				
INF:PUR	4.0117	2.315	1.6967	21.1867	17.175	0	51.3	0	2.315				
PLA:PRO	0	0	0	0	0	0	0	100	0				
PLA:PUR	2.4033	12.5533	10.15	0.3	2.1033	0	0.3	0	72.18				
Indirect esti	mates												
5-ASA: ANT	0.9895	42.435	3.68	0.132	0.8575	47.1045	0.132	0	4.6695				

5-ASA: INF	12.975	13.8792	13.13	19.1275	6.1525	0	20.8567	0	13.8792
5-ASA: PRO	0.9895	42.435	3.68	0.132	0.8575	0	0.132	47.1045	4.6695
ADA: ANT	11.16	13.401	2.241	2.136	18.5783	31.8743	2.136	0	18.4733
ADA:PLA	16.74	19.55	2.81	2.67	27.85	0	2.67	0	27.71
ADA:PRO	11.16	13.401	2.241	2.136	18.5783	0	2.136	31.8743	18.4733
ANT:INF	5.465	8.507	3.042	11.7145	6.2495	28.4112	16.6967	0	19.9042
ANT:PRO	0	0	0	0	0	50	0	50	0
ANT:PUR	1.8175	8.5842	6.7667	0.24	1.5775	44.6742	0.24	0	36.09
INF:PLA	7.2867	11.0892	3.8025	15.3658	8.0792	0	25.045	0	29.3217
INF:PRO	5.465	8.507	3.042	11.7145	6.2495	0	16.6967	28.4112	19.9042
PRO:PUR	1.8175	8.5842	6.7667	0.24	1.5775	0	0.24	44.6742	36.09

## Appendix 8. Endoscopic relapse: CINeMA quality assessment report

Compari- son	Number of studies	Within- study bias	Across- studies bias	Indirect- ness	Impreci- sion	Hetero- geneity	Incoher- ence	Confidence rating						
Mixed evidence														
5-ASA vs ADA	1	Some concerns	Suspected	No concerns	No concerns	No concerns	Some concerns	Very low						
5-ASA vs PLA	2	No concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Low						
5-ASA vs PUR	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low						
ADA vs INF	1	Major con- cerns	Suspected	No concerns	Major con- cerns	No concerns	No concerns	Very low						
ADA vs PUR	2	Major con- cerns	Suspected	No concerns	No concerns	No concerns	Some concerns	Very low						

ANT vs PLA	2	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF vs PUR	1	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low
PLA vs PRO	3	No concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Low
PLA vs PUR	1	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
Indirect evide	ence							
5-ASA: ANT	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA:INF	0	Some concerns	Undetected	No concerns	Some concerns	Some concerns	No concerns	Low
5-ASA:PRO	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:ANT	0	Some concerns	Suspected	No concerns	No concerns	Some concerns	No concerns	Very low
ADA:PLA	0	Some concerns	Suspected	No concerns	No concerns	Some concerns	No concerns	Very low
ADA:PRO	0	Some concerns	Suspected	No concerns	No concerns	Some concerns	No concerns	Very low
ANT:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PUR	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:PLA	0	Some concerns	Undetected	No concerns	Some concerns	Some concerns	No concerns	Low
INF:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Very low
PRO:PUR	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low

Random OR	5-ASA: ADA	5-ASA: PLA	5-ASA: PUR	ADA: PUR	ANT: PLA	BUD: Pla	INF: PUR	PLA: PRO	PLA: PUR	PLA:SUL
Mixed esti	mates									
5-ASA: ADA	37.33	5.6533	22.855	28.5083	0	0	0	0	5.6533	0
5-ASA: PLA	0.43	60.5	19.105	0.43	0	0	0	0	19.535	0
5-ASA: PUR	1.205	13.21	71.18	1.205	0	0	0	0	13.21	0
ADA: PUR	15.885	3.15	12.735	65.08	0	0	0	0	3.15	0
ANT: PLA	0	0	0	0	100	0	0	0	0	0
BUD: PLA	0	0	0	0	0	100	0	0	0	0
INF: PUR	0	0	0	0	0	0	100	0	0	0
PLA: PRO	0	0	0	0	0	0	0	100	0	0
PLA: PUR	0.37	16.855	16.485	0.37	0	0	0	0	65.92	0
PLA:SUL	0	0	0	0	0	0	0	0	0	100
Indirect es	timates									
5-ASA: ANT	0.3225	30.25	12.7367	0.3225	43.3092	0	0	0	13.0592	0
5-ASA: BUD	0.3225	30.25	12.7367	0.3225	0	43.3092	0	0	13.0592	0
5-ASA: INF	0.8033	8.8033	35.59	0.8033	0	0	45.1967	0	8.8033	0
5-ASA: PRO	0.3225	30.25	12.7367	0.3225	0	0	0	43.3092	13.0592	0
5-ASA: SUL	0.3225	30.25	12.7367	0.3225	0	0	0	0	13.0592	43.3092

## Appendix 9. Withdrawal due to adverse events: per comparison contribution matrix

ADA: ANT	12.0133	13.8858	1.8725	20.6958	32.7092	0	0	0	18.8233	0
ADA: BUD	12.0133	13.8858	1.8725	20.6958	0	32.7092	0	0	18.8233	0
ADA: INF	10.8525	2.3625	8.49	32.54	0	0	43.3925	0	2.3625	0
ADA: PLA	18.02	20.5167	2.4967	30.7317	0	0	0	0	28.235	0
ADA: PRO	12.0133	13.8858	1.8725	20.6958	0	0	0	32.7092	18.8233	0
ADA: SUL	12.0133	13.8858	1.8725	20.6958	0	0	0	0	18.8233	32.7092
ANT: BUD	0	0	0	0	50	50	0	0	0	0
ANT: INF	0.222	8.4645	8.2425	0.222	30.4378	0	30.4378	0	21.9733	0
ANT: PRO	0	0	0	0	50	0	0	50	0	0
ANT: PUR	0.2775	11.2675	10.99	0.2775	44.2275	0	0	0	32.96	0
ANT: SUL	0	0	0	0	50	0	0	0	0	50
BUD: INF	0.222	8.4645	8.2425	0.222	0	30.4378	30.4378	0	21.9733	0
BUD: PRO	0	0	0	0	0	50	0	50	0	0
BUD: PUR	0.2775	11.2675	10.99	0.2775	0	44.2275	0	0	32.96	0
BUD: SUL	0	0	0	0	0	50	0	0	0	50
INF:PLA	0.2775	11.2675	10.99	0.2775	0	0	44.2275	0	32.96	0
INF: PRO	0.222	8.4645	8.2425	0.222	0	0	30.4378	30.4378	21.9733	0

(Continued)

INF:SUL	0.222	8.4645	8.2425	0.222	0	0	30.4378	0	21.9733	30.4378
PRO: PUR	0.2775	11.2675	10.99	0.2775	0	0	0	44.2275	32.96	0
PRO: SUL	0	0	0	0	0	0	0	50	0	50
PUR: SUL	0.2775	11.2675	10.99	0.2775	0	0	0	0	32.96	44.2275

## Appendix 10. Withdrawals due to adverse events: per study contribution matrix

Ran- dom OR	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Mixed esti- mates															
5- ASA: ADA	8. 0627	0	1. 8453	0. 5543	0	0	1. 8848	8. 8754	0	5. 1689	0	4. 1943	2. 8106	66. 6037	0
5- ASA: PLA	6. 7398	0	19. 7475	5.932	0	0	20. 1707	24. 7467	0	4. 3208	0	14. 4932	2. 3494	1. 4998	0
5- ASA: PUR	25. 1107	0	4. 3118	1. 2952	0	0	4. 4042	25. 4422	0	16. 0981	0	9. 8006	8. 7534	4. 7937	0
ADA: PUR	4. 4926	0	1. 0282	0. 3089	0	0	1. 0502	4. 9455	0	2. 8802	0	2.337	1. 5661	81. 3915	0
ANT: PLA	0	0	0	0	0	0	0	0	0	0	100	0	0	0	0
BUD: PLA	0	0	0	0	22. 192	0	0	0	77. 808	0	0	0	0	0	0
INF: PUR	0	100	0	0	0	0	0	0	0	0	0	0	0	0	0

PLA: PRO	0	0	0	0	0	100	0	0	0	0	0	0	0	0	0
PLA: PUR	5. 8155	0	5. 5015	1. 6526	0	0	5. 6195	25. 4568	0	3. 7283	0	48. 9065	2. 0273	1. 2921	0
PLA: SUL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	100
Indi- rect esti- mates															
5- ASA: ANT	4. 4932	0	9. 8737	2.966	0	0	10. 0853	14. 0655	0	2. 8805	43. 3092	9. 6887	1. 5663	1. 0715	0
5- ASA: BUD	4. 4932	0	9. 8737	2.966	9. 6112	0	10. 0853	14. 0655	33. 698	2. 8805	0	9. 6887	1. 5663	1. 0715	0
5- ASA: INF	12. 5553	45. 1967	2. 8734	0. 8632	0	0	2.935	13. 8208	0	8. 0491	0	6. 5313	4. 3767	2. 7985	0
5- ASA: PRO	4. 4932	0	9. 8737	2.966	0	43. 3092	10. 0853	14. 0655	0	2. 8805	0	9. 6887	1. 5663	1. 0715	0
5- ASA: SUL	4. 4932	0	9. 8737	2.966	0	0	10. 0853	14. 0655	0	2. 8805	0	9. 6887	1. 5663	1. 0715	43. 3092
ADA: ANT	0. 6606	0	4. 5324	1. 3615	0	0	4. 6295	8. 7161	0	0. 4235	32. 7092	13. 9652	0. 2303	32. 7718	0
ADA: BUD	0. 6606	0	4. 5324	1. 3615	7. 2588	0	4. 6295	8. 7161	25. 4503	0. 4235	0	13. 9652	0. 2303	32. 7718	0
ADA: INF	2. 9951	43. 3925	0. 7711	0. 2316	0	0	0. 7877	3. 4282	0	1. 9201	0	1. 7528	1. 0441	43. 6768	0
ADA: PLA	0. 8808	0	6. 6967	2. 0117	0	0	6. 8403	12. 9158	0	0. 5646	0	20. 9478	0.307	48. 8353	0
ADA: PRO	0. 6606	0	4. 5324	1. 3615	0	32. 7092	4. 6295	8. 7161	0	0. 4235	0	13. 9652	0. 2303	32. 7718	0

ADA: SUL	0. 6606	0	4. 5324	1. 3615	0	0	4. 6295	8. 7161	0	0. 4235	0	13. 9652	0. 2303	32. 7718	32. 7092
ANT: BUD	0	0	0	0	11. 096	0	0	0	38. 904	0	50	0	0	0	0
ANT: INF	2. 9078	30. 4378	2. 7629	0. 8299	0	0	2. 8221	9. 9017	0	1. 8641	30. 4378	16. 3022	1. 0136	0.72	0
ANT: PRO	0	0	0	0	0	50	0	0	0	0	50	0	0	0	0
ANT: PUR	3.877	0	3. 6778	1. 1048	0	0	3. 7566	14. 143	0	2. 4855	44. 2275	24. 4533	1. 3515	0.923	0
ANT: SUL	0	0	0	0	0	0	0	0	0	0	50	0	0	0	50
BUD: INF	2. 9078	30. 4378	2. 7629	0. 8299	6. 7548	0	2. 8221	9. 9017	23. 6831	1. 8641	0	16. 3022	1. 0136	0.72	0
BUD: PRO	0	0	0	0	11. 096	50	0	0	38. 904	0	0	0	0	0	0
BUD: PUR	3.877	0	3. 6778	1. 1048	9.815	0	3. 7566	14. 143	34. 4125	2. 4855	0	24. 4533	1. 3515	0.923	0
BUD: SUL	0	0	0	0	11. 096	0	0	0	38. 904	0	0	0	0	0	50
INF: PLA	3.877	44. 2275	3. 6778	1. 1048	0	0	3. 7566	14. 143	0	2. 4855	0	24. 4533	1. 3515	0.923	0
INF: PRO	2. 9078	30. 4378	2. 7629	0. 8299	0	30. 4378	2. 8221	9. 9017	0	1. 8641	0	16. 3022	1. 0136	0.72	0
INF: SUL	2. 9078	30. 4378	2. 7629	0. 8299	0	0	2. 8221	9. 9017	0	1. 8641	0	16. 3022	1. 0136	0.72	30. 4378
PRO: PUR	3.877	0	3. 6778	1. 1048	0	44. 2275	3. 7566	14. 143	0	2. 4855	0	24. 4533	1. 3515	0.923	0
PRO: SUL	0	0	0	0	0	50	0	0	0	0	0	0	0	0	50

PUR:	3.877	0	3.	1.	0	0	3.	14.	0	2.	0	24.	1.	0.923	44.
SUL			6778	1048			7566	143		4855		4533	3515		2275

# Appendix II. Withdrawal due to adverse events: CINeMA quality assessment report

Compari- son	Number of studies	Within- study bias	Across- studies bias	Indirect- ness	Impreci- sion	Hetero- geneity	Incoher- ence	Confidence rating	
Mixed evidence									
5-ASA:ADA	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
5-ASA:PLA	4	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
5-ASA:PUR	5	Some concerns	Undetected	No concerns	Some concerns	Some concerns	Some concerns	Low	
ADA:PUR	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low	
ANT:PLA	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
BUD:PLA	2	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
INF:PUR	1	Major con- cerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Very low	
PLA:PRO	1	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
PLA:PUR	2	No concerns	Undetected	No concerns	Major con- cerns	Some concerns	No concerns	Low	
PLA:SUL	1	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
Indirect evidence									
5-ASA: ANT	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	
5-ASA: BUD	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low	

5-ASA:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
5-ASA:SUL	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:ANT	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:BUD	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:PLA	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ADA:SUL	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:BUD	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:PUR	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
ANT:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:INF	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
BUD:PUR	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low

BUD:SUL	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:PLA	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:PRO	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
INF:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PRO:PUR	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PRO:SUL	0	Some concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low
PUR:SUL	0	No concerns	Undetected	No concerns	Major con- cerns	No concerns	No concerns	Low

## CONTRIBUTIONS OF AUTHORS

• Zipporah Iheozor-Ejiofor co-ordinated the review; extracted data and contacted authors; checked the quality of data extraction; performed statistical analysis; checked the quality of the statistical analysis; interpreted data; undertook and checked quality assessment; produced the first draft of the review; contributed to writing and editing the review; made an intellectual contribution to the review; contributed to previous version of the review; approved the final review prior to submission.

• Morris Gordon performed screening of titles and abstracts and full-text articles, checked the quality of data extraction and interpreted data; contributed to writing and editing the review; made an intellectual contribution to the review; contributed to previous version of the review; approved the final review prior to submission.

• Andrew Clegg made an intellectual contribution to the review; contributed to previous version of the review; approved the final review prior to submission.

• Suzanne C Freeman performed statistical analysis; checked the quality of the statistical analysis; contributed to editing the review; made an intellectual contribution to the review; approved the final review prior to submission.

• Teuta Gjuladin-Hellon performed screening of titles and abstracts and full-text articles; extracted data; contributed to writing the review; made an intellectual contribution to the review; approved the final review prior to submission.

• John K MacDonald checked the quality assessment; contributed to editing the review; made an intellectual contribution to the review; contributed to previous version of the review; approved the final review prior to submission.

• Anthony K Akobeng initiated and conceptualised the review; contributed to previous version of the review; made an intellectual contribution to the review; approved the final review prior to submission.

#### DECLARATIONS OF INTEREST

• Zipporah Iheozor-Ejiofor: None known.

• Morris Gordon has received travel fees from Abbott, Nutricia, BioGaia, Ferring, Allergan, and Tillots to attend international scientific and training meetings such as DDW, Advances in IBD, ESPGHAN, BSPGHAN, and Cochrane-focused international events. None of these companies has had any involvement in any works completed by Morris Gordon, and he has had no payments for any other activities.

- Andrew Clegg: None known.
- Suzanne C Freeman: None known
- Teuta Gjuladin-Hellon: None known.
- John K MacDonald: None known.
- Anthony K Akobeng: None known.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

• Inclusion criteria was limited to studies with a minimum of 3 months of treatment to ensure consistency with similar reviews (Gjuladin-Hellon 2019a; Gjuladin-Hellon 2019b) in the Cochrane IBD portfolio

• According to the protocol, studies that recruited participants in any sort of relapse (clinical, endoscopic, or histologic, etc.) were to be excluded. We included a study that recruited people in endoscopic relapse (Reinisch 2010). To avoid transitivity, we only included it in the network meta-analysis (NMA) for the outcome withdrawal due to adverse events.

• We carried out an all-domain risk of bias where we assigned four ratings (very high, high, low and unclear), but grouped 'low' and 'unclear' risk of bias together following methods reported in Norman 2018.

• We intended to generate funnel plot (Assessment of reporting biases); assess for statistical heterogeneity using 90% significance level, use the ifplot command on Stata 2017 as a local approach for evaluating inconsistency and use Chi<sup>2</sup> as global approach for evaluating inconsistency (Subgroup analysis and investigation of heterogeneity). None of these was feasible with our Markov Chain Monte Carlo (MCMC) model; alternative methods were used instead.

• We have reported the risk ratio (RR) for pairwise comparisons and the hazard ratio (HR) for the NMA as planned due to the nature of the data. Our first primary outcome was dichotomous, and the second was survival data. The included studies did not report on time to relapse as survival data, but reported this as a dichotomous outcome instead (i.e. number of relapses). The NMA was carried out in such a way that takes time into account using the clog-log link. The pairwise comparison, on the other hand, did not take time into account and has been analysed using the RR as intended.

• Although we intended to contact leaders in the field and drug companies to identify additional studies, we did not do so.